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Abstract
Obesity is now one of the most common medical disorders of companion animals 
(dogs, cats and horses) and is defined by the expansion of white adipose tissue mass. 
This tissue is now known to be major endocrine and secretory organ, releasing 
different protein hormones and signals termed adipokines. A number o f these are 
linked to inflammation and immunity, and a role for inflammation-related adipokines 
in the development of obesity-associated diseases in humans is increasingly 
recognised. The specific aim of this project was to examine the extent to which 
canine adipose tissue produces various adipokines and to determine some of the 
factors which regulate their production. The Staffordshire bull terrier was the main 
breed employed.
Studies by RT-PCR indicated that the major adipose tissue depots in the dog 
(subcutaneous inguinal, gonadal, omental, per-renal and falciform ligament) 
expressed major adipokine genes including leptin, adiponectin, TNFa, IL-6 and 
MCP-1. Using real-time PCR, no significant difference was found in inflammatory 
adipokine mRNA levels between the depots examined. However, mRNA levels o f 
the adipocyte hormone leptin were found to be higher in four out o f the five white 
adipose tissue depots examined, in female compared to male dogs. A primary cell 
culture system was established in which fibroblastic preadipocytes from both visceral 
and subcutaneous depots were successfully isolated and induced to differentiate into 
mature adipocytes as a tool for examining adipokine expression and secretion in 
vitro.
The expression profile of the adipocyte hormones leptin and adiponectin, as well as 
that of a series of inflammation-related adipokine genes, was examined during the 
differentiation of canine preadipocytes to adipocytes from both depots. Expression 
for some genes, notably leptin and adiponectin, was highly differentiation-dependent, 
being evident only after the induction of differentiation. In contrast, that of other 
adipokines such as NGF and TNFa was similarly expressed both before and after 
differentiation. Canine white adipocytes of both visceral and subcutaneous depots 
were found to synthesise and release several protein-factors including adiponectin,
xvm
TNFa, IL-6, MCP-1 and NGF and as such these can be referred to as adipokines in 
the dog.
The effects of several agents, including the pro-inflammatory cytokines TNF-a and 
IL-6, and LPS, on the expression and secretion of adipokines by canine adipocytes 
were investigated. Treatment of differentiated adipocytes with these agents led to 
substantial increases in the mRNAs encoding several adipokines, including IL-6 and 
MCP-1. In contrast, dexamethasone and the PPARy agonist rosiglitazone, both of 
which have anti-inflammatory effects, led to a marked reduction in the level o f 
expression and secretion o f several inflammation-related adipokines.
Studies reported herein also show that the intracellular enzyme 11(3-HSD-1, 
responsible for the conversion o f inactive cortisone to cortisol, is expressed in all five 
main white adipose tissue depots in the dog. Although there was little difference in 
level of expression between depots, 1 ip-HSD-1 mRNA level was found to be higher 
in the omental depot of female than in male dogs. Both pro-inflammatory agents, and 
agents with an anti-inflammatory effect, such as the PPARy agonist rosiglitazone, 
increased the level o f expression of lip-HSD-1 in cells of both visceral and 
subcutaneous depots. Thus, the local regulation of cortisol metabolism in canine 
adipocytes may be in a delicate balance, where regulation by inflammatory and anti­
inflammatory agents may play a significant role.
In conclusion, these studies indicate that canine white adipocytes, from both visceral 
and subcutaneous depots, are able to synthesise and actively secrete several key 
adipokines. Strong evidence has been provided that canine adipocytes are able to 
synthesise and actively secrete these adipokines in response to specific stimuli and 
this may have a significant role in the metabolic profile of the dog in obesity.
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Chapter 1
Introduction
1.1 Obesity
Obesity stems from an imbalance between levels of energy intake and expenditure. 
Prolonged excessive energy (food) intake coupled with low levels of energy 
expenditure lead to a state of positive energy balance where excessive deposition of 
energy in the form of triglycerides in white adipose tissue (WAT) occurs. Obesity is 
the main nutritional disorder affecting both humans and companion animals (dogs, 
cats & horses) in westernised society (Shibata et al., 2003; Kearns et al., 2006; Bach 
et al., 2007; Wells et al., 2007). In humans, it has reached epidemic proportions in 
countries such as the USA and it is also a growing concern worldwide, including in 
developing nations. Factors in an individual’s lifestyle such as decreased level of 
physical activity, coupled with greater availability of highly palatable, cheap, energy- 
rich foods are thought to be the main contributor for the global rise in levels o f 
human obesity.
However, susceptibility to obesity is also dependent upon genetic background. The 
heritability o f obesity, is considered to be relatively high (up to 60-70%), and there is 
evidence that several major genes contribute to the variation in obesity related 
phenotypes in humans (O'Rahilly & Farooqi, 2006). However, the current levels of 
obesity cannot be attributed to genetic changes, for which the timescale would be too 
short, but rather to environmental and socio-economic factors coupled with both 
genetic and epigenetic factors (Rolls, 2007; Speakman et al., 2007). In dogs, it has 
been shown that factors related to lifestyle such as the socio-economic and dietary 
habits o f owners as well as breed susceptibility influence the development of obesity 
(Colliard et al., 2006).
1.1.1 Clinical definition and prevalence of obesity
Obesity can be defined as a condition resulting from a positive energy balance, 
where energy intake exceeds expenditure leading to weight gain and excess body fat. 
A working definition o f overweight for dogs has been suggested as an excess of 
10%, and obese when weight exceeds 20%, above the ideal level recommended for a 
certain breed (Lund et al., 2006). It is critical to have a method for the diagnosis of 
obesity. Imprecise methods would either over or under diagnose the condition 
resulting in shifts in estimates of its incidence and prevalence (Misra, 2003).
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1.1.1.1 BMI in humans
Obesity can be measured using various advanced imaging techniques such as dual­
energy X-ray absorptiometry (DEXA) and magnetic resonance imaging (MRI). 
However, these methods require expensive equipment and are therefore limited to a 
clinical research setting. Alternatively, body mass index (BMI) can be used indirectly 
to quantify overweight and obesity, and is defined as the weight in kilograms divided 
by the square of the height in metres (kg/m2). This is a valid and reproducible 
method that is cheap and convenient for the assessment of the weight status of an 
individual in the clinical setting (where weight is a surrogate for body fatness) 
(O'Neill et al., 2007). The World Health Organisation (WHO) has proposed a 
classification of overweight and obesity that applies to adult men and women o f a 
BMI of > 25 kg/m2 as overweight, > 30 kg/m2 as obese and > 40 kg/m2 as morbidly 
obese (WHO, 2007).
These cut off points were derived primarily in European and North American 
populations. There is strong ongoing debate as to whether these criteria are 
appropriate for non-Europeans where, for example, people from China or South Asia 
have higher levels of blood glucose and blood pressure for a given BMI compared to 
Caucasians (Razak et al., 2007). Thus, for most such populations, the reported BMI 
cut-offs would be lower than those currently accepted (Misra, 2003). This has been 
taken into account in the current WHO recommendations where the cut-off points of 
23, 27.5, 32.5 and 37.5 kg/m2 are added to the current classification as points for 
public health action. For the medical management and treatment of overweight and 
obesity in humans BMI alone should not be considered diagnostic.
Measurement of the presence of abdominal obesity based on a measure o f waist-to- 
hip ratio (WHR) is also important (Kuczmarski & Flegal, 2000), and several studies 
indicate a link between increased adiposity in the upper part of the body male-type 
fat distribution (i.e., visceral or abdominal) and increased risk of obesity-associated 
diseases (Vgontzas et al., 2003; Wajchenberg et al., 2003; Bray, 2004). In contrast, 
those with fat stores in gluteal-femoral or peripheral depots, the so called lower body 
obesity or female-type fat distribution, have been found to have a lower risk of 
morbidity/mortality from these diseases (Wajchenberg et al., 2003). Visceral adipose 
tissue has been found to be functionally and morphologically different from
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subcutaneous adipose tissue in that visceral adipocytes have a higher fatty acid 
turnover and are less responsive to the anti-lipolytic effects of insulin compared to 
adipocytes from subcutaneous depots (Wajchenberg et al., 2003).
Recent figures indicate that 23% of men and 25% of women in the United Kingdom 
(UK) are obese. This represents an approximate trebling in the prevalence o f obesity 
since 1980 (Rennie & Jebb, 2005). There has also been an alarming rise in the levels 
o f childhood obesity, with 22% of boys and 28% of girls aged 2-15 being overweight 
or obese (Rennie & Jebb, 2005). Data for other European countries (excluding the 
UK) estimate that 43.5% of Europeans aged 50 to 79 years are overweight and 
18.2% are obese (Peytremann-Bridevaux et a l, 2007). Figures for the United States 
o f America (USA) estimate that approximately one third of adults are obese 
(Marcason, 2007), and 17.1% of children and adolescents are overweight (Ogden et 
al., 2006). Levels of obesity in some lower-income and transitional countries is as 
high, or even higher than, the prevalence reported in developed nations and rates 
seem to be rising increasingly rapidly (Filozof et al., 2001; Wijesinghe, 2006; 
Hossain et al., 2007).
1.1.1.2 Companion animals and Body Condition Score
The measurement of body composition in any species is vital not only for assessment 
and control o f obesity, but also for the re-alimentation of sick animals and the 
evaluation o f energy requirements (Munday, 1994). All measures o f adiposity in 
dogs involve defining body composition, or the relative amounts of the various 
biological components of the body, namely fat and lean body mass (German, 2006). 
Various techniques are available to measure body composition and can either be 
direct (chemical analysis of a cadaver) or indirect (based upon the model o f the body 
as distinct compartments) (Munday, 1994). Anthropomorphic measurements such as 
skin-fold thickness in humans, DEXA analysis, MRI, ultrasonography (subcutaneous 
and abdominal), isotope dilution (deuterium and tritium oxide) are just a few o f the 
techniques used, mainly in a research setting (Wilkinson & McEwan, 1991; Munday 
et al., 1994; Toll et al., 1994; Morooka et al., 2001; Speakman et al., 2001; Mawby 
et al., 2004).
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Clinically, morphometric methods (defined as the measurement of ‘form’) are the 
most common way to assess body condition in companion animals. The three main 
morphometric approaches are measurement of skin fold thickness (not suitable in 
cats or dogs due to the large amount of subcutaneous fascia), dimensional 
evaluations (in which various measurements of stature and weight are combined) and 
body condition score (BCS) (German, 2006). Body condition scoring is a subjective 
semi-quantitative assessment of body condition with a range of categories (each 
given a number) from cachectic to severely obese. A number of different schemes 
are in existence, of which the most widely-adopted in general practice is a 9-point 
scheme (Laflamme & Kuhlman, 1995), whereas a newly devised 7-point scheme has 
been shown to be suitable for scoring by owners (German et al., 2006). Both systems 
have been validated by DEXA and assess both palpable and visual characteristics to 
correlate abdominal and subcutaneous fat as well as superficial musculature with 
degree of adiposity (Fig. 1.1).
5
Figure 1.1 Waltham S.H.A.P.E ™ guide for dogs
S .H .A .P .E ." "
S c o re
D e s c r ip tio n
A
E x tre m e ly  T h in
Your dog has a very small amount or no total body fat. 
Recommendation: Seek veterinary advice promptly.
B
T h in
Your dog has only a small amount of total body fat.
Recommendation: Seek veterinary advice to ensure your dog Is offered the appropriate amount of food. Reassess 
using the S.H.A.P.E.™ chart every 2 weeks.
C
L e a n
Your dog Is at the low end of the ideal range with less than normal body fat.
Recommendation: Increase food offered by a small amount. Monitor monthly using the S.H.A.P.E.™ chart and seek 
veterinary advice If no change.
D
Id e a l
Your dog has an Ideal amount o f total body fat.
Recommendation: Monitor monthly to ensure your dog remains in this category and have him/her checked by the 
veterinarian at your next visit.
E
M ild ly  O v e rw e ig h t
Your dog is at the upper end of the ideal range with a small amount of excess body fat.
Recommendation: Seek veterinary advice to ensure your dog is offered the appropriate amount o f food and consider 
increasing activity levels. Avoid excessive treats and monitor monthly usinq the S.H.A.P.E.™ chart.
F
M o d e ra te ly  O v e rw e ig h t
Your dog has an excess of total body fat.
Recommendation: Seek veterinary advice to implement safely an appropriate weight loss plan including increasing 
activity levels.
Reassess using the S.H.A.P.E.™ chart every 2 weeks.
G
S e v e re ly  O v e rw e ig h t
Your pet has a large amount o f excess total body fat that Is affecting Its health and well being.
Recommendation: Seek veterinary advice promptly to introduce a weight loss plan to reduce your dog’s weight, 
increase activity levels and improve health.
N B : S o m e  b re e d s  a n d  d if fe re n t  l ife -s ta g e s  m a y  h a v e  d if fe r e n t  id e a l S .H .A .P .E  s c o re s . C o n s u lt  y o u r  v e te r in a r ia n  if  y o u  a re
u n s u re .
TM Registered Trademark ©  2005 Mars, Incorporated
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Obesity is one of the most common medical disorders of dogs and, the most common 
form of malnutrition in dogs in western society (Edney & Smith, 1986; Mawby et al., 
2004; McGreevy et al., 2005). Unfortunately, the study of the pathogenesis and 
treatment of naturally-occurring obesity in animals has not kept pace with the 
perceived increase in the frequency o f the disease (Buffington, 1994). Previous 
estimates o f the prevalence of obesity in clinical practice have suggested that 25 to 
33% of dogs are overweight (Markwell et al., 1990). However, recent figures from 
Australia and France estimate 33.5% and 38.8% of dogs as being overweight, while 
7.6% and 5% as obese (McGreevy et al., 2005; Colliard et al., 2006; Lund et al., 
2006; Holmes et al., 2007).
Factors which are thought to contribute to this include living indoors, inactivity, age 
(with older dogs being increasingly predisposed) (Donoghue et al., 1991; McGreevy 
et al., 2005; Colliard et al., 2006) and being neutered (Edney & Smith, 1986; 
Markwell et al., 1990; Colliard et al., 2006). Neutering has been shown to be one of 
the predisposing factors for obesity in the dog, with effects on energy balance 
through increased appetite coupled with reduced levels of activity. In addition, 
neutering may predispose animals to obesity by reducing the concentration of 
oestrogens and androgens that induce behaviours associated with breeding, including 
searching for a mate. Furthermore, oestrogen contributes to leptin sensitivity in the 
central nervous system (CNS), its removal may therefore contribute to leptin 
resistance in companion animals (Clegg et al., 2006) (Mayes & Watson, 2004).
Over the past few hundred years considerable inbreeding has occurred in the dog 
population to generate specific genetic isolates referred to as breeds. These have both 
physical and in some cases physiological characteristics which are specific to a 
certain breed and which differ among the dog population (Sutter & Ostrander, 2004). 
One such example is hip osteoarthritis due to degenerate joint disease, which is seen 
in German shepherd dogs, rottweilers, Labrador retrievers and golden retrievers 
(Smith et al., 2001).
Overweight and obesity has been linked to breeds such as the Labrador retriever 
(Colliard et al., 2006), cocker spaniel, long-haired dachshunds, Shetland sheepdogs, 
cairn terriers, Cavalier King Charles spaniels, beagles and basset hounds (Edney &
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Smith, 1986). Moreover, it has been suggested that obese owners may be more likely 
to own obese dogs (Mason, 1970; Edney & Smith, 1986; Holmes et al., 2007). 
However, it is not clear whether this is related to a failure to exercise their dogs, a 
relationship between overeating and overfeeding or a failure to recognise obesity in 
their pets. It is likely to be a complex mixture o f these, with many owners failing to 
estimate accurately the weight of their dogs or to consider their pet as overweight 
(Mason, 1970; Colliard et al., 2006).
1.1.2 Metabolic syndrome
The metabolic syndrome as defined in humans, represents a group of metabolic and 
vascular disorders which increase the risk of an individual developing type II 
diabetes mellitus and cardiovascular disease (Reisin & Alpert, 2005). Over the past 
two decades, the definition has been modified to include measures of blood pressure 
and albumin-to-creatinine ratio due to the rising levels o f diabetic nephropathy 
(Hossain et al., 2007). The most recently described definition was proposed by the 
International Diabetes Federation, and it requires the presence of central (visceral) 
obesity with specific ethnic cut-off points plus two additional factors described in 
Table 1.1. Adopting ethnic-specific criteria, improves the usefulness of the term 
‘metabolic syndrome’ in identifying individuals at risk from obesity related co­
morbidities (Banerjee & Misra, 2007).
Type II diabetes mellitus, also known as non-insulin-dependent diabetes, results from 
an inability of the tissues in the body to respond appropriately to insulin produced by 
pancreatic P-cells (Yach et al., 2006). Its prevalence has increased dramatically in the 
last decade, primarily because of the link with obesity. In the 1950s 200,000 people 
were diagnosed with type II diabetes in the UK, whereas in 2004 the figure stood at
1.8 million (Diabetes, 2005). In other countries such as the USA, it is estimated that 
the number of individuals diagnosed with diabetes will increase by 165% between 
the years 2000 and 2050, with the most rapid increases occurring in older and 
minority populations (Narayan et al., 2003). The risk o f developing diabetes 
increasing with increasing BMI; individuals with a BMI >30 kg/m'2 are 10 times 
more likely to develop type II diabetes mellitus than those with a BMI < 25 kg/m'2 
(Ayata et al., 2000).
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Cardiovascular disease is also strongly associated with obesity, especially central 
obesity, independent of gender (Carr & Brunzell, 2004). The obese have higher 
incidences of coronary heart disease, arthrosclerosis, hypertension and 
dyslipidaemias (Shaw et al., 2005). A meta-analysis, that collected data from 26 
separate studies, found coronary heart disease to be the most common cause of 
premature death in obese individuals (McGee, 2005). Furthermore, a 16-year 
prospective study has linked obesity with an increased risk of death from various 
forms of cancer, such as those o f the breast, prostate and ovary in individuals in the 
United States (Calle & Thun, 2004). Other co-morbidities associated with obesity in 
humans include renal disease (mainly characterised by diabetic nephropathy) 
(Rutkowski et a l, 2006), osteoarthritis (Pottie et al., 2006) and respiratory 
impairment (including obstructive sleep apnoea) (Vgontzas et al., 2003).
Table 1.1 Medical criteria used to define the Metabolic Syndrome
Criteria Defining levels
Serum  trig lyceride level, mg/dl >1 5 0  or specific treatm ent
Serum  high density lipoprotein cholesterol, 
m g/dl
< 4 0  (m ale), <50  (fem ale) or 
specific treatm ent
Blood pressure, mmHg £1 3 0 /8 5
Fasting plasm a glucose, mg/dl >100
A lbum inuria , m g/g album in-to-creatinine ratio £30
Table adaptedfrom (Diabetes, 2005).
In a manner similar to humans, obesity has a detrimental effect on the health and 
longevity o f dogs (German, 2006). Co-morbidities associated with obesity in dogs 
include orthopaedic disease where obesity is a major risk factor for the development 
o f osteoarthritis (Kealy et al., 2000; Smith et al., 2001). A prospective clinical trial 
carried out in the United States found that weight reduction alone leads to a 
substantial improvement in clinical lameness in dogs suffering from osteoarthritis 
(Impellizeri et al., 2000). Cats, unlike dogs, most often suffer from a condition which 
resembles type II diabetes in humans and obesity therefore is a major risk factor in 
this species (Nelson et al., 1990; Feldhahn et al., 1999).
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In contrast, dogs more commonly suffer from a form of diabetes resembling type I 
diabetes mellitus in humans caused by an autoimmune-mediated destruction of 
pancreatic p-cells. Dogs with this form of diabetes are prone to developing 
ketoacidosis and need exogenous insulin for survival (Hoenig, 2002). In dogs, 
obesity causes marked insulin resistance leading to hyperinsulinaemia and impaired 
glucose tolerance (Bailhache et al., 2003; Larson et al., 2003; Gayet et al., 2004), 
and this has been linked to an increased risk of type II diabetes (Klinkenberg et al., 
2006; Lund et al., 2006).
In a similar manner to obstructive sleep apnoea in humans, dogs experience an 
increased expiratory airway resistance with obesity (Bach et al., 2007). In addition, 
obesity is an important risk factor for the development of tracheal collapse in small 
breeds o f dogs (White & Williams, 1994). Other respiratory diseases which can be 
exacerbated by obesity include laryngeal paralysis and brachycephalic airway 
syndrome. Obesity also leads to abnormal lipid profiles in dogs in a similar manner 
to obese humans, characterised by increases in plasma triacylglycerol and very-low- 
density lipoprotein (VLDL) concentrations and lower plasma high-density 
lipoprotein (HDL) cholesterol concentrations (Bailhache et al., 2003).
Furthermore, obesity is thought to be a risk factor for fatal acute pancreatitis in dogs 
(Hess et al., 1999). Dietary restriction has been shown to increase longevity in both 
humans and rodents (Fontana & Klein, 2007), as well as dogs where it is also 
associated with a longer median time to first treatment for chronic diseases such as 
osteoarthritis (Kealy et al., 2002; Larson et al., 2003; Lawler et al., 2005). Although 
animals also suffer from diseases associated with obesity, many of their specific 
disease-associations are different from those of obese humans (Buffington, 1994). 
For example, of the tumours commonly associated with obesity in humans, only 
adenocarcinoma of mammary tissue has been reported as significantly correlated 
with obesity in dogs (Sonnenschein et al., 1991).
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1.1.3 Treatment of obesity
Given the scale of the obesity epidemic and the profound implications for public 
health, treatment is directed towards those at greatest risk of developing co­
morbidities associated with obesity. Although weight loss is one aim of therapy, the 
main goal is an improvement in metabolic parameters coupled with long-term weight 
loss (Wilding, 2007). The two most conventional approaches used are those o f 
calorie restriction, usually involving both a decrease in the overall amount consumed 
as well as a switch to a low-calorie diet, combined with increased physical activity. 
Cognitive behavioural therapy is also vital in achieving long-term weight loss 
(Wilding, 2007).
Diet and exercise has been the cornerstone of weight management therapy in 
humans, but this has been found to have limitations, especially in terms of weight 
maintenance. Thus, pharmacotherapy has also become an important aspect of obesity 
management (Hanif & Kumar, 2002). Three drugs are currently licensed for the 
treatment of obesity in humans in the UK; these are orlistat, sibutramine and 
rimonabant (Wilding, 2007). Orlistat is a gastrointestinal lipase inhibitor which acts 
to reduce intestinal fat absorption. It has been shown to be both effective and cost- 
effective in the treatment of obese patients (Lacey et al., 2005; Padwal & Majumdar, 
2007). Sibutramine acts on the CNS to inhibit the reuptake of norephinephrine and 
serotonin thereby amplifying satiety signals inducing a sensation o f fullness. In 
addition, it is thought to also have important thermogenic effects (Aronne, 2007). 
Rimonabant is a cannabinoid receptor Type 1 blocker preventing hyperphagia 
(Gelfand & Cannon, 2006). In clinical trials, both have been shown to produce 
greater weight loss than lifestyle alone and importantly, to help maintain weight loss 
(Wilding, 2007).
Thiazolidinediones (TZDs) are peroxisome proliferator-activated receptor (PPARy) 
ligands which are used clinically to improve insulin sensitivity in type II diabetes 
patients. PPARs are ligand-dependent transcription factors which after ligand 
binding and activation are able to either enhance or repress expression of target 
genes. Three PPARs have been identified, each with differential expression patterns 
and physiological functions. PPAR5 (also known as PPARP) is ubiquitously 
expressed, with highest level o f expression in skin, brain and adipose tissue. Deletion
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of PPAR8 in animal models causes alterations in these target tissues, such as 
impaired wound healing through effects on keratinocyte proliferation (Hammarstedt 
et al., 2005). PPARa is predominantly expressed in the liver, heart, skeletal muscle 
and also in the vascular wall. It is involved in the regulation o f genes related to fatty 
acid metabolism in the liver (Kersten et al., 2000a).
PPARy exists as two isoforms, PPARyl and y2, that differ in their N-terminal end as 
a result o f alternative promoter usage and differential splicing (Zhu et al., 1995). 
PPARyl has a similar expression pattern to PPARa while PPARy2 is predominantly 
expressed in adipose tissue where it regulates adipocyte differentiation and fatty acid 
storage (Ren et al., 2002; Hammarstedt et al., 2005). By activating PPARy receptors 
in adipocytes and promoting adipocyte differentiation, these agents are thought to 
promote a redistribution of fat from liver and muscle into adipocytes, thereby 
improving insulin sensitivity (Shulman, 2000). PPARy2 knock-out mice have a 
reduced fat mass, lower lipid accumulation and impaired insulin sensitivity (Zhang et 
al., 2004). PPARy agonists such as rosiglitazone (Avandia) and pioglitazone (Actos) 
have been used clinically to improve insulin sensitivity in type II diabetes. 
Rosiglitazone has been shown to improve insulin sensitivity directly by reducing 
inhibitory serine phosphorylation of insulin receptor substrate-1 (IRS-1) whereas 
pioglitazone improves insulin sensitivity by increasing IRS-2 gene expression 
(Hammarstedt et al., 2005).
Another important class of PPAR agonists are fibrates. They lower plasma 
triglyceride levels by stimulating fatty acid oxidation and reducing apoCIII 
expression and increasing HDL levels by induction o f apolipoprotein Al and 
apolipoprotein All, both effects mediated by binding to PPARa. Fibrates may also 
have hypoglycaemic and thus anti-diabetic effects as a consequence of their 
hypolipidaemic action (Kersten et al., 2000a).
Surgical procedures are currently only recommended for those suffering from severe 
obesity (BMI >40 kg/m'2 or >35 kg/m‘2 with co-morbidities), who have not been able 
to lose weight through other treatment strategies. The three approaches most 
commonly used include laparoscopic gastric banding, gastric bypass or a duodenal 
switch (Wilding, 2007).
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1.1.3.1 Treatment of obesity in dogs
In dogs, dietary therapy and increased level o f exercise is paramount in developing 
an effective weight loss management programme. The reduction in the amount fed 
should be tailored to the individual patient and this is best achieved through the use 
o f a purpose-formulated diet (German, 2006). An important development for the 
pharmaceutical management of body weight in dogs is the recent introduction of 
dirlotapide and mitratapide (EMEA, 2007; Wren et al., 2007). These are microsomal 
triglyceride transfer protein inhibitors, which act primarily within the endoplasmic 
reticulum of enterocytes preventing the formation and release o f chylomicrons into 
the lymphatics. This leads to fat malabsorption resulting in a 10% reduction in 
energy intake (Gossellin et al., 2007).
Following administration, there also appears to be a marked reduction in food 
intake, which accounts for 90% of the total reduction in energy intake, and limited 
evidence suggests that this may be related to the release of peptide YY (PYY) and 
glucagon-like peptide 1 (GLP-1) into the circulation (Wren et al., 2007). PYY is a 36 
amino acid peptide related to neuropeptide Y (NPY) and is co-secreted with GLP-1. 
Administration has been found to decrease food intake in both rodents and humans 
through inhibition o f NPY production in the brain (le Roux & Bloom, 2005). 
Lifestyle management including increasing exercise and behavioural management 
(decrease in begging behaviour) is also essential (Yaissle et al., 2004). Owner 
education is key to achieving long-term weight loss, with one study reporting that 
31% of owners of obese pets considered their dog’s weight to be ‘just right’ (Mason, 
1970).
In human and companion animals, weight loss is accompanied by an improvement in 
glycaemic profile (Larson et al., 2003; Phelan et al., 2007), with a reduction in the 
odds of developing the metabolic syndrome (Phelan et al., 2007). In dogs, as in 
humans, failure to maintain weight loss is a common outcome o f strategies for 
weight reduction (Laflamme & Kuhlman, 1995). Thus, long-term monitoring and 
regular weighing are essential to ensure long-term weight loss (Yaissle et al., 2004; 
German, 2006).
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1.1.4 Obesity as an inflammatory state
Obesity is characterised by a state of chronic low-grade systemic inflammation 
(Trayhurn & Wood, 2004; Fantuzzi, 2005). Levels of inflammatory markers such as 
C-reactive protein (CRP) as well as several proinflammatory cytokines including 
interleukin-6 (IL-6) and tumour necrosis factor-a (TNFa), are raised systemically in 
obese individuals compared with lean subjects (Das, 2001). Weight-loss in these 
subjects has been shown to reverse this low-grade inflammatory state and to improve 
insulin sensitivity (Manco et al., 2007). As will be discussed in section 1.4, adipose 
tissue is an important source of these pro-inflammatory cytokines and acute phase 
proteins (Trayhum & Wood, 2004; Ahima, 2006). Thus adipose tissue itself is 
thought to be an important source of raised circulating levels of these 
proinflammatory cytokines in obesity (Yudkin et al., 1999), providing a link between 
obesity, insulin resistance and the metabolic syndrome (Trayhurn, 2005a; Phelan et 
al., 2007).
One proposed explanation for the increased production o f these pro-inflammatory 
cytokines is that the expansion of WAT in obesity leads to a general state of hypoxia 
with a decreased oxygen perfusion of the tissue (Lolmede et al., 2003; Trayhurn & 
Wood, 2004; Trayhum et al., 2008). This leads to increased levels o f pro- 
inflammatory cytokines in response to the transcription factor hypoxia inducible 
factor-la (HIF-la) (Wood et al., 2007). HIF-la is a heterodimeric protein composed 
of a and p subunits. The p subunit is constitutively expressed, whilst expression of 
the a-subunit is induced under hypoxic conditions leading to a functional protein 
(Wenger, 2002). It is a key transcription factor involved in cellular response to 
hypoxia, and studies have shown both a markedly decreased production of the 
insulin-sensitising hormone adiponectin and increased expression of PAI-1 through 
induction of HIF-la (Chen et al., 2006).
Another proposed mechanism for the observed activation o f inflammatory pathways 
in obesity is a link to the induction of stress in the endoplasmic reticulum, which is 
involved in protein synthesis and post-translational processing, leading to impaired 
insulin signalling (Ozcan et al., 2004). Furthermore, studies in rodents and humans 
have also linked obesity to an increase in the production o f reactive oxygen species 
(ROS) within WAT itself, leading to oxidative stress and elevated production of pro­
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inflammatory markers (Furukawa et al., 2004). It is important to note that the 
different proposals for the basis for the inflammatory response in adipose tissue in 
obesity are not mutually exclusive; where, for example, hypoxia has been reported to 
induce endoplasmic reticulum stress and the generation of ROS (Koumenis et al., 
2002; Carriere et al., 2004).
Macrophages are components o f adipose tissue and actively participate in its 
activities (Fantuzzi, 2005). The number of macrophages present in WAT is directly 
correlated with adiposity and with adipocyte size in both humans and mice, with no 
significant differences between depots (Weisberg et al., 2003; Xu et al., 2003; Curat 
et al., 2004). Despite clear similarities between macrophages and adipocytes having 
been reported, and the fact that preadipocytes can differentiate into macrophages, 
these two cell types are distinct (Cousin et al., 1999).
Experiments have shown that WAT macrophages are derived from the bone marrow, 
indicating that macrophages present in WAT do not derive in situ from 
differentiation of preadipocytes, but rather from circulating monocytes infiltrating 
WAT (Weisberg et al., 2003). This process is augmented in the obese with the 
increased expression of monocyte/macrophage chemoattractant protein-1 (MCP-1) (a 
chemoattractant for monocytes and macrophages) and macrophage migration 
inhibitory factor (MIF) (responsible for increasing the life span of macrophages thus 
prolonging inflammatory responses) by WAT in the obese (Weisberg et al., 2003; 
Dahlman et al., 2005; Skurk et al., 2005a).
Obesity is thought to induce a phenotypic switch in adipose tissue macrophage 
phenotype from an M2 or ‘alternatively activated’ state in lean individuals to an Ml 
or ‘classically activated’ state in the obese, capable of increasing gene expression of 
pro-inflammatory cytokines such as TNFa, which (as will be discussed in section 
1.4.3), is thought to have an important role in the development of insulin resistance 
(Permana et al., 2006; Lumeng et al., 2007; Zeyda et al., 2007). Thus the arrival of 
macrophages is likely to result in a significant amplification of the inflammatory 
state within adipose tissue, involving extensive cross-talk between macrophages and 
adipocytes themselves (Trayhurn, 2005a).
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1.1.5 Study of obesity
The study o f obesity and energy balance has been greatly aided by the use o f several 
rodent models. The obese nature of these rodents may result from spontaneous 
mutations, or deliberately induced via genetic manipulation. The most well 
characterised model used for the study of obesity has been the ob/ob (obese) mouse, 
which displays clinical signs such as type II diabetes mellitus, hyperphagia, and 
profound obesity (Zhang et al., 1994). A recessive mutation of the Ob gene (leptin) 
on chromosome 6 was found to result in the non-functional form of the leptin 
hormone seen in affected mice. The Zucker fa/fa  (fatty) rat and its mouse homolog 
the db/db (diabetic) mouse, also display the obese phenotype as well as type II 
diabetes mellitus. However, in both these models, the defect is due to a point 
mutation in the gene coding for the leptin receptor (Chua et al., 1996).
The yellow Ay (Agouti) mouse develops the obese phenotype, moderate hyperphagia 
and reduced thermogenesis due to over-expression of agouti peptide in the 
hypothalamus leading to antagonism of the melanocortin 4 receptor (MC4R) (Beck,
2000). A splicing defect in the tub gene leads to mature-onset obesity and 
neurosensory deficits in the tubby mouse. Although tubby-like proteins are thought to 
function in intracellular signalling, possibly in relation to insulin metabolism, then- 
function is as-yet not fully understood (Carroll et al., 2004). A mutation in the gene 
coding for carboxypeptidase E in the fa t  mouse results in very low levels o f this 
protein (which is involved in proinsulin and pro-opiomelanocortin (POMC) 
production) and dysregulation of several other neuropeptides, leading to obesity 
despite the absence of overt hyperphagia (Beck, 2000). Further insights into the 
molecular mechanisms underlying the development of obesity have arisen through 
the use of transgenic and knockout mice, in which the aim has been to identify the 
genetic factors that underlie the complex, polygenic inheritance o f obesity 
(Brockmann & Bevova, 2002).
At the time of writing, there are no recognised molecular models of obesity in the 
dog. However, the dog offers distinct advantages over rodents in the study o f obesity: 
firstly, obesity can be induced in the dog through modest changes in dietary 
composition (Kim et al., 2003); second, the dog has a long history o f accurate 
methods for metabolic assessment; third, longitudinal studies may be performed
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allowing multiple physiologic measurements and full control over dietary intake and 
assessment of energy expenditure (Bergman et al., 2007). In addition, dog breeds 
offer all the advantages of geographically isolated human populations but with a 
higher degree of isolation, narrower bottlenecks and much better genealogical 
records (Ostrander & Kruglyak, 2000).
Many of the ~ 400 modern dog breeds also show a high prevalence o f specific 
diseases including cancers, heart disease, epilepsy, cataracts and hip dysplasia 
(Patterson, 2000). Most of these diseases are also commonly seen in the human 
population and the clinical manifestations in the two species are often similar 
(Sargan, 2004). The high prevalence of specific diseases in certain breeds suggests 
that a limited number of loci are involved, making their identification easier in the 
dog than humans (Chase et al., 2002).
In 2005, the dog became the fifth mammal to have its genome fully sequenced 
(Lindblad-Toh et al., 2005). More than 650 million base pairs (>25%) of the dog 
sequence align uniquely to the human genome (Kirkness et al., 2003). The canine 
genome is a powerful tool for identifying genetic factors which contribute to human 
health and disease (Ostrander & Comstock, 2004) (Mellersh, 2007). It is hoped that 
over the next few years advances in several areas of disease research, including that 
o f the inheritance of common skin diseases such as atopic dermatitis in both dogs 
and humans, will help to improve the understanding of the genetic basis of disease 
(Pennisi, 2007).
1.2 Energy balance and body weight regulation
On a short term basis (hour-to-hour), energy intake and expenditure may not match. 
This is why it is necessary to have short-term storage compounds such as glycogen 
and triacylglycerol (TG). In the long term, if energy intake consistently exceeds 
energy expenditure, triglycerides (TGs) accumulate in WAT leading to obesity.
1.2.1 Energy intake
In order to maintain a relatively constant body weight, intake should be balanced 
over the long term by an equal amount of energy expenditure. Failure to do so, will
17
result in an imbalance, leading on one hand to weight gain (in the event of excessive 
intake, as outlined above) and on the other hand to wasting and cachexia (if there is a 
net energy deficit). Energy is used for basic metabolic processes (basal metabolic 
rate, BMR) and also for the performance of physical activity. This mechanism of 
long-term storage is vital for the survival o f several species through hibernation and 
migration (Speakman et al., 2007).
For the majority of adult animals, energy intake is normally closely matched to 
energy expenditure leading to the maintenance of a stable body weight (Frayn,
2003). Therefore, a period of weight gain due to overfeeding would be compensated 
for by a subsequent reduction in meal size, inducing weight loss until the original 
body weight is regained. Conversely, depletion of fat stores due to decreased intake 
would be reversed by increased intake once food is again freely available. This led to 
the concept of a ‘set-point’ for body weight originally suggested by the British 
physiologist G.C. Kennedy, in the 1950s, linking central control of energy intake by 
the brain with the body’s fat stores (Kennedy, 1953).
1.2.1.1 Central control of appetite
Over half a century ago, the hypothalamus emerged as an important site for appetite 
regulation. This was supported by studies showing that lesions o f specific 
hypothalamic areas generate marked and consistent effects on the regulation of body 
weight. For instance, bilateral lesions of several of the mediobasal hypothalamic 
nuclei, including the arcuate nucleus (ARC), the ventromedial nucleus (VMN) or 
paraventricular nucleus (PVN) leads to marked hyperphagia, weight gain, decreased 
physical activity and neuroendocrine abnormalities such as hypogonadism (Stanley 
et al., 2005). Conversely, lesions of the lateral hypothalamic area (LHA) induce 
hypophagia, increased energy expenditure and weight loss (McMinn et al., 2000).
More recent studies suggest that these areas contain peptide systems which are 
important in body weight regulation. Thus, neuronal circuits signalling through 
specific neuropeptides are vital in the regulation o f energy homeostasis. 
Identification of these central effectors is an ongoing process that is accomplished, in 
part, by quantifying changes in expression and release of neuropeptides in candidate
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hypothalamic areas in response to interventions that alter energy balance, for 
example food restriction and re-feeding (McMinn et a l, 2000).
Within the ARC, there are two distinct subpopulations o f neurones associated with 
food intake. One has a medial location and expresses orexigenic peptides 
neuropeptide Y (NPY) and agouti-related peptide (AgRP), whilst the other has a 
more lateral location and express anorexigenic peptides cocaine and amphetamine- 
related transcript (CART) and pro-opiomelanocortin (POMC). Peripheral signals, 
particularly leptin, act on these neurones, which project to secondary hypothalamic 
nuclei and the CNS, where the release o f further peptides is modulated (Stanley et 
a l,  2005).
The most potent orexigenic neuropeptide currently known is NPY, with central 
administration resulting in marked hyperphagia and chronic obesity. There are 
several known NPY receptors all of which are expressed in the hypothalamus. Whilst 
NPY may mediate its effects via a combination of these receptors, the Y i and Y5 
subtypes appear to be the most important with regard to the regulation of energy 
homeostasis. NPY has recently been classified as an adipokine being expressed and 
secreted by human adipocytes (Kos et a l, 2007). Adipocyte derived NPY is thought 
to mediate a reduction in leptin secretion and thus may have implications for the 
central control of appetite (Kos et al., 2007). AgRP and NYP neurones are co­
localised within the ARC with AgRP acting as a potent agonist to both melanocortin 
3 and 4 receptor (MC3R and MC4R), thereby antagonising the effects of a-MSH (a- 
melanocyte stimulating hormone) a potent anorexigenic peptide (Stanley et a l,
2005).
There is increasing evidence that the endocannabinoid system plays a central role in 
regulating metabolism and body composition by enhancing the central orexigenic 
drive and increasing peripheral lipogenesis. The cannabinoids exert their 
pharmacological action through the interaction with specific receptors CBi and CB2 
(cannabinoid receptors 1 & 2). The CBi receptors are primarily located in the brain 
and adipose tissue, but are also found in the myocardium, vascular endothelium and 
sympathetic nerve terminals, while CB2 receptors are primarily located in lymphoid 
tissue and peripheral macrophages (Gelfand & Cannon, 2006). Both
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endocannabinoid receptors and their ligands are present in all tissues which play an 
important role in the regulation o f food intake. However, it is the CBi receptor which 
is mainly responsible for the orexigenic effect of endogenous cannabinoids (Gelfand 
& Cannon, 2006). Antagonism of this receptor by specific drugs such as rimonabant 
leads to hypophagia and weight loss, and as mentioned earlier, it is currently 
marketed for the treatment of human obesity. Other orexigens include MCH 
(melanocortin concentrating hormone), orexin-A, galanin and nitric oxide (Stanley et 
al., 2005).
In contrast to orexigenic peptides, anorexigenic peptides suppress appetite, and these 
include a-MSH, which is derived from POMC expressed by the ARC neurones, and 
is the main endogenous ligand for MC3R and MC4R (McMinn et al., 2000) (Fig. 
1.2). CART has been found to be co-expressed with a-MSH in the lateral ARC. Food 
deprivation induces a marked decrease in CART mRNA within the ARC, while 
peripheral administration o f leptin has the opposite effect. Other anorexigenic 
neurotransmitters include serotonin and glucagon-like peptide 1 (GLP-1),
neurotensin and corticotrophin releasing factor (CRF) (Wilding, 2002).
The criteria defining candidates for the long-term hormonal control of appetite 
regulation (Schwartz & Porte, 2005) include:
• Circulating plasma levels should be proportional to body fat content
• The factor should be able to enter the brain in proportion to its circulating 
level
• Administration o f the signal would have anorexigenic effects, whilst a deficit 
of the signal should have the opposite effect
• A signal transduction pathway mediating the effects of the signal should be 
present in areas of the brain known to control appetite.
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Figure 1.2 Neuroanatomical model representing regulation of food
intake and body weight
Leptin secrected from WAT and insulin from pancreatic P-cells both circulate in 
proporition to adipose stores and both hormones entre the CNS through a saturable 
uptake mechanism, the blood brain barrier. Once in the CNS, they bind then- 
receptors located on neurones of the ARC and alter the expression of neuropeptides 
responsible for the regulation o f energy balance; anabolic neurones (NPY/AgRP) are 
inhibited, and catabolic neurones (a-MSH/CART) are upregulated. PVN, 
praventricular nucleus; DVC, dorsal vagal complex; LHA, lateral hypothalamus; 
ARC, arcuate nucleus; PBN, parabrachial nucleus.
2 1
Insulin can be considered as one such signal since plasma levels rise in adiposity. 
Binding sites for insulin have been localised to nuclei of the brain associated with 
energy homeostasis and a saturable transport system that carries insulin from the 
circulation into the brain has been identified. The binding of insulin to its recepots 
centrally leads to appetite suppression and, therefore, to a decrease in energy intake. 
Although insulin remains a candidate humoral adiposity signal, several observations 
suggest that additional peripheral signals such as leptin are also vital to body weight 
regulation (McMinn et al., 2000). Leptin has pervasive effects on the hypothalamic 
control of food intake by upregulating the expression of anorexigenic neuropeptides 
and downregulating that of orexigenic neuropeptides (Trayhurn & Bing, 2006), these 
will be discussed in greater detail in section 1.4.1
1.2.1.2 Peripheral signals
The long-term regulation o f food intake, involves the hypothalamic effects of insulin 
and leptin. In contrast, short-term control o f food intake on a meal-to-meal basis 
involves neural and humoral signals from the gastrointestinal tract and liver 
generated in response to nutrient intake (McMinn et al., 2000). Generally, these 
signals serve to produce satiety, bringing about the end of a meal. One of these 
hormones is cholecystokinin (CCK). This is released from the duodenum after food 
ingestion and acts to enhance satiety both at a local level by acting on CCK-A 
receptors, and centrally within the hypothalamus through CCK-B receptors (Wilding,
2002). Peptide YY (PYY) is secreted from L cells in the intestine, its level of release 
being closely correlated with the level o f calorie intake. Administration o f PYY has 
been shown to reduce food intake in both rodents and humans, and it may also act on 
NPY neurones in the ARC inducing anorexia (Stanley et al., 2005).
Ghrelin is a potent orexigenic factor produced by gastric oxyntic cells and is the 
natural ligand of the growth hormone secretagogue receptor (GHS-R). Ghrelin 
secretion rises during fasting and is suppressed following feeding. Administration of 
ghrelin strongly stimulates endogenous growth hormone release centrally through 
binding to hypothalamic and pituitary GHS-R (Espelund et al., 2005). Ghrelin is 
derived from a prohormone by posttranslational processing. It has been established 
that another peptide exists, that is also derived from proghrelin, and whose effects on 
appetite are opposite to those of ghrelin; this peptide has been named obestatin
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(Zhang et al., 2005). Obestatin appears to act as an anorexic hormone decreasing 
food intake, gastric emptying and jejunal motility (Zhang et al., 2005). Other satiety 
hormones produced by the gut include pancreatic polypeptide (PP), bombesin and 
glucagon (Stanley et al., 2005).
1.2.2 Energy expenditure
Energy is continuously being expended over a 24 h period. Some of this energy 
represents requirements for BMR, physical activity and diet induced thermogenesis. 
The BMR is closely related to the amount of non-fat tissue or lean body mass. The 
larger the fat free mass, the higher the BMR. BMR is also regulated by hormones, 
primarily thyroid hormone. During conditions of starvation or food deprivation 
thyroid hormone levels fall and BMR decreases (Frayn, 2003). As mentioned earlier 
(see section 1.1.4) increasing energy expenditure, by increasing levels o f exercise, 
goes hand-in-hand with methods of decreasing food intake used to treat obesity.
1.2.2.1 Thermogenesis
Thermogenesis (heat production) plays a role in all metabolic processes and consists 
o f two major categories, obligatory and facultative (Himms-Hagen, 2001). 
Obligatory thermogenesis is the equivalent of BMR, whereas facultative 
thermogenesis represents heat production which can be switched on and off 
according to different circumstances. Facultative thermogenesis can be further 
subdivided into heat generated by shivering of skeletal muscles in response to cold 
(cold-induced shivering), non-shivering thermogenesis, voluntary activity (exercise), 
non-exercise activity (fidgeting) and diet-induced thermogenesis. Adaptive 
thermogenesis occurs in response to changes in environmental temperature or diet, 
with the aim o f maintaining body temperature or energy homeostasis. Adaptive 
thermogenesis has a genetic component, and can compensate for the prescribed 
energy deficit in weight loss programs (Major et al., 2007).
Non-exercise activity thermogenesis is argued to be a valuable component of energy 
expenditure in humans, especially for those living a sedentary lifestyle. It has been 
proposed to be a key factor in the inter-individual variation in human susceptibility to 
gain weight, as activation of non-exercise induced thermogenesis in response to 
higher energy intake may help to dissipate excess energy and prevent weight gain
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(Levine, 2004). Diet-induced thermogenesis is thought to have evolved as a 
mechanism for regulating energy balance and has been shown to take place in brown 
adipose tissue (BAT) (Rothwell & Stock, 1997). As with non-exercise induced 
thermogenesis, individual variation in the capacity to activate diet-induced 
thermogenesis (although not necessarily through BAT), may play a role in the 
propensity to develop obesity. Other mechanisms of thermogenesis have, of course 
been proposed; including substrate cycles and sodium pump (Himms-Hagen, 1981; 
Braun et al., 1996).
1.2.2.2 Brown adipose tissue
Mammals contain two different types of adipose tissue: white and brown, which 
form part of ‘the adipose organ’ (Cinti, 2005). These have distinct anatomy and 
physiology and are organised in distinct depots, which can be broadly categorised as 
visceral or subcutaneous. BAT is specialised for the generation o f heat through non­
shivering thermogenesis and, in this tissue, the stored lipid droplets serve primarily 
as a fuel for the production of heat (Trayhum, 2007). Compared with WAT, BAT has 
a rich vascular supply, dense with multiple capillaries. This, in combination with 
densely packed mitochondria at the ultrastructural level account for its ‘brown’ 
colour.
Unlike white adipocytes, brown adipocytes have a centrally located nucleus and 
lipids within brown adipocytes are organised into multiple smaller ‘multilocular’ 
droplets (Avram et al., 2005). Noradrenergic fibres in WAT are mostly confined to 
the capillary wall, whereas in BAT they directly interface with the plasma membrane 
of individual adipocytes (Cinti, 2005). Increased sympathetic activity in BAT results 
in both hypertrophic and hyperplastic expansion of the tissue, combined with an 
increase in blood flow and utilisation o f lipid and carbohydrate substrates for 
oxidative metabolism and increased heat production per se (Avram et al., 2005).
The thermogenic ability of BAT has several physiological functions. The tissue was 
originally observed in hibernating mammals, being referred to as the ‘hibernation 
gland’ (Cannon & Nedergaard, 2004). In rodents, energy balance and body weight 
are subject to regulation by BAT thermogenesis in relation to diet-induced 
thermogenesis. Rats fed on a palatable ‘cafeteria’ diet increase their BAT activity
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and do not become obese despite having a higher energy intake (Rothwell & Stock, 
1983). Furthermore, experiments on transgenic mice have shown that over-activity o f 
BAT results in resistance to obesity. However, hypoactivity of the tissue does not 
necessary lead to the obesogenic phenotype (Klaus, 2001a).
BAT is also present in humans where its development begins at around the 20th week 
of pregnancy and continues until shortly after birth. In the neonate and newborn, 
BAT can be found in several areas including: the interscapular region (shoulder), 
perivascularly, in the strap muscles o f the neck, surrounding the abdominal aorta, the 
pancreas, adrenal glands and kidneys (Ricquier & Bouillaud, 2000). In small 
mammals, such as rodents, BAT persists throughout life. However, in large 
mammals and humans, until recently, it was thought that all brown fat underwent 
morphologic transformation to white adipocyte morphology and consequently that 
there were no discrete collections o f BAT in human adults (Avram et a l, 2005). 
Recent evidence from studies using fluorodeoxyglucose positron emission 
tomography to trace tumour metastasis has identified BAT, with prevalence in the 
range of some tens of percent in the adult human population. Furthermore, as 
expected, BAT activity in man was found to be stimulated by cold and sympathetic 
nervous system (SNS) activity (Nedergaard et a l, 2007).
1.2.2.3 Mitochondrial uncoupling proteins
The thermogenic activity o f BAT is mediated by the uncoupling of mitochondrial 
respiration. In BAT, the proton electrochemical gradient generated during the 
production of ATP by mitochondrial Fo-Fi ATPase during p-oxidation o f fatty acids 
is dissipated by a protein uniquely expressed by BAT; uncoupling protein 1 (UCP-1) 
(Dulloo & Samec, 2000). The net effect of activation o f UCP-1 by the SNS, cold 
stimulus or diet is that substrate oxidation is effectively uncoupled from 
phosphorylation, with a resultant increase in heat production. Thermogenesis by 
BAT is also subject to hormonal control by insulin, thyroid hormone and possibly 
leptin via the SNS (Ricquier & Bouillaud, 2000; Klaus, 2001a). Brown adipocytes, 
including those from neonatal dogs, express a combination o f adrenoceptor isoforms 
ai, Pi, P2 and p3 , with P3-adrenoceptors being the most abundant and <X2 being 
completely absent in the case o f the dog (Champigny et a l, 1991; Lin & Li, 2004).
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The SNS acts on the tissue mainly via these receptors to induce UCP-1 gene 
expression and thereby modulate thermogenesis (Bray, 2004).
Over the past decade there has been a rise in interest in the roles of UCP 
homologues. These are members o f the same UCP family based on their high 
sequence homologies and include UCP-2, UCP-3, UCP-4 and BMCP-1. Unlike 
UCP-1, which is expressed only in BAT, UCP-2 is expressed ubiquitously and UCP- 
3 is highly expressed in skeletal muscles and BAT, whereas UCP-4 and BMCP-1 are 
expressed solely in the brain (Dulloo & Samec, 2000). Despite the initial enthusiasm 
for the hypothesis that by analogy to UCP-1 in BAT, these UCPs may mediate 
thermogenesis in other tissues and thus control adaptive thermogenesis in sites other 
than in BAT, this is unlikely and their role in metabolic regulation is not yet fully 
understood (Ricquier & Bouillaud, 2000).
1.3 White adipose tissue
Obesity is characterised and defined by the expansion in adipose tissue mass. 
Adipose tissue can also be found diffusely associated around or within organs and 
also in close association with blood vessels (Cinti, 2001). Whereas BAT utilises TGs 
for the generation of heat through non-shivering thermogenesis, WAT stores TGs 
providing a long-term fuel reserve (Trayhum, 2007). Discrete depots are 
predominantly composed of either white or brown fat, but both white and brown 
adipocytes may be found in any particular depot, which may reflect the ability o f 
mature adipocytes to trans-differentiate between the two types (Cinti, 2005).
1.3.1 Morphology of white adipose tissue
Mature adipocytes comprise only one third of adipose tissue mass. The remaining 
two thirds is composed of a combination o f small blood vessels, nerve tissue and 
fibroblasts collectively referred to as the stromal vascular (SV) fraction (Cinti, 2001). 
In addition, as alluded to earlier, adipose tissue may be infiltrated by macrophages, 
particularly in obesity (Weisberg et al., 2003). Histologically, white adipocytes are 
spherical and much larger than their brown counterparts ranging in diameter from 
15-150 pm (Cinti, 2001). Lipids within white adipocytes are normally organised 
within one large ‘unilocular’ droplet which occupies the majority of the intracellular
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space, compressing the cytoplasm and the nucleus into a thin visible rim (Avram et 
al., 2005). They also have fewer, less well-developed mitochondria when compared 
to brown adipocytes (Cinti, 2005). WAT is well-vascularised and receives both 
sympathetic and sensory innervation (Cinti, 2005). Recently, evidence has been 
presented for a parasympathetic supply to WAT (Kreier et al., 2002; Romijn & 
Fliers, 2005). However, this has been seriously questioned with strong counter­
evidence being presented (Giordano et al., 2006).
1.3.2 Innervation of white adipose tissue
The SNS has regulatory influences on a wide range o f WAT functions. In adipose 
tissue, catecholaminergic effects appear to be modulated by a.2 and p-adrenergic 
receptors, with P3 being the key subtype present in rodents (Rayner & Trayhurn,
2001). Activation of P-receptor subtypes stimulates lipolysis, but the degree to which 
each subtype is involved in the lipolytic process varies according to fat pad, species, 
gender and degree of obesity (Lafontan et al., 1995). The 012-acrenoceptor, like Pa- 
adrenoceptors, is G-protein coupled but decreases rather than increases adenyl cylase 
levels (Rayner, 2001). Therefore, 012-adrenoceptor stimulation may be expected to 
have the opposite effects to P3-receptor stimulation.
Thus the effectiveness o f catecholamine-stimulated lipolysis depends on the balance 
between p- and 012-adrenoceptor activation. That is, when P-adrenoceptor activation 
predominates, lipolysis is stimulated via activation of hormone sensitive lipase 
(HSL). Conversely, when a 2 -adrenoceptor activation predominates lipolysis is 
inhibited (Bartness & Bamshad, 1998). The P3-adrenoceptor is the predominant P- 
subtype in adipose tissue of rodents (although not in humans were they have been 
estimated to be only 20% of the total population of P-adrenoceptors) (Rayner, 2001). 
In dogs, all 3 adrenoceptor subtypes have been detected and in a manner similar to 
humans, lipolysis appears to be mainly mediated thorough Pi and P2 subtypes with 
activation of the P3-subtype only occurring at higher levels o f catecholamine 
stimulation (Galitzky et al., 1993).
Studies in rodents have shown that sympathetic denervation results in increased fat 
pad weight, while stimulation of sympathetic nerves to WAT leads to fatty acid 
secretion (Bartness & Bamshad, 1998). The SNS has also been strongly implicated in
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the modulation of fat cell number. In vivo studies using Siberian hamsters have 
demonstrated that denervation o f inguinal subcutaneous WAT depots promotes 
increases in fat cell number without affecting fat cell size. These differences in 
adipocyte proliferation between depots have been linked to neuroanatomical origins 
and function of the SNS innervation to each individual depot (Youngstrom & 
Bartness, 1998). The SNS has been shown to modulate the secretion of key proteins 
by adipocytes including that of the adipocyte hormone leptin (Trayhurn et al., 1995). 
This will be discussed in greater detail in section 1.4.1.
1.3.3 White adipose tissue function
As demonstrated by various models of lipodystrophy, white adipose tissue is 
essential to the maintenance of energy and metabolic homeostasis, whereby the 
absence of WAT leads to marked insulin resistance, and other clinical signs 
including hypertrophy of skeletal and cardiac muscle as well as hepatic cirrhosis 
(Ganda, 2000). Over the past decade, the idea of WAT acting merely as a storage 
depot for TGs has become obsolete. With the discovery o f the hormone leptin in 
1994 (Zhang et al., 1994), there has been an appreciation o f WAT as an endocrine 
organ whose function in this respect will be discussed in detail in section 1.4.
1.3.3.1 Lipid metabolism
After a meal, adipose tissue buffers digested nutrients in the form of fatty acids 
stored as TG. This provides a reservoir of energy stores which can be utilised in 
times o f fasting. The energy density o f lipid is twice that of carbohydrate or protein 
(39.1 kJ/g compared to 15.4-17.5 kJ/g for protein and carbohydrate) and because, in 
contrast to carbohydrates, TGs can be stored with little associated water, lipid storage 
is 8- 12-fold more efficient in energy terms compared to either carbohydrate or 
protein (Klaus, 2001b). In states of positive energy balance, lipoprotein lipase (LPL) 
produced by adipocytes is exported to the capillary endothelium, where hydrolysis of 
TGs in lipoprotein particles occurs releasing fatty acids which can diffuse into the 
interstitial space reaching the adipocyte. The activity o f LPL in adipose tissue is 
stimulated by insulin. Chronic treatment of human adipocytes with insulin has been 
shown to stimulate both lipolysis and LPL protein expression (McTeman et al., 
2002b). In vivo, adipose tissue LPL activity is mediated in response to a post­
prandial elevation in insulin and blood glucose concentration.
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In states of negative energy balance, energy is released from fat stores by lipolysis by 
HSL. The activity of HSL is very closely regulated by phosphorylation brought about 
by raised levels of cyclic adenosine 3 ’, 5’-monophosphate (cAMP), in response to 
adrenaline (systemically) or noradrenaline (released by sympathetic nerves) (Frayn,
2003). Although the SNS is the major regulator of lipolysis in WAT, there is also 
regulation via nutrient and hormonal signals, including glucose and in&a^^(which 
both decrease the activity o f HSL) (Ahima & Flier, 2000) (Bartness & Balkshad, 
1998). The increase in insulin-induced lipolysis in human adipocytes is not explained 
by a concomitant rise in HSL expression. This may explain, in part, why 
hyperinsulinaemia coexists with increased circulating non-esterified fatty acids and 
increased adiposity in humans suffering from obesity and type II diabetes mellitus 
(Trayhurn et al., 2008) (McTeman et al., 2002b).
1.3.3.2 Glucose metabolism
Adipocytes contribute to glucose metabolism in several ways. First, adipose tissue, in 
conjunction with heart and skeletal muscle, are the main tissues to express the 
insulin-dependent glucose transporter (GLUT 4). Once within the adipocyte, glucose 
provides the substrate for de novo fatty acid and glycerol synthesis (lipogenesis). 
Second, increased lipolysis o f TGs in adipocytes generates increased levels of 
circulating free fatty acids. In the liver, these have a negative regulatory role on 
several important functions including hepatic clearance of insulin and insulin- 
mediated suppression of hepatic glucose production, while at the same time exerting 
a positive effect on the rate of gluconeogenesis. The net effect of free fatty acids in 
the liver, therefore, results in the promotion o f increased plasma glucose 
concentrations (Avram et al., 2005).
1.3.3.3 Other functions of white adipose tissue
Additional functions of adipose tissue include thermal insulation which is 
particularly important in minimising heat loss in aquatic mammals. Adipose tissue 
also affords a degree o f mechanical protection when interposed between body 
structures and soft tissues; an example is the eye socket area. Fat stores can also act 
as a source of ‘metabolic water’ (which is a bi-product o f P-oxidation) (Klaus, 
2001b).
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1.3.4 Adipocyte differentiation and development
Adipose tissue mass can be increased in one of two ways: hypertrophy of existing 
adipocytes by increased intracellular lipid accumulation or hyperplasia of adipose 
depots by an increase in the number of mature adipocytes (Wabitsch et al., 2003). 
The latter is achieved by inducing differentiation of pre-existing preadipocytes into 
mature adipocytes (Gregoire, 2001). These preadipocytes (fibroblast-like cells 
committed to becoming adipocytes) along with pleuripotent precursor cells found in 
adipose tissue can be induced to differentiate into mature adipocytes. Unlike many 
other cell types, this ability to increase the quantity of mature fat cells is retained into 
adulthood (Gregoire, 2001).
The process of adipocyte differentiation (adipogenesis) is complex and highly 
controlled. At the cellular level, committed preadipocytes have to withdraw from the 
cell cycle, undergoing a period of growth arrest, before conversion to mature 
adipocytes. This is normally achieved through contact inhibition. However, contact 
inhibition per se is not a pre-requisite for adipogenesis since cells plated at low 
densities in serum-free medium still undergo differentiation (Gregoire, 2001). 
Differentiation is also dependent on hormonal and nutritional signalling, where 
insulin (in supra-physiological concentrations)^/£erves to accelerate lipid 
accumulation (Gregoire et a l, 1998). The onset of differentiation is associated with 
the promotion of gene expression and the initiation of a complex transcription 
cascade. Two families of transcription factors, CAAT/enhancer binding proteins a, p 
and 8 (C/EBP-a and C/EBP-P and C/EBP8) and the PPAR family o f transcription 
factors (mainly PPARy) have been shown to activate transcription of adipocyte 
specific genes and are involved in the growth arrest necessary for adipocyte 
differentiation (Gregoire et al., 1998).
During adipogenesis, stimulation of C/EBP-P and 8 occur early in clonal expansion 
in response to exposure of preadipocytes to adipogenic hormones (Lane et al., 1999). 
These then induce the expression of PPARy, leading to the production of PPARy 
ligands. Once PPARy has been activated, it then controls terminal adipogenesis by 
inducing expression of C/EBPa, which is required for the production of adipogenic 
genes and terminal differentiation (Farmer, 2005).
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1.3.5 Adipose tissue and adipocyte studies
In vivo studies enable the full integrated physiological response to a stimulus to be 
characterised. Certain investigations, such as response to fasting/feeding or cold 
exposure, can only be conducted using living animals. Studies investigating the 
effect of compounds in vivo require the use of a range of techniques for the 
administration of different agents including oral administration, internal sampling via 
cannulae, and direct injection.
One key disadvantage of in vivo studies is that it can be problematic to identify the 
specific causal agent that leads to an effect, as certain stimuli may be acting directly 
or indirectly via downstream mediators. In vitro studies have the advantage in this 
regard, where if an effect is observed it is likely to be due to a specific and direct 
response to the applied stimulus. Disadvantages of in vitro work include the lack of 
interaction between cultured cells and endocrine and neural signals which would 
occur in the whole animal, and the absence of paracrine interactions with other cell 
types. In addition, substrate availability and clearance of metabolites is likely to 
differ in culture from that provided by the vascular system. As far as possible, 
treatment agents used in vitro are used at concentrations likely to be found at the 
cellular level in vivo.
Currently, three main in vitro systems are in use for investigating adipocyte 
physiology: isolated mature adipocytes, primary culture of preadipocytes and clonal 
cell lines. Mature adipocytes can be harvested from freshly dissected adipose tissue 
by collagenase digestion and once isolated, these cells are fragile and can only be 
maintained in culture for a short period (up to 48 h) (Fain et al., 2003). It can be 
argued that this is the closest to the in vivo situation, as it involves only limited 
intervention in transferring the cells from the animal to the culture system. However, 
the in vitro culture of primary adipose cells, at least in rodents, may be associated 
with down-regulation o f GLUT4 mRNA and the induction o f many genes encoding 
inflammatory mediators such as TNFa and IL-6 (Ruan et al., 2003). The mechanisms 
underlying these alterations are unknown, but there appears to be a strong link 
between the induction of these proinflammatory mediators and collagenase digestion 
(Ruan et al., 2003).
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Adipose cells differentiate well in culture, and in vitro differentiation leads to 
activation of most of the same set of genes characteristic of adipose tissue in vivo 
(Spiegelman et al., 1993). This makes preadipocyte conversion an attractive model 
for the study of mammalian cell differentiation. Both primary culture and cell lines 
involve the differentiation of preadipocytes into mature adipocytes. There are three 
main agents (which form part of the ‘adipogenic cocktail’) used to induce 
differentiation in vitro; insulin, dexamethasone (representative of natural 
glucocorticoids) and 3-isobutyl-1-methylxanthine (IBMX; acts to raise intracellular 
concentrations of cAMP) (Gregoire, 2001). In addition, the use of PPARy agonists, 
has also been adopted in several protocols as part of the adipogenic cocktail for in 
vitro primary adipocyte cell culture (Hauner et al., 2001; Eisele et al., 2005).
Primary culture involves the isolation of fibroblastic preadipocytes from adipose 
tissue, which are induced to differentiate into mature adipocytes (Hauner et al., 
2001). These cells can then be maintained in culture for a period of 2-4 weeks. A 
drawback to this technique is that a significant quantity of starting material is 
required, as preadipocytes make up only a small portion of WAT. In addition, careful 
isolation is needed in order to separate preadipocytes from fibroblasts and other 
components o f the SV fraction. Cells in primary culture tend to have a low 
proliferative capacity and repeated subculture results in a rapid decline in their ability 
to differentiate into mature adipocytes. However, one significant advantage of the 
primary culture system is that it is only one step removed from the culture o f mature 
adipocytes, and as much may be just as reliable (Hauner et al., 2001).
Clonal cells lines such as murine 3T3-L1 and 3T3-F442A cells spontaneously arrest 
growth at confluence and can be induced to differentiate after treatment with 
adipogenic compounds (Spiegelman et al., 1993). These have several advantages 
over cells isolated from tissue in that being immortal allows an endless supply of 
cells, as long as they are passaged and stored correctly. Clonal lines also provide a 
homogeneous cell population and therefore are more likely to yield consistent and 
reproducible results. One disadvantage is that due to genetic modifications which had 
to take place in order for them to gain their immortality (many such cell lines are
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derived from tumour cells); their properties may differ from those isolated from 
tissues and cultured using primary culture.
Although the use of murine clonal cell lines such as the 3T3-L1 and 3T3-442A is 
well established, until very recently, few studies have described the use of such cell 
lines in human preadipocytes. One such study involves the generation of a human 
preadipocyte clonal cell line, ‘human multipotent adipose-derived stem cells’ 
(hMADS). These have been shown to display the key features of human adipocytes 
once differentiated in vitro (Rodriguez et al., 2004; Dani, 2006). A human 
preadipocyte cell strain has also been shown to be a useful in vitro tool in the study 
o f adipocyte metabolism. These cells are derived from the subcutaneous white 
adipose tissue of an infant with Simpson-Golabi-Behmel syndrome (SGBS). This is 
characterised by generalised tissue overgrowth and clinically affected individuals 
suffer from expanded subcutaneous WAT depots and other changes including a 
disproportionately large head with prominent features (Wabitsch et al., 2001). Due to 
their lack of immortality these cells cannot be referred to as a cell line. However, 
they show a high capacity for adipose' differentiation over many generations and the 
differentiated cells are functionally indistinguishable from human adipocytes 
differentiated in primary culture (Wabitsch et al., 2001).
At present no canine adipose tissue cell lines have been characterised. Thus to date, 
work on canine adipocytes in vitro has involved the use of a primary cell culture 
system. Two methods currently in the literature describe the culture of primary 
preadipocytes from various depots, including visceral (omental, perirenal and 
gonadal) and subcutaneous (abdominal and inguinal-subcutaneous) (Wu et al., 2001; 
Eisele et al., 2005). Canine preadipocytes in primary culture can be induced to 
differentiate in a preconfluent state (Eisele et al., 2005), in a similar manner to 
human primary cell culture (Hauner et al., 2001). Therefore, cellular interaction does 
not appear to be a pre-requisite for differentiation. Both systems also make use of 
different ‘adipogenic cocktails’ with cortisol and the PPARy agonist rosiglitazone 
used in one system in a similar manner to that used for human primary cell culture 
(Hauner et al., 2001; Eisele et al., 2005). While the use o f a non-steroidal anti­
inflammatory drug (NSAIDs) indomethacin is present in the adipogenic cocktail of 
the other published protocol (Wu et al., 2001). Both systems appear to be equally
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successful in terms of inducing preadipocyte differentiation, with cells from the 
subcutaneous inguinal depot being the most susceptible to differentiation in vitro 
(Wu et al., 2001).
1.4 Endocrine function of white adipose tissue
Although once considered a passive fuel depot, adipose tissue is now recognised as 
an active endocrine organ that communicates with the brain and peripheral tissues by 
secreting a wide range of hormones and protein factors, collectively termed 
adipokines (Trayhum & Beattie, 2001; Trayhum, 2005c; Ronti et al., 2006). 
Previously, these secreted proteins were referred to as adipocytokines (Fasshauer & 
Paschke, 2003; Pittas et al., 2004). This is potentially misleading as it might be taken 
to infer that all adipocyte-secreted proteins are in fact cytokines, which is not the 
case. More than 50 o f these different proteins have now been characterised; the 
‘adipokinome’, together with lipid moieties released by the adipocyte, constitute the 
‘secretóme’ of the fat cell.
This description is restricted to proteins secreted by adipocytes themselves and not 
by WAT as a whole, as this would include proteins secreted by other cells types 
found in WAT such as macrophages (Trayhurn & Wood, 2004).
It is important to note that, quantitatively, the main components of the adipocyte 
secretóme are fatty acids from TG lipolysis. Cholesterol and retinol are two lipid 
moieties secreted into the circulation by white adipocytes and, although the tissue is 
unable to synthesise steroids de novo, WAT expresses the enzymes necessary for the 
conversion of androstenedione to testosterone, androgens to oestrogens and oestrone 
to oestradiol. These are, therefore, also secreted by white adipocytes (Trayhurn & 
Beattie, 2001). The current view o f the key biological function of WAT is 
summarised in Fig. 1.3. This includes key examples of its secretory products which 
will be discussed in further detail in later sections.
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Figure 1.3 Evolving views of the biological functions of white adipose
tissue
Inert storage depot
Fatty acids Glucose
Secretory & endocrine gland
A p p e tite  &  e n e rg y  b a lan ce
Leptin, andiponectin C y to k in es
H ae m o s ta tic  &  h a e m o d y n a m ic  A c u te  p h ase  p ro te in s
fa c to rs  Serum amyloid -A,
Anglotenslnogen, PAI-1 Metallothionein,
haptoglobin
Adaptedfrom  (Trayhurn & Wood, 2004; Romijn & Fliers, 2005)
Adipocytes were previously considered to be inert storage depots releasing fuel as fatty acids 
and glycerol in time of fasting or starvation. It has become increasingly clear that adipocytes 
are endocrine glands which secrete important hormones, cytokines, vasoactive substances 
and other peptides. This figure outlines the range o f such proteins secreted from WAT, 
although it does not aim to be a comprehensive list. Many o f the proteins mentioned will be 
discussed in detail in the following sections. TNFa, tumour necrosis factor-a; IL, interleukin; 
PAI-1, plasminogen activator inhibitor-1; TGFp, transforming growth factor-P; MIF, 
macrophage migration inhibitory factor; MCP-1, monocyte chemoattractant protein-1.
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1.4.1 Leptin
The identification of the Ob (obese) gene and its protein product, leptin (also known 
as the OB protein) in 1994 (Zhang et al., 1994), has been pivotal in the development 
o f the current understanding o f WAT as an endocrine organ (Trayhum & Beattie, 
2001). Leptin (Greek leptos, meaning thin or small), is synthesised as an 18 kDa pro­
hormone, which is cleaved to yield a 16 kDa mature ‘cytokine-like’ protein. 
Although quantitatively, WAT is the main site of Ob gene expression and leptin 
secretion (both exclusively by differentiated adipocytes), leptin is also produced by 
several cell types in other organs. For example, in follicular papilla cells o f hair 
follicles (Iguchi et al., 2001), in the gastric cells (Cinti et al., 2000), BAT (Moinat et 
al., 1995), the placenta (Hoggard et al., 1997a) and skeletal muscle (Wang et al., 
1998), and in oestoblasts (Reseland et al., 2001). In each o f these cases, it is probable 
that the effect of leptin is of a local (autocrine/paracrine) nature rather than endocrine 
(Trayhurn & Bing, 2006).
Despite the range of tissue specific sites of leptin synthesis, WAT is quantitatively 
the main site o f production of the hormone and is thus the primary determinant of 
circulating levels. This is reflected in the close link between the degree o f adiposity 
and circulating leptin levels (Maffei et al., 1995). As mentioned earlier, the 
underlying mutation responsible for the obese phenotype o f the ob/ob mouse is in the 
Ob gene itself, which thus encodes a non-functional leptin protein. The mutations 
responsible for the obese phenotype of db/db mice and fa/fa  rat on the other hand, are 
in the leptin receptor gene (Chua et al., 1996). Thus, obese mutants can occur 
involving either the hormone or its receptor. Although examples of human obesity 
due to mutations in the Ob gene and Ob receptors have been documented (Clement et 
al., 1996; Montague et al., 1997a), these are rare.
1.4.1.1 Functions of leptin
Leptin is a satiety factor, and there is no doubt that it has a substantial effect on food 
intake (Campfield et al., 1995; Mercer et al., 1997) Leptin also has a stimulatory 
effect on energy expenditure, thus interacting with both components of the energy 
balance relationship (Campfield et al., 1995). Other functions of leptin include a key 
role in the reproductive system. Ob/ob mice are infertile, and exogenous leptin 
restores their fertility (Chehab et al., 1996). Leptin has been increasingly described
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as a general ‘metabolic’ hormone, in that there is an ever expanding range of 
processes with which it is thought to interact. These include stimulation o f glucose 
utilisation (particularly in skeletal muscle) (Kamohara et al., 1997), inhibition of 
insulin secretion from pancreatic P-cells (Emilsson et al., 1997) and the stimulation 
o f lipolysis in adipocytes (Fruhbeck et al., 1997).
Leptin also has an important role in the regulation o f insulin sensitivity, as 
demonstrated by the improved insulin sensitivity in a mouse model of severe 
lipoatrophic diabetes when leptin was over-expressed (Ebihara et al., 2001). Leptin 
has also been shown to improve insulin action on both the inhibition of hepatic 
glucose production and in the stimulation of glucose uptake in rats (Barzilai et al., 
1997). Furthermore, leptin has been found to reduce significantly insulin-mediated 
glucose uptake in isolated mature human omental and subcutaneous adipocytes 
(Zhang et al., 1999). Leptin appears to be a significant modulator o f both immune 
and inflammatory responses, including in the activation of neutrophils, macrophages 
and natural killer cells and lymphocyte proliferation (Otero et al., 2005).
1.4.1.2 Leptin receptors
The leptin receptor (Ob-R) is a product of the Lepr gene (Tartaglia et al., 1995). Due 
to alternative splicing of a single gene product, the leptin receptor has a series of 
different splice variants (Ob-Ra to Ob-Rf) (Lee et al., 1996). This level o f variation 
is unsurprising given the range of functions o f leptin. All splice variants share the 
same extracellular and transmembrane domains, but differ in the nature of their 
intracellular domains (Ahima & Osei, 2004). Of the short forms of the receptor, Ob- 
Ra has been found to be highly expressed in the choroid plexus and is thought to 
facilitate leptin transport across the blood-brain-barrier (McClain, 1998). Of these, 
the variant which has received most attention is Ob-Rb. This is the Tong form’ o f the 
receptor containing a full-length intracellular domain (Lee et al., 1996).
The Ob-Rb receptor has been identified in a number of tissues, including the kidney, 
adrenal medulla, pancreatic P-cells and adipose tissue (Emilsson et al., 1997; Guan et 
al., 1997; Hoggard et al., 1997b). In situ hybridisation studies have demonstrated the 
presence o f the leptin receptor in several regions of the rat CNS, including the 
choroid plexus, the leptomeninges and importantly the hypothalamus, with Ob-Rb
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having a particularly high level of expression in regions o f the hypothalamus such as 
the ARC (Mercer et al., 1996; Guan et al., 1997). Further studies, looking at the 
presence o f the Ob-Rb protein by immunohistochemistry, have further supported the 
hypothalamus as being a clear target for leptin (Hakansson et al., 1998), which is in 
accordance with the role o f this region in the brain in terms of the regulation of 
energy balance (Trayhum et al., 1999).
Ob-Rb regulates gene transcription via janus kinase (JAK) and signal transducer and 
activator of transcription (STAT) proteins (Vaisse et al., 1996). Evidence also 
suggests that in addition to the JAK-STAT signalling pathway, leptin activates 
phosphatidylinositol-3 kinase (PI3K) and phosphodiesterase 3B (PDE3B) reducing 
cAMP levels in the hypothalamus, where intra-hypothalamic cAMP administration 
has been found to increase food intake in mice (Gillard et al., 1997). The state of 
hyperleptinaemia in obesity will be discussed in detail in section 1.4.1.5.
1.4.1.3 Regulation of leptin expression and secretion
Plasma leptin concentrations are subject to complex regulation (Sahu, 2004; Howard 
& Flier, 2006). Systemically, leptin concentrations and are subject to diurnal 
variation with a nocturnal peak, although a pulsatile release pattern is also observed 
on top of this circadian rhythm (Fruhbeck et al., 1998). The expression of the Ob 
gene and circulating leptin concentrations are acutely regulated by nutritional status, 
with a rapid fall in both occurring in rodents when subject to fasting, or acute cold 
exposure, and a substantial rise on overfeeding and re-warming (Trayhurn et al.,
1995). This is suggestive o f an important role o f the SNS in leptin production. This is 
supported by leptin gene expression being inhibited by the direct administration of 
noradrenaline and the sympathomimetic drug isoprenaline (Trayhum et al., 1995). 
These agents have subsequently been shown to exert the same effects on leptin 
production by adipocytes in culture (Gettys et al., 1996; Mitchell et al., 1997).
The production of leptin is therefore regulated by the SNS through a negative 
feedback mechanism (Mark et al., 2003). Further evidence o f this is provided by 
rodent studies where increases in leptin mRNA and circulating levels are seen after a 
blockade of noradrenaline synthesis (Rayner et al., 1998). This negative feedback 
loop has also been found to exist in humans, as well as rodents, where the
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administration of adrenaline (Carulli et al., 1999) or isoprenaline (Pinkney et al., 
1998) to human subjects led to raised circulating levels of leptin. While in rodents, 
the SNS appears to mediate its effects on leptin through p3-adrenoceptors (Gettys et 
al., 1996; Trayhurn et al., 1996); in humans it is likely to occur through Pi and P2 
receptors (Rayner & Trayhurn, 2001).
Leptin production is also subject to control by other factors, particularly insulin, 
whose effect is likely to be mediated via the stimulation of glucose metabolism in 
adipose tissue (Havel, 2001). Administration of TZDs has been shown to inhibit 
leptin gene expression, indicating that the Ob gene is under the transcriptional 
control of PPARy (De Vos et al., 1996). Endogenous glucocorticoids such as cortisol 
and growth hormone may also regulate leptin secretion, although they are unlikely to 
play a major role (Havel, 2001). Oestrogen treatment has been shown to raise leptin 
concentrations (Castracane et al., 1998) and increase leptin sensitivity (Clegg et al.,
2006), with exogenous testosterone having the opposite effect (Blum et al., 1997). In 
addition, leptin mRNA levels have been found to differ between WAT depots. 
Higher levels are found in subcutaneous compared to visceral depots, and therefore, 
unsurprisingly higher levels are seen in women rather than men (Montague et al., 
1997b). Leptin levels have been shown to rise in response to acute infection, sepsis 
and increased levels of inflammatory cytokines such as TNFa and IL-ip (Sarraf et 
al., 1997; Zumbach et al., 1997; Faggioni et al., 1998; Gualillo et al., 2000).
1.4.1.4 The role of leptin in appetite control
Circulating leptin is transported into the brain across the blood-brain-barrier by a 
saturable process, which is independent of insulin (Banks et al., 1996), where the 
short form of the leptin receptor (Ob-Ra) is thought to be particularly important. 
Once in the CNS, leptin interacts via the long-form of the receptor (Ob-Rb), with 
both orexigenic and anorexigenic pathways. The expression of orexigens such as 
NPY, MCH, AgRP and orexin-A are inhibited by leptin, while those of anorexigenic 
peptides such as POMC (the precursor to a-MSH), CART and CRF are upregulated 
by leptin (McMinn et al., 2000). Furthermore, the endocannabinoid system is also 
considered to be inhibited by leptin, where acute leptin administration decreases the 
hypothalamic level of endogenous cannabinoids in both rats and the ob/ob mouse (Di 
Marzo et al., 2001).
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1.4.1.5 Leptin in the obese state; the concept ofleptin resistance
Since the first reports of elevated serum leptin levels in the obese (Considine et al.,
1996), and the clear failure o f these high levels to produce changes in energy intake, 
it has been proposed that the obese are ‘leptin resistant’ in a manner analogous to 
type II diabetics being resistant to the effects of insulin. However, there is little direct 
evidence for leptin resistance in humans (Arch et al., 1998). In terms of the analogy 
with type II diabetes, insulin levels rise after a meal, not due to insulin resistance, but 
in response to a raised influx o f glucose. Similarly, leptin might be raised in obesity 
not due to leptin resistance, but because of elevated fat stores (Arch et al., 1998). 
Proposed mechanisms underlying leptin resistance in the obese include; decreases in 
the hypothalamic leptin levels (Banks et al., 1999) and receptor expression; and 
impairment in leptin signalling, all offering increased susceptibility to diet-induced 
obesity in affected individuals (Zhang & Scarpace, 2006)
1.4.1.6 Leptin and companion animals
Rising levels of obesity in companion animals have led to increased research into 
molecular mechanisms underlying obesogenic pathways in these species (Iwase et 
al., 2000b; Sasaki et al., 2001). Leptin gene expression has been documented in all 
five main WAT depots in the dog, with expression being confined to mature 
adipocytes (Eisele et al., 2005). In addition, canine adipocytes in vitro have been 
shown to express leptin. However, unlike human adipocytes (Wang et al., 2004), 
expression has been documented in both pre- and post-differentiation (Eisele et al.,
2005), with higher levels o f expression post-differentiation, as is also the case in both 
rodents and humans (Wang et al., 2004; Eisele et al., 2005).
In a similar manner to humans and rodents, plasma leptin concentrations in 
companion animals increase with rising levels of adiposity (Appleton et al., 2000; 
Sagawa et al., 2002; Kearns et al., 2006). However, in dogs, unlike humans and 
rodents where leptin levels are higher in females, there appears to be no association 
between sex and systemic levels ofleptin (Ishioka et al., 2002; Ishioka et al., 2007). 
In addition, it has been proposed that leptin has less of an effect in terms of 
decreasing food intake and body weight in obese animals than other factors such as 
neutering status, suggesting the presence of leptin resistance (Jeusette et al., 2006).
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However, a study investigating leptin concentrations in the cerebrospinal fluid (CSF) 
o f lean versus obese dogs has shown no significant difference in levels before or 
after weight gain suggesting no decrease in leptin transport across the blood-brain- 
barrier (Nishii et al., 2006). Thus, to date there is no evidence of impaired transport 
o f leptin into the CNS or of a Teptin resistant’ state in the dog.
1.4.2 Adiponectin
Adiponectin, also called GB-28, apMl, AdipoQ and Acrp30, is an adipose tissue- 
specific protein, which circulates at high levels in human plasma (Diez & Iglesias,
2003). Adiponectin circulates as three discrete protein complexes in mice and 
humans: a 90-kDa trimer and a 180 kDa low molecular weight (LMW) hexamer, and 
a higher order complex (> 360 kDa) comprised of 4 to 6 trimers termed the high 
molecular weight (HMW) form. The LMW hexameric from of the protein is thought 
to be required for its basal activity. In contrast, the HMW form selectively disappears 
(with no increase in the LMW form) in mice treated with insulin or glucose, 
suggesting that HMW adiponectin complexes in serum represent a precursor pool 
that can be activated by metabolic stimuli and subsequently dissociate into the 
bioactive LMW form (Pajvani et al., 2003).
Studies have shown that the ratio of HMW to HMW plus LMW forms, and not 
necessarily absolute levels of the different forms, can be used as a quantitative 
indicator of insulin sensitivity in humans (Pajvani et al., 2004). Furthermore, there 
appears to be a sexual dimorphism in adiponectin levels in humans, with females 
having significantly higher circulating concentrations than males (Arita et al., 1999). 
A similar dimorphism also exists in terms of adiponectin complexes; the vast 
majority o f these in the male being the LMW form, whereas in females, the two 
complexes are more equally distributed (Pajvani et al., 2003). In the dog, a protein 
band at 180 kDa, which is analogous to the LMW form in humans, has been 
identified. However, the HMW form has not yet been isolated via either sodium 
dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) or Western 
immunoblotting techniques. Despite this, data from velocity sedimentation studies 
has suggested that the HMW form is also present in canine serum (Brunson et al.,
2007).
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1.4.2.1 Functions of adiponectin
Unlike most adipokines, adiponectin levels are inversely related to body weight, with 
reduced expression occurring in obesity and type II diabetes mellitus (Abbasi et al.,
2004). There also appears to be inverse correlations between plasma adiponectin 
concentrations and risk factors associated with cardiovascular disease, such as 
impaired vasoreactivity and levels of CRP (whose levels are closely related to 
parameters associated with cardiovascular disease and the metabolic syndrome) 
(Ouchi et al., 2003; Putz et al., 2004). Adiponectin has also been documented to have 
anti-artherogenic properties including as an endogenous angiogenesis inhibitor and 
thus may have therapeutic benefits in the treatment of angiogenesis-dependent 
diseases (Brakenhielm et al., 2004).
Impaired glucose and lipid metabolism, a hallmark of obesity and type II diabetes 
mellitus, leads to an increase in lipid stores in insulin target tissues such as muscle 
and liver, thereby leading to insulin resistance (Shulman, 2000). Adiponectin acts as 
an insulin sensitiser by increasing fatty-acid oxidation, which reduces the TG content 
of these tissues in obese and type II diabetic mice (Yamauchi et al., 2001). 
Complementary DNA-encoding adiponectin receptors (AdipoRl and AdipoR2) have 
been cloned (Yamauchi et al., 2003). AdipoRl is found abundantly in skeletal 
muscle, whereas AdipoR2 is expressed predominantly in the liver. These receptors 
are suggested to mediate the insulin sensitising effect of adiponectin via an increase 
in activity o f 5’-AMP-activated protein kinase (AMPK) (an enzyme concerned with 
fatty-acid oxidation and glucose metabolism in liver and skeletal muscle) (Yamauchi 
et al., 2002).
Both receptors are expressed in human adipose tissue and isolated adipocytes, with 
levels of AdipoRl expression being higher than those for AdipoR2. Thus it is 
possible that adiponectin may have similar effects on fatty acid oxidation and 
glucose metabolism in white adipose tissue (Rasmussen et al., 2006). Evidence from 
rodent experiments also suggests that adiponectin may act centrally through the 
melanocortin pathway in mice to decrease body weight (Qi et al., 2004), although the 
exact mechanism through which this is thought to occur remains to be elucidated.
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Besides the well-established anti-artherogenic and insulin sensitising properties o f 
adiponectin, evidence also supports a strong anti-inflammatory function (Tilg & 
Wolf, 2005). Studies have demonstrated that adiponectin suppresses production of 
the potent pro-inflammatory cytokine TNFa by monocytes, as well as attenuating its 
biological effects systemically in humans (Ouchi et al., 2001). In addition, 
hypoadiponectinaemia has been associated with raised levels of several pro- 
inflammatory cytokines such as IL-6 and IL-8 and TNFa itself in obese individuals 
(Engeli et al., 2003a), where it is suggested that raised levels of these endogenous 
cytokines may be directly responsible for the inhibition of adiponectin secretion 
(Bruun et al., 2003a).
In humans, omental adipocytes in vitro have been found to express little adiponectin 
when compared to other depots. Furthermore, studies on samples obtained from 
diabetic patients have shown that once diabetic status is reached, non-visceral depots 
have a reduced capacity to express adiponectin. Thus, depot specific expression o f 
adiponectin may influence the pattern of serum adiponectin concentrations and 
associated disease risk (Fisher et al., 2002).
Administration o f TDZs such as the PPARy agonist rosiglitazone, which has potent 
anti-inflammatory effects, has been shown to increase serum adiponectin levels and 
is used clinically to treat type II diabetes mellitus in humans (Ghanim et al., 2006). 
In experiments carried out in rodents, the use of a PPARa agonist has been shown to 
enhance the effects of rosiglitazone on serum adiponectin concentrations and the 
expression of AdipoRs in WAT of mice (Tsuchida et al., 2005). Further evidence, of 
the role o f adiponectin in obesity, comes from rodent studies where adiponectin 
enhances energy expenditure as well as impairing adipocyte differentiation in obese 
mice (Bauche et al., 2007).
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1.4.2.2 Adiponectin and companion animals
Plasma adiponectin concentrations have been found to decrease in dogs, in a manner 
similar to humans, with increasing body weight and similarly subsequent weight loss 
results in a rise in serum adiponectin levels (Ishioka et al., 2005b). Like leptin, 
adiponectin gene expression has also been documented in all five main WAT depots 
in the dog, where expression is again confined to mature adipocytes and not cells of 
the SV fraction (Eisele et al., 2005). Canine adipocytes in vitro also express mRNA 
for adiponectin and, in a manner similar to humans; expression is confined to mature 
adipocytes (Wang et al., 2004; Eisele et al., 2005). Serum concentrations o f 
adiponectin in dogs have been found to range from 2.6 to 73.5 pg/ml in some reports 
(Ishioka et al., 2005b), with others reporting much lower serum concentrations o f the 
order of 0.85 to 1.5 pg/ml (Brunson et al., 2007). Those in the latter range are 
comparable to levels found in humans and rodents (Chandran et al., 2003). It is 
widely recognised that atherosclerosis and type II diabetes are rare in dogs compared 
to other species (Ettinger & Feldman, 2000). Therefore, the role of adiponectin as an 
insulin sensitiser and whether high levels o f the adipokine are associated with 
improvement in metabolic parameters in the obese dog remains to be proven.
1.4.3 Tumour necrosis factor-a
TNFa is synthesised as a 26-kDa transmembrane pro-hormone, which subsequently 
undergoes proteolytic cleavage to yield a 17-kDa soluble TNFa molecule. Despite 
differences in both size and location, both forms of TNFa are capable of mediating 
biological responses, and together may be responsible for both local and systemic 
actions of this cytokine. Plasma levels of TNFa are raised in obesity in both humans 
and dogs (Hotamisligil et al., 1997; Gayet et al., 2004). TNFa acts on two distinct 
cell surface receptors, type 1 and 2 (TNFR1 and TNFR2). To date, most known 
cellular functions of TNFa have been ascribed to signals transduced by TNFR1, with 
TNFR2 being thought to play a modulatory role in ligand trafficking. Both TNFa 
receptors can also be released from the cell surface through proteolytic cleavage and 
exist in soluble form. Circulating levels o f these receptors have been found to be 
elevated in many pathological states including obesity (Hotamisligil et al., 1997), 
and may serve to modulate the bioactivity o f TNFa both spatially and temporally 
(Sethi & Hotamisligil, 1999). Binding of TNFa to either of its receptors, activates 
multiple kinases and phosphatases thereby utilising all major transduction pathways
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(Vilcek & Lee, 1991). One such pathway is that resulting in the activation o f nuclear 
factor kB (NFkB), see Fig. 1.3.
1.4.3.1 Role of TNFa in insulin resistance
TNFa production by WAT is well documented, with neutralisation of the protein in 
obese rodent models leading to improvements in insulin sensitivity (Hotamisligil et 
a l,  1993). However, whilst TNFa is recognised as an adipokine being synthesised 
and released from adipocytes, it may be that, at least in humans, the majority o f the 
production occurs in cells of the SV fraction of WAT (Fain et a l, 2004). With the 
increased influx of macrophages into WAT depots in the obese (Weisberg et a l,
2003), this could contribute significantly to the chronic inflammatory state seen in 
obesity.
The role o f TNFa in insulin resistance is thought to occur at various levels, both 
centrally in the hypothalamus and in adipocytes themselves, with TNFa being firmly 
established as an important mediator of obesity-related insulin resistance 
(Hotamisligil et a l, 1993; Hotamisligil et a l, 1994; Hotamisligil et a l, 1995). Both 
diet and drug treatment of obesity has been shown to improve insulin sensitivity, and 
correlates with a decreased production of TNFa (Hotamisligil et a l, 1995). The 
inhibitory actions of TNFa can also be reversed by insulin-sensitising drugs such as 
TZDs, which in vivo coincide with a decrease in the levels of TNFa expression 
(Miles et a l, 1997). In terms of glucose transport, TNFa has been shown to down- 
regulate GLUT 4, thereby decreasing insulin-stimulated intracellular glucose 
transport in adipocytes (Stephens et al., 1997). TNFa has also been shown to act on 
the proximal steps of insulin signalling by an increase in phosphorylation of 1RS-1 at 
serine residues, inhibiting down-stream events of the insulin signalling pathway 
(Hotamisligil et a l, 1994), see Fig 1.4. Such modification o f IRS-1 has been 
observed in obesity and insulin resistance (Hotamisligil elal., 1993). Conversely, in 
3T3-L1 adipocytes, treatment with TNFa decreases IRS-1 mRNA levels, but does 
not appear to have an effect on down-stream events in insulin signalling (Stephens et 
a l,  1997).
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Figure 1.4 Molecular pathways integrating inflammatory responses
with insulin action
Adapted from (Shoelson et a l, 2003; Hotamisligil, 2006)
NF-kB is a transcription factor which is activated by inflammatory cytokines such as TNFa. 
It drives the production of numerous proinflammatory cytokines including IL-(î, IL-6 and 
TNFa itself. Under basal conditions, NF-kB is inhibited by IkB and remains in the cytoplasm 
and upon activation, the kinase complex referred to as IKK is activated and catalyses the 
phosphorylation of IkB. This leads to IkB degradation, liberating NF-kB which translocates 
into the nucleus and stimulates the transcription of several proinflammatory mediators. 
Expression of IKKp (one of the kinases of the IKK complex), inhibits 1RS-1/2 leading to 
TNFa-induced insulin resistance.
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1.4.3.2 Role of TNFa in adipose tissue
There is also an increasing body o f evidence to support a role for TNFa in 
modulating lipid metabolism in WAT. In obesity, the elevated levels o f TNFa may 
contribute to the increase in basal lipolysis characteristic of adipocytes from obese 
subjects (Ramsay, 1996). Moreover, TNFa-deficient mice exhibit lower circulating 
free fatty acids and TGs than their wild-type littermates (Uysal et al., 1997). Since 
elevated concentrations o f free fatty acids have been associated with insulin 
resistance, the role of TNFa in mediating insulin resistance may be potentiated by 
increased lipolysis. TNFa has also been shown to down-regulate LPL activity and 
protein expression (Semb et al., 1987), and in addition to inhibiting free fatty acid 
uptake, TNFa also acts to decrease the expression of key enzymes involved in 
lipogenesis (Doerrler et al., 1994). Furthermore, TNFa has also been found to play 
an important role in the induction of apoptosis of both human preadipocytes and 
adipocytes in vitro (Prins et al., 1997). Treatment of cells with dexamethasone, 
which has both anti-inflammatory and adipogenic properties, has been found to 
inhibit TNFa-induced adipocyte apoptosis (Zhang et al., 2001).
Within adipose tissue itself, TNFa has been shown to be an important regulator o f 
the expression of other pro-inflammatory adipokines. It has been shown to 
upregulate gene expression of IL-6, MCP-1, nerve growth factor (NGF), vascular 
endothelial growth factor (VEGF) (Wang et al., 2005; Wang & Trayhurn, 2006), 
plasminogen activator inhibitor-1 (PAI-1) (Cigolini et al., 1999; Wang & Trayhurn,
2006) and haptoglobin (Chiellini et al., 2002; do Nascimento et al., 2004) in 
adipocytes in vitro. TNFa also appears to have a substantial effect on its own level of 
gene expression, with a greater than 2,000-fold upregulation with acute treatment of 
human adipocytes in vitro (Wang & Trayhurn, 2006).
TNFa has been shown not only to inhibit adipocyte differentiation but also to be 
capable of suppressing the expression of adipocyte-specific genes in fully 
differentiated adipocytes (Ruan et al., 2002; Wang & Trayhum, 2006). Interestingly, 
the anti-adipogenic action of TNFa also appears to be reversed by subsequent 
treatment with adipogenic agents such as dexamethasone and indomethacin raising 
the possibility that adipocyte differentiation may be a reversible process under 
control of both positive and negative regulators (Sethi & Hotamisligil, 1999; Zhang
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et al., 2001). The exact mechanism whereby TNFa alters the adipocyte 
differentiation programme is not clear. However, TNFa has been shown to down- 
regulate the expression of key transcription factors involved in adipogenesis, namely 
PPARy and C/EBPa (Loftus & Lane, 1997). This may explain the parallel 
downregulation of adipose-specific genes (such as GLUT 4 and aP2) which contain 
binding sites for PPARy and or C/EBPa in their promoters, upon treatment with 
TNFa (Williams et al., 1992).
TNFa gene expression has been reported in canine adipocytes after collagenase 
digestion to separate mature adipocytes and cells of the SV fraction. Expression in 
canine WAT was not found prior to digestion thus indicating that mature adipocytes 
and cells o f the SV fraction of dog WAT can express TNFa, but do not appear to do 
so in the tissue as a whole entity (Eisele et al., 2005).
1.4.4 Interleukins
The interleukins are a group of cytokines that were first seen to be expressed by 
white blood cells (leukocytes, hence the -leukiri) as a means o f communication 
(inter-). Their role is to mediate and control immune and inflammatory responses. In 
addition to white blood cells, interleukins have been found to be expressed and 
secreted by other cell types including white adipocytes (Trayhurn & Wood, 2004).
IL-6 is a multifunctional cytokine and has a ubiquitous tissue distribution. Human 
WAT produces substantial amounts of IL-6 and this may represent 10-30% of 
circulating concentrations (Mohamed-Ali et al., 1998). Circulating IL-6 
concentrations are elevated in obesity and insulin resistance, and sympathetic 
stimulation has been shown to increase plasma IL-6 concentration in both humans 
and mice (Mohamed-Ali et al., 2001). IL-6 is thought to play a direct role in insulin 
resistance by altering insulin signalling in hepatocytes (Senn et al., 2002). This effect 
is mediated by the induction of SOCS3, which inhibits insulin-dependent insulin 
receptor autophosphorylation (Lagathu et al., 2003; Senn et al., 2003). Adipose 
tissue expression o f IL-6 is stimulated by TNFa (Wang et al., 2005; Wang & 
Trayhurn, 2006). Like TNFa, IL-6 decreases adipose tissue LPL activity and has 
been implicated in the WAT wasting that occurs in cancer cachexia (Greenberg et 
al., 1992). Studies have also demonstrated a high rate of production of IL-6 in
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adipose tissue of obese subjects, particularly in visceral depots. This suggests that as 
well as a central role, IL-6 also has an important autocrine and paracrine role as a 
regulator of regional adipose tissue metabolism (Fried et a l, 1998).
Other interleukins synthesised by WAT include IL-ip, IL-10 and IL-18 (Fain et a i, 
2004; Juge-Aubry et a l, 2005; Wood et a l, 2005). IL1-P exerts its biological 
function by binding to the IL-1 receptor and activating the NFkB signalling pathway. 
IL-ip has been shown to mediate leptin induction in mice after an inflammatory 
stimulus (Faggioni et a l, 1998), and to stimulate IL-6 release from human adipocytes 
in vivo (Flower et a l, 2003). In a similar manner to IL-6, IL-ip levels are increased 
in the obese (Um et a l, 2004). Moreover, individuals with a combined raised level of 
IL-ip and IL-6 have an increased risk o f type II diabetes and the metabolic syndrome 
(Spranger et a l, 2003). In addition, treatment of human adipose tissue expiants with 
IL-P has been shown to decrease levels of adiponectin (Lihn et a l, 2004). Long-term 
treatment with IL-ip has been shown to induce insulin resistance in both human and 
rodent adipocytes (Lagathu et a l, 2006). This is thought to be mediated through 
decreased IRS-1 expression (Jager et a l, 2007).
In contrast to most cytokines secreted by white adipocytes, IL-10 is thought to play 
an anti-inflammatory role, where its level of expression is upregulated by pro- 
inflammatory agents such as lipopolysaccharide (LPS) and TNFa. Its level of 
expression is raised in both human and rodent obesity due to increased WAT mass 
(Juge-Aubry et a l, 2005). The plasma level of IL-18, a pro-inflammatory cytokine, is 
also elevated in obesity and its levels fall in response to weight loss (Esposito et a l,
2002). Increased serum IL-18 concentration has been associated with 
hypoadiponectinaemia in obesity independently of insulin resistance (Straczkowski 
et a l, 2007). Recently, it has been established that WAT is an important site of IL-18 
gene expression, with a marked upregulation of expression by human adipocytes in 
vitro with TNFa treatment. However, there is mixed evidence as to whether it is 
secreted by adipocytes (Skurk et a l, 2005b; Wood et a l, 2005).
IL-6 gene expression has also been documented in canine adipocytes in vitro, with 
levels of expression being greater pre- compared to post-differentiation (Eisele et a l,
2005). This is unlike what is seen in human adipocytes, where levels o f expression
49
appear to fall markedly post differentiation, followed by a gradual rise, until they 
reach pre-differentiation levels (Wang et al., 2004).
1.4.5 Chemokines
Chemokines are low molecular weight peptides that play a central role in 
inflammatory processes by regulating leukocyte migration into sites of tissue 
damage. In excess of 50 chemokines have been described, and they exert their effects 
through G-protein-coupled receptors (Zlotnik et al., 1999). As discussed earlier, 
obesity is associated with an increased infiltration of macrophages into WAT leading 
to an increase in the level of expression of several inflammation and macrophage- 
specific genes (Weisberg et al., 2003; Xu et al., 2003). This process of macrophage 
infiltration is thought to be regulated by chemokines secreted from adipocytes 
themselves; these include MCP-1, MIF and IL-8 (Gerhardt et al., 2001). All three 
have been shown to be expressed in human preadipocytes in vitro and their level of 
expression is markedly upregulated by treatment with pro inflammatory cytokines 
such as TNFa (Gerhardt et al., 2001).
MCP-1, as the name suggests, is responsible for the attraction of macrophages and T- 
lymphocytes to sites of inflammation. Circulating levels o f MCP-1 have been shown 
to be significantly raised in obesity (Kim et al., 2006). TZDs have been found to 
reduce MCP-1 mRNA levels in WAT. The decreased adipocyte expression o f MCP- 
1 by TZDs, results in decreased macrophage recruitment into the tissue, along with 
decreased expression o f other inflammatory cytokines such as TNFa (Di Gregorio et 
al., 2005). Studies have shown a potent stimulation of MCP-1 gene expression and 
protein secretion in human adipocytes in vitro with TNFa treatment (Wang et al., 
2004; Wang et al., 2005). Since TNFa produced by adipocytes is known to induce 
insulin resistance, MCP-1 may play an important role in the mechanism of insulin 
resistance observed in obesity and type II diabetes mellitus. Studies, using human 
preadipocytes in vitro, have shown that levels of both MCP-1 gene expression and 
protein secretion increase during adipocyte maturation (Wang et al., 2004).
Given that MCP-1 is expressed by adipocytes and plays a key role in monocyte 
recruitment into WAT, it is thought that obesity-related adipocyte expression of 
MCP-1 results in the recruitment of resident monocytes, which then themselves
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secrete proinflammatory cytokines, contributing to the state of chronic-low grade 
inflammation seen in the obese state (Chen et al., 2005; Di Gregorio et al., 2005). 
MCP-1 has also been shown to have a direct angiogenic effect on endothelial cells 
(Salcedo et al., 2000), and may thus be involved in the expansion and remodelling of 
adipose tissue in obesity. This indicates that MCP-1 may have other roles in 
adipocyte physiology in addition to inflammatory cell recruitment (Sartipy & 
Loskutoff, 2003).
MIF has been identified as a critical mediator of inflammatory responses and, like 
MCP-1, is also thought to play an active role in angiogenesis (Lue et al., 2002). It is 
a potent inhibitor of monocyte/macrophage migration, and thus regulates 
macrophage accumulation in tissues. Human preadipocytes have been found to 
secrete MIF in a differentiation-dependent fashion, with maximal concentrations in 
mature adipocytes, although secretion is also evidenced in preadipocytes. 
Furthermore, MIF production by human adipocytes in culture has been shown to be 
positively correlated with donor BMI (Skurk et al., 2005a), with raised circulating 
levels in the obese (Dandona et al., 2004; Ghanim et al., 2004) and falling levels 
after weight loss (Church et al., 2005). Hence, MIF is thought to be an obesity- 
dependent mediator of macrophage infiltration o f adipose tissue in obesity (Skurk et 
al., 2005a).
Studies documenting the response of MIF to TNFa treatment have yielded 
contradictory results, where in vitro studies using human adipocytes, appear to show 
little or no change in the level of MIF gene expression with TNFa treatment (Wang 
et al., 2005). This is in contrast to rodent adipocytes, where in vitro treatment of cells 
with TNFa led to a marked upregulation o f both gene expression and protein 
secretion (Hirokawa et al., 1997). MIF is also expressed by pancreatic P-cells and its 
production is regulated by glucose in a time- and concentration-dependent manner, 
with a progressive decrease in MIF action within the islets of Langerhans, 
contributing to P-cell dysfunction and diminished insulin release in type II diabetes 
mellitus (Waeber et al., 1997). Therefore, in the presence of raised plasma 
concentrations of glucose, elevated MIF may be used as a marker for p-cell 
dysfunction (Church et al., 2005). Thus MIF may affect the pathophysiology of both 
obesity and type II diabetes mellitus (Sakaue et al., 1999).
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IL-8 is a chemokine shown to be produced and released from human adipocytes both 
in vitro and in vivo and its level o f production is stimulated by both IL-ip and TNFa 
(Braun et al., 2001). Circulating concentrations o f IL-8 have been found to correlate 
with adiposity and insulin sensitivity, suggesting an involvement in obesity-related 
diseases (Braun et a l, 2003b).
1.4.6 Nerve growth factor
Certain organs and cell types produce neurotrophic factors responsible for the control 
of the level o f tissue innervation, which is essential for the maintenance and survival 
of sympathetic and certain sensory neurones (de Romo, 2007). NGF was the first 
target-derived neurotrophin to be identified, and is now recognised to be a member 
of a family o f such proteins which include brain-derived neurotrophic factor 
(BDNF), neurotrophin 3 (NT3) and neurotrophin 4/5, NT-6 and NT-7 and are all 
known to be expressed in the vertebrate brain. These proteins play key roles in the 
development of the nervous system (Hennigan et al., 2007).
All members of the neurotrophin family bind, with different affinities, to the TrK 
family of receptor tyrosine kinases (TrkA, TrkB and TrkC) and with similar affinities 
to the p75 neurotrophin receptor (Salton, 2003). NGF exists as a pentameric protein 
complex consisting of three subunits (a, p and y), and studies have determined that 
the P-subunit is that responsible for the biological activity o f NGF (Shooter, 2001). 
The trophic functions of NGF have been ascribed to its interaction with TrkA, and 
are responsible for neuronal cell survival, proliferation and axonal growth (Chao & 
Hempstead, 1995; Scully & Otten, 1995). Activation of TrkA by NGF has also been 
reported to stimulate PPARy activity in neurones, raising the possibility of a 
therapeutic role for NGF as an inducer of anti-inflammatory effects in neurological 
disorders (Fuenzalida et al., 2005). In contrast, binding of NGF to p75 alone (or in 
combination with receptors other than TrkA), leads to the induction of programmed 
cell death during neuronal development and after neural injury (Frade & Barde, 
1998). The interaction between p75 and the neurotensin receptor sortilin is a key 
aspect of this apoptotic effect, where sortilin binds to the unprocessed form of NGF 
(proNGF) and forms a complex with p75 which can then induce cell death (Nykjaer 
et al., 2004).
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1.4.6.1 Functions of nerve growth factor
As mentioned earlier, target tissues secrete specific neurotrophins, and these initiate 
programs of cellular differentiation, and support the survival of neuronal populations 
which express the appropriate receptors. NGF acts primarily, as a trophic factor for 
sympathetic and some neural crest-derived sensory neurones (Salton, 2003). 
However, NGF is also recognised to have a range of biological functions which 
include endocrine, immune and inflammatory roles (Scully & Otten, 1995; Levi- 
Montalcini et al., 1996).
Several lines of evidence have been shown to implicate NGF in inflammation (Scully 
& Otten, 1995; Levi-Montalcini et al., 1996). Monocytes and mast cells release 
NGF, and are a possible source of the elevated plasma concentrations o f the 
neurotrophin in allergic states (Rost et al., 2005). Inflammatory cytokines, such as 
IL-ip and TNFa, are found at sites of injury and induce NGF synthesis in both the 
peripheral and central nervous systems (Gadient et al., 1990; Steiner et al., 1991). 
NGF can also be released by non-neuronal cells under the influence o f inflammatory 
mediators at sites of inflammation, thereby potentiating the immune response and 
enhancing regeneration o f damaged nerves (Scully & Otten, 1995). Such an example 
is NGF secretion by human airway epithelial cells in vitro with treatment with IL-ip 
and TNFa. This effect can subsequently be reversed by treatment with 
dexamethasone (Pons et al., 2001).
1.4.6.2 Nerve growth factor and adipose tissue
Due to its high degree of sympathetic innervation, much o f the early work 
investigating the role of NGF and adipose tissue has focused on brown fat, where 
studies have demonstrated that NGF is produced by brown adipocytes (Nechad et al., 
1994; Nisoli et al., 1996). It has now been established that NGF is expressed by all 
major WAT depots of mice was well as human white fat (Peeraully et al., 2004), and 
that NGF is secreted from both rodent and human adipocytes in culture (Peeraully et 
al., 2004; Wang et al., 2004; Bullo et al., 2005). In addition, the genes encoding the 
low-affinity p75 and the high-affinity TrkA NGF receptors are also expressed in 
WAT (Peeraully et al., 2004). The proinflammatory cytokine TNFa, is a major factor 
in the stimulation o f NGF gene expression and secretion, in both rodent (Peeraully et 
al., 2004) and human adipocytes (Wang et al., 2004; Wang & Trayhurn, 2006). This
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is consistent with the role of the neurotrophin in inflammatory responses. NGF 
expression has been demonstrated in all main WAT depots in the dog, with 
expression being evident in both mature adipocytes and cells of the SV fraction 
(Eisele et al., 2005). However, it is not established whether this important 
neurotrophin is in fact also an adipokine in the dog.
1.4.7 Haemostatic and haemodynamic factors
The renin-angiotensin aldosterone system (RAAS) is an important regulator of 
systemic blood pressure and renal electrolyte balance. Identification of the RAAS 
locally within adipose tissue is suggestive of a potential causal role for it in obesity- 
associated hypertension (Harte et al., 2005). Circulating angiotensinogen is 
converted by renin to angiotensin II, which is a potent vasoconstrictor and key 
regulator of vascular tone. Although the liver is the main source of angiotensinogen, 
it is also produced and secreted by WAT (Engeli et al., 2003b). In addition, human 
subcutaneous adipose tissue is a significant source of angiotensin II (Harte et al., 
2005). Adipocyte expression and secretion of angiotensinogen is stimulated by 
glucocorticoids and inhibited by insulin and TNFa (Aubert et al., 1997; Aubert et al., 
1998; Wang et al., 2005).
Angiotensinogen levels have been shown to fall in response to weight loss in humans 
with an associated reduction in expression in WAT. This is thought to contribute to 
the fall in blood pressure seen in obese hypertensive patients with subsequent weight 
loss (Engeli et al., 2005). The PPARy agonist rosiglitazone has been shown to 
downregulate the RAAS in subcutaneous adipose tissue, further contributing to the 
long-term reduction in blood pressure levels in humans suffering from obesity- 
related hypertension (Harte et al., 2005). Angiotensinogen gene expression has been 
documented in the main WAT depots of the dog. Expression is also seen in canine 
adipocytes in vitro, with similar levels of expression pre- and post-differentiation 
(Eisele et al., 2005).
The pro thromboembolic factor PAI-1 is a key regulator of vascular haemostasis. By 
inhibiting the activation of plasminogen (the precursor to plasmin), it suppresses 
fibrinolysis (Sprengers & Kluft, 1987). Elevated levels o f PAI-1 have been linked to 
insulin resistance (Juhan-Vague et al., 1991). Adipose tissue expression and
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circulating concentrations o f PAI-1 are elevated in obese individuals (Koistinen et 
al., 2000) and may represent the main source of elevated circulating plasma PAI-1 in 
obesity. The increased production of PAI-1 in the obese has been linked to several 
proinflammatory cytokines, including TNFa (Wang et al., 2005) and IL-6, and is 
also known to be implicated in the increased risk of cardiovascular and 
atherosclerotic complications associated with obesity (Ziccardi et al., 2002; Cao et 
al., 2007). Like angiotensinogen, PAI-1 gene expression has been documented in 
canine adipocytes in primary culture, and in a similar manner, levels of expression 
appear not to differ pre- and post-differentiation (Eisele et al., 2005).
1.4.8 Acute phase proteins
Acute phase proteins are a group of protein factors secreted mainly by the liver, with 
raised levels during the early part of the inflammatory response (Gabay & Kushner, 
1999). However, several are also both synthesised and secreted by WAT and are thus 
recognised as adipokines. Acute phase proteins secreted by white adipocytes are a 
potential contributor to raised circulating levels seen in obesity (Trayhurn & Wood,
2004) . One such protein is PAI-1; another example is serum amyloid A (SAA), a 
precursor of amyloid A, which is a constituent of the amyloid fibrils involved in 
amyloidosis. SAA is a well-characterised independent risk factor for coronary artery 
disease and AA amyloidosis. Serum SAA concentrations are correlated with BMI, 
adiposity and adipose tissue SAA mRNA levels (Poitou et al., 2005), with WAT 
being a major expression site of SAA (Sjoholm et al., 2005). Both WAT gene 
expression, and protein circulating concentrations, is under nutritional control and 
both decrease in response to weight loss. This indicates that, if amyloidosis is seen in 
the context of obesity, it is possible that production by adipocytes could be a 
contributing factor to amyloidosis seen in cardiovascular disease (Poitou et al.,
2005) .
Haptoglobin binds free haemoglobin released by red blood cells in the event of 
haemolysis. During such events it sequesters iron found within haemoglobin, 
preventing iron-utilising bacteria from benefiting from events associated with 
haemolysis. As a result, haptoglobin is classified as an acute phase protein, and is a 
classical marker of inflammation, the expression of which has been documented in 
human, murine and canine white adipocytes in vitro. In all three models, expression
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levels increase with differentiation, gene expression being virtually undetectable in 
preadipocytes (do Nascimento et al., 2004; Wang et al., 2004; Eisele et al., 2005). A 
significant upregulation of haptoglobin expression has been documented in WAT of 
rodent models such as the yellow agouti and ob/ob mice (Chiellini et al., 2002). 
Haptoglobin expression is stimulated by pro-inflammatory cytokines TNFa 
(Chiellini et al., 2002) and IL-6, and inhibited by the TZD rosiglitazone in 3T3-L1 
adipocytes (do Nascimento et al., 2004). This is in contrast to human adipocytes, 
where TNFa treatment has been shown to reduce levels o f gene expression after 24 h 
in vitro. Thus in contrast to rodents, it is unlikely that haptoglobin synthesis is 
stimulated in WAT as part o f the inflammatory response (Wang et al., 2004).
Metallothionein (MT) is a low-molecular-weight-metal-binding protein, the 
production of which is strongly induced in both the liver and kidney by the 
administration of heavy metals such as cadmium or zinc (Bremner & Beattie, 1990). 
The MT gene is strongly expressed in BAT, where it is suggested that it may play an 
important role as an antioxidant (Beattie et al., 2000). It has also been demonstrated 
that both MT-1 and MT-2 genes are expressed in mature adipocytes of rodents, the 
mRNA being present in each of the main depots, with no substantial differences in 
the level of expression (Trayhum et al., 2000). It has been suggested that MT has an 
anti-oxidant role in WAT protecting fatty acids from oxidative damage (Trayhum et 
al., 2000). The differentiation of fibroblastic preadipocytes to adipocytes in primary 
culture has been shown to result in raised level o f MT mRNA and increased 
secretion o f MT protein (Trayhum et al., 2000).
MT gene expression in human adipocytes in vitro is upregulated by treatment with 
TNFa (Wang et al., 2005). Gene expression for both MT-1 and MT-2 has also been 
documented in canine WAT; with expression being evident in all main canine WAT 
depots. As documented in humans (Do et al., 2002), gene expression was evident for 
both genes in mature adipocytes and cells of the SV fraction (Eisele et al., 2005). 
Gene expression was also evident in canine adipocytes in vitro, where unlike human 
adipocytes (Wang et al., 2004), gene expression levels appear to be higher in mature 
cells compared to that seen in preadipocytes (Eisele et al., 2005).
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1.4.9 Resistin and visfatin
Resistin (also described as FIZZ3 and ADSF) is a 12.5 kDa cystine-rich protein that 
is secreted from adipocytes, is present in the circulation, and was initially thought to 
be the link between increased adiposity and type II diabetes mellitus by inducing 
insulin resistance (Steppan et a l, 2001). This was based on observations that diet- 
induced obese mice and genetically obese mice had raised levels o f resistin, and 
subsequent immuno-neutralisation of resistin in these animals improved insulin 
sensitivity and hyperglycaemia. Resistin administration to normal mice, led to an 
impairment o f glucose tolerance and insulin sensitivity. In vitro treatment of 3T3-L1 
adipocytes with TZDs decreased levels o f resistin gene expression (Steppan et a l, 
2001). In humans, resistin mRNA concentrations have been found to be similar 
between abdominal subcutaneous and omental depots. However, quantitative 
comparisons have shown there to be a marked difference in the level o f resistin 
mRNA expression between abdominal depots and depots located elsewhere in the 
body such as the thigh. (McTeman et a l, 2002a).
Resistin has been found to be both expressed and secreted by human adipocytes, with 
levels being higher in abdominal depots (subcutaneous abdominal and omental), 
compared to non-abdominal depots (thigh and breast) (McTeman et a l, 2002c). 
However, there is little evidence for a role for resistin as a link between obesity, 
insulin resistance and type II diabetes mellitus in humans, where administration of 
resistin has lead to the development of hepatic, but not peripheral, insulin resistance 
(Rajala & Scherer, 2003). Furthermore, in humans, unlike rodents, resistin is mainly 
secreted by macrophages in the SV fraction not by adipocytes themselves (Lehrke et 
a l,  2004). Studies carried out using human adipocytes reported barely detectable 
levels of resistin, and no differences were found in resistin gene expression when 
comparing cells from normal, insulin-resistant or type II diabetic individuals (Nagaev 
& Smith, 2001). In addition, reports have failed to establish either a clear mechanism 
by which resistin expression is regulated, or a definite physiological role for the 
protein (Rea & Donnelly, 2004). Thus, it appears that human and mouse resistin have 
different physiological roles and the postulated relationship of murine resistin and 
insulin resistance may not readily translate to humans (Savage et a l, 2001).
57
Visfatin, is a 52 kDa cytokine whose expression was primarily characterised in 
lymphocytes, but which has also been shown to be secreted by visceral WAT of both 
humans and mice, and is thus also an adipokine. Circulating concentrations have 
been shown to correlate with adiposity. Like resistin, it is also thought to be involved 
in glucose homeostasis and is a ligand for the insulin receptor. It appears to have 
insulin-like effects enhancing glucose uptake in 3T3-L1 cells and reducing glucose 
levels in mice. However, unlike insulin, visfatin levels have been shown to be 
unaffected by feeding or fasting (Fukuhara et al., 2005). In addition, plasma 
concentrations of visfatin and visfatin mRNA expression have been correlated with 
measures o f obesity, but not with visceral fat mass or waist-to-hip ratio in humans 
(Bemdt et al., 2005). Further studies into the physiological role of this novel 
adipokine may lead to new insights into glucose homeostasis including type II 
diabetes mellitus and the metabolic syndrome (Fukuhara et al., 2005).
1.4.10 Proteins of lipid and lipoprotein metabolism
Adipsin was first identified on the basis of the differentiation-dependent expression 
o f its mRNA in murine 3T3-F442A adipocytes (Spiegelman et al., 1983). Adipsin 
cDNA was found to encode a new serine protease with a high homology to human 
complement factor D. Adipsin is required for the synthesis of acylation-stimulating 
protein (ASP), which is derived from the end product of the alternative complement 
pathway, complement C3a (Trayhurn & Beattie, 2001). ASP is involved in the 
uptake and esterification of fatty acids to TGs for storage in adipocytes and has an 
additive effect with that of insulin by allowing adipose tissue to self-regulate its 
lipid-storage capacity (Cianflone et al., 1999). Furthermore, plasma levels of both 
adipsin and ASP are increased in human obesity (Cianflone et al., 1999; Ahima & 
Flier, 2000). Although there is a close similarity between human and murine 
complement factor D, mouse adipsin expression appears to be specific to adipose 
tissue, whereas human complement factor D is reported to be synthesised mainly by 
cells o f the macrophage/monocyte lineage (Bamum & Volanakis, 1985). With 
increased infiltration of WAT by macrophages in obesity, ASP may play a key role 
in adipose tissue metabolism and plasma TG clearance in the obese state.
Zinc-a2-glycoprotein (ZAG) is a lipid mobilizing factor which is over-expressed in 
several types of malignant tumour, and has been used as a cancer marker. Expression
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has been detected in both mature rodent adipocytes and in cells o f the SV fraction 
(Bing et al., 2004). ZAG mRNA has been detected in 3T3-L1 cells both before and 
after the induction of differentiation, with levels rising as cells mature (Bing et al.,
2004) . ZAG has been shown to stimulate lipolysis in a dose-dependent manner in 
rodent adipocytes in vitro (Hirai et al., 1998). In vivo administration o f ZAG to mice 
induces a rapid reduction in body fat stores and increases in serum free fatty acids via 
the activation of HSL. Both ZAG mRNA and protein have been detected in murine 
and human WAT. Thus, ZAG appears to play a key role in lipid metabolism and in 
the modulation of lipolysis in white adipocytes (Bing et al., 2004).
Retinol binding protein-4 (RBP4) is a protein required for the transport of retinol 
(vitamin A) from the liver and adipose tissue to target tissues. It is highly expressed 
by WAT, although liver and kidney are also a major source o f circulating levels 
(Trayhurn & Beattie, 2001). Raised serum concentrations have been reported in 
obese humans and mice, and it is thought that this may contribute to the development 
o f insulin resistance in obesity and type II diabetes mellitus (Yang et al., 2005). 
Fasting-induced adipose factor (FIAF) is an angiopoeitin-like protein which was 
originally identified as a result of it being a target gene for PPARa. Circulating levels 
have been found to rise on fasting (Kersten et al., 2000b). It has been shown to 
inhibit LPL regulating TG accumulation by white adipocytes (Backhed et a l, 2004). 
Furthermore, fasting induces increased expression of FIAF in the pituitary. This is 
suggestive o f a possible role for FIAF in both the peripheral and central regulation o f 
energy balance (Wiesner et al., 2004).
1.4.11 Growth factors
Adipokines include key growth factors and one such example is insulin-like growth 
factor-1 (IGF-1). This is secreted from WAT and stimulates preadipocyte 
differentiation and proliferation and further mediates the functions o f growth 
hormone in the tissue (Hausman et al., 2001). Transforming growth factor-p (TGFP) 
is an adipokine whose production by WAT is increased in murine genetic models of 
obesity (db/db and ob/ob) (Samad et al., 1998) and also in human obesity (Fain et al.,
2005) . TGFP is a negative regulator of adipocyte differentiation (Rahimi et al., 
1998), and stimulates production of PAI-1 by adipocytes (Samad et al., 1998). It is 
likely to play a key role in the expansion of WAT in obesity, as well as being part of
59
the increased cardiovascular risk associated with obesity, due to its link with raised 
levels o f PAI-1 production. One final adipokine which will be mentioned is vascular 
endothelial growth factor (VEGF). This is a potent angiogenic factor, whose plasma 
concentration is correlated with adiposity in db/db mice, and whose secretion has 
been found to be higher in visceral than subcutaneous WAT (Miyazawa-Hoshimoto 
et al., 2005). Adipocyte VEGF production is stimulated by insulin, but suppressed by 
dexamethasone (Fain & Madan, 2005). VEGF is likely to be a key player in the 
process of neovascularisation associated with expanded WAT depots in obesity.
1.5 11 p-hydroxysteroid dehydrogenase-1
Exposure to high circulating glucocorticoid concentrations, as found in Cushing’s 
syndrome, causes a metabolic disease which resembles features of idiopathic 
metabolic syndrome including pronounced visceral obesity (Seckl et al., 2004). 
However, idiopathic obesity is not associated with elevated circulating 
concentrations of glucocorticoids (Seckl et al., 2004). Rather, it seems that 
intracellular generation o f active cortisol from inactive cortisone locally in WAT, 
could amplify glucocorticoid signalling and may be responsible for co-morbidities 
associated with the metabolic syndrome in obesity (Stewart et al., 1999; Seckl et al., 
2004; Sandeep et al., 2005). A key factor in this process is the nicotinamide adenine 
dinucleotide (NAD)-dependent enzyme 11 P-hydroxysteroid dehydrogenase ( l ip-  
HSD). Two 1 ip-HSD isozymes have been characterised and their function and tissue 
specific expression is summarised in Fig. 1.5.
It has been demonstrated that both lip-HSD-1 mRNA levels and activity are 
elevated in visceral and abdominal subcutaneous WAT from obese individuals 
(Paulmyer-Lacroix et al., 2002; Rask et al., 2002; Alberti et al., 2007) and in 
omental WAT of Zucker fatty rats (Livingstone et al., 2000). Given the key 
association of visceral adipocity with metabolic and cardiovascular risk, it has been 
hypothesised that increased 1 ip-HSD-1 activity in visceral, rather than subcutaneous, 
adipose depots are responsible for the adverse metabolic consequences of obesity and 
the metabolic syndrome (Bujalska et al., 1997; Stewart et al., 1999). This has been 
supported by the observation that transgenic mice overexpressing lip-HSD-1 in 
WAT develop visceral obesity and the metabolic syndrome phenotype (Masuzaki ei
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al., 2001). Conversely global knockout mice are protected from the metabolic 
consequences o f dietary obesity (Morton et al., 2004). In addition, increased local 
conversion of cortisone to active cortisol through the expression o f 1 lp-HSD-1 has 
been primarily documented in omental compared to subcutaneous human adipocytes 
in vitro (Bujalska et al., 1999).
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Figure 1.5 Differential function and tissue expression of 11 P-HSD
isozymes
11P-HSD-1
Liver, adipose tissue, lung, macrophage, vascular 
tissue, central nervous system
ACTIVE steroids INERT steroids
Cortisol
◄-------------------------- Cortisone
Corticosterone 11-dehydroxycortosterone
Prednisolone Prednisone
11P-HSD-2
Kidney, colon, salivary gland, placenta, mid­
gestation fetus
Adaptedfrom  (Seckl et al., 2004)
lip-HSD-1 is predominantly al 1-ketoreductase, and is thus responsible for the reactivation 
o f inert cortisone into cortisol. In terms of isozymes, 11 P-HSD-1, but not lip-HSD-2, 
mRNA is expressed in white adipose tissue of both rodents and humans. lip-H SD-2 is a 
high-affinity (low nM for cortisol) NAD(H)-dependent dehydrogenase which rapidly 
converts cortisol to inert cortisone. In adults, lip-HSD-2 is primarily expressed in tissues 
where aldosterone induces its classical effects on sodium excretion, including the distal 
nephron, salivary glands and colonic mucosa.
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Increased expression o f lip-HSD-1 in visceral WAT has been associated with 
hypoadiponectinaemia. It has thus been proposed that this could play a role in 
decreased levels of insulin sensitivity associated with obesity (Alberti et al., 2007). 
Furthermore, 1 ip-HSD-1-driven cortisone reactivation regulates the synthesis and 
secretion o f PAI-1 by WAT, suggesting that local cortisol metabolism in adipose 
tissue may be involved in increasing risk of cardiometabolic diseases in obesity 
(Ayachi et al., 2006).
Mechanistically, glucocorticoids induce adipose tissue expansion by stimulating 
differentiation o f preadipocytes (Xu & Bjorntorp, 1990; Liu et al., 2006) and LPL- 
medated TG accumulation (Fried et al., 1993). A key factor in this process is tissue 
levels of the intracellular glucocorticoid receptor a  (GRa) and higher levels of GR 
have been found in omental compared to subcutaneous WAT (Rebuffe-Scrive et al., 
1990). The reasons for altered activity of lip-HSD-1 in obesity are not fully 
understood. There is mounting evidence that it may be dysregulated secondarily to 
factors that are altered in obesity, including substrates for metabolism, hormones and 
inflammatory mediators (Wake & Walker, 2006). 1 ip-HSD-1 is a potent therapeutic 
target for the treatment o f the metabolic syndrome, and although many specific 
inhibitors have now been developed (Tomlinson & Stewart, 2005), their efficacy in 
enhancing insulin sensitivity in WAT remains to be proven (Sandeep et al., 2005). 
To date, no research has been carried out linking 1 ip-HSD-1 with WAT in the dog, 
and with rising levels of companion obesity, this remains, as yet, an unexplored area 
o f canine obesity biology.
1.6 Aims of the thesis
Over the past two decades, there has been a radical change in the perception o f the 
role of WAT in the regulation o f energy balance and metabolism. It has been 
established that far from being a passive organ concerned with lipid storage, WAT is 
an important endocrine and secretory organ. In excess o f 50 protein factors and 
signals secreted by white adipocytes, termed adipokines, have been characterised. 
Thus, it is now apparent that WAT is a complex secretory and endocrine organ with 
extensive roles involving not only whole body energy metabolism but also the 
central control of appetite and energy intake (Trayhurn, 2005c).
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A key hypothesis is that adipose tissue-derived proinflammatory adipokines may 
play a direct role in the development of insulin-resistance and the associated 
pathologies o f obesity (Hotamisligil, 2003; Hotamisligil, 2006). There is now 
considerable evidence for support of this concept, with both circulating 
concentrations and adipocyte expression of several proinflammatory adipokines 
being raised in obesity, including leptin, IL-6 and TNFa (Considine et al., 1996; 
Mohamed-Ali et al., 1997; Bastard et al., 2000). In contrast, plasma concentrations 
o f adiponectin (an adipokine which has a role as an insulin sensitiser) (Yamauchi et 
al., 2001), are reduced in obesity (Abbasi et al., 2004).
Unlike humans and rodents, the study of adipose tissue biology in the context of 
obesity and energy balance in companion animals is in its infancy. Despite several 
reports of the metabolic consequences of obesity (Impellizeri et al., 2000; Gayet et 
al., 2004), further insights into the metabolic pathways involved remain to be 
elucidated. With the rapid rise in levels of obesity seen clinically in companion 
animals, work in this area has recently begun in earnest.
Therefore, the work presented in this thesis centres on characterising adipokine 
production from canine WAT and adipocytes in primary culture. It further addresses 
the hypothesis that white adipocytes are a source of several protein factors actively 
secreted by canine adipocytes, and that synthesis is regulated by both pro- 
inflammatory cytokines as well as anti-inflammatory agents. Furthermore, levels of 
gene expression of the key enzyme 11 p-HSD-1 responsible for the regulation of 
active glucocorticoid levels locally in WAT are also examined.
The first specific aim of the thesis was to investigate whether the expression of 
several proinflammatory adipokine genes could be detected in canine WAT. 
Subsequently, a robust system of primary culture of canine adipocytes was 
established with the aim of investigating whether these proteins where actively 
secreted by canine adipocytes, and therefore can be classified as adipokines in the 
dog.
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Conventional RT-PCR was initially employed, with the more sensitive technique o f 
qPCR used in subsequent parts of the study for quantitative comparisons. ELISA was 
used to detect levels of secreted protein in cell culture supernatant. Use o f these 
techniques allowed the investigation of the following:
1. A comparison of adipokine gene expression in the main WAT depots 
of the dog.
2. The study of adipokine gene expression and protein secretion by 
canine adipocytes, from both subcutaneous and visceral depots, 
during differentiation and development in primary culture.
3. Examination of whether proinflammatory cytokines such as TNFa 
and IL-6 regulate adipokine gene expression and secretion by canine 
adipocytes in vitro.
4. Exploration of the effect of both pro-inflammatory agents and 
compounds with an anti-inflammatory role in adipocyte metabolism 
in canine adipocytes in vitro.
5. Examination of the effect of treatment with both pro- and anti­
inflammatory mediators on the level of gene expression of the key 
enzyme 11P-HSD-1.
The project will provide important insights into obesity biology in the dog. By 
investigating whether synthesis and secretion of key adipokines occurs in canine 
WAT, it is expected that the understanding of the role o f adipose tissue as an 
important endocrine organ in the dog will be significantly enhanced.
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Chapter 2
Materials and Methods
2.1 Animals
Tissue samples were obtained from dogs euthanased at an animal shelter for reasons 
unrelated to the study, and from dogs undergoing surgery for routine neutering at the 
Fern Grove veterinary surgery, first opinion practice at the University of Liverpool. 
The study adhered to the University’s Guidelines on Animal Ethics. The breeds 
included were Staffordshire bull terrier (SBT) and Labrador, and all animals were 
entire at the time of sample collection (not neutered). Animals used for tissue 
expression studies were 6 male and 7 female SBT dogs between the ages of 2-6 years 
(estimated on dentition). Their nutritional status prior to the study for logistical 
reasons was unknown.
2.1.1 Tissue samples
Samples from liver, spleen, kidney, and from the five main WAT depots in the dog 
(subcutaneous inguinal, omental, peri-renal, gonadal and falciform ligament) were 
obtained within thirty minutes of euthanasia and immediately frozen in liquid 
nitrogen for future total RNA extraction. Further samples o f subcutaneous inguinal 
WAT were taken for primary culture of canine preadipocytes. Once tissues were 
collected animals were subjected to a DEXA scan (GE Healthcare) to determine 
body composition (Fig. 2.1). Data was analysed using enCORE 2004 software (GE 
Healthcare).
2.1.2 Surgical samples
Samples from the broad ligament of entire bitches undergoing routine surgery for 
neutering at Fem Grove veterinary surgery, University of Liverpool were used for 
primary culture of canine preadipocytes. Samples of peri-lipomatous and lipomatous 
tissue from an entire male Labrador undergoing surgery for an excision biopsy of a 
lipomatous ventral abdominal mass were also used. All owners gave written consent 
for collection of samples.
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Figure 2.1 DEXA scan image
This figure is a representative DEXA scan from an entire male SBT dog illustrating the 
typical image obtained from such a scan. DEXA is a non-invasive method of quantifying 
body composition (fat and lean content), which can be used in companion animals. It utilises 
x-ray of two different energy levels to distinguish the type and amount of tissue scanned. 
The x-ray source is positioned underneath the table supporting the subject, with the detector 
housed in an arm above. The detector measures the amount of x-rays which pass through the 
subject at any given time. X-rays of the two different energy levels are impeded differently 
by different tissues. The body can be compartmentalised and algorithms used to calculate 
both the quantity and type of tissue in each compartment (Toll e t a l., 1994).
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2.2 Preadipocyte primary cell culture
2.2.1 Reagents
All media and reagents for cell culture were prepared immediately using Coming 
filter systems (containing a 0.22 pm sterilising filter membrane) in a category II 
biological safety cabinet. Prepared media and buffers were pre-warmed to 37°C in a 
water bath and any excess discarded after use, unless stated otherwise.
(i) lOx HEPES (pH 7.4)
100 mM HEPES
12.5 mM sodium dihydrogen orthophosphate
12.5 mM disodium hydrogen phosphate 
Autoclaved distilled water
Aliquots were stored at -20°C.
(ii) 10% BSA (pH 7.4)
A 10% BSA solution was made up in autoclaved distilled water and left overnight at 
4°C to allow full dissolution prior to use. The pH was adjusted to 7.4 and aliquots 
were stored at -20° C.
(iii) lx Phosphate Buffered Saline (PBS)
137 mM sodium chloride
2.7 mM potassium chloride
8.1 mM disodium hydrogen phosphate
1.5 mM potassium dihydrogen orthophosphate 
Autoclaved distilled water
The pH adjusted to 1.2-1 A, and aliquots were stored at -20°C.
(iv) Transport Medium
15 mM HEPES
15 mM sodium hydrogen carbonate 
33 |iM D-biotin 
17 pM D-panthothenate 
lx DMEM
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100 U/ml penicillin G sodium 
100 pg/ml streptomycin sulphate
2.5 pg/ml amphotericin B
(v) Digestion Medium
1 mg/ml Collagenase 
4 mg/ml BSA 
20 mM HEPES 
lx  DMEM
100 U/ml penicillin G sodium 
100 pg/ml streptomycin sulphate
2.5 pg/ml amphotericin B
(vi) Washing Medium
10% FCS 
lx DMEM
100 U/ml penicillin G sodium 
100 pg/ml streptomycin sulphate
2.5 pg/ml amphotericin B
(vii) Erythrocyte lysis buffer (pH 7.4)
155 mM ammonium chloride 
10 mM potassium hydrogen carbonate
0.1 mMEDTA
(viii) Inoculation Medium
5% FCS 
4 pM D-biotin 
lx  DMEM
100 U/ml penicillin G sodium 
100 pg/ml streptomycin sulphate
2.5 pg/ml amphotericin B
70
(ix) Induction Medium
5% FCS
100 (iM indomethacin 
10 pg/ml insulin
0.5 mM IBMX 
lx  DMEM
100 U/ml penicillin G sodium 
100 pg/ml streptomycin sulphate
2.5 pg/ml amphotericin B
(x) Feeding Medium
5% FCS
100 pM indomethacin 
10 pg/ml insulin 
lx DMEM
100 U/ml penicillin G sodium 
100 pg/ml streptomycin sulphate
2.5 pg/ml amphotericin B
2.2.2 Collection of samples
On the day of collection, the required number o f aliquots of lOx HEPES, 10% BSA 
and lx  PBS were thawed. The transport and digestion media were freshly prepared. 
After dissection, WAT samples from each depot were rinsed immediately in lx  PBS. 
A portion o f each sample (2-5 g) was placed in transport medium for canine 
preadipocyte cell culture, and the remainder (1-2 g) as well as samples from liver, 
spleen and kidney, were snap frozen in liquid nitrogen for future total RNA 
extraction.
2.2.3 Fractionation method
The next steps were carried out in a category II biological safety cabinet. All items 
introduced into the cabinet were sprayed beforehand with 70% ethanol. Samples 
were transported from the dissection room to the laboratory within 30 min of 
collection. The sample in transport medium was placed in a Petri dish and carefully
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dissected, removing any blood vessels and other non-adipose tissue. The cleaned 
WAT was then finely minced using disposable scalpels before being transferred into 
freshly prepared digestion medium in universals. The universals were sealed with 
Nescofilm, placed in an HB-1000 hybridisation oven, and rotated at 100 cycles/min 
at 37°C for 50-60 min (or until the tissue was digested). The universals were 
removed from the oven every 15 min during the digestion process and shaken by 
hand to encourage thorough digestion and homogenisation of the tissue.
2.2.4 Culture method
After digestion was complete, the disrupted tissue was centrifuged at 200xg for 10 
min at room temperature. The mature adipocytes at the top of the supernatant were 
aspirated along with the supernatant into a sealed flask containing a solution of 1% 
Virkon, leaving the pellet of stromal vascular cells at the bottom. The pellet was then 
re-suspended in washing medium.
Once in washing medium the pellet was thoroughly homogenised and the suspension 
filtered through a 10 cm2 100 pm pore size mesh, to remove any remaining mature 
adipocytes and blood vessels. The filtrate was centrifuged at 200xg for 10 min at 
room temperature. The supernatant was aspirated, washing medium added, and the 
filtration step repeated. After the second filtration step, the supernatant was aspirated 
and washing medium added. The cells were then re-suspended and homogenised 
thoroughly. The suspension was again centrifuged at 200xg for 10 min and the 
supernatant aspirated. This washing step was repeated, the supernatant aspirated and 
the stromal vascular pellet re-suspended in pre-warmed erythrocyte lysis buffer. 
Cells were kept in the buffer for 10 min to allow adequate lysis o f any remaining 
erythrocytes. This was followed by centrifugation at 200xg for 10 min and aspiration 
of the supernatant. The remaining pellet was re-suspended in pre-warmed inoculation 
medium. An aliquot of this cell suspension was then stained with trypan blue and 
intact cells counted using a haemocytometer. Further inoculation medium was added
J
to achieve the required plating density (40,000-60,000 cells/cm2). Cells were seeded 
in 6-, 12 or 24-well plates as required and cultured at 37°C in an Mk II incubator 
(LEEC) with a humidified atmosphere of 5% C02/95% air.
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After 24 h, gonadal cells were thoroughly washed three times in lx  PBS and the 
inoculation medium replaced by induction medium. Cells from the subcutaneous 
inguinal depot had the inoculation medium replaced after 48 h and 24 h later (72 h 
after they were initially inoculated), the cells were thoroughly washed three times in 
lx PBS and the inoculation medium replaced by induction medium. Cells from both 
depots were allowed to stay in induction medium for 48 h after which this was 
replaced by feeding medium. The feeding medium was changed every 48 h.
2.2.5 Collection of conditioned media and cells
Conditioned media was collected by transferring the medium from each well into 2 
ml tubes and centrifuging at 200xg for 10 min at room temperature in order to pellet 
any cells or debris. After the centrifugation, the supernatants were transferred into 
fresh 2 ml tubes and stored at -20°C until further analysis.
Cells were harvested by firstly either collecting or discarding the media, then adding 
Tri-Reagent to each well. After allowing the plate to sit for 5 min, the Tri-Reagent 
was pipetted over the surface of the well several times to disrupt the cells. These cell 
suspensions were transferred to 2 ml tubes and stored at -80°C until further use.
2.2.6 Cell treatment
Time course studies using cells from both the subcutaneous inguinal and gonadal 
depots were performed by collecting media on the day of induction (day 0), and then 
on days 1, 2, 3, 4, 6, 8, 10, 12, and 15 post-induction. Cells were harvested in Tri- 
Reagent at the appropriate time points. In studies on the dose response of treatment 
agents on adipokine gene expression, canine adipocytes were first deprived of 
medium containing foetal calf serum (FCS) and indomethacin for 24 h on day 12 
after the induction of differentiation and subsequently treated with different 
concentrations of each agent for 2, 4 or 24 h.
2.2.7 Oil red O staining
2.2.7.1 Reagents
Oil red O 
haematoxylin
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37% formaldehyde 
lx  PBS
Both stains were filtered through a 0.22 pm membrane to remove any dye not in 
solution.
2.2.7.2 Method
Conditioned media was either collected or discarded and the remaining cells washed 
twice with lx  PBS and fixed using a 3.7% solution of formaldehyde for no more than 
1 h at room temperature. Once fixed, cells were again washed with lx  PBS and the 
same volume of Oil red O added to each well. Cells were incubated on a shaking 
platform at room temperature for 1 h. The washing step was repeated and the same 
volume of haematoxylin was added to each well. Cells were incubated on a shaking 
platform at room temperature for a further 5 min. The stained cells were washed with 
distilled water at 45°C and images captured using a Zeiss Axiovert 200M inverted 
microscope (Hitachi High-Technologies).
2.3 Total RNA isolation from tissues and cells
2.3.1 Tri-Reagent RNA extraction
2.3.1.1 Reagents
RNase AWAY 
Tri-Reagent 
Chloroform 
Isopropanol
Molecular biology grade ethanol, 75%
Ultra-pure water (0.1 pm filtered, DNase and RNase free) 
UV-irradiated distilled water
2.3.1.2 RNA extraction method
Ribonucleic acid (RNA) extraction from both cells and tissues was carried out in a 
category I chemical fume cabinet. Dressing forceps, dissecting scissors and electric 
homogenizer blade attachments were treated with RNase AWAY and rinsed with
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UV-irradiated distilled water several times prior to use to avoid contamination with 
RNases. For each group o f tissue samples, the homogenizer was rinsed twice in UV- 
irradiated distilled water.
For RNA extraction from white adipose tissue, 50-150 mg of snap-frozen tissue was 
cut from the sample using a fresh sterile scalpel, dissecting scissors and forceps, 
while on dry ice. Alternatively, extraction from denser tissues such as liver and 
spleen was carried out by placing the sample in a polythene sachet and gently 
breaking it into approximately 50 mg pieces with a hammer. One ml of Tri-Reagent 
was added to the 4 ml tube into which the tissue sample was placed, and the sample 
homogenized using an electric homogenizer (Polytron Ultra-Turrax T25). The tissue 
homogenate was transferred into a 2 ml tube and centrifuged at 14000xg for 10 min 
at 4°C. The clear supernatant was aspirated and transferred into a fresh 2 ml tube. 
Care was taken to avoid aspirating any cell debris or any lipid overlying the 
supernatant. RNA extraction from cells was carried out as described by collecting 
cells using Tri-Reagent and subsequently homogenizing the sample by repeat 
aspiration using a sterile 1 ml syringe with a 23 gauge needle.
After leaving the tissue or cell homogenate at room temperature for 5 min, 200 pi o f 
chloroform were added per ml of Tri-Reagent. Each tube was then vortexed for 15 
sec and allowed to stand for 10 min at room temperature. This was followed by 
centrifugation at 14000xg for 15 min at 4°C, leading to separation of the solution into 
three layers; a colourless upper aqueous phase containing the total RNA, a white 
interphase layer containing DNA and a lower red phenol phase containing protein. 
The uppermost layer containing the total RNA was transferred into a fresh 2 ml tube.
To minimise any possible contamination o f the sample with genomic DNA, a further 
purifying step was carried out as follows; 50 pi of isopropanol were added to the 
sample per ml of Tri-Reagent. The sample was vortexed, allowed to stand for 10 min 
at room temperature and then centrifuged at 14000xg for a further 10 min at 4°C. The 
supernatant was transferred into a 1.5 ml tube, taking care to avoid aspirating the 
area where any genomic DNA would have been precipitated.
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A larger volume of isopropanol was added to the sample (450 pi per ml o f Tri- 
Reagent in the initial sample preparation) to precipitate the total RNA. This was 
followed by vortexing, incubation of the sample for 10 min at room temperature and 
centrifugation at 14000xg for a further 10 min at 4°C. Once this step was complete, 
the precipitated RNA pellet could usually be visualised at the bottom of the tube.
The supernatant was discarded and 100 pi of a 75% solution of molecular grade 
ethanol in ultra-pure water was added to the RNA pellet. This was followed by 
vortexing and centrifugation at 14000xg for 5 min at 4°C. The supernatant was again 
discarded and the RNA pellet allowed to air dry for 2-3 min at room temperature. 
The pellet was dissolved by adding 10 pi o f ultra-pure water, briefly vortexed and 
spun. Samples were then either stored briefly at -20°C prior to DNase treatment and
quantification or placed at -80°C for long-term storage. All non-disposable
equipment used was cleaned of any tissue debris, rinsed and soaked for 1 -2 h in a 1% 
Virkon solution before being further rinsed with distilled water and stored.
2.3.2 DNase treatment of RNA
2.3.2.1 Reagents
Turbo DNA-free Kit:
120 pi TURBO DNase (2 Units/pl)
600 pi lOx TURBO DNase Buffer 
600 pi DNase Inactivation Reagent 
1.75 ml Nuclease-free water
2.3.2.2 Method
RNA samples which were to be analysed by real time polymerase chain reaction 
(qPCR) were treated to further minimise any genomic DNA contamination. One pi 
of turbo DNase and the same volume o f lOx turbo DNase buffer were added to each 
10 pi RNA sample. The sample was then gently vortexed, centrifuged and incubated 
at 37°C in a hybridisation oven (HB-1000) for 20-30 min. Two pi of DNase 
inactivation reagent were added and the sample vortexed gently. This was followed 
by a further incubation o f 2 min at room temperature during which the samples were 
gently agitated to re-disperse the DNase inactivation reagent. The sample was
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centrifuged at lOOOOxg for 1.5 min at room temperature to pellet the DNase 
inactivation reagent. The supernatant containing total RNA was aspirated and placed 
in a separate tube for further use or storage at -80°C.
2.3.3 RNA quantification
RNA samples were quantified using a spectrophotometer (BioPhotometer). One pi o f 
total RNA was added to 69 pi of distilled water, a 1 in 70 dilution (dilution factor 
(DF) of 70). The diluted sample was placed in a disposable plastic cuvette (UVette), 
and the absorbance measured at 260 nm (A2 6 0) and 280 nm (A2 8 0) using distilled 
water as a blank.
Nucleic acids have their maximal light absorbance at A2 6 0 , whilst proteins absorb 
light maximally at A28o- The extinction coefficient of RNA at A26o is approximately 
40. The concentration of each RNA sample was determined by the 
spectrophotometer using the Beer-Lambert law:
[RNA] pg/ml = A2 6 0  x 40 x DF / 1000
The ratio between A26o and A28o was calculated as an indication of the purity o f the 
RNA in the sample. A ratio of 1.8 to 2.0 was indicative o f a sample o f high purity, a 
low ratio of 1.6 or less was suggestive o f protein contamination (increased 
absorbance at A28o), whereas a high ratio above 2.0 was indicative o f genomic DNA 
contamination.
2.3.4 RNA integrity
More than 80% of the total RNA extracted from mammalian cells is comprised of 
ribosomal RNA (rRNA), mainly consisting of 28S and 18S species. The remainder is 
made up o f the other RNA, o f which messenger RNA (mRNA) comprises only 1- 
3%. The method used to check RNA integrity (denaturing gel electrophoresis) relies 
on the assumption that rRNA quality and quantity reflect that of other RNA species 
including that of mRNA (Palmer & Prediger, 2007). There may also be a degree of 
difference between the integrity of the long-lived and abundant rRNA molecules and 
that o f the mRNA population, which has a much more rapid turnover.
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As will be described in section 2.5, RT-PCR (reverse transcription-polymerase chain 
reaction) was performed for each total RNA sample. Once complementary DNA 
(cDNA) had been synthesised from existing mRNA by RT, the quality was assessed 
by performing PCR using primers for P-actin (the housekeeping gene of choice), and 
running the products on an agarose gel. The intensity o f the DNA band observed on 
the gel, at a specified number of cycles of amplification, was used as an indication o f 
the integrity o f the original mRNA template. Faint or undetectable bands were 
suggestive of degradation of the mRNA or of a failed RT reaction. The former was 
investigated by checking the integrity of the mRNA directly by running a specified 
amount (usually 1 pg) of total RNA on a gel, and if found to be significantly 
degraded the sample was re-extracted from the tissue (see Fig. 2.2).
2.3.4.1 Reagents
Ultra-pure water
Sample buffer (1 ml 40% glycerol, 40 pi saturated BPB solution
Reagents used for agarose gel electrophoresis (see section 2.5.3)
2.3.4.2 Method
One pg of total RNA was diluted with ultra-pure water to a total volume of 5 pi in a
0.2 ml tube and a further 2 pi o f sample buffer added. The sample was then briefly 
vortexed and loaded onto a pre-prepared 1% agarose gel (see section 2.4.3) and run 
at 80-100 V for 30-40 min. An image of the gel was photographed as described in 
section 2.4.3.2. An undegraded RNA sample would have two clearly visible and 
well-defined bands representing 28S and 18S rRNA with little or no visible debris at 
the base o f the gel. Degradation would be inferred from the absence or smudging of 
the rRNA bands coupled with a strong signal at the base of the gel.
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Figure 2.2 Checking mRNA integrity from a sample of total RNA
This figure illustrates how the integrity of the mRNA in a sample o f total RNA can be 
inferred from that of the rRNA present. RT-PCR of total RNA extracted from tissues shows 
a faint band for spleen (usually more resilient to RNA degradation compared to other tissues 
such as liver), indicative of degradation (A). When total RNA samples were run on a 
denaturing gel no clear 28 or 18S bans were visible with a pooling o f RNA fragments at the 
bottom of the gel (B). Spleen samples were re-extracted in duplicate and the RNA run on a 
gel. Distinct 28 and 18S bands can be seen in approximately a 2:1 ratio as expected (C). 
Samples were subjected to RT-PCR and a clear bands showing good product amplification 
were seen (D). sc, subcutaneous inguinal; om, omental; gon, gonadal; pr, peri-renal; fal, 
falciform ligament; liv, liver; sp, spleen; kid, kidney, p-actin (25 cycles). Amplicon size 289 
bp.
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The most critical factor in determining the quality of extracted RNA is the 
physiological state of the tissue at the point of removal (Palmer & Prediger, 2007). 
Isolating RNA from companion animal tissue presents many challenges which are 
not always present in laboratory animal work. Factors which may affect the quality 
o f the RNA sample include the physiological state of the tissue prior to death (agonal 
state), and the post-mortem interval (the delay between time o f death and tissue 
collection). Thus it is rare that RNA extracted from tissues will have 28S:18S ratios 
o f exactly 2.0. The level of degradation has also been found to vary, to some degree, 
with the tissue of origin. This is likely to be due to tissue-specific responses to 
physiological stress both prior to and following death. Lower rRNA ratios are 
characteristic of some tissues such as liver and lung, regardless of whether the tissue 
is sourced from rodent or human (Palmer & Prediger, 2007). Other tissues such as 
spleen and kidney are known to be more resilient and if faint bands are seen on RT- 
PCR, re-extraction will usually yield a good quality product.
2.4 Reverse-transcription polymerase chain reaction
2.4.1 Reverse transcription
Once samples of total RNA had been quantified and treated for any remaining 
genomic DNA contamination, RT was used to generate single-stranded DNA 
(ssDNA) strands complementary to those of the mRNA sequences in the total RNA. 
These ssDNA sequences are referred to as complementary DNA (cDNA). Anchored 
oligo dT primers were used as they are specifically designed to anneal at the 
mRNA/poly-A junction rather than at random points along the poly-A tail o f the 
mRNA molecule (as is the case with standard dT primers), or at random points along 
the mRNA sequence as occurs with random decamers. Commencing transcription at 
the start of the 3’ end of the coding mRNA sequence results in an increased yield of 
cDNA with fewer truncated sequences, which is an advantage when later using PCR 
or real-time PCR (qPCR) to study genes which are not highly expressed.
2.4.1.1 Reagents
Ultra-pure water
Reverse-iT 1st Strand Synthesis Kit:
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500 ng/fj.1 Anchored oligo dT 
5x 1st Strand Synthesis buffer 
5 mM each dNTP mix 
50 units/pl Reverse-iT RTase Blend 
100 mM DTT
2.4.1.2 Method
For this procedure, sterile RNase/DNase-ffee 0.2 ml tubes and filter tips were used. 
All incubations were performed using a thermal cycler (PCR Express). Reactions 
were performed in either a 10 or 20 pi reaction volume. For a 20 pi reaction volume,
1 pg of total RNA and lp l of anchored oligo dT were placed into a 0.2 ml tube, 
together with ultra-pure water to a total volume of 13 pi. A negative control tube was 
always used where the total RNA template was replaced with ultra-pure water. The 
samples were then incubated at 70°C for 5 min to denature the RNA. Samples were 
then rapidly cooled on ice to minimise the formation of any secondary structures.
A master mix was made containing 4 pi of 5x 1st Strand Synthesis buffer, 2 pi of 
dNTP mix, 1 pi o f Reverse-iT RTase Blend and 1 pi of DDT per sample o f total 
RNA (with a 5-10% excess). Eight pi of this master mix were added to each sample 
tube and each tube vortexed and centrifuged. The reaction was performed by 
incubating the tubes at 47°C for 30 min during which the cDNA was synthesised. 
The reaction was terminated by incubating at 75 °C for 10 min to denature the RTase. 
The final reaction was then diluted 1 in 4 with ultra-pure water to generate cDNA 
template for PCR use. The cDNA product was stored at -20°C if not used 
immediately for PCR.
2.4.2 Polymerase chain reaction
PCR uses DNA polymerase and gene-specific primers to amplify the cDNA of 
interest. The process begins with a denaturation phase, followed by 15-40 cycles of 
product amplification. Each cycle consists of three steps: denaturation, annealing and 
extension. The initial denaturation at 94°C for 4 min allows the dissociation of any 
double-stranded DNA (dsDNA) into ssDNA and the unwinding of the helical 
structure of DNA. The annealing temperature (Ta) is primer specific, and depends on 
several factors such as primer length and GC content (the higher the GC content the
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lower the annealing temperature a primer will have). The Ta enables the primers to 
hybridise to their complementary bases on the ssDNA. This is followed by an 
extension phase during which the DNA polymerase synthesises a complementary 
DNA strand starting from the site where the primer anneals in a 5’-3’ direction.
When assessing the level of gene expression of a particular gene, it is compared with 
that of a gene whose level o f expression is known to be stable; such a gene is referred 
to as a ‘housekeeping’ gene. This is one which ideally should be expressed at a 
constant level in different tissues, and within the same tissue under all conditions. 
The selection o f an appropriate housekeeping gene is critical as it is used to assess 
the relative degrees of expression of the genes of interest as well as indicate the 
quality of the template material used. Typical housekeeping genes are P-actin, 
glyceraldehyde-3-phosphate (GAPDH) 18S rRNA and RNA polymerase Ha. Studies 
examining gene expression in WAT have successfully used P-actin as the 
housekeeping gene (Gorzelniak et al., 2001; Eisele et al., 2005; Zhang et al., 2005) 
and this therefore was the gene o f choice for both PCR and real-time PCR (qPCR) 
assays. However, if its level of expression was affected by experimental conditions, a 
second gene, RNA polymerase Ha (RNAPolIIa) was used instead.
2.4.2.1 Primer design and optimisation
Primers were designed using Primer Premier 5 software and synthesised 
commercially (Eurogenetec Romsey, UK). The sequence for the gene of interest was 
obtained by searching the NCBI PubMed Entrez Nucleotide database 
('www.nchi.nlm.nih.gov/entrez) for the most complete sequence available. The 
protein coding sequence (CDS) in FASTA file format, together with the locations on 
the CDS or mRNA sequence for exon-exon boundaries were identified.
Identifying exon-exon boundaries was important, as a pair of primers (forward and 
reverse) could then be designed to span at least one such junction, ideally containing 
a large intron. This would make any genomic DNA contaminants present in the 
cDNA template easily identifiable as a much larger band on the agarose gel. The 
location of introns were established either directly (using NCBI’s Map Viewer 
utility), or calculated from the chromosomal exon locations when the sequence was 
subjected to a BLAST search (http://www.ncbi.nlm.nih.gov/BLAST/) against the
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genome. Ideally, all primers would be sited so as to generate a product from the 
CDS. However, if necessary, one of the primers could be sited up or down-stream of 
this region so as to still span an intron.
The design of primers was carried out according to several parameters. The optimal 
primer length was chosen to be between 18 and 24 bases. Longer primers were 
preferred as they are more specific during amplification (allowing a lower Ta, and 
thus a faster reaction). However, these are more likely to dimerise and form 
secondary structures. Primers with the least and most unstable secondary structures 
were always chosen as these structures would tend to disappear at higher Tas. Any 
secondary structure or false priming at the 3’ end of the primer was especially 
avoided, as these could theoretically be extended and therefore amplified by the 
DNA polymerase.
The primer melting temperature (Tm) was ideally between 60-65°C (and within 2 C 
of each other for a primer pair), so that the Ta would not be below 55 C since a low 
Ta promotes non-specific binding of primers. The guanine-cytosine (GC) content of 
each primer was in the region o f 50-60%, and roughly equal between the two 
primers, as with increasing GC content the Tm increases. The ideal amplicon size was 
between 200-600 bp as larger products require longer annealing and extension times. 
Finally, after designing each primer, both forward and reverse primer sequences as 
well as that of the expected amplicon were subjected to a BLAST search to ensure 
specificity.
On receipt, primers were tested by performing PCR with one or more cDNA samples 
in which a signal for that gene might be expected. A high cycle number (>35), and a 
low annealing temperature (53-55°C) were used initially to maximise the chances of 
obtaining a product. If a product was obtained, the primer was then optimised by 
performing PCR over a range of Tas (5°C below, at the recommended Ta, and 5°C 
above the Ta), and selecting the highest at which a strong signal was obtained with no 
non-specific product formation. Finally, the cycle number was optimised by 
performing PCR over a range of cycle numbers and selecting that at which a distinct 
signal could be detected. RT-PCR primer sequences and optimal cycling conditions 
are detailed in Table 2.1.
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2A.2.2 Reagents
Ultra-pure water
10 pM each sense and anti-sense primer mix 
ReddyMix PCR Master Mix Kit:
1. lx  ReddyMix
2A.2.3 Method
As for reverse transcription, this procedure was carried out using sterile 0.2 ml 
RNA/DNA-free tubes and filter tips. Reactions were performed using a thermal 
cycler (PCR Express). A master mix containing 11.25 pi of 1.1 x ReddyMix, 0.25 pi 
of primer mix and 0.5 pi o f ultra-pure water per sample was prepared (with a 5-10% 
excess to allow for pipetting inaccuracies). Samples were then vortexed and 
centrifuged. Twelve pi of this master mix were transferred into each tube and 0.5 pi 
o f the appropriate cDNA template added for a 12.5 pi final reaction volume. All 
volumes were proportionally scaled up for 25 and 50 pi reactions as needed. Ultra- 
pure water was used as the non-template control (NTC). The tubes were vortexed, 
centrifuged and placed into the thermal cycler with the PCR program as follows:
1. 94°C for 2 min (denaturation step)
2. 20-35 cycles (specified by the optimal cycle number for each primer pair) of:
i. 94° C for 20 sec (denaturation)
ii. 53-62°C for 30 sec (annealing; Ta optimised for each primer pair)
iii. 72°C for 30 sec (extension)
3. 72°C for 5 min (final product extension)
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Table 2.1 Sequences of RT-PCR primers
P rim er T a(°C) C ycles Product (bp) Sequence (5’-3’)
ß-actin s 55.0 25 289 AGG ACTCCT ACGTGGGCG AT G A
ß-actin as CCAGAGGCXtACÄGGGACAGCA
NGF-ß s 56.0 28 368 CCACTGGACTAAACT TCAGCATTC
NGF-ß as T CACCTCCTTGCCCTTGÀTG
T N Fa s 56.0 34 248 AACCCCAAGTGACAAGCCAGTA
T N Fa as T CTGGTAGGAGACGGCGAAG
IL-6 s 55.0 34 237 GCTACTGCTTTCCCTACCCC
IL-6 as GC AT CC AT CTTTT CCCT CCA
IL-18 s 54.0 30 345 AGGATATGCCCGATTCTGACTG
IL-18 as CCCCATTTT CAT CCTT GT CTTT
Leptin s 56.0 32 387 CTGTGCCAATCCGAAAAGTC
Leptin as GTCTGTTCAGAGCCACCACC
Adiponectin s 60.0 26 416 AAGGAGATCCAGGTCTTGTTGG
Adiponectin as TTCCAGATGAAGGAGCACAGAG
M CP-1 s 51.2 23 234 GCTCACCCAGCCAGATGC
M CP-1 as GCAGTTTGGGTTTGGCTTTT
M IF s 60.0 32 225 TCATCGTAAACACCAACGTGCCC
M IF as GCTTGCTGTAGGAGCGGTTCTGC
G L U T 4s 57.0 32 403 TTGGTCTCGGTGTTCCTGGTC
GLUT4 as CGGGTTTCAGGCACTTTTAGGA
L P L s 59.0 32 193 TT G AG AAAGGGCTTT GCCT GAG
LPL as GGCCTGGTTGGTCTGTGCATCA
Haptoglobin s 60.0 26 409 GTAGAGCACATGATTCGCTACCAG
Haptoglobin as GTAGGACCACCTTTTCAACCTCC
Adipsin s 57.1 27 176 CAGCCTCGTGGGCGCATCCT
Adipsin as AGCACCCGCACCTTCCCGTC
PAI-1 s 56.0 32 325 ATGTTCATCGCCGCTCCCT AT
PAI-1 as CG AT AAT GGC AGT AG AGG AGG AC
V E G F s 61.5 32 344, 373, 283 CATCTTCCAGGAGTACCCTGACG
VEG F as AAACAAATGCTTTCTCCGCTCT
PPAR yl s 57 25 410 CATCTTTCAGGGGTGTCAGTTCC
PP A R yl as TCCAAGGCTTGTAGCAGGTTGT
PPARy2 s 57.9 25 400 ATCCCTCTTCCATGCTGTTATG
PPARy2 as GGCTCTTCGTGAGGCTTATTGT
S A A s 60.4 28 334 AGGGAGAAGCAGCGAACC
SAA as ACCCAGGACCAAGGAACAG
This table shows the sequences of primers used for RT-PCR reactions together with the 
expected product sizes and annealing temperatures (Ta). The amplification cycle numbers are 
those used, unless stated otherwise. All primers were designed based on sequences obtained 
from the canine genome.
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2.4.3 Agarose gel electrophoresis
2.4.3.1 Reagents
Agarose 
5 mg/ml EtBr 
lOx TBE buffer
100 bp DNA ladder (Superladder-Low 100 bp Ladder with ReddyRun) 
Distilled water
1% agarose gel (final volume 60/90 ml):
0.6/0.9 mg agarose
60/90 ml lx  TBE buffer
2/3 pi EtBr (final concentration of 0.167 pg/ml)
Distilled water was used to dilute lOx TBE buffer to prepare lx  TBE for use.
2A.3.2 Method
A  gel casting tray of appropriate size was prepared by sealing both ends with a strip 
of autoclave tape. The agarose was weighed and placed into a 500 ml conical flask 
containing lx  TBE and the flask heated for ~ 5 min in a microwave. The flask was 
removed every few seconds and agitated until the agarose was completely dissolved. 
The solution was placed in a category I chemical safety cabinet and once cool, the 
EtBr was added and mixed by gentle swirling o f the flask. The mixture was poured 
into the casting tray and any bubbles pushed to the edges o f the tray with one of the 
combs. The combs were then placed into their slots, and the gel allowed to set for at 
least 30 min. Once set, the autoclave tape and combs were removed and the gel 
placed into the gel tank. The tank was filled with lx  TBE until the gel was fully 
submerged.
Ten pi of PCR product and 1.5 pi of ladder were loaded into separate wells. The gel 
was run at 85-100 V for 30-60 min or until it was judged that the samples had run far 
enough for adequate separation of the bands on the ladder. Bands were detected by 
placing the gel under a UV Transilluminator (2011 Macrovue). The images were 
recorded by a DC 120 digital camera (Kodak) and analysed using digital Science ID 1 
image analysis software (Kodak).
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2.4.4 PCR product purification and sequencing
If PCR primers are designed correctly, the product obtained should be the 
amplification of the desired mRNA. However, in order to confirm that the target 
cDNA had indeed been amplified, the product obtained was sequenced. All 
sequencing was performed commercially by MWG Biotech (Germany).
2.4.4.1 Reagents
ReddyMix PCR Master Mix Kit (1. lx Reddy Mix)
NucleoSpin Extract 2-in-l Kit:
Buffer NT1 
Buffer NT2 
Buffer NT3 
NucleoSpin columns 
NucleoSpin collecting tubes 
Ultra-pure water 
100 bp ladder GeneRuler
Sample buffer (1ml 40% glycerol, 40 pi saturated BPB solution)
2.4.4.2 Method
Two 50 pi PCR reactions using a single template cDNA previously identified as 
strongly expressing the gene o f interest were performed to obtain a total reaction 
volume of 100 pi. High cycle numbers were used to generate a large quantity of PCR 
product. The reaction volumes were pooled and run on a pre-prepared 1% agarose 
gel using a single composite well (obtained by placing autoclave tape over several 
teeth of the desired comb in advance), large enough to accommodate both reaction 
volumes. The gel was then run at 80-100 V or 30 min and the band visualised under 
UV light. Once visualised, the band was excised with a scalpel, weighed and the 
entire gel fragment transferred into a pre-weighed 2 ml tube and its mass determined. 
The PCR product was extracted from the gel according to instructions in the 
NucleoSpin Extract 2-in-l kit as follows:
Three hundred pi of NT1 was added to the tube containing the PCR product in the 
gel per 100 mg o f gel fragment. This was incubated at 50°C in a water bath with 
gentle agitation until the gel had dissolved (~ 10 min). A NucleoSpin column was
87
placed in a sterile 2 ml tube and 700 pi o f the sample loaded. This was centrifuged 
for 1 min at 8000xg. The flow-through the collecting tube was discarded. If  the 
sample volume was >700 pi, the procedure was repeated and the flow-through 
discarded every time until the total volume had been processed. Once this step was 
complete, the PCR product (impure) was bound to the membrane of the column. A 
washing step was undertaken which was designed to remove any inhibitors or 
contaminants from the agarose gel. This was performed by adding 500 pi of NT2 to 
the column and centrifuging for 1 min at llOOOxg. The flow-through was again 
discarded and a further washing step was carried out by adding 600 pi o f NT3 to the 
column which was centrifuged for a further 60 sec at 1 lOOOxg. After discarding the 
flow-through, 200 pi of NT3 was added and the column centrifuged for a further 2 
min at 1 lOOOxg to dry the membrane. The column was transferred into a 1.5 ml tube 
and 30 pi of ultra-pure water added. The column was allowed to stand for 1 min at 
room temperature to allow full dissolution of the DNA product. Finally, the column 
was centrifuged for 1 min at llOOOxg to collect the eluted DNA within the 1.5 ml 
tube.
For a gene product to be accurately sequenced, a minimum of 20 ng of DNA product 
is needed per 100 bp of product. The concentration of the purified DNA in solution 
was estimated by preparing a sample consisting o f 1 pi o f the purified DNA, in 5 pi 
o f ultra-pure water and 2 pi of sample buffer. This was loaded into a pre-prepared 
1% agarose gel and run as described previously alongside 2 pi of quantifying 100 bp 
ladder (GeneRuler). The concentration of DNA in the solution could be estimated 
according to the brightness of the band. If the band was faint or absent, the whole 
procedure was repeated from the PCR reaction onwards.
The 100 bp GeneRuler was prepared by adding 1 pi (0.5 pg) of ladder DNA, 1 pi o f 
loading dye solution and 4 pi o f ultra-pure water. The ladder DNA was therefore 
diluted 1:6 (working concentration o f 0.083 pg/pl). Two pi of ladder, containing 
0.17 pg of DNA, were loaded onto the gel alongside the sample to be quantified. 
According to the manufacturer’s protocol, a specific quantity of DNA is present in 
each band seen on the gel when 1 pg of the ladder DNA is used. Thus, the amount of 
DNA present in each band when 0.17 pg of ladder were used could be determined.
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A set volume (1 pi), of the purified DNA solution was run alongside the ladder and 
the brightness of the purified DNA band was compared to that of each o f the Gene 
Ruler ladder’s bands by eye and that of the nearest intensity identified. The DNA 
concentration of that ladder band was then taken to be the approximate concentration 
o f DNA in the purified solution. An aliquot (in duplicate), of this solution containing 
the required amount of DNA for sequencing was then placed in a 1.5 ml tube and 
dried using a Heptovac VR-1 vacuum centrifuge (Thermo). Both aliquots were then 
sent for sequencing as well as a solution containing 10 pi o f the sense and anti-sense 
primers. When results from the sequencing were returned, these were subjected to a 
basic local alignment search tool (BLAST) search to confirm their identity.
2.5 Real-time polymerase chain reaction
Real-time PCR (qPCR) is a technique which allows the absolute or relative 
quantification of the initial amount of template in a sensitive, specific and 
reproducible manner. This is possible as qPCR monitors the fluorescence emitted 
during the reaction as an indicator of product production during each PCR cycle, the 
fluorescence signal increasing in direct proportion to the amount of PCR product (or 
amplicon). During the exponential phase of the reaction, there is a marked increase in 
the amount of product produced. The more of the initial template there is, the earlier 
during the reaction the florescence signal will begin its exponential rise.
2.5.1 Detection chemistries
There are a range of different detection chemistries available for qPCR; these include 
not only the hydrolysis or TaqMan Probes system and SYBER Green I, but also 
molecular beacons, scorpions and hybridisation probes.
2.5.1.1 Hydrolysis or Taqman® system
This system involves the use of a pair of primers (forward and reverse) and a 
Taqman probe (Applied Biosystems) to amplify the mRNA of interest. The probe is 
an oligonucleotide with a fluorescent (reporter) dye (usually FAM -  6- 
carboxyfluorescein) on the 5’base, and a quenching dye (usually TAMRA -  6 
carboxytetrametheyrhodamine) located on the 3 ’base. All three oligonucleotides are 
specific for the target and are able to bind to it. When the probe is intact, energy is
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transferred from the reporter dye to the nearby quenching dye by fluorescence 
resonance energy transfer (FRET), rather than be emitted as fluorescence detectable 
by the machine (Giulietti et al., 2001). When the Taq polymerase replicates a 
template onto which the probe is bound, its 5’ exonuclease activity cleaves the probe 
separating the reporter and quenching dyes ending the FRET. The reporter dye is 
now able to emit fluorescence (at 518 nm for FAM) which the machine can then 
detect (Fig 2.3 A). The amount of fluorescence increases in each cycle in a manner 
proportional to DNA amplification. This accumulation of PCR product is detected by 
monitoring the increase in fluorescence (AR) of the reporter dye plotted as ARn after 
normalisation o f the reporter dye signal to a reference dye, usually ROX (carboxy-X- 
rhodamine). The reference dye is used to correct for differences in reaction mix 
volumes between wells.
2.5.1.2 SYBERGreenl
SYBER Green I is a DNA-binding dye which can be used for the detection of PCR 
product formation avoiding the need for an expensive, albeit specific probe. Its 
fluorescence is virtually undetectable when free in solution, but when bound to 
double-stranded DNA (dsDNA), the fluorescence increases by over 1000-fold (Fig
2.3 B). As DNA is amplified, the amount of dsDNA increases and the more binding 
sites there are for the dye, so fluorescence increases in proportion with DNA 
concentration. This property allows the dye to be used to track the accumulation of 
PCR product as the increasing concentration of dsDNA in the solution can be 
directly measured by the increase in fluorescence signal. One limitation of such an 
assay is the non-specificity o f this method, as SYBER Green I will lead to an 
increase in fluorescence when bound to any dsDNA molecule. The specificity o f the 
reaction is determined solely by the primers. Its many uses include optimising primer 
concentrations prior to optimising that of the probe (see section 2.5.2).
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Figure 2.3 Detection chemistries used in qPCR
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This figure illustrates the two forms o f detection chemistries for qPCR used in this study. 
The TaqMan assay utilises as specific probe oligonucleotide with a reporter dye at the 5’ end 
(FAM), and a quenching dye at the 3’ end (TAMRA). As product is amplified the 5 ’ to 3 ’ 
exonuclease activity o f the polymerase cleaves probe ending the FRET and allowing 
fluorescence emission from the reporter dye to occur (A). DNA-binding dyes such SYBER 
Green I emit barely detectable levels o f fluorescence in solution. However, once bound to 
dsDNA product the level of fluorescence is markedly increased and this is then detected 
allowing the amount of template to be quantified (B).
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2.5.2 Design of primers and Taqman probes
Canine primers and probe sequences were designed using Beacon Designer 4.02 
software (Premier Biosoft International) and synthesised commercially 
(Eurogenetec). Gene sequences and intron/exon data were obtained as in section
2.5.2.1. Primers were designed to span an intron and be 20-30 bases in length, with 
primer Tms of 58-60°C. The probe was designed to have a Tm 10°C higher than that 
o f the primers. This allows both the hybridisation of the probe and primers, and 
cleavage o f the probe. The product size was designed to be between 60-120 bases, as 
PCR is more efficient with smaller amplicons. A specific requirement of Taqman 
probes was that there be no G at the 5’ end, as a G adjacent to the reporter dye results 
in quenching of the reporter fluorescence even once the probe has been cleaved.
Canine primer and TaqMan probe sequences, as well as the optimised final reaction 
concentrations for each, are detailed in Table 2.2. The optimal concentration for each 
new pair of primers was determined by performing an assay with final concentrations 
o f sense and anti-sense primers ranging from 100 nM to 600 nM, in all possible 
combinations, using SYBER Green I. The resulting amplification plots were 
examined, and the primer concentration providing the lowest CT (threshold cycle, the 
cycle at which fluorescence measured by the instrument is at a statistically 
significant level above that of the background signal) and the highest ARn was 
selected for use. All products generated during a qPCR amplification reaction are 
melted at 95°C, then annealed at 55°C and subjected to a gradual increase in 
temperature to 95°C. The result is a plot of raw fluorescence data versus temperature 
where one should aim to see a rapid decline in fluorescence between 82°C and 84°C 
where the main PCR product melts. If this same data is analysed by plotting the 
negative first derivative of raw fluorescence against increasing temperature, a single 
peak (indicating one major product) should be observed between 84.5°C and 88°C. 
TaqMan probes were optimised at concentrations of 100-200 nM using the optimised 
primer pair concentrations. The amplifications plots were used to select the optimal 
probe concentrations using the same criteria (lowest Ct and highest ARn) as used for 
primer concentration selection.
92
Table 2.2 Sequences of primers and TaqMan probes used for qPCR
P rim er Product
(bp)
Final cone. 
(nM )
Sequence (5’-3 ’)
P-actin s 96 300 GCAT CCT GACCCTCAAGTACC
P-actin as 300 AGCTCGTTGTAGAAGGTGTGG
P-actin P 200 CGÂGC ACGGCAT CGTC ACC AACT G
RNApolIIa s 122 600 TC M cW C C fC A G TTA C G TG G TC
RNApolIIa as 600 GGCÂGCÂACCAffGGÂTAAGC
RNApolIIa P 200 CCCAGCCÂGÂGÂGGÂGACGACAACAAT
NGF-P s 99 300 TCTAGGCACCACCCCTCTG
NGF-P as 300 ÂTCAGÀGTGfÂGÂACÀÀCÀTC
NGF-p P 200 AGGÀATTÀtCÀCCCTCCCTGGACAGTGC
T N Fa s 78 300 CCGTGÂGÂÀGATGÂCCCÂGAT C
T N Fa as 300 GACAGCACAGCCTGGATGG
T N Fa P 200 CGAGACTTTCAACACCCCAGCCATGTACG’
M CP-1 s 128 600 T CCT CT GCCTGCTGCT CAT AG
M CP-1 as 600 G GCCÀGC CT CT GÀATT GAGATC
M CP-1 P 200 CGCCGCCCTCACCACCCAGG
IL-6 s 125 600 AAAGAGCAAGGT AAAGAAT CAGGÀTG
IL-6 as 600 GCAGGATGAGGTGAATTGTTGTG
IL-6 P 200 ACT CCT G ACCCAACC AC AG ACGCC A
Leptin s 99 600 AGG AT C AAT G ACATTT C AC AC ACG
Leptin as 600 GGACAAACT CAGGACT GGTT GG
Leptin P 200 CCAGGAATGAAGTCCAGACCAGCGÀCC
Adiponectin s 119 600 CCGT GAT GGCAGAGAT GGC
Adiponectin as 600 AGCCTCGGGGACCTTCAAC
Adiponectin P 200 CCAGTT ACT CCAGTTT CACCAGT GT CACCC
11P-HSD1 s 149 600 CAGACCAGAGATGCTCCAAGG
11P-HSD1 as 600 GGGATACCACCTTCTTTAGAGTTTC
l lp -H S D l P 200 CCTTGCTGTCACCACCACATGGGCTC
This table shows the sequences of canine primers and TaqMan probes used in real-time PCR 
(qPCR) analysis for relative quantification of canine gene expression. P, TaqMan probe.
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2.5.3 Preparation of 96 well plates for real-time PCR
2.5.3.1 Reagents
qPCR Core Kit:
lOx reaction buffer 
50 mM magnesium chloride 
5 mM dNTP mix 
5 U/pl Hot Goldstar enzyme
Sense primer, anti-sense primer and Taqman probe stock solutions 
Ultra-pure water
2.5.3.2 Method
A  master mix was made up for each gene of interest containing all the necessary 
components for the qPCR reaction, except for the cDNA template, as follows:
lOx reaction buffer 
50 mM magnesium chloride 
5 mM dNTP 
Sense primer 
Anti-sense primer 
Taqman probe 
5 U/pl Hot Goldstar enzyme 
Ultra-pure water
1.25 pi per well
1.25 pi (2.5 mM)
0.5 pi (100 mM)
0.075 pi (see table 2.2) 
0.075 pi (see table 2.2) 
0.5 pi (see table 2.2) 
0.063 pi (0.025 U/pl) 
7.79 pi
Having made up the master mix, 11.5 pi were aliquoted into each well of a 96-well 
plate. One pi of the appropriate template cDNA was then added to each well for a 
total reaction volume of 12.5 pi. The plate was then sealed with an adhesive optical 
cover. All samples were run in duplicate. NTCs were included on each plate for each 
set of primers and probes used. The plate was spun at 1000 rpm for 30 sec (to ensure 
the reaction mix was at the bottom of each well and no air bubbles were present) in 
an IEC Centra-7R Centrifuge (Damon). If the assay was not to be performed 
immediately, the plate could be stored for up to 5 days at 4°C. If a set of samples 
(comprising more than one group) required analysis over several plates, at least one 
sample (usually from the control group) was present on all plates. Data was
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normalised so that the mean ACt for that sample (see section 2.6.5), had the same 
value for each assay. This enabled the data on the different plates to be directly 
compared.
2.5.4 Taqman system real-time PCR setup
All reactions were performed using an Mx3005P real-time machine (Stratagene). 
Once the heat lamp stabilised, the plate was inserted into the heat block. 
Amplifications were performed as follows:
1. 50°C for 2 min (activation of Hot Goldstar enzyme)
2. 95°C for 10 min (denaturation)
3. 35-40 cycles (dependent on the level of expression of each gene)
i. 95°C for 15 sec (denaturation)
ii. 60°C for 60 sec (combined primer annealing and extension)
Data was collected automatically by the software after each cycle o f amplification 
and analysed once the run was complete (total run time was ~ 2 h).
2.5.5 Analysis of qPCR data
The amplification plots were displayed on a log scale using the MxPro-Mx3005P 
software (Stratagene). The threshold was manually adjusted to ensure that it was 
clear o f any background noise. The software automatically re-calculated the Ct value 
for each well. The results were exported as a Microsoft Excel file and gene 
expression analysed by relative quantification with the 2'AACt method (Livak & 
Schmittgen, 2001). All samples were normalised to values for either p-actin or 
RNAPolIIa, and results expressed as fold changes of Ct value relative to controls. 
For example, to compare a treated versus a non-treated control group with IL-6 as the 
target gene and P-actin as the housekeeping gene, the formulae would be:
ACt = Ct(IL-6) -  CT(P-actin)
AACt = Mean A n im a ted  samples) -  Mean ACT(control samples) 
Fold Change = 2'AACT
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In order to ensure that the use of this method was appropriate, a validation 
experiment was performed for each set of primers and probe to check that the 
amplification efficiencies were adequate (see Fig. 2.4).
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Figure 2.4 Validation of the 2'AACT method
Standard Curve
Amplification Plots
This figure shows the results o f a representative validation experiment for a set o f qPCR 
primers and probe. A 5-fold dilution series was carried out using a positive control template 
encompassing the expected levels of target within experimental samples. The slope o f the 
standard curve is used to determine the efficiency of the reaction. Since the PCR reaction is 
based on exponential amplification, if  the efficiency is 100%, the amount of template will 
double with each cycle. This will generate a linear fit with a slope between ~  -3.1/-3.6 (in 
this example -3.57). The reaction efficiency should be between 90-110%, (here 90.7%). 
These assays were run at least in duplicate to determine the precision of pipetting, the 
reproducibility and the overall sensitivity o f the assay. If all the data lie perfectly on the line 
Rsq (the fit of all data to the standard curve plot) will be 1.00 (here 0.982). An Rsq value > 
0.985 is acceptable for most assays (Stratagene, 2004).
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2.6 Enzyme-linked immunosorbent assay
Secreted adipokine protein levels were measured in conditioned media (collected as 
described in section 2.3.5) by immunoassay. All assays were performed in Nunc 
MaxiSorp 96-well microplates.
2.6.1 NGF Emax Immunoassay System (Promega)
Secreted NGF protein levels in conditioned media were measured using the NGF 
Emax Immunoassay System (Promega). This is an enzyme-linked immunosorbent 
assay (ELISA) kit designed for the detection of NGF in an antibody sandwich 
format. The kit displays cross-reactivity across several species including rat, mouse 
and human. No cross-reactivity with the dog was known prior to this study. The kit is 
specific for NGF demonstrating a very low level o f cross-reactivity with other 
neurotrophic factors. The intra-assay coefficient of variation is reported to be in the 
region of 4.1-4.2%. The level o f detection (or sensitivity), is 7.8 pg/ml o f NGF.
2.6.1.1 Reagents
(i) NGF Emax Immunoassay System:
Anti-NGF Polyclonal Antibody (pAb)
5x Block and Sample Buffer (BSB)
1 pg/ml NGF standard
Anti-NGF Monoclonal Antibody (mAb)
Anti-rat IgG, HRP (horseradish peroxidiase) conjugate 
TMB One solution
(ii) Carbonate coating buffer
25 mM sodium bicarbonate 
25 mM sodium carbonate 
Distilled water
Buffer prepared and pH adjusted to 9.7
(iii) TBST wash buffer
20 mM Tris hydrochloride (pH 7.6)
150 mM sodium chloride
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0.05% (v/v) Tween® 20 
Distilled water
(iv) 1 N hydrochloric acid (HC1)
2.6.1.2 Method
Ten pi of the Anti-NGF pAb were added to 10 ml o f carbonate coating buffer to 
prepare enough reagent for a 96-well plate. 100 pi were then added to each well, the 
plate sealed, and incubated overnight at 4°C. The following day the plate was 
allowed to reach room temperature, its contents were discarded and all wells washed 
with TBST buffer. A 1 in 4 dilution o f block and sample buffer (BSB) was made 
using distilled water, and 200 pi of lx  BSB were added to each well. The plate was 
incubated at room temperature for 1 h.
The NGF standard was diluted with lx  BSB to a final dilution of 1:4,000. Serial 1:2 
dilutions were made using lx  BSB to generate 7 standards with a maximal 
concentration of 250 pg/ml. An eighth standard contained no NGF. Following 
blocking, the plate contents were discarded and the wells washed with TBST buffer. 
100 pi of each standard and the same volume of conditioned media were added to the 
plate in duplicate. Samples were diluted in lx  BSB if necessary. In all cases, a 
preliminary assay was performed with serial dilutions o f representative samples of 
media (conditioned and fresh) to identify the appropriate dilution for each assay. 
The plate was again sealed and incubated at room temperature on a plate shaker at 
500 rpm for 6 h. The plate was washed 5 times with TBST buffer and 10 ml o f lx  
BSB were mixed with 2.5 pi o f Anti-NGF mAb (1:4,000 dilution) and 100 pi were 
added to each well. The plate was sealed and incubated overnight at 4°C.
Fresh lx  BSB was prepared and 100 pi o f Anti-Rat IgG HRP conjugate were mixed 
with 9.9 ml o f lx  BSB. The seal was removed and the plate washed 5 times with lx  
BSB and 100 pi o f the diluted antibody conjugate added to each well. The plate was 
sealed and incubated at room temperature for 2.5 h on a plate shaker at 500 rpm. 
During this incubation step the TMB One solution was allowed to reach room 
temperature. After the incubation, the wells were washed with TBST buffer and 100 
pi of TMB One solution added to each well and the plate incubated for a further 10
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min at room temperature to allow colour development. The reaction was then 
stopped by adding 100 pi of 1 N HC1 to each well and the absorbance measured at 
450 nm using a Benchmark Plus microplate spectrophotometer (Bio-Rad). Data was 
collected and analysed using Microplate Manager v5.2 software (Bio-Rad) to 
determine the concentration of NGF protein in each well (see Fig. 2.5)
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Figure 2.5 ELISA standard curve
This figure illustrates a typical standard curve obtained with the ELISA kits used in this 
study. Once the plate had been read by the plate reader, the software was able to calculate the 
concentration o f standard at each serial dilution step. By identifying the concentrations of 
each o f the standards, a curve could be plotted with a line of best fit. This was then used by 
the software to calculate the protein concentration in each sample well based on its 
absorbance.
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2.6.2 IL-6, TNFa and MCP-1 assays (R&D)
Levels of canine interleukin 6 (IL-6), tumour necrosis factor-alpha (TNFa) and 
monocyte chemoattractant protein-1 (MCP-1) in conditioned media were measured 
using DuoSet® ELISA Development System kits (R&D Systems). These are also 
sandwich ELISA kits but here designed specifically for the detection the canine 
protein. The kits displayed cross-reactivity across several species including rat, 
mouse, cat and human to varying degrees. The sensitivity of each were canine IL- 
6, 1.5 pg/ml ; canine TNFa, 0.9 pg/ml; canine MCP-1, 1.2 pg/ml. Any value below 
these was considered non-detectable.
2.6.2.1 Reagents
(i) DuoSet® ELISA -  Canine CCL2/MCP-1
4.0 pg/ml Capture Antibody mouse anti-canine MCP-1 
50 ng/ml Detection Antibody goat anti-canine MCP-1
1000 pg/ml Canine MCP-1 Standard 
1 ml diluted 1:200 Streptavidin-HRP
(ii) DuoSet® ELISA -  Canine IL-6
0.8 pg/ml Capture Antibody goat anti-canine IL-6 
200 ng/ml Detection Antibody goat anti-canine IL-6 
4000 pg/ml Canine IL-6 Standard 
1 ml diluted 1:200 Streptavidin-HRP
(iii) DuoSet® ELISA -  Canine TNFa
1.0 pg/ml Capture Antibody mouse anti-canine TNFa 
100 ng/ml Detection Antibody goat anti-canine TNFa 
1000 pg/ml Canine TNFa Standard
1.0 ml diluted 1:200 Streptavidin-HRP
(iv) lx  PBS (see section 2.3.1)
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(v) Wash Buffer
0.05% (v/v) Tween® 20 
lx  PBS
(vi) Reagent Diluent
1% BSA Fraction V, Protease free 
lx  PBS
(vii) Substrate Solution
50% H20 2
50% Tetramethylbenzidine
(viii) Stop Solution
2 N H2S04
2.6.2.2 Method
The capture antibody was diluted to the stated working concentration in PBS without 
carrier protein (0.8 pg/ml goat anti-canine IL-6, 1.0 pg/ml mouse anti-canine TNFa 
and 4.0 pg/ml mouse anti-canine MCP-1). One hundred pi of the diluted capture 
antibody was added to each well of a 96-well microplate, the plate was sealed and 
incubated overnight at room temperature.
The contents of each well were discarded and the wells washed three times with 400 
pi o f wash buffer. The plates were blocked by adding 300 pi o f reagent diluent (RD) 
to each well, sealed and incubated at room temperature for 1 h. The wash step was 
then repeated. The standards for each protein were allowed to sit with gentle 
agitation for 15 min prior to use. The standards were reconstituted using RD and 
diluted to a high standard o f specified concentration for each protein (4000 pg/ml IL- 
6 and 1000 pg/ml for both TNFa and MCP-1). Serial 1:2 dilutions were made using 
RD to generate 7 standards with the desired maximal concentration. An eighth 
standard contained no protein. After washing, 100 pi of sample (diluted in RD if 
required) or standard was added to each well. The plates were covered and incubated 
at room temperature for 2 h. A 1 in 200 solution of streptavidin-HRP conjugate was
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made using RD and 100 pi added to each well. The plates were sealed and incubated 
at room temperature for 20 min.
After incubation, the plates were washed as described previously and 100 pi of 
substrate solution added to each well. The plates were sealed and incubated at room 
temperature for 20 min to allow colour development. 50 pi of stop solution was 
added to each well and the absorbance determined immediately using a Benchmark 
Plus microplate spectrophotometer (Bio-Rad), at 450 nm corrected to 540 nm. Data 
was collected for each protein, analysed and a standard curve generated for each 
plate as described in section 2.7.1.2.
2.6.3 Leptin and adiponectin assays (LINCO)
Due to the lack of availability o f in-house ELISA assays for both canine leptin and 
adiponectin, levels of these two key adipocyte hormones in cell culture supernatant 
was assayed externally by LINCO using Beadlyte and LINCOplex Multiplex 
immunoassays. The technology involves the use of 5.6 pm beads, call microspheres, 
which are colour coded to distinct sets, each representing a protein of interest. Each 
bead set is conjugated with a unique monoclonal antibody with high specificity for 
the protein o f interest. Samples are mixed with the beads allowing capture of the 
specific protein. A complementary secondary antibody is then added, completing the 
immunological sandwich reaction. The reaction is detected with streptavidin- 
phycoerythrin. Lasers are used to excite both the internal dye that identifies each 
microsphere particle and the phycoerythrin bound to the reporter antibody in the 
assay allowing quantification.
2.7 Statistical analysis
The statistical significance between the means of 2 groups of samples was assessed 
by Student’s t-test (Excel 2003 software, Microsoft). Differences were considered to 
be significant when P < 0.05. All results are presented as means ± standard error of 
the mean (SE); the group size is indicated in the legends to the figures.
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Chapter 3
Adipokine gene expression in canine white adipose tissues
3.1 Introduction
As described in Chapter 1, in mammals the majority of adipose tissues are contained 
in a multi-depot organ which can be broadly characterised as consisting of both 
subcutaneous and visceral depots (Cinti, 2005). These can be further classified 
according to anatomical location (such as abdominal and inguinal subcutaneous) or 
in terms of association with specific organ systems, such as the kidney in the case o f 
the perirenal depot. In the dog, five main WAT depots are recognised; subcutaneous 
inguinal, omental, perirenal, gonadal and falciform ligament (the falciform ligament 
is a ‘sickleshaped’ saggital fold o f peritoneum responsible for the attachment of the 
liver to the diaphragm, separating the right and left liver lobes).
(T
In the obese state, expansion of white fat mass occurs through both hypertrophy of 
existing mature adipocytes and increased hyperplastic proliferation o f preadipocytes 
(Hausman et al., 2001). The main function of WAT is as a store for TG providing a 
long-term fuel reserve (Trayhum, 2007). In addition, adipose tissue is also an 
important source of endocrine signals, these include the adipocyte hormone leptin, 
which is involved in appetite regulation and energy balance (Trayhum et al., 1999; 
Rayner & Trayhum, 2001). Other protein signals, termed adipokines, include several 
linked to inflammation and the inflammatory response such as TNFa and IL-6. Their 
levels rise in obesity which is now thought to be characterised by a state of chronic 
low-grade inflammation (Fantuzzi, 2005; Trayhurn, 2005a).Thus, WAT may be the 
main site of inflammation in obesity, with increased levels of inflammation related 
bio-markers reflecting a spillover from an ‘inflamed’ tissue contributing to obesity- 
related pathologies (Trayhurn, 2005c).
Previous studies have indicated that genes encoding several adipokines are expressed 
in canine white adipocytes (Eisele et al., 2005). These include leptin, where in vivo 
studies have demonstrated that in a similar manner to humans and rodents, plasma 
levels o f leptin in the dog increase with obesity (Sagawa et al., 2002). In humans, 
both mRNA and systemic levels of leptin are raised in women compared to men 
(Montague et al., 1997b; Castracane et al., 1998). However, in dogs there currently 
appears to be no association between sex, and systemic or mRNA levels o f leptin 
(Ishioka et al., 2002; Ishioka et al., 2007).
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This Chapter aims to further characterise gene expression in the main WAT depots in 
the dog. The importance of research in this area has been outlined in Chapter 1. 
Despite the increase in the level of interest in WAT biology, there is still a paucity of 
information on companion animals. As such, the expression of a number o f classical 
adipocyte markers including PPARy and LPL are examined in dog WAT. The 
mRNA levels of the adipocyte hormones leptin and adiponectin were also examined 
in WAT of both male and female dogs, where quantitative comparisons between 
sexes was carried out. In addition, expression levels of proinflammatory adipokines 
including TNFa and IL-6 were also investigated in all depots examined.
Over the past few hundred years dogs have been bred for different phenotypic 
characteristics including coat colour, coat length and body size. This has led to the 
formation o f distinct genetic isolates referred to as breeds (Sutter & Ostrander,
2004). Several show a high prevalence of specific diseases (Patterson, 2000), many 
of which are also commonly seen in the human population and the clinical 
manifestations in the two species are often similar (Sargan, 2004). In terms of 
choosing a suitable breed for these studies the Staffordshire bull terrier (SBT) was 
the clear choice in that it is a medium sized breed which has a tendency to weight 
gain, and is common in the locality.
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3.2 Methods
3.2.1 Animals and tissues
Tissues from entire adult male and female SBT dogs were obtained from those 
euthanased at an animal shelter, for reasons unrelated to the study. Animals were 
only included if there was no indication of disease, both externally and during gross 
examination o f abdominal organs. In addition, animals suffering from cachexia or 
emaciation were also excluded. All WAT samples (subcutaneous inguinal, omental, 
perirenal, gonadal and falciform ligament depots) and samples from liver, spleen and 
kidney were obtained within thirty minutes of euthanasia and immediately frozen in 
liquid nitrogen.
3.2.2 RT-PCR and qPCR
RNA was extracted from tissues using Tri-Reagent as described in section 2.3.1. 
RNA which was to be analysed by qPCR was subsequently treated using a DNA-free 
kit to minimise levels o f genomic DNA contamination (section 2.3.2). Once 
extracted, the total RNA was quantified using a BioPhotometer and reverse 
transcribed using the Reverse-iT First Strand Synthesis kit (sections 2.3.3 and 2.4.1). 
The cDNA was then analysed by PCR using the Reddymix PCR Master Mix kit and 
PCR Express thermal cyclers (sections 2.4.1 and 2.4.2).
Faint or undetectable bands at high PCR cycle numbers (>35) were suggestive of 
either very low levels of mRNA, mRNA degradation or a failed RT reaction. In such 
cases, the integrity of the mRNA was checked by running a specified amount of total 
RNA on a gel and, if found to be significantly degraded, the sample was re-extracted 
from the tissue (see section 2.3.4). PCR products were purified using a NucleoSpin 
Extract 2-in-l kit and sequenced commercially (see section 2.5.4). Real-time PCR 
(qPCR) was carried out using the qPCR Core Kit and an Mx3005P real-time machine 
(section 2.5.3 and 2.5.4). All qPCR data was analysed using MxPro-Mx3005P 
software.
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3.3 Results
3.3.1 Expression of adipocyte-related genes by canine WAT
In initial studies, RT-PCR was used to establish whether dog adipose tissues express 
genes encoding proteins indicative o f WAT; specifically GLUT-4 (insulin sensitive 
facilitative glucose transporter), LPL and PPARy (the gamma-2 isoform). PPARy 
isoforms, PPARyl and y2, differ in their N-terminal end as a result of alternative 
promoter usage and differential splicing (Zhu et al., 1995). Whilst PPARyl is 
ubiquitously expressed, PPARy2 is predominantly expressed in adipose tissue where 
it regulates adipocyte differentiation and fatty acid storage (Ren et al., 2002; 
Hammarstedt et al., 2005). Primers were designed specifically to detect expression o f 
the gene coding for PPARy2 (canine gamma-2, accession number AJ972913), see 
Fig. 3.1.
To confirm the expected product identity, all products obtained using newly designed 
primer pairs were subject to sequencing and comparison against the dog genome 
database. PPARy2 gene expression was examined in all five separate adipose tissue 
depots (subcutaneous inguinal, omental, perirenal, gonadal and falciform) as well as 
in liver, spleen and kidney. As expected, a band consistent with PPARy2 was 
detected exclusively in WAT, unlike PPARyl where, expression was detected in all 
tissues examined (Fig. 3.2A). The level of PPARy2 expression appeared not to vary 
between depots. Bands observed for all genes examined were found to be fainter in 
the liver of both animals compared to that of other organs.
Having identified that PPARy2 mRNA can be detected in dog WAT, the expression 
of other adipocyte-related genes was investigated by examining LPL and GLUT4 
mRNAs. In a similar manner to PPARy2, expression was detected in all WAT depots 
examined with little apparent difference between depots (Fig. 3.2B).
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Figure 3.1 Canine PPARy2 sequence alignment
human AACGGATTGATCTTTTGCTAGATAGAGACAAAATATCAGTGTGAATTACAGCAAACCCCT 120
canine AATGGATTGGTCTTTTGCAAGAAATAGACAAAATATCAGTGTGAATTACAGAAAATCCCT 75
★ ★  ★ ★ ★ ★ ★ ★  ★ ★ ★ ★ ★ ★ ★ ★  ★ ★ ★  ★  ★ ★ ★ *★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★  ★ ★ ★  *★ ★ ★
human ATTCCATGCTGTTATGGGTGAAACTCTGGGAGATTCTCCTATTGACCCAGAAAGCGATTC 180
canine CTTCCATGCTGTTATGGGTGAAACTCTGGGAGATTCTCTCATTGACCCAGAAAGCGACTC 135
************************************* ***************** **
240 
195
human CTTCACTGATACACTGTCTGCAAACATATCACAAGAAATGACC
canine CTTTGCTGATACACTGTCTGCAAGCACTTCACAAGAAACTACC
human GCCATTCTGGCCCACCAACTTTGGGATCAGCTCCGTGGATCTCTCCGTAATGGAAGACCA 300
canine GCCATTCTGGCCCACCAACTTTGGAATCAGTTCAGTGGATCTGTCCGTAATGGATGACCA 255★ ★ ★ ★ * ★ ★  ★ ★ ★ ★ ★ ★ ★ ★  ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★  ★ ★ ★ ★ ★
human
canine
360 
315
★ ★ ★ ★ ★ ★  ★ ★  ★ ★ ★ ★ ★  *★ ★ ★ ★ ★ ★ ★  ★ ★ ★ ★ ★  ★ ★  ★ ★  *★  ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★  ★ ★ ★ ★ ★
CTCCCACTCCTTTGATATCAAGCCCTTCACTACTGTTGACTTCTCCAGCATTTCTACTCC
CTCCCATTCTTTTGACATCAAGCCATTCACCACCGTGGATTTCTCCAGCATTTCCACTCC
human
canine
ACATTACGAAGACATTCCATTCACAAGAACAGATCCAGTGGTTGCAGATTACAAGTATGA 420 
ACACTATGAAGACATTCCATTCTCAAGAGCGGACCCGATGGTTGCAGATTATAAGTATGA 375
★ ★  ★ *★ ★ ★ ★ ★ ★ ★ ★ ★ ★ *★ ★  * ** ★ ★ ★ ★ ★ ★ ★ ★ ★ **★ ★ ★ ★  ★ ★ ★ ★ ★ ★ ★ ★
human
canine
480 
435
CCTGAAACTTCAAGAGTACCAAAGTGCAATCAAAGTGGAGCCTGCATCTCCACCTTATTA
TCTGAAGCTCCAAGAGTATCAAAGTGCAATCAAAGTGGAGCCTGCATCCCCACCTTATTA
human
canine
540 
495
★ ★ ★ ★ ★ ★  ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★  ★ ★ *★ ★ *★ *★ ★ ★ ★ ★ ★  ★ ★ ★ *★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ *★ ★ ★ *★ ★
TTCT'
TTCT'
GAGAAGACTCAGCTCTACAAl 
GAAAAGACTCAGCTGl
4GCCTTCCAACTCCCTCATGGC 
rCCAACTCCCTCATGGC
human AATTGAATGTCGTGTCTGTGGAGATAAAGCTTCTGGATTTCACTATGGAGTTCATGCTTG 600
canine AATTGAATGCCGAGTCTGTGGAGATAAAGCTTCTGGGTTCCACTATGGAGTTCATGCTTG 555★ ★ ★ ★ ★ ★ ★ ★ ★  ★ ★  *★ ★ ★ ★ ★ ★ *★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★  ★ ★  ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★
There are 1830 nucleotides that code for the canine PPARy sequence, of which 1681 
comprise the protein coding region (CDS). By comparing the full sequence for the human 
PPARy2 with that of canine PPARy we were able to identify the canine y2 region and design 
primers such that the forward primer (red bold) would span the 5 ’- untranslated region 
immediately upstream of the initial 82 nucleotides of the CDS coding specifically for the 
gamma-2 component of the gene (yellow block). The reverse primer was designed to be 
immediately downstream of the gamma-2 region (yellow bold). Remaining nucleotides of  
the gene coding for PPARyl are indicated in blue block. Sequences were aligned using 
ClustalW software (http://www.ebi.ac.uk/clustalw). Percentage similarity between canine 
and human PPARy was 91%.
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Figure 3.2 Expression of adipocyte-related genes by canine white
adipose tissue
LPL
GLUT-4
(3-actin
'% 'V S  % 'S'
Total RNA was extracted from subcutaneous inguinal (sub), omental (om), perirenal (peri), 
gonadal (gon) and falciform (fal) WAT depots, and from liver (liv), spleen (spl) and kidney 
(kid) o f two entire female SBT dogs (1 and 2). RT-PCR was performed using dog-specific 
primers. In (A), representative gels for PPARyl and y2 are shown. In (B), representative gels 
for other adipose tissue-related genes are shown. Amplification cycle numbers were: 
PPARyl and -y2, 27; LPL and GLUT4, 30; (3-actin, 25; -T, no template control.
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3.3.2 Expression of adipokine genes in canine WAT
WAT depots were next screened for the expression of key adipokine genes. These 
included established adipokines such as the hormones leptin and adiponectin. mRNA 
encoding both leptin and adiponectin were detected in all WAT depots (Fig. 3.3A 
and Fig. 3.4A). A very faint signal was also detected in kidney tissue o f animal 1 
(Fig. 3.3A). Although RT-PCR established that both genes were expressed in all 
WAT depots, it was unclear whether the level of expression varied between depots, 
or indeed, if there was a difference in the level o f expression between male and 
female dogs.
Therefore, the levels o f mRNA encoding leptin and adiponectin were quantified 
using qPCR. Although there were no differences in the level of leptin gene 
expression amongst depots in either male of female dogs, when male and female data 
were directly compared, there was found to be a significant upregulation in the level 
o f leptin mRNA in four out of the five depots examined in female compared to male 
dogs; these were subcutaneous inguinal, omental, perirenal and falciform ligament 
depots (Fig. 3.3B). There were no differences in the level of adiponectin gene 
expression between depots or between genders in dogs (Fig. 3.4B).
3.3.3 Expression of pro-inflammatory adipokine genes in canine 
tissues
WAT depots were also examined for the expression of proinflammatory adipokine 
genes. These included the adipokines TNFa, IL-6 and IL-18, and chemokines MCP-1 
and MIF, the target-derived neurotrophin NGF, VEGF (an important factor in 
angiogenesis) and PAI-1 (an adipokine involved in vascular haemostasis). In initial 
studies, mRNA levels were examined using RT-PCR, where all adipokine mRNAs 
were detected in all WAT depots (Fig. 3.5). The level of expression of certain 
adipokines; namely IL-6, IL-18, MCP-1 and NGF, appeared to be similar between 
different depots. In contrast, the expression o f adipokines such as MIF, PAI-1, TNFa 
and VEGF appeared to differ between depots. In some cases analysis by qPCR was 
also carried out in order to quantify these changes (Figs. 3.6A, B, C, and D).
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Figure 3.3 Expression of leptin by canine white adipose tissue
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Total RNA was extracted from subcutaneous inguinal (sc), omental (om), perirenal (pr), 
gonadal (gon) and falciform (fal) WAT depots, and from liver (liv), spleen (sp) and kidney 
(kid) o f two entire female SBT dogs (1 and 2). RT-PCR was performed using dog-specific 
primers. In (A), representative gels are shown for leptin and P-actin. Amplification cycle 
numbers were: Leptin, 32; P-actin, 25. In (B), real-time PCR was used for relative 
quantification of leptin mRNA levels. Results are expressed relative to the expression of p- 
actin in the subcutaneous inguinal depot for each gender and are presented as means ± SE 
(bars) 6-7 individuals f P  <  0 .05 ,ft P  <  0.01, compared to male animals.
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Figure 3.4 Expression of adiponectin by canine white adipose tissue
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Total RNA was extracted from, subcutaneous inguinal (sc), omental (om), perirenal (pr), 
gonadal (gon) and falciform (fal) WAT depots, and from liver (liv), spleen (sp) and kidney 
(kid) o f two entire female SBT dogs (1 and 2). RT-PCR was performed using dog-specific 
primers. In (A), representative gels are shown for adiponectin and P-actin. Amplification 
cycle numbers were: Adiponectin, 27; p-actin, 25. In (B), real-time PCR was used for 
relative quantification o f adiponectin mRNA levels. Results are expressed relative to the 
expression P-actin in the subcutaneous inguinal depot for each gender and are presented as 
means ± SE (bars) 6-7 individuals.
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Figure 3.5 Expression of pro-inflammatory adipokine genes by canine
white adipose tissue
Adipsin
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Total RNA was extracted from, subcutaneous inguinal (sc), omental (om), perirenal (pr), 
gonadal (gon) and falciform (fal) WAT depots of two female entire SBT dogs (1 and 2). RT- 
PCR was performed using dog-specific primers for different proinflammatory adipokine 
genes. Amplification cycle numbers were: Adipsin, 27; IL-6, 34; IL-18, 28; MCP-1, 30; 
MIF, 35; NGF, 32; PAI-1, 34; TNFa, 27; VEGF, 32; p-actin, 25; -T, no template control.
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Figure 3.6 Quantification of the level of expression of pro- 
inflammatory adipokine genes by canine white adipose tissue
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Total RNA was extracted from subcutaneous inguinal (sc), omental (om), perirenal (pr), 
gonadal (gon) and falciform (fal) WAT depots. Real-time PCR was used for relative 
quantification o f  (A) IL-6, (B) MCP-1, (C) NGF and (D) TNFa mRNA levels; Results are 
expressed relative to the expression P-actin in the subcutaneous inguinal depot for each 
gender and are presented as means ± SE (bars) 6-7 individuals * P  <  0.05, " P  <  0.01, 
compared to male animals. * P  <  0.05, compared to same gender depot control. Reference 
depot used was subcutaneous inguinal.
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There was no significant difference in the level of mRNA, encoding IL-6 , amongst 
depots and between genders in the dog (Fig. 3.6A). In contrast, the levels o f mRNA 
encoding MCP-1 were significantly elevated in both perirenal and falciform depots 
in male compared to female dogs. There was also a small, but statistically significant, 
down-regulation of MCP-1 mRNA level in the perirenal depot in female dogs 
compared to the control depot (Fig. 3.6B).
In terms o f NGF, there was a small but nevertheless statistically significant 
upregulation in the mRNA level in the female for the gonadal depot (Fig. 3.6C). 
TNFa, mRNA levels were significantly elevated in three out of the five depots 
examined in female compared to male dogs; these were subcutaneous inguinal, 
omental and falciform ligament. There were however, no significant differences in 
mRNA level of TNFa between depots for either sex (Fig. 3.6D).
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3.4 Discussion
Isolating RNA from the tissue o f non-laboratory animals presents many challenges 
which are not always present in laboratory animal work. In the present work, dog 
tissues were collected with up to half an hour delay from the time o f euthanasia. 
Thus, there was an initial concern about the quality o f the RNA extracted and 
whether this would be suitable for further analysis. However, despite these initial 
concerns, RNA quality was consistently good with minimal evidence of degradation. 
It is of note that, regardless of the species examined liver tissue is known to yield 
RNA of lower quality than tissues such as spleen and kidney where the mRNA is 
thought to be more resistant to degradation (Palmer & Prediger, 2007). This was 
reflected in the present results where, despite tissues being frozen in liquid nitrogen 
as soon as possible after collection, signals obtained in the liver did appear to be 
lower (including that for the housekeeping gene, p-actin), when compared to that of 
other tissues.
The studies described in this chapter demonstrate that the genes encoding several key 
adipose tissue-related proteins are expressed in canine WAT. One such protein is the 
adipose tissue-specific transcription factor PPARy2, whose signal was documented 
in all depots examined. In contrast, PPARyl is ubiquitously expressed, and as such, a 
signal was obtained in all tissues. Genes whose expression is characteristic of 
adipocytes (although not exclusively) namely LPL and GLUT4, were shown to be 
expressed in all depots examined, with little difference in the level of expression 
between depots.
Signals for both leptin and adiponectin mRNAs were detected in all WAT depots, 
whilst expression in all other organs examined was minimal to non-existent. Levels 
o f mRNA encoding leptin were found to be higher in the adipose tissues o f female, 
compared with male, dogs for four out of the five depots examined, with only the 
gonadal depot not reaching statistical significance. All female dogs were entire at the 
time of sampling, and none were overweight/obese. In humans, mRNA levels of 
leptin appear to be higher in subcutaneous compared to omental depots (Montague et 
al., 1997b; Montague et al., 1998). Since in females this is the main depot to expand 
in obesity, women have been found to have higher levels of circulating leptin
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compared to age matched men (Castracane et al., 1998). Studies looking at systemic 
levels of leptin in the dog have found a clear association between weight and levels 
of leptin, but no gender association (Ishioka et al., 2002; Ishioka et al., 2007). In 
dogs, unlike humans, leptin mRNA levels are raised not only in the subcutaneous 
depot but also in several visceral depots (omental, perirenal and falciform ligament) 
in the female. Furthermore, despite raised mRNA levels in WAT of female dogs, this 
does not seem to reflect the situation seen systemically in relation to circulating 
levels of leptin (Ishioka et al., 2005a).
There were no differences in the level o f expression between depots or between 
genders in the dogs of this study. In contrast, studies in humans have demonstrated 
an association between the male sex and visceral depots with lower levels of 
circulating adiponectin (Lihn et al., 2004; Dullaart et al., 2007). It is speculated that 
this effect may be due to systemic levels o f the male hormone testosterone (Andersen 
et al., 2007). In terms of gene expression in WAT, no such association was evident in 
the dog.
The current study also demonstrated expression of key proinflammatory adipokine 
genes in the main WAT depots in the dog, and results are consistent with the 
exploratory study of Eisele et al., 2005. The adipokines examined include genes 
encoding adipsin, PAI-1 and VEGF. Adipsin is an important protein required for the 
synthesis of acylation-stimulating protein (ASP), which is derived from complement 
C3a (Trayhurn & Beattie, 2001). A signal for adipsin was found in all WAT depots 
o f the dog with little difference in the level of expression between depots. There is a 
similarity between adipsin and human and murine complement factor D. However, 
mouse adipsin expression appears to be specific to adipose tissue, whereas human 
complement factor D is reported to be synthesised mainly by cells o f the 
macrophage/monocyte lineage (Barnum & Volanakis, 1985). With increased 
infiltration of WAT by macrophages in obesity (Weisberg et al., 2003), ASP may 
play a key role in adipose tissue metabolism in the obese state.
PAI-1 is an acute phase protein and a key factor in vascular homeostasis, inhibiting 
the activation of plasminogen, the precursor o f plasmin (Sprengers & Kluft, 1987). 
Increased PAI-1 production occurs in WAT in obese humans, and increased
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circulating levels o f the protein in obesity may be largely due to contribution by 
WAT (Mutch et al., 2001). PAI-1 expression was established in all depots examined 
in the dog.
VEGF is an important angiogenic factor expressed in a variety of cell types including 
WAT in both humans and rodents (Fain & Madan, 2005; Miyazawa-Hoshimoto et 
al., 2005). In the dog, as in humans and rodents (Robinson & Stringer, 2001; 
Miyazawa-Hoshimoto et al., 2005), VEGF is encoded by a single gene; however, 
several isoforms are produced as a result of alternate splicing (Jingjing et al., 2000). 
Here we have shown VEGF expression in all main dog WAT depots identifying the 
expression of both 182 and 164 isoforms. As demonstrated in other dog tissues 
(Jingjing et al., 2000), VEGF 164 was expressed at a higher level compared to other 
iso forms. No difference in the level o f VEGF expression was evident between depots 
in the dog. This is unlike rodents where a higher level of VEGF expression has been 
demonstrated in visceral compared to subcutaneous depots (Miyazawa-Hoshimoto et 
al., 2005). The identification o f VEGF iso forms in dog WAT should prove a useful 
tool in study of angiogenesis in WAT in obesity.
A signal for several important cytokines particularly TNFa, IL- 6  and IL-18, and 
chemokines MCP-1 and MIF was identified in all five depots examined in the dog. 
Both IL- 6  and TNFa are increased in obesity in humans and rodents, and both have 
been implicated in the development of insulin resistance in adipocytes (Bastard et al., 
2000; Hotamisligil, 2003). Quantitatively, IL- 6  mRNA levels were not significantly 
different amongst depots or between genders in dogs. Conversely, levels o f mRNA 
encoding TNFa were elevated in three out of the five depots examined in female as 
compared to male dogs. These, depots; namely subcutaneous inguinal, omental and 
falciform were also found to have significantly raised levels of leptin mRNA. Leptin 
levels have been shown to rise in response to increased levels of TNFa in humans 
(Zumbach et al., 1997). Thus raised levels o f leptin expression seen in dog WAT 
depots may have been in response to raised levels of TNFa.
IL-18 is also an important pro-inflammatory cytokine whose expression is elevated 
in obesity and reduced in response to weight loss (Esposito et al., 2002). Recently, it 
has been established that IL-18 is expressed in WAT, where a marked upregulation
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of expression by human adipocytes is seen with TNFa treatment (Wood et a l, 2005). 
However, there is mixed evidence as to whether it is secreted by adipocytes (Skurk et 
al., 2005b; Wood et al., 2005). This study has shown that IL-18 is expressed in all 
WAT depots in the dog. The apparent difficulty experienced in terms of identifying 
whether IL-18 is in fact secreted by adipocytes, and is thus an adipokine in its own 
right, clearly raises questions as to the extent to which this cytokine plays a role in 
the inflammatory and immune response in WAT.
This study has further demonstrated that genes for MCP-1 and MIF, which both play 
a central role in inflammatory processes by regulating leukocyte migration (in the 
case o f MCP-1), and as a potent inhibitor of monocyte/macrophage migration (in the 
case of MIF), are expressed in all main WAT depots in the dog. Unlike results for 
other proinflammatory cytokines, levels o f MCP-1 mRNA were found to be raised in 
perirenal and falciform depots in male compared to female dogs. Furthermore, there 
was a small but significant down-regulation of MCP-1 mRNA level in female dogs 
for the perirenal depot when compared to the subcutaneous inguinal depot. Levels of 
MCP-1 gene expression in endometrial stromal cells in humans are inversely related 
to levels of oestrogen (Arid et al., 1999). Thus, the results seen in the dog may be 
representative of a similar picture in canine WAT.
The target-derived neurotrophin, NGF, has recently been shown to be expressed and 
secreted from mouse and human white adipocytes (Peeraully et al., 2004; Wang et 
al., 2004; Wang et al., 2005). NGF is not only responsible for the growth and 
survival o f sympathetic neurones, but is involved in both inflammatory and immune 
responses (Levi-Montalcini et al., 1996). In white adipocytes, expression and 
secretion are strongly stimulated by the proinflammatory adipokine TNFa (Wang et 
al., 2004; Wang et al., 2005). NGF expression was observed in all WAT depots of 
dog (Fig 3.5). Quantification of NGF mRNA levels by qPCR demonstrated a small 
but significant upregulation of NGF mRNA levels for the gonadal depot relative to 
the subcutaneous inguinal depot in female dogs. This is similar to what has been 
documented in rodents, where NGF gene expression is significantly higher in 
epididymal compared to subcutaneous WAT (Peeraully et al., 2004). NGF gene 
expression has been established in both subcutaneous and omental depots in humans, 
where relative levels of expression have been found to be higher in omental
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compared to subcutaneous depot (Peeraully et al., 2004). No sexual dimorphism in 
NGF gene expression has been reported for WAT or other tissues where the gene is 
expressed, such as the hippocampus of the developing rat brain (Komack et al., 
1991).
This initial study has demonstrated that genes encoding a number of key adipokines 
are expressed in dog WAT, in a manner similar to humans and rodents. All PCR 
products were confirmed by sequencing. Genes identified include not only those 
encoding key adipose tissue proteins LPL and GLUT4, and the transcription factor 
PPARy2, but also the adipocyte hormones leptin and adiponectin. In addition, the 
detection and quantification o f these adipokines and others which have a pro- 
inflammatory role in adipose tissue biology has been established providing a basis 
for further investigations into adipose tissue and adipokine biology in the dog.
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Chapter 4
Establishment of a canine primary cell culture protocol: 
Adipokine gene expression and protein secretion during 
canine adipocyte differentiation and development
4.1 Introduction
In Chapter 3, the main WAT depots of the dog were characterised by expression of 
key molecular markers, including three genes whose expression occurs in white 
adipocytes namely; PPARyl, LPL and GLUT4. In addition, the adipose tissue 
specific expression of the gamma-2 isoform of PPARy, and the expression o f two 
adipocyte hormones, leptin and adiponectin was demonstrated in dog WAT. 
Furthermore, the expression profile of key proinflammatory adipokine genes 
including TNFa and IL- 6  was also established in dog WAT depots. Expression of 
adipokine genes in WAT does not necessarily imply adipocyte-specific expression, 
thus, in this chapter, studies focused on developing a cell culture protocol for the 
study of canine adipocytes in vitro. Such a system would ultimately allow the 
investigation o f adipokine gene expression in adipocytes themselves and further 
allow the characterisation of canine adipocyte differentiation and protein secretion by 
canine adipocytes.
As discussed in Chapter 1, there are currently three main in vitro systems in use for 
investigating adipocyte physiology, clonal cell lines, isolated mature adipocytes and 
primary culture of preadipocytes. Clonal cells lines such as the murine 3T3-L1 
(Chang & Polakis, 1978) and 3T3-F442A cells (Green & Meuth, 1974), undergo 
spontaneous growth arrest at confluence and can be induced to differentiate after 
treatment with adipogénie compounds (Spiegelman et a l, 1993). Mature adipocytes 
can be harvested from freshly dissected adipose tissue by collagenase digestion and 
once isolated; these can be maintained in culture for up to 48 h (Fain et a l, 2003). 
The use o f adipose tissue expiants is also an important tool for investigating adipose 
tissue metabolism in vitro. These are slightly more robust than mature adipocytes and 
can be maintained in culture for several days (Smith, 1974). It can be argued that the 
use of mature adipocytes and or tissue expiants are the closest to the in vivo situation, 
as they involve only limited intervention in transferring the cells from the source to 
the culture system. They do not, however, allow the differentiation process to be 
studied and in addition, expiants involve all cells in a specific organ or tissue, a 
disadvantage where secretion by a given cell type cannot be studied in detail.
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Adipose cells differentiate well in culture, and in vitro differentiation leads to 
activation o f most of the same set of genes characteristic of adipose tissue in vivo 
(Spiegelman et al., 1993), this makes preadipocyte conversion an attractive model 
for the study of adipose cell differentiation. At a set point after inoculation, cells are 
exposed to an ‘adipogenic cocktail’ containing several agents responsible for the 
activation o f differentiation. These cells can then be maintained for a period of 2-4 
weeks. An advantage of the primary culture system is that it is only one step 
removed from the culture of mature adipocytes, and as such may be just as reliable 
(Hauner et al., 2001).
As discussed in Chapter 1, no canine adipose tissue cell lines have been 
characterised. Thus to date, work on canine adipocytes in vitro has involved the use 
of primary cell culture systems. Two methods currently in the literature describe the 
culture of primary preadipocytes from various depots, including visceral (omental, 
perirenal and gonadal) and subcutaneous (abdominal and inguinal-subcutaneous) 
(Wu et al., 2001; Eisele et al., 2005). These methods make use of different 
‘adipogenic cocktails’ and both appear successful in terms of inducing adipocyte 
differentiation. This chapter will outline the establishment of a system for the 
differentiation of canine fibroblastic preadipocytes from both a visceral and 
subcutaneous depot in vitro based on these two techniques. Thus, allowing the 
characterisation o f canine adipocyte differentiation and development through the 
expression of key molecular markers and immunodetection o f adipokines secreted 
into the cell culture medium by canine adipocytes.
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4.2 Methods
4.2.1 Cell culture -  Eisele eta!., 2005 protocol
This method o f canine primary adipocyte cell culture was developed at the Obesity 
Biology Unit, University of Liverpool, and is largely based on that by Wu et al, 
2001 and on the method of culture of human fibroblastic preadipocytes by Hauner et 
al, 2001. Differences in both reagents used and cell culture methods from those 
described in section 2 . 2  are outlined below:
4.2.1.1 Reagents
(i) Transport/Basal Medium
15 mM HEPES
15 mM sodium hydrogen carbonate 
33 pM D-biotin 
17 pM D-panthothenate 
lx DMEM/Ham’s F12
(ii) Digestion Medium (pH 7.4)
1 mg/ml Collagenase 
4 mg/ml BSA 
lx PBS
(iii) Washing Medium
10% FCS 
lxDMEM
100 U/ml penicillin G sodium 
1 0 0  pg/ml streptomycin sulphate
(iv) Erythrocyte lysis buffer (pH 7.4)
155 mM ammonium chloride
5.7 mM potassium dihydrogen orthophosphate
0.1 mMEDTA
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(v) Inoculation Medium
10% FCS 
15 mM HEPES
15 mM sodium hydrogen carbonate 
33 pM D-biotin 
17 pM D-panthothenate 
lx  DMEM/Ham’s F I2 
100 U/ml penicillin G sodium 
1 0 0  pg/ml streptomycin sulphate
(vi) Induction Medium
2% FCS 
15 mM HEPES
15 mM sodium hydrogen carbonate 
33 pM D-biotin 
17 pM D-panthothenate 
1 0  pg/ml human transferrin 
I n MT j
1 0  pg/ml insulin
0.1 pM cortisol
0.5 mM IBMX
1 pg/ml rosiglitazone
lx  DMEM/Ham’s F12
100 U/ml penicillin G sodium
1 0 0  pg/ml streptomycin sulphate
(vii) Feeding Medium
2% FCS 
15 mM HEPES
15 mM sodium hydrogen carbonate 
33 pM D-biotin 
17 pM D-panthothenate 
1 0  pg/ml human transferrin 
1 nM T3
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10 pg/ml insulin
0.1 pM cortisol
lx  DMEM/Ham’s F I2
100 U/ml penicillin G sodium
100 pg/ml streptomycin sulphate
4.2.1.2 Culture method
Cells were collected and fractionated as described in sections 2.2.2 and 2.2.3 
respectively. The cell culture method was as described in section 2.2.4. However, in 
this case only a single filtration step was carried out. In addition, 24 h after 
inoculation, preconfluent cells were thoroughly washed three times in lx  PBS and 
the inoculation medium replaced by induction medium. Cells were then exposed to 
this adipogénie medium for 72 h, after which the induction medium was replaced by 
feeding medium, which was replaced every 48 h.
4.2.2 Cell culture -  Wu et al., 2001 protocol
The fundamental protocol for canine primary adipocyte cell culture adopted in the 
current study was largely based on that by Wu et al., 2001, and as such is described 
in detail in section 2.2. Any differences in both reagents used and cell culture 
methods relating specifically to the Wu et al., 2001 protocol are outlined below:
4.2.2.1 Reagents
(i) Digestion Medium
2 mg/ml Collagenase 
4 mg/ml BSA 
20 mM HEPES 
lx  DMEM
None of the media used contained fungicide and only inoculation and induction 
medium contained penicillin/streptomycin.
4.2.2.2 Culture method
Cells were collected and fractionated as described in sections 2.2.2 and 2.2.3 
respectively. The cell culture method was as described in section 2.2.4, with the
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following exceptions: all centrifugation steps were carried out at lOOOxg for 5 min. 
Only a single filtration step was carried out after the tissues were subjected to 
digestion with collagenase. Cells were inoculated at a density o f 0.5 x 104 cells/cm2. 
Twenty four hours after inoculation, the preconfluent cells were thoroughly washed 
three times in lx  PBS. Adherent cells were maintained in the same medium for an 
undisclosed period of time until they reached confluence and once cells were 
confluent, the inoculation medium replaced by induction medium. Cells were then 
exposed to this for 48 h, after which the induction medium was replaced by feeding 
medium, which was replaced every 48 h.
4.2.3 Cell culture -  Current method -  adapted from Wu et al., 2001 and 
Eisele etal., 2005
4.2.3.1 Culture method
White adipose tissue from both the subcutaneous inguinal and gonadal depots of 
SBT dogs were harvested as described in sections 2.1.1 and 2.1.2. Cells were 
cultured as described in section 2.3 at 37°C in a humidified atmosphere o f 5% 
C02/95% air. 24 h after they were inoculated, cells from the gonadal depot were 
washed three times in lx  PBS and the inoculation medium replaced by induction 
medium. Cells from the subcutaneous inguinal depot had their inoculation medium 
changed 48 h post-inoculation and 24 h later (at 72 h post-inoculation) were washed 
three times in lx  PBS and the inoculation medium replaced by induction medium. 
Cells of both depots were exposed to the adipogénie medium for 48 h. This was 
replaced by feeding medium, which was renewed every 48 h.
To investigate the time course of gene expression and protein secretion during 
adipocyte differentiation, conditioned media and cells from both depots were 
collected as described in section 2.2.5 from three individual wells o f culture plates 
when cells were induced (day 0) and subsequently at days 1-4, 6, 8, 10, 12 and 15 
post-induction. Cell cultures were carried out in triplicate for each depot.
4.2.4 RT-PCR, qPCR and ELISA.
RNA was extracted from cultured cells using Tri-Reagent as described in section
2.4.1. RNA which was to be analysed by qPCR was subsequently treated using a
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DNA-free kit to minimise levels of genomic DNA contamination (section 2.3.2). 
Once extracted, the total RNA was quantified using a BioPhotometer and reverse 
transcribed using the Reverse-iT First Strand Synthesis kit (sections 2.3.3 and 2.4.1). 
The cDNA was then analysed by PCR using the Reddymix PCR Master Mix kit and 
PCR Express thermal cyclers (sections 2.4.1 and 2.4.2) and by real-time PCR 
(qPCR) using the qPCR Core Kit and an Mx3005P real-time machine (section 2.5.3 
and 2.5.4).
PCR products were purified using a NuceloSpin Extract 2-in-l kit and sequenced 
commercially (see section 2.4.4). All qPCR data was analysed using MxPro- 
Mx3005P software. Conditioned media samples were analysed for NGF protein 
concentration using the NGF Emax Immunoassay System (section 2.6.1). TNFa, IL-6 
and MCP-1 protein concentration were analysed using ELISA kits from R&D 
Systems (see section 2.6.2). Adiponectin protein concentration in conditioned media 
was assayed commercially by LINCO (section 2.6.3).
4.2.5 Oil red O staining
Oil red O staining of cells at various points during differentiation and maturation was 
carried out as described in section 2.3.7. Conditioned media was discarded and the 
remaining cells washed twice with lx PBS and fixed using a 3.7% solution of 
formaldehyde. Once fixed, cells were stained with Oil red O and haematoxylin. The 
stained cells were washed with distilled water and images captured using an inverted 
microscope. Percentage differentiation was estimated at various stages according to 
the number of cells displaying evidence o f intracellular lipid accumulation.
4.3 Results -  Part A
Establishment of a canine primary cell culture protocol
With the success of Eisele et al., 2005 in inducing cells from the gonadal depot to 
differentiate, initial studies attempted to achieve the same goal, as tissue from this 
depot could be obtained from routine neutering of dogs at the University of 
Liverpool Small Animal Practice. However, despite several attempts, differentiation 
of preadipocytes from the gonadal depot using the Eisele et al., 2005 protocol proved 
unsuccessful. The only study outlining a comparison of the level o f differentiation
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capacity o f canine adipocytes in vitro was that by Wu et al, 2001. They reported that 
according to glycerol-3-phosphate dehydrogenase (GPDH) activity, which has been 
successfully used as a sensitive marker for adipocyte differentiation (Ailhaud, 1982 
940), cells of the subcutaneous inguinal depot exhibited greatest capacity for 
differentiation compared to other depots in vitro (Wu et a l, 2001). Thus, tissues from 
the subcutaneous inguinal depot were used in order to compare the efficacy of the 
two protocols at inducing preadipocyte differentiation.
4.3.1 Protocol comparison
Tissues were harvested from the subcutaneous inguinal depot of three dogs of 
different breeds; a female a SBT, a female German shepherd dog and a male 
Japanese akita as they became available. The protocol comparison was thus carried 
out in triplicate. Cells were cultured according to both protocols, inoculated onto 6- 
well plates and induced to differentiate at specified times post-inoculation, namely 
24, 48, 72 and 96 h. Cells were inoculated at densities of 40,000-60,000 cells/cm2 as 
per Eisele et al., 2005.
Clonal cell lines such as 3T3L-L1 adipocytes must undergo a period of growth arrest 
before successful differentiation (Chang & Polakis, 1978), one of the ways in which 
this is achieved is through contact inhibition once cells reach a state of confluence. In 
contrast, both human and canine preadipocyte cells appear not to need to reach a 
confluent state to achieve successful differentiation (Hauner et al., 2001) (Eisele et 
al., 2005). Thus, this first investigation not only compared the efficacy of the two 
protocols using the ideal depot in different breeds, but also whether rates of 
differentiation were dependent on the state of cell confluency and at what stage this 
was achieved. In all cases, successful preadipocyte differentiation was characterised 
by visual inspection of cells, where a change from a fibroblastic preadipocyte 
morphology, to one where cells were considerably larger and contained multiple 
lipid droplets which stained positive for lipid using Oil red O, was used as an 
indication of terminal differentiation.
Both protocols were successfully able to induce preadipocyte differentiation to 
mature adipocytes as characterised by intracellular lipid accumulation in cells of the
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subcutaneous inguinal depot (Fig. 4.1 A and B). Cells cultured according to the 
protocol established by Wu et a l, 2001 were most successful in accumulating lipid 
when induced 72 h post-inoculation, with a differentiation rate in excess of 85% (Fig. 
4 .IB). Although cells differentiated using the Eisele et a l, 2005 protocol did 
successfully accumulate intracellular lipid, the highest recorded percentage 
differentiation was of the order of 55-60% (Fig. 4.1 A). Confirmation of lipid 
accumulation was achieved by staining cells with the lipid specific stain, Oil red O 
(Fig. 4.2C). Once cells were allowed to reach confluence, approximately 96 h post­
inoculation, no intracellular lipid droplets were visible on staining with Oil red O 
(Fig. 4. ID).
4.3.2 Subcutaneous inguinal and gonadal depot comparison
All subcutaneous inguinal white adipose tissues were obtained from animals 
euthanased at a local animal shelter for reasons unrelated to the study. This was the 
preferred depot according to the literature, where cells have been shown to have the 
greatest capacity to differentiate and accumulate lipid when compared to those of 
other depots; namely, omental, perirenal and abdominal subcutaneous tissue in the 
dog (Wu et a l, 2001). However, Eisele et a l, 2005 had shown success using cells 
from the gonadal depot obtained during routine neutering (Eisele et a l, 2005). Cells 
from this depot would also have been a reasonable choice due to the freshness of the 
tissue, as it was obtained during routine surgery.
As mentioned previously, attempts to induce gonadal preadipocytes to differentiate 
using the Eisele et a l, 2005 protocol had been unsuccessful. Therefore, in this study 
cells from both depots were cultured using the Wu et a l, 2001 protocol. Cells were 
again induced to differentiate at a pre-confluent state at 24, 48 and 72 h post- 
inoculation. Cells from both depots were successfully induced to differentiate using 
the Wu et a l, 2001 protocol. Cells from the subcutaneous inguinal depot induced to 
differentiate 24 h post-inoculation (Fig. 4.2A) accumulated lipid readily. However, in 
terms of percent o f cells containing multiple lipid droplets, on average as had been 
shown previously, cells from this depot did better if they were induced to 
differentiate 72 h post-inoculation (Fig. 4.2B). Cells from the gonadal depot induced 
to differentiate 24 h post-inoculation accumulated lipid droplets in a comparable 
manner to those of the subcutaneous inguinal depot induced at 72 h post-inoculation
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(Fig. 4.2C). In contrast, cells from the gonadal depot induced at 72 h post-inoculation 
were unable to accumulate lipid to the same extent. (Fig. 4.3D).
4.3.3 Well size as an indication of stress
Cells cultured in vitro are not only removed from their original physiological 
environment, but are also exposed to a range of potential stressors. These include, 
hypoxia, aberrant nutritional conditions such as reduced substrate availability, and in 
addition, clearance of metabolites is likely to differ in culture from that provided by 
the vascular system. In order to further optimise culture conditions and investigate 
levels of possible stressors, cells from the subcutaneous inguinal depot were seeded 
at the higher densities suggested by the Eisele et al., 2005 protocol in 6, 12 and 24- 
well plates, where it was hypothesised that constraints in plate area in terms of 
diffusion of nutrients could potentially affect cell metabolism and hence the ability o f 
cells to differentiate. Cells were otherwise cultured as per Wu et al., 2001 and 
induced 72 h post-inoculation. As is evident from Figs 4.3 A, B and C, well size did 
not appear to play a role in the ability of cells to differentiate and it was decided 
therefore, to use the 6-well plate as the plate of choice for further experiments as a 
mater of convenience, and so as to be able to extract enough total RNA for future 
analysis.
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Figure 4.1 Comparison between Wu and Eisele protocols
Representative phase contrast images of canine preadipocytes from the subcutaneous 
inguinal depot induced to differentiate (day 0) at different time points post-inoculation and 
cultured according to both protocols. Images represent adipocytes at day 14 post-induction. 
(A) Cells induced 24 h post-inoculation and cultured according to the Eisele et al., 2005 
protocol. (B) Cells induced 72 h post-inoculation and cultured according to the Wu et al., 
2001 protocol. (C) Cells induced 72 and (D) 96 h post-inoculation and cultured according to 
the Wu et al, 2001 protocol stained with Oil red O. Cells were cultured in triplicate. The 
bars represent 100 pm.
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Figure 4.2 Depot comparison using the protocol by Wu e t al., 2001
Representative phase contrast images o f canine preadipocytes from the subcutaneous 
inguinal and gonadal depots induced to differentiate (d a y  0 ) into mature adipocytes at 
different time points and cultured until d a y  10  post-induction according to the protocol by 
Wu e t a l ,  2005. (A) Cells from the subcutaneous inguinal depot induced 24 h post­
inoculation. (B) Cells from the subcutaneous inguinal depot induced 72 h post-inoculation. 
(C) Cells from the gonadal depot induced 24 h post-inoculation. (D) Cells from the gonadal 
depot induced 72 h post-inoculation. Cells were cultured in triplicate. The bars represent 100 
pm.
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Figure 4.3 Comparison of well size as a potential stress for cells in
culture
Representative phase contrast images o f canine preadipocytes from the subcutaneous 
inguinal depot induced to differentiate (d a y  0) into mature adipocytes 72 h post-inoculation 
and cultured until d a y  14  post-induction according to the protocol by Wu e t a l., 2005. Cells 
were cultured in triplicate. (A) Cells cultured in 24 -w ell plates. (B) Cells cultured in 12 -  
well plates. (C) Cells cultured in 6 -w ell plates. Cells were stained with Oil red O. The bars 
represent 100 pm.
137
4.4 Results -  Part B
Adipokine gene expression and protein secretion during adipocyte 
differentiation and development
4.4.1 Differentiation and development of canine adipocytes in primary 
cell culture
Having established a robust system for the differentiation of canine fibroblastic 
preadipocytes to mature adipocytes in primary culture from both a visceral and 
subcutaneous depot in the dog, the process of differentiation and maturation of these 
cells from both depots was then investigated in detail initially through the phenotypic 
characterisation o f the cells in culture. At induction (day 0), cells displayed a typical 
fibroblastic appearance (Fig. 4.4A). Terminal differentiation, as referred to by the 
accumulation o f intracellular lipid droplets (Ailhaud, 1990), was first observed in 
cells of both depots by day 3 post-induction and by day 6, several cells could be seen 
to contain multiple lipid droplets (Fig. 4.4B). These then increased both in number 
(Fig. 4.4C), and size (Fig. 4.4D), as cells matured. The depot of choice for many o f 
the friture investigations using primary cell culture was the subcutaneous inguinal, 
for reasons of tissue availability. However, where possible, investigations also used 
cells from the gonadal depot not only to characterise this depot in terms of adipokine 
expression and secretion, but also to identify any differences between adipocytes 
from visceral and subcutaneous sources.
4.4.2 Characterisation of canine adipocyte differentiation and 
development: expression of molecular markers
Adipose cell differentiation is characterised by a series of events during which cells 
become committed to differentiate and this can be investigated through the 
expression of key molecular markers and those indicative of terminal differentiation 
include LPL, GLUT4, PPARy2 (Ailhaud, 1990). In addition, the gene for 
haptoglobin has also been found to be expressed late during the differentiation 
process, with expression being evident from day 4 post-induction in murine cell lines 
(do Nascimento et al., 2004). A similar pattern of expression was documented in 
canine adipocytes where a signal for haptoglobin was also detected at day 4 post­
induction of differentiation (Fig. 4.5).
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4.7.3 Expression and secretion of adipocyte hormones in 
preadipocytes and differentiated adipocytes
Having characterised canine adipocytes through the expression o f adipose tissue- 
related molecular markers, the expression o f the key adipocyte hormones leptin and 
adiponectin was then investigated in canine adipocytes of both depots during 
differentiation and development in vitro. A signal for leptin was detected by RT-PCR 
from day 3 post-induction of differentiation in cells of the subcutaneous inguinal 
depot (Fig. 4.6A). Relative levels o f leptin mRNA were quantified by qPCR, where 
levels were raised from day 2 post-induction by over 30-fold and were essentially 
unchanged thereafter (Fig. 4.6B). A signal for leptin was detected at the same time 
point, from day 3 post-induction, in gonadal cells by RT-PCR (Fig. 4.7A). Leptin 
mRNA reached a peak at day 6 post-induction (11-fold), and subsequently there was 
little change in relative levels o f expression (Fig. 4.7B). Thus, leptin mRNA levels in 
cells from the gonadal depot peaked later and levels were less than half those seen in 
cells o f the subcutaneous inguinal depot. Furthermore, leptin mRNA levels in cells of 
the subcutaneous inguinal depot were on average over four times higher from day 3 
post-induction, when compared to cells of the gonadal depot.
In a similar manner to leptin, adiponectin gene expression was only detected post­
induction in cells o f both depots. A signal was obtained with RT-PCR by day 4 post­
induction in subcutaneous inguinal adipocytes (Fig. 4.8A). Relative levels were 
quantified by qPCR, where a significant rise in levels o f adiponectin mRNA o f >25- 
fold were detected as early as day 1 post-differentiation (Fig. 4.8B). Adiponectin 
mRNA levels then continued to rise as cells matured reaching a peak at day 15 post­
induction of >18,000-fold. Active secretion of adiponectin into the cell culture 
medium by canine adipocytes from the subcutaneous inguinal depot was established 
by commercial analysis of cell culture supernatant using a canine specific 
adiponectin ELISA (Fig. 4.8C).
A signal for adiponectin was present from day 1 post-induction in cells from the 
gonadal depot. However, a strong signal was only detected, in a similar manner to 
cells from the subcutaneous inguinal depot, at day 4 post-induction (Fig. 4.9A). 
Quantitatively, adiponectin mRNA levels were elevated by 32-fold by day 2 post­
induction. Levels continued to rise reaching > 1,700-fold by day 4 post-induction,
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with little change in relative mRNA levels as cells matured (Fig. 4.9B). In a manner 
similar to leptin, adiponectin mRNA levels were on average four times higher in 
cells from the subcutaneous inguinal depot compared to gonadal cells.
Adiponectin secretion was also documented from cells of the gonadal depot. As 
outlined earlier, the main depot used for experimental investigations was the 
subcutaneous inguinal. In the case of the gonadal depot, the aim was to establish that 
(in a similar manner to cells o f the subcutaneous inguinal depot), the protein was 
indeed secreted and to detect any differences in the level o f secretion between mature 
cells and cells at the preadipocyte stage. Thus, only two time-points were chosen, in 
this case cells at day 0 and mature cells at day 10 post-induction of differentiation. In 
a similar manner to cells from the subcutaneous inguinal depot, adiponectin secretion 
into the medium by cells from the gonadal depot was established in both 
preadipocytes and mature adipocytes (Fig. 4.9C).
The fact that a reading was obtained for adiponectin protein in preadipocytes o f both 
depots was surprising given the absence of an mRNA signal at day 0. In both cases 
the signal obtained for canine preadipocytes was several times above the reported 
sensitivity of the assay (22.1 pg/ml). However, readings for mature adipocytes of 
both depots were approximately 100 times that of preadipocytes allowing a greater 
degree of confidence in terms of the specificity o f the assay, which according to the 
commercial lab had no cross-reactivity with adiponectin from other species. 
Furthermore, as the assay was carried out commercially, unlike those for other 
adipokines, there may be uncertainties in these values which may have been due to 
cross-reactivity with other canine proteins present in cell culture media, thereby 
contributing to the detection of adiponectin early during the differentiation process.
Unlike mRNA levels, adiponectin protein concentrations were >30% higher in cells 
o f the visceral depot (gonadal) compared to those of the subcutaneous inguinal depot 
at day 10 post-induction (Fig. 4.9C). However, quantitative protein comparisons 
between depots should nevertheless be treated with caution as they assume an 
identical number of cells being present and this was not directly measured.
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Figure 4.4 Time course of differentiation and development of canine
adipocytes in primary culture
Representative phase contrast images of cells from the subcutaneous inguinal depot. 
Preadipocytes were harvested, cultured and induced to differentiate (day 0) into adipocytes. 
Cells were sampled at d a y  0  (A), d a y  6  (B), d a y  1 0  (C) and d a y  12  (D) post-differentiation 
and stained with the lipid specific stain, Oil red O. Bar represents 100 pm.
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Figure 4.5 Time course of gene expression of adipose tissue-related
markers in canine adipocytes in primary culture
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Representative RT-PCR gels of cells from the subcutaneous inguinal depot. Canine 
adipocytes in culture were collected at various time points both before (day 0) and after the 
induction of differentiation into adipocytes (days 1-4, 6, 8, 10, 12 and 15). Total RNA was 
extracted and examined by RT-PCR using dog-specific primers to determine the expression 
of adipose tissue-related markers during differentiation and development in vitro. Cells 
represented are from the subcutaneous inguinal depot. Amplification cycle numbers were: 
LPL, 30; GLUT4, 30; PPARy2, 27; haptoglobin, 27; P-actin 25; -T, no template control.
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Figure 4.6 Time course of leptin gene expression in adipocytes of the
subcutaneous inguinal depot differentiated in primary culture
Leptin
P-actin
Days post-induction
Canine adipocytes and media were collected at various time points both before (day 0) and 
after the induction of differentiation into adipocytes (days 1-4, 6, 8, 10, 12 and 15). In (A), 
total RNA was extracted and leptin gene expression examined by RT-PCR using dog- 
specific primers. Amplification cycle numbers were: Leptin, 32 and (3-actin, 25; -T, no 
template control. In (B), relative quantification was carried out by qPCR. The mRNA levels 
were normalised to canine P-actin relative to day 0. Results are ± SE (bars) for groups of 3 at 
each time point. N = 3 individuals.
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Figure 4.7 Time course of leptin gene expression in adipocytes of the
gonadal depot differentiated in primary culture
Days post-induction
Canine adipocytes and media were collected at various time points both before (day 0) and 
after the induction of differentiation into adipocytes (days 1-4, 6, 8, 10, 12 and 15). In (A), 
total RNA was extracted and leptin gene expression examined by RT-PCR using dog- 
specific primers. Amplification cycle numbers were: Leptin, 32 and p-actin, 25; -T, no 
template control. In (B), relative quantification was carried out by qPCR. The mRNA levels 
were normalised to canine P-actin relative to day 3, as no signal was evident at day 0. Results 
are ± SE (bars) for groups of 3 at each time point. N = 3 individuals.
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Figure 4.8 Time course of adiponectin gene expression and protein
secretion in adipocytes of the subcutaneous inguinal depot
differentiated in primary culture
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Canine adipocytes and media were collected at various time points both before (day 0) and 
after the induction of differentiation into adipocytes (days 1-4, 6, 8, 10, 12 and 15). In (A), 
total RNA was extracted and adiponectin gene expression examined by RT-PCR using dog- 
specific primers. Amplification cycle numbers were: Adiponectin, 26 and P-actin, 25; -T, no 
template control. In (B), relative quantification was carried out by qPCR. The mRNA levels 
were normalised to canine P-actin relative to day 0. (C) Adiponectin protein levels in the 
media were determined by canine-specific ELISA; values shown are actual concentrations in 
the medium. Results are ± SE (bars) for groups of 3 at each time point. N = 3 individuals.
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Figure 4.9 Time course of adiponectin gene expression and protein
secretion in adipocytes of the gonadal depot differentiated in
primary culture
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Canine adipocytes and media were collected at various time points both before (day 0) and 
after the induction of differentiation into adipocytes (days 1-4, 6, 8, 10, 12 and 15). In (A), 
total RNA was extracted and adiponectin gene expression examined by RT-PCR using dog- 
specific primers. Amplification cycle numbers were: Adiponectin, 26 and p-actin, 25; -T, no 
template control. In (B), relative quantification was carried out by qPCR. The mRNA levels 
were normalised to canine P-actin relative to day 0. (C) Adiponectin protein levels in the 
media were determined by canine-specific ELISA; values shown are actual concentrations in 
the medium. Results are ± SE (bars) for groups of 3 at each time point. N = 3 individuals.
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4.7.4 Expression of inflammation-related adipokines in preadipocytes 
and differentiated adipocytes
The expression of several inflammation-related adipokines during canine adipocyte 
differentiation and development was investigated by RT-PCR in cells o f the 
subcutaneous inguinal depot; these were PAI-1, SAA and VEGF, where a signal for 
all three adipokines was detected both pre- and post-induction of differentiation (Fig. 
4.10).
4.7.5 Expression and secretion of inflammation-related adipokines in 
preadipocytes and differentiated adipocytes
Having characterised the expression of several inflammation-related adipokines 
during the differentiation and development of canine adipocytes from the 
subcutaneous inguinal depot in vitro, the next set of experiments set out to explore 
this further by investigating the expression and possible secretion o f key 
inflammation-related adipokines including TNFa and IL-6 during the differentiation 
of canine adipocytes from both the subcutaneous inguinal and gonadal depots.
TNFa gene expression was initially examined by RT-PCR, where a signal was 
readily detected both pre- and post-differentiation in cells of both depots (Fig. 4.11A 
and 4.12A). In terms of cells from the subcutaneous inguinal depot, the signal 
appeared most intense early-on in the differentiation process at around day 1-2 post­
induction (Fig. 4.11 A). This inference was substantiated by the quantification of 
TNFa mRNA levels through qPCR (Fig. 4.1 IB). In contrast, the signal for TNFa 
detected by RT-PCR in cells of the gonadal depot suggested a more uniform level of 
expression during differentiation of cells in culture (Fig. 4.12A). However, when 
mRNA levels were quantified by qPCR, a similar trend to that observed in cells from 
the subcutaneous inguinal depot was demonstrated, with a decrease in TNFa mRNA 
levels detected as cells reached maturity (Fig. 4.12B).
TNFa protein was detected in conditioned media collected from cultures of 
adipocytes from both depots pre- and post-differentiation using an ELISA specific 
for canine TNFa (Fig. 4.11C and Fig. 4.12C). Levels o f protein secreted by cells of 
both depots into the media decreased as cells matured, where by day 10 post­
induction, TNFa protein in conditioned media from cells of the subcutaneous
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inguinal depot had fallen by nearly 50% (Fig. 4.11C). This fall was even more 
marked in media collected from cells o f the gonadal depot where TNFa levels fell by 
nearly 80% by day 10 post-induction (Fig. 4.12C). At the preadipocyte stage, levels 
o f TNFa protein were >80% higher in cells of the gonadal depot compared to those 
o f the subcutaneous inguinal depot. This persisted as cells matured where at day 10 
post-differentiation, where levels o f TNFa secreted by cells from the gonadal depot 
were still >50% higher than those secreted by cells o f the subcutaneous inguinal 
depot. However, as with adiponectin, these comparisons in terms of levels o f protein 
secreted should be treated with caution as they do depend to a large extent on the 
number of cells present in each sample and this was not directly measured.
The time course of the expression o f another important inflammation-related 
adipokine IL-6, was also examined by RT-PCR for cells o f both depots, where a 
signal was evident both pre- and post-differentiation (Fig. 4.13A and 4.14A). For 
cells of the subcutaneous inguinal depot, signal intensity appeared higher pre- and 
during differentiation (Fig. 4.13A). These inferred changes in level of expression 
were substantiated by quantification of IL-6 expression by qPCR, where levels were 
raised early on during the differentiation process. IL-6 mRNA levels then decreased 
markedly by >90% from day 3 post-induction with levels remaining low as cells 
matured (Fig. 4.13B). The same trend in IL-6 mRNA level was observed in cells 
from the gonadal depot (Fig. 4 .14B).
IL-6 protein was readily detected in conditioned medium from cells o f both depots 
both pre- and post-differentiation by a canine IL-6 specific ELISA (Fig. 4.13C and 
4.14C). In a similar manner to TNFa, levels of IL-6 actively secreted by cells o f both 
depots decreased as cells matured. In terms of cells from the subcutaneous inguinal 
depot, levels of IL-6 protein in conditioned medium peaked at day 2 post-induction, 
after which levels fell by >70% by day 3 (Fig. 4.13C). By day 10 post-induction, 
levels o f IL-6 protein had fallen by >90 and >80% in media from cells o f the 
subcutaneous inguinal and gonadal depots, respectively. IL-6 protein secreted by 
cells at the preadipocyte stage were >85% higher in cells of the gonadal depot 
compared to those of the subcutaneous inguinal depot and despite the decline in IL-6 
protein levels for both depots as cells matured, cells from the gonadal depot still had
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IL-6 levels which were >75% greater than those o f the subcutaneous inguinal depot 
at day 10 post-induction.
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Figure 4.10 Time course of pro-inflammatory adipokine gene
expression in adipocytes of the subcutaneous inguinal depot
differentiated in primary culture
PAI-1
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Canine adipocytes in culture were collected at various time points both before (day 0) and 
after the induction of differentiation into adipocytes (days 1-4, 6, 8, 10, 12 and 15). Total 
RNA was extracted and examined by RT-PCR using dog-specific primers to determine the 
expression of proinflammatory adipokine genes during differentiation and development in 
vitro. Cells represented are from the subcutaneous inguinal depot. Amplification cycle 
numbers were: PAI-1, 32; SAA, 28; VEGF, 30; P-actin 25; -T, no template control.
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Figure 4.11 Time course of TNFa gene expression and protein
secretion in canine subcutaneous inguinal adipocytes in primary
culture
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Canine adipocytes from the subcutaneous inguinal depot and media were collected at various 
time points both before (day 0) and after the induction of differentiation into adipocytes 
(days 1-4, 6, 8, 10, 12 and 15). (A) Total RNA was extracted and TNFa gene expression 
examined by RT-PCR using dog-specific primers. Amplification cycle numbers were: TNFa, 
34 and P-actin, 25; -T, no template control. (B) Relative quantification was carried out by 
qPCR. The mRNA levels were normalised to canine P-actin relative to day 0. (C) TNFa 
protein levels in the media were determined by canine-specific ELISA; values shown are 
actual concentrations in the medium. Results are ± SE (bars) for groups of 3 at each time 
point. N = 3 individuals.
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Figure 4.12 Time course of TNFa gene expression and protein
secretion in canine gonadal adipocytes in primary culture
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Canine adipocytes from the gonadal depot and media were collected at various time points 
both before (day 0) and after the induction of differentiation into adipocytes (days 1-4, 6, 8, 
10, 12 and 15). (A) Total RNA was extracted and TNFa gene expression examined by RT- 
PCR using dog-specific primers. Amplification cycle numbers were: TNFa, 34 and (3-actin, 
25; -T, no template control. (B) Relative quantification was carried out by qPCR. The 
mRNA levels were normalised to canine P-actin relative to day 0. (C) TNFa protein levels in 
the media were determined by canine-specific ELISA; values shown are actual 
concentrations in the medium. Results are ± SE (bars) for groups of 3 at each time point. N = 
3 individuals.
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Figure 4.13 Time course of IL-6 gene expression and protein secretion
in canine subcutaneous inguinal adipocytes in primary culture
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Canine adipocytes from the subcutaneous inguinal depot and media were collected at various 
time points both before (day 0) and after the induction of differentiation into adipocytes 
{days 1-4, 6, 8, 10, 12 and 15). (A) Total RNA was extracted and IL-6 gene expression 
examined by RT-PCR using dog-specific primers. Amplification cycle numbers were: IL-6, 
34 and P-actin, 25; -T, no template control. (B) Relative quantification was carried out by 
qPCR. The mRNA levels were normalised to canine P-actin relative to day 0. (C) IL-6 
protein levels in the media were determined by canine-specific ELISA; values shown are 
actual concentrations in the medium. Results are ± SE (bars) for groups of 3 at each time 
point. N = 3 individuals.
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Figure 4.14 Time course of IL-6 gene expression and protein secretion
in canine gonadal adipocytes in primary culture
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Canine adipocytes from the gonadal depot and media were collected at various time points 
both before (day 0) and after the induction of differentiation into adipocytes (days 1-4, 6, 8, 
10, 12 and 15). (A) Total RNA was extracted and IL-6 gene expression examined by RT- 
PCR using dog-specific primers. Amplification cycle numbers were: IL-6, 34 and (3-actin, 
25; -T, no template control. (B) Relative quantification was carried out by qPCR. The 
mRNA levels were normalised to canine (3-actin relative to day 0. (C) IL-6 protein levels in 
the media were determined by canine-specific ELISA; values shown are actual 
concentrations in the medium. Results are ± SE (bars) for groups of 3 at each time point. N = 
3 individuals.
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A signal for MCP-1 was detected in cells of both depots pre- and post-differentiation 
(Fig. 4.15A and 4.16A). Quantitative changes in MCP-1 gene expression in cells o f 
both depots during differentiation were analysed by qPCR. For cells of the 
subcutaneous inguinal depot, MCP-1 mRNA levels were highest at day 1 post­
induction and in a manner similar to other inflammation-related adipokines, mRNA 
levels then declined as cells matured (Fig. 4.15B). Quantitatively, MCP-1 mRNA 
levels in cells of the gonadal depot fell by 70% after the induction of differentiation. 
There was then little change until day 4 post-induction were levels recovered to the 
pre-differentiation value. However, levels of expression then fell by a similar extent 
and remained low as cells reached maturity (Fig. 4.16B).
MCP-1 protein was detected in conditioned media secreted by canine adipocytes of 
the subcutaneous inguinal and gonadal depot both pre- and post-differentiation (Fig. 
4.15C and 4.16C). Secretion o f MCP-1 protein by cells o f the subcutaneous inguinal 
depot reached a peak at day 2 post-induction (shortly after the peak for MCP-1 
mRNA levels). Subsequently, levels o f protein secreted into the medium declined as 
cells reached maturity (Fig. 4.15C). This is unlike what was seen for cells of the 
gonadal depot, where MCP-1 levels were highest in mature adipocytes compared to 
preadipocytes (Fig. 4.16C). In a similar manner to other proinflammatory adipokines, 
levels of MCP-1 protein were raised in cells o f the gonadal depot at the preadipocyte 
stage by >30% compared to those of the subcutaneous inguinal depot. By day 10 
post-differentiation this difference had increased to >80%.
NGF expression was examined in canine adipocytes, in a similar manner to other 
inflammation-related adipokines by RT-PCR, where a signal was present for cells of 
both depots both pre- and post-differentiation (Fig. 4.17A and 4.18A). Quantitative 
changes in NGF gene expression were analysed by qPCR where NGF mRNA levels 
increased post-induction o f differentiation. However by day 3, mRNA levels fell by 
nearly 60% and changed little thereafter as cells matured (Fig. 4.17B). In contrast, 
NGF mRNA levels in gonadal cells fell sharply immediately post induction of 
differentiation by >75%, and in a similar manner to cells from the subcutaneous 
inguinal depot, levels remained low and relatively unchanged as cells matured (Fig. 
4.18B).
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Having established that canine adipocytes express the NGF gene, an anti-murine 
NGF ELISA which was shown to be cross-reactive to canine NGF was used to 
determine whether the cells also secrete immunoreactive NGF protein. Cells from the 
subcutaneous inguinal depot were chosen in this case, as they represent those from 
the depot which was chosen as that to be used as the main depot for further in vitro 
investigations. NGF was readily detected in the cell culture medium, both before and 
after the induction of differentiation (Fig. 4.17C). Here, in a similar manner to IL-6, 
the rate of release reached a peak shortly after the induction of differentiation at day 
2, and levels of secretion fell as cells reached maturity.
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Figure 4.15 Time course of MCP-1 gene expression and protein
secretion in canine subcutaneous inguinal adipocytes in primary
culture
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Canine adipocytes from the subcutaneous inguinal depot and media were collected at various 
time points both before (day 0) and after the induction of differentiation into adipocytes 
(days 1-4, 6, 8, 10, 12 and 15). (A) Total RNA was extracted and MCP-1 gene expression 
examined by RT-PCR using dog-specific primers. Amplification cycle numbers were: MCP- 
1, 23 and P-actin, 25; -T, no template control. (B) Relative quantification was carried out by 
qPCR. The mRNA levels were normalised to canine P-actin relative to day 0. (C) MCP-1 
protein levels in the media were determined by canine-specific ELISA; values shown are 
actual concentrations in the medium. Results are ± SE (bars) for groups of 3 at each time 
point. N = 3 individuals.
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Figure 4.16 Time course of MCP-1 gene expression and protein
secretion in canine gonadal adipocytes in primary culture
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Figure 4.17 Time course of NGF gene expression and protein
secretion in canine subcutaneous inguinal adipocytes in primary
culture
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Canine adipocytes from the subcutaneous inguinal depot and media were collected at various 
time points both before (d a y  0 ) and after the induction o f differentiation into adipocytes 
(d a y s  1-4, 6, 8, 10, 12  and 15). (A) Total RNA was extracted and NGF gene expression 
examined by RT-PCR using dog-specific primers. Amplification cycle numbers were: NGF, 
28 and P-actin, 25; -T, no template control. (B) Relative quantification was carried out by 
qPCR. The mRNA levels were normalised to canine p-actin relative to d a y  0. (C) NGF 
protein levels in the media were determined by canine-specific ELISA; values shown are 
actual concentrations in the medium. Results are ± SE (bars) for groups of 3 at each time 
point. N = 3 individuals.
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Figure 4.18 Time course of NGF gene expression in canine gonadal
adipocytes in primary culture
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Canine adipocytes from the gonadal depot and media were collected at various time points 
both before (d a y  0 ) and after the induction o f differentiation into adipocytes (d a y s  1-4, 6, 8, 
10 , 12  and 15). (A) Total RNA was extracted and NGF gene expression examined by RT- 
PCR using dog-specific primers. Amplification cycle numbers were: NGF, 28 and p-act in, 
25; -T, no template control. (B) Relative quantification was carried out by qPCR. The 
mRNA levels were normalised to canine P-actin relative to d a y  0. Results are ± SE (bars) for 
groups of 3 at each time point. N = 3 individuals.
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4.5 Discussion
In Chapter 3, the expression of key adipose tissue-related genes (LPL and PPARy2), 
hormones (leptin and adiponectin) and proinflammatory markers (TNFa and IL-6 ) 
was demonstrated in WAT depots in the dog. This chapter outlines investigations 
into the establishment of a protocol for the development of a primary cell culture 
system for the differentiation o f fibroblastic canine preadipocytes in vitro. Once 
established, this would prove to be a powerful tool for further investigations into 
adipose tissue differentiation and development.
O f the two published protocols outlining this procedure, the one by Eisele et al, 
2005 was the first to be attempted as it had demonstrated success using a depot to 
which we had access during routine surgery. Furthermore, Eisele had previously 
attempted to differentiate cells from the gonadal depot unsuccessfully using the Wu 
et al., 2001 protocol (unpublished observations). Despite initial expectations, 
attempts to differentiate canine preadipocytes from the gonadal depot using the 
Eisele at al., 2005 protocol were unsuccessful.
Our efforts were then focused on comparing both protocols using the ‘ideal’ depot 
(subcutaneous inguinal) as outlined by Wu et a l, 2001. In addition, it has been 
documented that preadipocytes isolated from different depots in humans, exhibit 
different capacities to undergo replication and differentiation. Those found in 
subcutaneous WAT are able to undergo more extensive lipid accumulation and 
exhibit higher C/EBPa expression than those from the omental depot. Thus, it has 
been proposed that preadipocytes can be divided into subtypes which contribute to 
different extents to the overall preadipocyte population in individual depots and these 
have different capacity to undergo replication and differentiation in vitro (Tchkonia 
et a l, 2005).
Investigations comparing both protocols using the subcutaneous inguinal depot were 
carried out in triplicate using animals o f various breeds including the breed of choice, 
the SBT. Cells were induced at different times post-inoculation to investigate the 
effect of confluency (in terms o f cell-to-cell contact) on the ability of cells to 
differentiate. Cells were seeded according to Eisele et a l, 2005, where seeding
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densities were ten-fold higher than those recommended by Wu et al., 2001. Both 
protocols were successfully able to induce differentiation of canine fibroblastic 
preadipocytes from the subcutaneous inguinal depot. Although cells cultured using 
the Eisele et al., 2005 protocol successfully induced cells to accumulate lipid, which 
was most successful if cells were induced 24 h post-inoculation, this was not to the 
same extent as that observed with cells induced 72 h post-inoculation cultured using 
the Wu et al., 2001 protocol. Here in excess o f 85% of cells were shown to have 
intracellular lipid droplets when stained with Oil red O. Unfortunately, due to limited 
availability of tissue, we were unable to detect an effect of breed or gender on the 
ability of canine preadipocytes to differentiate in culture.
In terms of cell culture technique, that by Wu et al., 2001 utilises a centrifugation 
rate which is five times higher than that by Eisele et al., 2005. It was found that at 
such high rates of centrifugation a much lower cell yield was obtained for the same 
amount of starting material. Furthermore, the seeding density used in the Wu et al, 
2001 protocol is ten times less than that in the Eisele et al., 2005 protocol. Cells 
inoculated at seeding densities of < 40 000 cells/cm did not accumulate lipid and as 
such did not successfully undergo differentiation. In addition, it was found that in 
order to remove contamination from other cell types, two filtration steps were 
required, instead o f the single filtration step suggested by both protocols. Finally, the 
medium used in each protocol was also different, where in the Eisele et al. 2005, 
protocol, in a manner similar to that used in human preadipocyte cell culture, the 
main medium was DMEM/F12 (Hauner et al., 2001). Amongst other components, 
DMEM/F12 contains a several more amino acids and inorganic compounds 
compared to DMEM used by Wu et al., 2001.
There are numerous hormones and other factors which play a role in proliferation 
and differentiation of adipocytes (Ailhaud, 1990). Insulin and T3 have both been 
shown to be important for terminal differentiation in adipocyte cell models (Hauner, 
1990). Glucocorticoids are also known to be involved in fat metabolism and 
adipocyte differentiation through the activation of C/EBP8  (Yeh et al., 1995), 
although their effect seems to be dependent on the time of addition relative to the 
cell-cycle and the presence o f insulin (Hauner, 1990; Xu & Bjorntorp, 1990). The 
addition of an agent responsible for the elevation in intracellular cAMP levels such
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as 3-isobutyl-l-methylxanthine (IBMX) is also needed for successful induction of 
adipogenesis. cAMP plays an important role as a second messenger for intracellular 
signal transduction and is involved in the activation o f protein kinases (Ailhaud, 
1990; Hauner, 1990). Furthermore, IBMX is also responsible for the activation o f 
C/EBPp, thus playing a key role in the activation of the cascade of transcription 
factors which lead to successful adipocyte differentiation (Yeh et a l, 1995).
The Eisele et a l, 2005 protocol, as described in section 4.2.1, makes use o f an 
adipogénie cocktail based on that used in human primary cell culture, using insulin, 
cortisol, IBMX, T3 and human transferrin (as a means for chelating iron, making it 
unavailable for bacterial use) (Hauner et a i, 2001). In addition, it incorporates the 
PPARy agonist rosiglitazone, which is a well-characterised regulator of adipose 
differentiation (Spiegelman, 1998). In contrast, the Wu et a l, 2001 protocol lacks a 
PPARy agonist, T3 and transferrin. In addition, instead of a glucocorticoid, it makes 
use a non-steroidal anti-inflammatory drug (NSAID), indomethacin which functions 
as a PPARy ligand thereby playing a key role in the induction o f adipogenesis 
(Lehmann et a l, 1997).
Earlier investigations had established that the Wu et a l, 2001 protocol, rather than 
that outlined by Eisele et a l, 2005, successfully induced in excess o f 85% 
differentiation in cells o f the subcutaneous inguinal depot, with best results if cells 
were induced to differentiate 72 h post-inoculation. Thus a study comparing the 
subcutaneous inguinal and gonadal depots was carried out using the Wu et al, 2001 
protocol. Here, cells from the subcutaneous inguinal depot displayed successful 
intracellular lipid accumulation when induced to differentiate 24 and 72 h post- 
inoculation, with best results being obtained at 72 h (as had been previously 
demonstrated when the two protocols were compared) see Fig 4.2B. In terms of cells 
from the gonadal depot, numbers of cells displaying intracellular lipid accumulation 
were comparable to those of the subcutaneous inguinal depot if cells were induced 24 
h post-inoculation. If induced any later, differentiation rates were markedly reduced.
The induction of cells prior to 96 h post-inoculation meant inducing them at a 
preconfluent stage. Cells from different depots, inoculated at the same density, 
achieved maximal differentiation when induced at different time points post-
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inoculation. Growth arrest at the Go/Gj stage of the cell cycle, rather than contact 
inhibition per se amongst arrested cells, is the main requirement for successful 
adipose differentiation (Ailhaud, 1990). This discrepancy in the time post-inoculation 
leading to optimal differentiation in the different depots may be explained by the fact 
that a population of precursor cells may not be at the same stage in the cell cycle at 
the time of inoculation in culture dishes. Thus, hormonal effects on cell 
differentiation may depend not only on the hormonal environment these cells are 
exposed to, but also on exposure happening at a ‘critical window’ were cells will be 
more or less susceptible to those effects (Ailhaud, 1990), and this may vary between 
different depots.
The present work has documented the successful isolation o f viable canine 
preadipocytes from both visceral and subcutaneous depots in the dog. It has further 
outlined the establishment of a robust method of canine adipocyte cell culture in 
which fibroblastic preadipocytes were successfully induced to differentiate into 
adipocytes. The method outlined in section 2.3, was largely based on that by Wu et 
al in terms of reagents used at each of the stages of the cell culture protocol (Wu et 
a l,  2001). However, the experimental technique, including inoculation density and 
centrifugation speed was as described for Eisele et al (Eisele et a l, 2005). The 
validity of the culture system was demonstrated by profiling the expression of 
differentiation dependent genes, such as; LPL, GLUT4, PPARy2 and haptoglobin. 
The expression of these genes has been documented to increase during differentiation 
and development of adipocytes in both human and murine culture systems (Wabitsch 
et a l, 2001; do Nascimento et a l, 2004), and as such their expression increased in 
canine adipocytes as cells matured.
Subsequent studies used the preadipocyte cell culture system, RT-PCR (to identify 
the expression of key adipokine genes) and qPCR to examine quantitative changes in 
the relative levels of expression of these genes, during the differentiation and 
development of canine adipocytes of both depots in vitro. Using RT-PCR, a signal 
for leptin was only visible post-differentiation in both depots examined. This is in 
accordance with leptin being a late marker of differentiation in this and other species 
(Wabitsch et a l, 2001; Wang et a l, 2004; Eisele et a l, 2005). Quantitatively, levels 
o f leptin mRNA from day 3 post-induction were four times higher in cells of the
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subcutaneous inguinal compared to the gonadal depot. Higher levels o f leptin gene 
expression in subcutaneous compared to visceral depots has been documented in 
humans (Montague et al., 1997b; Schoof et al., 2004). This difference is thought to 
be due to the fact that adipocytes from visceral and subcutaneous depots differ in 
their sensitivity to the effects of insulin on lipolysis, those from visceral depots being 
less sensitive than those from a subcutaneous depot (Engfeldt & Arner, 1988). As 
insulin promotes leptin gene expression, this mechanism might be an explanation for 
the reduced levels of leptin mRNA documented in visceral as compared to 
subcutaneous depots. However, the sympathetic nervous system is the primary 
regulator of lipolysis (Penn et al., 2006) and leptin increases sympathetic outflow to 
WAT depots in rodents and thus these differences may also be due to differences in 
sympathetic tone between depots.
Only in the last few years have canine specific protein assays been available 
commercially and at the time o f writing only one such assay is available for canine 
leptin. This assay, from LINCO, has a sensitivity of 250 pg/ml. This is over thirty 
times higher than that reported by human kits, o f the order of <10 pg/ml (Wang et 
al., 2004). A sandwich ELISA assay system has been developed and validated for 
canine leptin again with sensitivity in the order of 1.4 ng/ml (Iwase et al., 2000a). 
This, however, is not commercially available. An attempt was made to quantify 
leptin secreted by canine adipocytes from both depots by LINCO. However, levels in 
the cell culture supernatant were below the level of detection of the available assay 
system.
A signal for the adipocyte hormones leptin and adiponectin was documented in 
canine adipocytes of both depots post-differentiation using RT-PCR. Like leptin, 
adiponectin is also a marker for terminal differentiation in canine adipocytes (Wang 
et al., 2004), and as such expression was evident post-differentiation in both depots. 
In contrast to leptin, the adiponectin gene appears to be highly expressed in dog 
adipocytes as only 26 cycles of amplification were needed to obtain a strong signal; 
this is in keeping with evidence from other species. Adiponectin is generally a highly 
expressed gene, and the protein comprises 0.01% of total serum protein in humans 
(Wolf, 2003).
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There was a marked difference in relative levels of adiponectin mRNA in cells o f the 
two depots, where on average, adiponectin gene expression was more than 4-fold 
higher in cells of the subcutaneous inguinal compared to those of the gonadal depot. 
This difference in the level o f expression between depots has been also documented 
in humans (Fisher et al., 2002; Hernandez-Morante et al., 2007). Immunoreactive 
adiponectin was detected in cell culture supernatant of canine adipocytes from both 
the subcutaneous inguinal and gonadal depots. Thus, these results indicate that in 
addition to synthesising adiponectin mRNA, canine adipocytes synthesise and 
subsequently release adiponectin protein. In accordance with data from other species 
(Fasshauer et al., 2003b; Degawa-Yamauchi et al., 2005), canine adipocytes are 
therefore a source of the protein, which can thus be considered an adipokine, and in 
addition to having a local autocrine/paracrine effect, adiponectin enters the 
circulation to act in an endocrine manner in the dog (Brunson et al., 2007).
It is now evident that obesity is characterised by chronic low-grade inflammation and 
adipocytes are active participants in the generation of the inflammatory state 
(Fruhbeck et al., 2001; Fasshauer & Paschke, 2003). A number o f adipokines are 
linked to inflammation and the inflammatory response (Rajala & Scherer, 2003; 
Trayhurn & Wood, 2004; Trayhum & Wood, 2005), and as such the expression 
profile o f a series o f adipokine genes linked to inflammation was examined by both 
RT-PCR and qPCR techniques during the differentiation of canine preadipocytes to 
adipocytes in primary culture. Initially, the expression of a panel o f inflammation- 
related adipokines was examined in cells of the subcutaneous inguinal depot. A 
signal was obtained in preadipocytes and also late during the differentiation process 
for all adipokines examined.
PAI-1, an acute-phase protein whose elevated circulating levels are characteristic of 
obesity has been studied in WAT in relation to its role in thrombosis (Skurk & 
Hauner, 2004). PAI-1 was expressed both before and after differentiation in the dog. 
This is in accordance with studies carried out using human cells (Wang et al., 2004). 
The expression o f another acute-phase protein was also examined, this was SAA. 
SAA has been established has an important risk factor for coronary artery disease 
and serum concentrations are correlated with BMI, adiposity and adipose tissue SAA 
mRNA levels (Poitou et al., 2005). Here, in a similar manner to PAI-1, expression of
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SAA was detected both pre and post-differentiation in canine adipocytes of the 
subcutaneous inguinal depot. The expression o f VEGF was also examined by RT- 
PCR and in a similar manner to both PAI-1 and SAA expression was again detected 
throughout differentiation and maturation of canine adipocytes in vitro.
Next, expression and secretion of two major cytokines, TNFa and IL-6 were 
investigated in canine adipocytes. TNFa has a well-established role in inflammatory 
responses (Sethi & Hotamisligil, 1999; Qi & Pekala, 2000) and production o f the 
cytokine by human fat cells has been widely documented (Kern et al., 2001; Wang et 
al., 2004; Wang et al., 2005). As in the present study, TNFa expression levels have 
been found to decline during adipogenesis (Gerhardt et a t, 2001; Wang et a t, 2004; 
Eisele et a t, 2005). Here, this effect was documented for both cells of the 
subcutaneous inguinal and gonadal depots and quantitatively, changes were 
comparable to those documented for human adipocytes (Wang et a t, 2004).
Immunoreactive TNFa protein was detected in cell culture supernatant of canine 
adipocytes from both depots both pre- and post-differentiation. These results indicate 
that in a similar manner to adiponectin in the dog, in addition to synthesising TNFa 
mRNA, canine adipocytes synthesise and subsequently release TNFa protein. In 
accordance with data from both humans and rodents (Hotamisligil et a t, 1993; Kern 
et a t,  2001), canine adipocytes are therefore a source of the protein, which can thus 
be considered an adipokine. Higher levels of the protein were secreted from cells o f 
the gonadal as opposed to those of the subcutaneous inguinal depot. There is a strong 
link between visceral adiposity and increased levels of proinflammatory cytokines, 
and local expression of TNFa is higher in adipose tissue of subjects with visceral 
obesity and insulin resistance (Kern et a t, 2001). Thus, the insulin resistance seen in 
obese dogs may be related to TNFa levels produced locally by visceral WAT.
IL-6 is an important cytokine produced by many cell types including white adipose 
tissue (Fried et a t, 1998). Serum IL-6 concentrations have been found to be 
positively correlated with BMI in humans (Mohamed-Ali et a t, 2001). IL-6 levels 
have been found to decline sharply shortly after differentiation o f human adipocytes, 
with levels subsequently reaching pre-induction levels as cells mature (Wang et a t, 
2004). In the dog, unlike human cells, expression levels of IL-6 decline during
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adipocyte differentiation and development. This was documented for cells o f both 
depots. In addition, the initial decline seen immediately post-induction in humans is 
seen later in the dog, from day 3 post-induction, and levels remain low throughout 
adipocyte differentiation and development.
Immunoreactive IL-6 was found in medium collected from cells of both depots both 
pre- and post-induction. Thus, this cytokine, in a manner similar to adiponectin and 
TNFa, can be classified as an adipokine in the dog. Levels of IL-6 protein detected in 
medium collected from cells of both depots declined significantly during 
differentiation. For cells of the subcutaneous inguinal depot this decline was slightly 
later than that detected for IL-6 mRNA, from day 6 post-induction. Levels o f IL-6 
detected in media collected from cells o f the gonadal depot at both day 0 and 10 
post-induction were substantially higher than in conditioned media from cells o f the 
subcutaneous inguinal depot at the same time-points. This difference in secretion 
levels by different depots has also been documented for human adipocytes in culture 
(Fried et al., 1998), and as such, like TNFa may play an important role in the 
development of metabolic derangements in obesity in the dog.
Obesity has been associated with macrophage infiltration and accumulation in WAT 
(Weisberg et al., 2003). MCP-1 is responsible for the attraction of macrophages and 
T-lymphocytes to sites of inflammation and circulating levels o f MCP-1 have been 
shown to be significantly raised in obesity (Kim et al., 2006). Like IL-6, MCP-1 is 
produced by a variety of cells, including human adipocytes (Rollins, 1997; Gerhardt 
et al., 2001) and its production has been linked to inflammatory stimuli (Rollins,
1997). In addition, MCP-1 has been implicated in the development of insulin 
resistance and impaired differentiation of murine adipocytes in vitro (Sartipy & 
Loskutoff, 2003). In dogs, MCP-1 is expressed both before and after differentiation 
in cells o f both the subcutaneous inguinal and gonadal depots. Levels of expression 
then appear to fall in cells of the subcutaneous inguinal depot as cells mature. This is 
unlike what is seen in human adipocytes in culture, where MCP-1 gene expression 
levels either exhibit no change (Gerhardt et al., 2001), or increase, as cells mature 
(Wang et al., 2004). Cells from the gonadal depot appeared to resemble more closely 
the situation seen in human cells, were semi-quantitatively there was little evidence
168
of change in levels of MCP-1 gene expression. However, the decrease in level of 
MCP-1 gene expression was again documented quantitatively as cells matured.
MCP-1 protein was also detected in cell culture supernatant from cells of both depots 
both pre- and post-differentiation. Thus, like adiponectin, TNFa and IL-6, MCP-1 
can also be characterised as an adipokine in the dog and as such may contribute to 
circulating levels seen in obesity with expansion of WAT mass. Similar to mRNA 
levels, MCP-1 protein concentration in the subcutaneous inguinal depot appeared to 
be greater pre- than post-differentiation. However, this is unlike the changes 
observed in the gonadal depot, and what has been documented in human adipocytes 
in culture where MCP-1 protein levels in the media increase as cells mature (Wang et 
al., 2004). Furthermore, the amount of protein secreted by canine adipocytes was 
considerably greater than that reported by human adipocytes in culture (Gerhardt et 
al., 2001; Wang et al., 2004), nearly ten-fold higher at their lowest level (day 10 
post-differentiation) in the dog. Thus, although numbers of cells in each cell culture 
system were not documented, quantitatively this adipokine may play a key role in 
adipose tissue and whole body metabolism in the dog, again with a strong link to 
visceral adiposity.
NGF mRNA levels in canine preadipocytes were higher than in mature adipocytes of 
both depots examined (Fig 4.17B and 4.18B) and this is in accordance with data for 
both murine and human adipocytes in vitro (Peeraully et al., 2004; Wang et al., 
2004). Immunoreactive NGF protein was detected in cell culture supernatant of cells 
of the subcutaneous inguinal depot both pre and post-differentiation. Thus this 
important target-derived neurotrophin can also be defined as an adipokine in the dog 
where release appeared to mirror closely changes in mRNA levels and it may 
therefore play an important part in the development and survival o f sympathetic 
neurones in canine WAT.
In summary, this chapter has examined the differentiation and development of canine 
adipocytes from two different depots (visceral and subcutaneous) in culture. Cells 
have been characterised not only histologically but also through the expression of 
key molecular markers. The expression of adipokine genes has been established both 
pre- and post-differentiation with pro inflammatory adipokines being expressed early
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on in the differentiation process in the dog with levels of expression decreasing as 
cells mature. Importantly, canine adipocytes have been shown to actively secrete key 
adipokines making them a valuable tool for the investigation of adipocyte biology in 
terms o f responses to the inflammatory stimuli and agents which may improve 
proinflammatory states and insulin sensitivity.
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Chapter 5
Adipokine expression and secretion by canine adipocytes in 
primary culture: Regulation by the inflammatory mediators
TNFa, IL-6 and LPS
5.1 Introduction
In Chapter 4, a robust method of canine primary adipocyte cell culture was outlined 
where cells from both the subcutaneous inguinal and gonadal depot were 
successfully induced to differentiate into mature adipocytes in vitro. This was 
characterised by histological changes, including the accumulation of intracellular 
lipid droplets, which were identified as such using the lipid specific stain Oil red O. 
The system was further validated by the expression and secretion of key molecular 
markers, such as the adipocyte hormone adiponectin, by cells of both depots. It was 
also established that canine adipocytes in culture express and secrete key adipokines 
including IL-6 and TNFa. Studies in this chapter focused on pro-inflammatory 
agents and their role in the regulation of adipokine gene expression and secretion by 
canine adipocytes.
A number of adipokines have been linked to inflammation and the inflammatory 
response (Coppack, 2001; Rajala & Scherer, 2003; Trayhurn & Wood, 2004), and 
these include cytokines such as IL-6 and TNFa and chemokines such as MCP-1 and 
MIF. Leptin itself has also been linked to inflammation (Sarraf et al., 1997; Faggioni 
et al., 1998), whereas the other major adipocyte hormone, adiponectin, has an anti­
inflammatory effect (Ouchi et al., 1999). The pro-inflammatory cytokine TNFa plays 
an extensive role in adipose tissue function, exerting a range o f actions such as the 
stimulation of lipolysis (Ryden et al., 2004) and the induction of apoptosis (Prins et 
al., 1997). In addition, TNFa has been reported to increase the expression of several 
adipokines; for example, IL-6 (Fasshauer et al., 2003a; Wang et al., 2004), and 
MCP-1 (Gerhardt et al., 2001; Wang et al., 2004), whereas leptin and adiponectin 
expression is inhibited by TNFa (Wang et al., 2005).
As discussed in Chapter 1, TNFa has been shown to be synthesised and secreted by 
human adipocytes (Kern et al., 1995) and importantly, TNFa has a substantial effect 
on its own level of expression in human adipocytes (Wang et al., 2005). 
Furthermore, in humans, a strong link between TNFa and insulin resistance in 
obesity has been established (Hotamisligil, 2003) and the production of the cytokine 
has been shown to increase in rodent models of obesity (Hotamisligil et al., 1993).
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IL-6 is another pro-inflammatory cytokine secreted by adipocytes in culture (Fried et 
al., 1998). Studies have indicated that up to a third of circulating levels of IL-6 are 
derived from adipose tissue, the production of which increases with obesity 
(Mohamed-Ali et al., 1997). Few studies have assessed the effect of IL-6 on 
adipocyte metabolism (Path et al., 2001); however, there is evidence that IL-6 has a 
strong autocrine effect on its own level of expression and secretion in murine 
adipocytes (Lagathu et al., 2003) and is also thought to play a key role in the 
induction of insulin resistance in murine adipocyte cell lines in vitro (Lagathu et al., 
2003; Rotter et al., 2003). In chapter 4, it was established that IL-6 can also be 
considered an adipokine in the dog, being actively secreted by adipocytes of both 
visceral and subcutaneous depots during differentiation. The role of IL-6 in terms of 
inflammation and regulation of secretion of other adipokines in canine adipocytes 
remains to be investigated.
Factors which regulate the secretion o f cytokines by WAT include inflammatory 
stimuli such as lipopolysaccharide (LPS) (Coppack, 2001). LPS is a major 
constituent of the membrane o f Gram-negative bacteria, and as such is responsible 
for the activation of the innate immune pathway via toll-like receptors (TLRs). These 
are important in terms o f antigen recognition allowing rapid and effective response to 
infection (Kaisho & Akira, 2002). Recent studies have reported the expression of 
TLR-2 and -4 in 3T3-L1 adipocytes. In those studies, LPS has been shown to signal 
through TLR-4 and induce both IL-6 and TNFa secretion (Lin et al., 2000). LPS has 
been shown to strongly upregulate both expression and secretion of adipokines such 
as NGF (Peeraully et al., 2004) and haptoglobin (Chiellini et al., 2002).
Earlier studies into adipokine expression and secretion in canine adipocytes allowed 
the time-point of stable expression of key adipokine genes to be identified (between 
days 10 and 15 post-differentiation). This formed the basis for subsequent 
experiments outlined in this chapter where the effects of the proinflammatory agents 
LPS, TNFa and IL-6 on the expression of adipokines in differentiated canine 
adipocytes were investigated. The adipokines studied include leptin, adiponectin, IL- 
6, MCP-1, NGF and TNFa itself. NGF has been described as an adipokine in mice 
(Peeraully et al., 2004) and humans (Wang et al., 2004) and as outlined in the 
previous chapter; this important target-derived neurotrophin is also an adipokine in
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the dog. Thus, one of the aims o f these investigations was to establish whether NGF 
is also linked to the inflammatory response in canine WAT.
5.2 Methods
5.2.1 Cell culture
White adipose tissue from both the subcutaneous inguinal and gonadal depots of 
SBT dogs were harvested as described in sections 2.1.1 and 2.1.2. Cells were 
cultured as described in section 2.2 at 37°C in a humidified atmosphere of 5% 
CC>2/95% air. Twenty four hours after they were inoculated, cells from the gonadal 
depot were washed three times in lx  PBS and the inoculation medium replaced by 
induction medium. Cells from the subcutaneous inguinal depot had their inoculation 
medium changed 48 h post-inoculation and 24 h later (at 72 h post-inoculation) were 
washed three times in lx  PBS and the inoculation medium replaced by induction 
medium. Cells of both depots were exposed to the adipogenic medium for 48 h. This 
was replaced by feeding medium, which was renewed every 48 h.
The cells were pre-incubated 12 days after differentiation for 24 h with FCS-free 
feeding medium. Cells were then treated with FCS-free feeding media containing 
each o f the specific agents; the control cells for each study had their pre-incubation 
media renewed. In preliminary studies, cells from the subcutaneous inguinal depot 
were treated with human recombinant TNFa at doses of 5 and 50 ng/ml. 
Subsequently, cells from both depots were treated with canine recombinant TNFa at 
the same doses used for human recombinant TNFa treatment studies. Cells were 
harvested at the time of treatment and at 2 and 24 h post-treatment as described in 
section 2.3.5. Only cells from the subcutaneous inguinal depot (see section 4.4), were 
treated with IL-6 at doses of 1 and 25 ng/ml, and LPS at doses of 10 and 100 ng/ml. 
Cells were harvested at the time of treatment and at 4 and 24 h post-treatment as 
described in section 2.3.5. Either 7 or 8 individual wells in cell culture plates were 
treated with each agent, or used as controls.
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5.2.2 qPCR and ELISA
RNA was extracted from cultured cells using Tri-Reagent as described in section
2.3.1. RNA, which was to be analysed by qPCR, was subsequently treated using a 
DNA-free kit to minimise levels o f genomic DNA contamination (section 2.3.2). 
Once extracted, the total RNA was quantified using a BioPhotometer and reverse 
transcribed using the Reverse-iT First Strand Synthesis kit (sections 2.3.3 and 2.4.1). 
The cDNA was then analysed by real-time PCR (qPCR) using the qPCR Core Kit 
and an Mx3005P real-time machine (section 2.5.3 and 2.5.4).
PCR products were purified using a NuceloSpin Extract 2-in-l kit and sequenced 
commercially (see section 2.4.4). All qPCR data was analysed using MxPro- 
Mx3005P software. Conditioned media samples were analysed for NGF protein 
concentration using the NGF Emax Immunoassay System (section 2.6.1). TNFa, IL-6 
and MCP-1 protein concentration were analysed using ELISA kits from R&D 
Systems (see section 2.6.2). Adiponectin protein concentration in conditioned media 
was assayed commercially by LINCO (section 2.6.3).
5.3 Results
5.3.1 Regulation of adipokine expression in canine adipocytes: 
Response to human recombinant TNFa
Initial studies examined the integrated effect of the pleiotropic pro-inflammatory 
cytokine TNFa on the expression of genes encoding inflammation-related adipokines 
in differentiated canine adipocytes. A dose response experiment was carried out 
where cells o f the subcutaneous inguinal depot were incubated with a low (5 ng/ml) 
and high (50 ng/ml) dose of human recombinant TNFa for periods of 2 and 24 h. 
From analysis carried out using NCBI and EMBL-EBI search engines, human and 
canine TNFa share a high level of homology, both at the mRNA (90%) and protein 
(88%) level (Fig. 5.1). Thus, as expected, treatment of canine adipocytes with human 
recombinant TNFa resulted in an increase in mRNA level for inflammation-related 
adipokines and TNFa itself (Fig. 5.2).
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This response, however, was muted in comparison to that reported for TNFa 
treatment of human adipocytes (Wang et al., 2004; Wang et al., 2005). An example 
is the effect of human TNFa on its own level of expression, where a response of 
nearly 2000-fold increase in TNFa expression is reported with TNFa treatment at 2 h 
post-treatment with 25 ng/ml o f human recombinant TNFa (Wang et al., 2005). In 
the dog, TNFa mRNA levels were significantly raised at both 2 and 24 h post 
treatment. However, the maximal effect of human recombinant TNFa treatment on 
canine adipocytes was just over 3-fold at 24 h post-treatment with the high dose of 
TNFa (Fig. 5.2A).
The same muted response was also observed for other adipokines such as IL-6 and 
MCP-1. IL-6 mRNA levels in human adipocytes were upregulated by nearly 50-fold 
at 2 h post-treatment (Wang et al., 2005), whereas in the dog, although a significant 
increase in IL-6 mRNA levels was observed at both 2 and 24 h with low and high 
dose treatment, mRNA levels only reached a peak of 5-fold at 24 h post-treatment 
with the high dose of TNFa (Fig. 5.2B). In terms of MCP-1, in human adipocytes, a 
maximal effect has been reported of close to 25-fold at 24 h post-treatment with 25 
ng/ml TNFa (Wang et al., 2005), whereas in the dog, despite a significant 
upregulation in MCP-1 mRNA levels at 2 and 24 h (with the effect at 2 h being dose 
dependent), levels peaked at around 5-fold at 24 h post-treatment with the high dose 
(50 ng/ml) of TNFa (Fig. 5.2B).
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Figure 5.1
A human 
canine
human
canine
human
canine
Human and canine TNFa coding sequence (mRNA) and 
amino acid sequence alignment
GGACGTGGAGCTGGCCGAGGAGGCGCTCCCCAAGAAG 60
********************************************* **************
A:***  * * * * * * * * * k ** * ********************* **
k ★ ***** ******** *************************************
I
 *
I
120
120
A G AG l 180 
CAGa I  180
****** **** * * * * * ************** ****** ****** *******
human
canine
*********** ********** t** * * * * * * * * * * * * * * * * *  ***********
human
canine
human
canine
human
canine
human
canine
************** *********** ***********tA
CCCTGCCAGAGGGAG 540
| 540 
*•** * * * * *  * * * * * *
human
canine
human
canine
human
canine
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *  * * * * * *  *****1(1
B  human 
canine
MSTESMIRDVELAEEALPKKTGGPQGSRRCLFLSLFSFLIVAGATTLFCLLHFGVIGPQR 60 
MSTESMIKDVELAEEPLPKKAGGPPGSRRCFCLSLFSFLLVAGATTLFCLLHFGVIGPPE 60 
*******.*******.****.*** *****..*******.******************. .
human EEFPRDLSLISPLAQAVRSSSRTPSDKPVAHWANPQAEGQLQWLNRRANALLANGVELR 120
canine EELPNGLQLISPLAQTVKSSSRTPSDKPVAHWANPEAEGQLQWLSRRANALLANAVELT 120
** • * . • * • * * * * * * *  • * • * * * * * * * * * * * * * * * * * *  . * * * * * * * *  . * * * * * * * * *  . * * *
human
canine
DNQLVVPSEGLYLIYSQVLFKGQGCPSTHVLLTHTISRIAVSYQTKVNLLSAIKSPCQRE 180 
DNQLIVPSDGLYLDSSQVLFKGQGCPSTHVLLTHTISRFAVSYQTKVNLLSAIKSPCQRE 180
* * * * . * * * . * * * * . . * * • r * * * * * * * * * * * * * *  • * * * * * * * * * * * * * * * * * * * * *
human TPEGAEAKPWYEPIYLGGVFQLEKGDRLSAEINRPDYLDFAESGQVYFGIIAL 233
canine TPEGTEAKPWYEPIYLGGVFQLEKGDRLSAEINLPNYLDFAESGQVYFGIIAL 233
* * * * • * * * * * * * * * * * * * * * * * * * * * * * * * * * * . * . * * * * * * * * * * * * * * * * *
The mRNA coding sequence and amino acid sequence for TNFa o f human and dog were 
obtained from the NCBI database. Sequences were aligned using ClustalW software 
(http://www.ebi.ac.uk/clustalw). In (A), blue blocks indicate matching nucleotides and in 
(B), yellow blocks indicate matching amino acids.
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(A) (B)
Figure 5.2 Regulation of adipokine gene expression in canine
adipocytes by human recombinant TNFa
D iffe r e n t ia te d  ca n in e  a d ip o c y te s  from  th e su b cu ta n eo u s in g u in a l d ep o t at d ay  12 p o st­
in d u ctio n  w e r e  p re-treated  w ith  F C S -fr ee  fe e d in g  m ed iu m  fo r  2 4  h and  then  in cu bated  in 
m ed iu m  co n ta in in g  hum an  reco m b in a n t T N F a  for  2 and 2 4  h. A d ip o k in e  m R N A  le v e l w a s  
m ea su red  b y  q P C R  and  n o rm a lised  to  ca n in e  P -actin  re la tiv e  to  th e  untreated  con tro l group  
(= 1 ) .  R e su lts  are m ea n s ±  S E  (bars) for  grou p s o f  8. (A ) , T N F a ; (B ) , IL -6; (C ) , M C P -1 . -5 , 5 
n g /m l T N F a ; -5 0 , 50  n g /m l T N F a . *P < 0 .0 5 , **P <  0 .0 1 , ***P <  0 .0 0 1  com p ared  w ith  
c o n tro ls .
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5.3.2 Regulation of adipokine expression in canine adipocytes: 
Response to canine recombinant TNFa
Due to the muted effects observed when canine adipocytes were treated with human 
recombinant TNFa, the next set of experiments set out to investigate whether such 
effects were due to species differences between dogs and humans in the response to 
TNFa or, due to the potency of the treatment agent itself. Despite the high level of 
homology between human and canine TNFa, amino acid differences and subsequent 
effects of this on protein structure may have rendered the human protein less 
effective at inducing a response in canine adipocytes. The experiment was carried out 
at same doses and time-points as outlined in section 5.3.1, however, this time using 
canine recombinant TNFa to treat cells o f both depots in order to also identify any 
depot differences in the effect of TNFa on canine adipocytes.
It was evident that the amino acid differences between human and canine TNFa were 
significant in terms of the biological activity o f the protein, where canine 
recombinant TNFa induced substantial and rapid increases of >600-fold with low 
dose TNFa (5 ng/ml) treatment on its own level o f mRNA as early as 2 h post­
treatment in the cells of the subcutaneous inguinal depot (Fig. 5.3A). A peak 
response o f a >1800-fold increase in TNFa mRNA occurred with high dose 
treatment (50 ng/ml) at 2 h post-treatment. This is similar, in both magnitude and 
time, to what has been reported in human adipocytes with TNFa treatment (Wang et 
al., 2005). TNFa mRNA levels then fell precipitously by 24 h post-treatment, but 
were still, on average 130-fold higher than in the controls (Fig. 5.3A). TNFa also had 
a potent autocrine effect on its own level of expression in cells of the gonadal depot. 
However, this was at best 100 times less than that observed for cells o f the 
subcutaneous inguinal depot (Fig. 5.4A).
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Figure 5.3 Regulation of adipokine gene expression in canine
subcutaneous inguinal adipocytes by canine recombinant TNFa
D iffe r e n t ia te d  ca n in e  a d ip o c y te s  from  th e su b cu ta n eo u s in g u in a l d ep o t at d ay  12 p o st­
in d u ctio n  w er e  pre-treated  w ith  F C S -fr ee  fe e d in g  m ed iu m  fo r  2 4  h and then  in cu b ated  in 
m ed iu m  co n ta in in g  ca n in e  recom b in an t T N F a  for  2  and 2 4  h at lo w  -5 , 5 n g /m l T N F a ; and 
h igh  -5 0 , 5 0  n g /m l T N F a . A d ip o k in e  m R N A  le v e l w a s  m easu red  b y  q P C R  and n o rm a lised  to  
ca n in e  R N A P o lI Ia  re la tiv e  to  th e  untreated  con tro l grou p  (= 1 ) .  R esu lts  are m ea n s ±  S E  (bars) 
for  g ro u p s  o f  8 . (A ) ,  T N F a ; (B ) , IL -6; (C ) , M C P -1 ; (D ) , N G F ; (E ) , L eptin ; (F ), A d ip o n ec tin .  
*P <  0 .0 5 ,  **P <  0 .0 1 , ***P < 0 .0 0 1  com p ared  w ith  co n tro ls .
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Figure 5.4 Regulation of adipokine gene expression in canine gonadal
adipocytes by canine recombinant TNFa
D iffe re n tia ted  ca n in e  a d ip o c y te s  from  th e  g o n ad a l d ep o t at d a y  12 p o st- in d u c tio n  w e r e  pre­
treated  w ith  F C S -fr e e  fe e d in g  m ed iu m  for  2 4  h and th en  in cu b a ted  in m ed iu m  co n ta in in g  
ca n in e  reco m b in a n t T N F a  fo r  2  and  2 4  h at lo w  -5 , 5 n g /m l T N F a ; and  h ig h  -5 0 , 5 0  n g /m l 
T N F a . A d ip o k in e  m R N A  le v e l w a s  m easu red  b y  q P C R  and n o rm a lise d  to  ca n in e  R N A P o lIIa  
re la tiv e  to  th e  u ntreated  con tro l grou p  (= 1 ) .  R esu lts  are m ea n s  ±  S E  (b ars) for  g rou p s o f  8. 
(A ), T N F a ;  (B ) , IL -6; (C ), M C P -1 ; (D ) , N G F ; (E ), L eptin ; (F ), A d ip o n e c tin . *P <  0 .0 5 , **P 
< 0 .0 1 ,  ***P <  0 .0 0 1  co m p a red  w ith  co n tro ls  at th e  sa m e t im e -p o in ts .
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IL-6 mRNA in cells of both depots reached a peak at 24 h post treatment with a 44- 
fold increase observed in cells of the subcutaneous inguinal depot (Fig. 5.3B). The 
response by cells of the gonadal depot, however, was even more marked with levels 
being >80% higher than those observed for cells of the subcutaneous inguinal depot, 
with a 330-fold increase in mRNA level with the high dose treatment at 24 h (Fig. 
5.4B). MCP-1 mRNA levels were substantially higher in cells o f the subcutaneous 
inguinal depot compared to those of the gonadal depot, reaching a peak at 24 h post­
treatment of 47-fold (Fig. 5.3C). This is in contrast to cells o f the gonadal depot 
where a modest 6-fold increase in mRNA levels was reached at 2 h post-treatment 
(Fig. 5.4C). The peak in NGF mRNA level with TNFa treatment was seen later in 
cells o f the subcutaneous inguinal depot than by cells of the gonadal depot. The 
magnitude o f the effect of TNFa in cells o f both depots was, however, similar at 
between 10- and 12-fold (Fig. 5.3D and 5.4D).
A significant reduction in leptin mRNA levels was observed both at 2 and 24 h o f 46 
and 39% respectively, post-treatment with canine recombinant TNFa in cells o f the 
subcutaneous inguinal depot (Fig. 5.3E). In contrast, cells o f the gonadal depot had a 
modest but significant increase of nearly 2-fold in leptin mRNA levels at 2 h post­
treatment with both low and high dose TNFa. However, this effect was no longer 
present by 24 h (Fig. 5.4E). Unlike leptin, levels o f adiponectin mRNA were 
significantly reduced to a similar extent (by approximately 60%) in cells o f both 
depots at the end of the 24 h treatment period (Fig. 5.3F and 5.4F).
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5.3.3 Regulation of adipokine secretion by canine adipocytes: 
Response to canine recombinant TNFa
The secretion into the medium of a selected group of adipokines was next examined 
during the treatment of canine adipocytes with canine recombinant TNFa using 
ELISA. The secretion o f inflammation-related adipokines such as IL-6, MCP-1 and 
NGF by canine adipocytes was substantially increased by TNFa treatment, the effect 
being more marked at 24 h post-treatment (Fig. 5.5). The secretion o f IL-6 into the 
medium by cells o f the subcutaneous inguinal depot was increased by 33-fold by 
treatment with low dose TNFa at 24 h. In this case, secretion was dose dependent, 
with the level o f IL-6 secreted into the medium increasing by 60-fold with high dose 
TNFa treatment at 24 h (Fig. 5.5A). Cells of the gonadal depot also responded in a 
similar manner, although the effect was not as marked, with a 30-fold increase in the 
level o f protein secreted into the medium at 24 h with the high dose treatment (Fig. 
5.5B).
There was a modest but nevertheless significant increase in MCP-1 protein secreted 
into the medium by canine adipocytes at 2 h post-treatment with the low dose of 
canine recombinant TNFa (Fig. 5.5C). MCP-1 secretion by cells of both depots was, 
however, markedly increased by 24 h post-treatment; for cells o f the subcutaneous 
inguinal depot, the concentration o f MCP-1 in the medium increased by 23-fold (Fig. 
5.5C), whereas for cells of the gonadal depot this effect was more muted at only just 
over 3-fold (Fig. 5.5D). The effect of TNFa treatment on NGF secretion was 
documented for cells of the subcutaneous inguinal depot. Here, unlike other 
adipokines, the level of NGF protein in the medium fell significantly; by on average 
38% at 2 h post-treatment with both low and high doses of TNFa (Fig. 5.5E). This 
effect, however, did not persist with levels rising by 15-fold at 24 h post-treatment. 
Unlike other adipokines, TNFa treatment had no effect on the amount of adiponectin 
secreted into the medium (Fig. 5.5F).
183
Figure 5.5 Regulation of adipokine protein secretion in canine
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adipocytes by canine recombinant TNFa
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D iffe re n tia ted  ca n in e  a d ip o c y te s  from  th e su b cu ta n eo u s in g u in a l and g o n ad a l d ep o ts  at d ay  
12 p o s t- in d u c t io n  w er e  pre-treated  w ith  F C S -fr ee  fe e d in g  m ed iu m  for  2 4  h and then  
in cu b ated  in m ed iu m  co n ta in in g  ca n in e  recom b in an t T N F a  fo r  2  and  2 4  h at lo w  -5 , 5 n g /m l 
T N F a ; and  h igh  -5 0 , 5 0  n g /m l T N F a . A d ip o k in e  co n cen tra tio n  w a s  m easu red  b y  E L IS A  
n o rm a lised  to  co n tro l at the sa m e t im e-p o in t. R esu lts  are m ea n s  ±  S E  (bars) for  g rou p s o f  3 -  
8. ( A ) ,  IL -6  sc; (B ) , IL -6  gon ; (C ), M C P -1  sc; (D ) , M C P -1  gon ; (E ), N G F  sc; (F ), 
A d ip o n e c tin  sc . S c , su b cu ta n eo u s in gu in a l d ep ot; g o n , g o n a d a l d ep o t. *P <  0 .0 5 , **P < 0 .0 1 ,  
***p <  0 .0 0 1  com p ared  w ith  con tro ls .
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5.3.4 Regulation of adipokine expression and secretion in canine 
adipocytes: Response to IL-6
In the next experiments, cells from the subcutaneous inguinal depot were treated with 
the pro-inflammatory cytokine IL-6. Canine recombinant IL-6 was available 
commercially from R&D Systems and this was the treatment agent of choice. In 
addition, there is less similarity between human and canine IL-6 (76% CDS 
similarity but only 57% similarity in terms of amino acid sequence) than between 
human and canine TNFa. Cells were sampled at 4 and 24 h, so initially 2 h later than 
cells treated with TNFa as studies have shown that optimaly results in terms of 
adipocyte metabolism can be detected with IL-6 treatment from this time-point 
(Greenberg et al., 1992). Logistically, it was possible to obtain a control sample at 
the first time-point (4 h post-treatment), in addition to that at time of treatment (Con 
Oh).
In contrast to TNFa, the effect of IL-6 treatment on canine adipocytes in terms of 
adipokine gene expression was muted (Fig. 5.6). Three distinct responses to the 
cytokine were observed. There was a moderate, but nevertheless significant, 
upregulation of TNFa mRNA of 2.3-fold at 4 h post-treatment with the high dose of 
IL-6 (Fig. 5.6A). However, there was a significant reduction in mRNA of IL-6 itself 
and NGF, of 48 and 25% respectively, with high dose IL-6 at 24 h post treatment 
(Fig. 5.6B and D). In addition, adiponectin mRNA was significantly reduced with 
both low and high dose IL-6 at 24 h post-treatment by just over 30% (Fig. 5.6F). No 
effect was observed in terms of MCP-1 and leptin gene expression (Fig. 5.6C and E).
The effect of IL-6 on adipokine secretion by canine adipocytes was also investigated. 
Due to its muted effects on adipokine expression, only a restricted number of 
adipokines were investigated in terms of secretion by canine adipocytes in response 
to treatment with recombinant IL-6. Treatment of cells with IL-6 had a small, but 
significant, effect on MCP-1 and NGF secretion of 24 and 11% respectively, into the 
medium at 24 h post-treatment with the high dose of IL-6 (Fig. 5.7).
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Figure 5.6 Regulation of adipokine gene expression in canine
adipocytes by canine recombinant IL-6
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D iffe re n tia ted  ca n in e  a d ip o c y te s  from  th e  su b cu ta n eo u s in g u in a l d ep o t at d ay  12 p o st­
in d u ction  w e r e  pre-treated  w ith  F C S -fr ee  fe e d in g  m ed iu m  fo r  2 4  h and  th en  in cu b ated  in 
m ed iu m  co n ta in in g  ca n in e  re co m b in a n t IL -6  for  2 and 2 4  h at lo w  - 1 , 1  n g /m l IL -6; and  h igh  
-2 5 , 2 5  n g /m l IL -6 . A d ip o k in e  m R N A  le v e l w a s  m easu red  b y  q P C R  and  n o rm a lised  to  
ca n in e  R N A P o lI Ia  re la tiv e  to  th e  untreated  con tro l grou p  (= 1 ) .  R e su lts  are m ea n s ±  S E  (bars) 
for g ro u p s o f  8 . (A ) ,  T N F a ; (B ) , IL -6; (C ) , M C P -1 ; (D ) , N G F ; (E ) , L ep tin ; (F ) , A d ip o n ec tin .  
*P <  0 .0 5 ,  **P <  0 .0 1  co m p a red  w ith  co n tro ls  at 4  and 2 4  h.
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Figure 5.7 Regulation of adipokine protein secretion in canine
adipocytes by canine recombinant IL-6
(A) (B)
D iffe re n tia ted  ca n in e  a d ip o c y te s  from  th e  su b c u ta n e o u s  in g u in a l d ep o t at day 12 p o st­
in d u ctio n  w e r e  pre-treated  w ith  F C S -fr ee  fe e d in g  m ed iu m  fo r  2 4  h and  then  in cu bated  in 
m ed iu m  co n ta in in g  ca n in e  recom b in an t IL -6  for  4  and  2 4  h at lo w  - 1 , 1  n g /m l IL -6; and h igh  
-2 5 , 2 5  n g /m l IL -6 . A d ip o k in e  con cen tra tio n  w a s  m ea su red  b y  E L IS A  n o rm a lised  to  con tro l 
at th e  sa m e  t im e -p o in t. R esu lts  are m ea n s ±  S E  (b ars) fo r  g rou p s o f  6 -7 . (A ) , M C P -1 ; (B ) ,  
N G F . *P <  0 .0 5 , **P < 0 .01  com p ared  w ith  con tro ls .
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5.3.5 Regulation of adipokine expression and secretion in canine 
adipocytes: Response to LPS
The next experiments examined the effect of the pro-inflammatory agent LPS on 
canine adipocytes of the subcutaneous inguinal depot. The response in terms of pro- 
inflammatory adipokine expression and secretion was much more marked than for 
IL-6 treatment (Fig. 5.8). Here, two distinct responses to the pro-inflammatory agent 
were observed. Treatment with LPS resulted in a marked increase in mRNA level for 
TNFa, IL-6, MCP-1 and NGF. An increase o f between 40 and 55-fold was seen in 
the case o f TNFa at 4 h o f treatment with LPS. The effect on TNFa mRNA was even 
more marked at 24 h post treatment reaching >145 and >135-fold with low and high 
doses of LPS, respectively (Fig. 5.8A).
The effect of LPS on IL-6 mRNA was even more marked than that observed for 
TNFa, with IL-6 mRNA increasing by 185 and >230-fold by 4 h o f treatment with 
LPS. Remarkably, the effect of LPS treatment on IL-6 mRNA levels was even more 
substantial at 24 h post-treatment, where levels were raised in a dose dependent 
manner by nearly 2,000 and 6,000-fold with low and high doses of LPS respectively 
(Fig. 5.8B). MCP-1 mRNA levels were raised by nearly 20-fold at 4 h o f treatment 
with low and high doses of LPS. The increase in MCP-1 mRNA was even more 
substantial at 24 h post-treatment with >30-fold and nearly 50-fold upregulation in 
MCP-1 mRNA with low and high doses of LPS treatment respectively (Fig. 5.8C). 
The effect of LPS on NGF mRNA was also documented as early as 4 h with an 
average increase of 8.5-fold. At 24 h, with the low dose of LPS the increase in NGF 
mRNA was similar to that seen at 4 h. In contrast, a significant dose effect was seen 
with the high dose of LPS, where NGF mRNA was increased by 20-fold at 24 h post­
treatment (Fig. 5.8D).
There was a significant reduction in mRNA level for both leptin (36%) and 
adiponectin (55%) at 24 h o f treatment with the low dose of LPS. No effect was 
observed for high dose LPS treatment at the same time-point (Fig. 5.8E and F).
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Figure 5.8 Regulation of adipokine gene expression in canine
adipocytes by LPS 
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Differentiated canine adipocytes from the subcutaneous inguinal depot at day 12 post­
induction were pre-treated with FCS-free feeding medium for 24 h and then incubated in 
medium containing LPS for 4 and 24 h at low -10, 10 ng/ml LPS; and high -100, 100 ng/ml 
LPS. Adipokine m R N A  level was measured by qPCR and normalised to canine R N A P olIIa  
relative to the untreated control group (=1). Results are means ±  SE (bars) for groups o f 6-7. 
(A ), T N Fa; (B ), IL -6 ; (C ), M CP-1; (D ), N G F; (E ), Leptin; (F ), Adiponectin. * * P  <  0.01, 
* * * p  <  0.001 compared with controls at 4 and 24 h.
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The secretion of a select group of adipokines into the medium during treatment of 
cells with LPS was next examined using ELISA. Treatment of cells with LPS 
induced a significant increase in TNFa, IL-6, MCP-1 and NGF secretion with both 
low and high doses of LPS as early as 4 h o f treatment (Fig. 5.9). TNFa secretion 
was increased by 8 and 6-fold by low and high doses of LPS at 4 h. The effect of 
LPS on TNFa secretion by canine adipocytes was substantially increased at 24 h 
post-treatment. A peak of 22-fold in TNFa secretion was observed with the low dose 
o f LPS (Fig. 5.9A).
IL-6 concentrations in the medium were also markedly elevated by 14-fold at 24 h o f 
treatment, and in contrast to TNFa, this effect was dose dependent, with levels rising 
by >55-fold with the high dose of LPS (Fig. 5.9B). MCP-1 protein levels in cell 
culture supernatant were also markedly elevated by an average of 40-fold at 24 h of 
treatment (Fig. 5.9C). In a similar manner to IL-6, NGF protein secretion into the 
medium by canine adipocytes at 24 h was elevated significantly in a dose dependent 
manner by 58 and 74-fold with low and high doses of LPS respectively (Fig. 5.9D).
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Figure 5.9 Regulation of adipokine protein secretion in canine
adipocytes by LPS 
(B)
U)c
co
c0)ocoo
(D)
60 
5 0 -  
4 0 -  
30 
20 
10 i 
0
X
A ' ^  'Vw
°° ** c f  **
J L
N*
D iffe r e n t ia te d  ca n in e  a d ip o c y te s  from  th e  su b cu ta n eo u s in g u in a l d ep o t at d ay  12 p o st­
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191
5.4 Discussion
The studies described in this chapter have used the canine preadipocyte system 
outlined in Chapter 4 to examine the effect o f the pro-inflammatory agents TNFa, 
IL-6 and LPS on adipokine expression and secretion by canine adipocytes. A detailed 
time-course study on the effect of TNFa on human adipocytes demonstrated that 
substantial effects of TNFa on adipokine expression and secretion can be detected as 
early as 2 h of treatment with TNFa at doses of 25 ng/ml (Wang et al., 2005). Thus, 
the 2 h time-point was chosen for the study of the acute effects of TNFa on canine 
adipocytes in vitro, with more long-term effects being examined at 24 h o f treatment. 
Analysis carried out using NCBI and EMBL-EBI search engines, revealed that 
human and canine TNFa share a high level o f homology at both the mRNA and 
amino acid level. Thus, initial studies investigated the effect of human recombinant 
TNFa on canine adipocytes. It has been widely documented that TNFa has a strong 
stimulatory effect on the expression of several inflammatory cytokine genes in 
human adipocytes, including a substantial stimulation of its own expression (Wang et 
al., 2004).
Treatment of canine adipocytes with human recombinant TNFa led to a significant 
upregulation in the level of expression of pro-inflammatory cytokine genes including 
IL-6, MCP-1 and TNFa itself by cells of the subcutaneous inguinal depot as early as 
2 h post-treatment. These effects, although significant, were muted in comparison to 
the effects of human recombinant TNFa (same source) on human adipocytes in 
culture (Wang et al., 2005). In contrast, studies using canine recombinant TNFa 
demonstrated effects which were similar in magnitude to those documented in human 
adipocytes with close to 2,000-fold upregulation in TNFa expression at 2 h post­
treatment by cells o f the subcutaneous inguinal depot. Thus, despite the close 
homology between the human and canine forms of the protein, significant 
differences in terms o f protein structure and function appear to exist between them. 
Effects of canine TNFa on cells o f the gonadal depot were less marked when 
compared to those of the subcutaneous inguinal depot where, despite levels being 
significantly elevated both at 2 and 24 h o f treatment, the effects were at best 100 
times less than that observed for cells o f the subcutaneous inguinal depot. Similar 
results have been documented in human adipocytes in culture, where expression of
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TNFa in visceral depots such as the omental depot, have been documented to be 
significantly less than that for adipocytes of the subcutaneous depot (Hube et al., 
1999). This finding highlights the importance of site-specific differences in adipocyte 
gene expression. One possible explanation may be the higher level o f sympathetic 
innervation in visceral depots, as catecholamines are known to suppress TNFa 
expression (van der Poll et al., 1996). The autocrine loop by which TNFa increases 
its own expression serves to amplify the effects of this key pro-inflammatory 
cytokine on adipocytes (Wang et al., 2005). Thus, with the expansion of WAT mass 
in obesity, TNFa may also prove to have significant effects in terms o f whole body 
metabolism in the dog.
A similar pattern o f expression was observed with IL-6, where an acute and dramatic 
up-regulation of IL-6 mRNA level was seen in cells o f both depots as early as 2 h 
post-treatment. However, in the case o f IL-6 expression, this effect was more marked 
in cells of the gonadal depot. Here, at 24 h of treatment, IL-6 mRNA levels were 
nearly 8-fold higher than those of the subcutaneous inguinal depot in response to 
TNFa treatment. TNFa also stimulated the secretion o f IL-6 by cells o f both depots. 
A significant rise in secreted levels o f IL-6 only occurred 24 h after treatment, 
suggesting that the secreted protein involved de novo protein synthesis. Overall, 
levels o f IL-6 secreted by cells o f the gonadal depot were nearly 10-fold higher than 
those of the subcutaneous inguinal depot. Isolated human omental adipocytes have 
been documented to release 2-3 times more IL-6 than subcutaneous inguinal adipose 
tissue (Fried et al., 1998). The present results demonstrate that canine adipocytes 
from visceral and subcutaneous depots secrete IL-6 in a manner similar to human 
adipocytes, and that the response to TNFa treatment is more marked in cells o f the 
visceral compared to the subcutaneous inguinal depot.
In addition to IL-6 and TNFa itself, MCP-1 and NGF was strongly up-regulated in 
canine adipocytes after treatment with canine recombinant TNFa, at both the gene 
expression and protein secretion levels. MCP-1 expression was induced by TNFa in 
cells of both depots by 2 h o f treatment. Expression and secretion increased by 24 h, 
again suggesting de novo MCP-1 protein synthesis in response to treatment with 
TNFa. In addition, TNFa had a greater stimulatory effect on total 24 h MCP-1 
release, than on the release o f the other adipokines examined by cells o f both depots.
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In humans, obesity is associated with an infiltration of adipose tissue by 
macrophages (Weisberg et al., 2003; Xu et al., 2003). MCP-1 is a chemokine 
involved in the recruitment of monocytes to sites of inflammation and whose 
circulating levels are elevated in humans with obesity and insulin resistance (Nomura 
et al., 2000; Sartipy & Loskutoff, 2003), and thus the high level of secretion o f MCP- 
1 documented in canine adipocytes may be significant in terms of 
macrophage/monocyte recruitment into WAT in obesity.
A substantial increase in NGF gene expression occurred in cells of both depots with 
TNFa treatment. NGF expression was significantly upregulated in cells o f both 
depots at both 2 and 24 h of treatment, and the magnitude of the response was similar 
in cells of both depots. However, cells of the gonadal depot had a maximal response 
earlier (2 h treatment) compared to cells of the subcutaneous inguinal depot. The 
amount of NGF protein in the medium was substantially elevated following 
treatment with TNFa for 24 h, suggesting de novo NGF protein synthesis in response 
to treatment with TNFa. A strong stimulation of NGF synthesis and secretion has 
been observed previously in human and murine adipocytes (Peeraully et al., 2004; 
Wang et al., 2005). NGF has been recognised as having an important role in 
immunity and inflammation, including in stimulating TNFa production by 
macrophages (Levi-Montalcini et al., 1996; Perez-Perez et al., 2003). Overall, the 
marked response of canine adipocytes to TNFa suggests that NGF is an important 
inflammatory factor in canine WAT.
There was a significant down-regulation of leptin gene expression by cells of the 
subcutaneous inguinal depot at both 2 and 24 h treatment with TNFa. In contrast, 
cells of the gonadal depot displayed a small but nevertheless significant upregulation 
in levels o f leptin mRNA acutely at 2 h treatment with TNFa. This effect was 
however, no longer present by 24 h. Previous studies have provided conflicting 
observations, with TNFa being reported to stimulate leptin secretion in short-term 
suspension culture or ceiling culture of human adipocytes (Zhang et al., 2000), 
whereas treatment of 3T3-L1 adipocytes has been reported to result in rapid 
stimulation followed by a decline in leptin to undetectable levels (Kirchgessner et al., 
1997). Recent studies on human adipocytes treated with TNFa have reported a 
down-regulation in both leptin gene expression and protein secretion (Wang &
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Trayhurn, 2006). These differences may reflect the impact o f varying culture 
conditions and differences between cell types. Another potential issue is whether 
discrepancies are introduced through chromosomal changes in clonal cell lines, such 
as the 3T3-L1 adipocytes.
In accordance with previous data published on the effect of TNFa on human 
adipocytes (Wang & Trayhurn, 2006), treatment of canine adipocytes with TNFa led 
to a significant decrease in adiponectin mRNA by 24 h in cells o f both depots. TNFa 
has also been shown to decrease adiponectin gene expression in both human 
preadipocytes (Kappes & Loffler, 2000) and 3T3-L1 adipocytes (Fasshauer et al., 
2002). However, in contrast to human data, TNFa had no effect on adiponectin 
release by canine adipocytes. This dissociation between adiponectin mRNA and 
protein levels with TNFa treatment has also been reported in human adipocytes 
(Wang et al., 2004), and may reflect differences in time course, since mRNA 
measurements relate to the situation in cells at the end point of treatment, whereas 
protein level in the medium is the sum of the secretion throughout the preceding 24 
h. Thus, as the reduction in mRNA level occurred only towards the end o f the 
incubation period, this would not be expected to affect the aggregated protein 
secretion over the full 24 h. In both dogs (Ishioka et al., 2005b) and humans (Weyer 
et al., 2001), adiponectin production is reduced in obesity, and its expression is 
regulated by agents which improve insulin sensitivity (Maeda et al., 2001). This 
suggests that increased TNFa levels may lead to the impairment of insulin sensitivity 
in dogs as well as in humans, through suppression of circulating levels o f 
adiponectin.
Although IL-6 is regarded as a potent pro-inflammatory cytokine (Trujillo et al., 
2004), its effects on canine adipocytes were muted compared to those of TNFa both 
in terms of adipokine gene expression and protein secretion. IL-6 treatment of canine 
adipocytes resulted in a modest, but nevertheless significant, upregulation in TNFa 
gene expression at 4 h of treatment. This effect, however, was short-lived and no 
longer significant after 24 h o f treatment. Furthermore, in the dog, there was a 
significant down-regulation of IL-6 expression by canine adipocytes at 24 h o f 
treatment. This is unlike reports in 3T3-L1 adipocytes, where IL-6 has been shown to 
have a marked autocrine effect on its own level of expression and secretion
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(Fasshauer et al., 2003a). There was also no effect of IL-6 treatment on MCP-1 gene 
expression, but nevertheless a significant increase in MCP-1 protein secretion by 
canine adipocytes by 24 h o f treatment. The magnitude o f this effect was small, and 
thus was likely to have been due to accumulation of protein secreted over 24 h, rather 
than a true effect of the treatment agent. In terms of NGF, there was also a down- 
regulation of expression with IL-6 treatment at 24 h and, despite there being a small 
but significant upregulation in the amount of secreted NGF in the cell culture 
medium at 24 h post-treatment, this effect was modest; as with MCP-1, this is likely 
to represent accumulation of the protein over the 24 h treatment period. A more 
marked down-regulation o f NGF expression and secretion has been documented in 
3T3-L1 cells with IL-6 (Peeraully et al., 2004). It has been reported that sympathetic 
neurones are able to secrete IL-6 (Marz et a l, 1998) so the inhibition of NGF by this 
cytokine may be equivalent to the effect of catecholamines in terms of a 
sympathetically induced down-regulation.
Both leptin expression and systemic levels o f the protein have been shown to be 
unaffected by IL-6 in humans (Keller et al., 2005), and this was also found to be the 
case in canine adipocytes in vitro. In contrast, IL-6 treatment induced a significant 
down-regulation in adiponectin expression by 24 h of treatment with both high and 
low-dose IL-6. This is similar to what has been observed in 3T3-L1 adipocytes, with 
IL-6 inducing a marked and reversible down-regulation in adiponectin gene 
expression and secretion (Fasshauer et al., 2003b). Adiponectin is an important 
adipokine whose expression and secretion is influenced by hormones and drugs 
affecting insulin sensitivity. Thus, these in vitro results suggest that IL-6 may be an 
important factor contributing to hypoadiponectinaemia and insulin resistance in the 
obese state in the dog.
Treatment of canine adipocytes with low and high doses o f LPS, led to a marked 
increase in the level of expression and secretion of TNFa, IL-6, MCP-1 and NGF at 
both 4 and 24 h of treatment. The effect on IL-6 expression and secretion was 
particularly significant with levels o f expression being elevated by nearly 6,000-fold 
with the high dose of LPS treatment at 24 h, and levels o f secreted protein being 
nearly 100 times greater than that documented by other treatment agents. Plasma 
concentrations of IL-6 are increased in human obesity, and secretion o f IL-6 from an
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expanded WAT mass is the likely explanation (Flower et al., 2003), Increased IL-6 
production and release, including from WAT in the obese state, may contribute to the 
pathogenesis of coronary artery disease (Yudkin et al., 2000) and insulin resistance 
(Lagathu et al., 2003; Rotter et al., 2003)in humans.
The increase in the level o f the expression and secretion o f pro-inflammatory 
adipokines by canine adipocytes with LPS treatment is likely to occur directly via 
Toll-like receptor (TLR)-4, which is located in adipocytes (Lin et al., 2000). 
Conversely, treatment of canine adipocytes with low doses of LPS led to a down- 
regulation o f leptin and adiponectin gene expression at 24 h. The fact that the down- 
regulation was not observed with the high dose of LPS may have been due to a subtle 
effect of the protein at its receptor with high levels o f the agent in the case o f these 
two adipokines. In terms of leptin, recent studies have shown an upregulation o f gene 
expression with LPS treatment of 3T3-L1 adipocytes (Poulain-Godefroy & Froguel,
2007). The anti-adipogenic effect of pro-inflammatory mediators such as LPS has 
been well documented and, therefore, is it unsurprising to find a down-regulation of 
adiponectin expression in canine adipocytes by LPS. The same has also been 
documented in murine 3T3-L1 adipocytes (Poulain-Godefroy & Froguel, 
2007).(Poulain-Godefroy & Froguel, 2007).
In summary, canine adipocytes from both visceral and subcutaneous depots appear to 
be able to respond to inflammatory agents such as TNFa and LPS in a time 
dependent manner. Pro-inflammatory agents thus appear to be important regulators 
of adipokine production in canine adipocytes. The neurotrophin NGF, as well as 
important pro-inflammatory cytokines including IL-6 and TNFa and chemokines 
such as MCP-1, would each appear to be linked with the inflammatory response of 
canine WAT.
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Chapter 6
Adipokine expression and secretion by canine adipocytes in 
primary culture: Regulation by PPARy agonists and
dexamethasone
6.1 Introduction
In Chapter 4 it was shown that canine adipocytes from both visceral and 
subcutaneous depots in primary culture express and secrete key adipokines. 
Subsequent studies, outlined in Chapter 5, demonstrated that adipocytes from both 
depots were responsive to the effects o f inflammatory mediators such as LPS and the 
pleiotropic pro-inflammatory cytokine TNFa. In this chapter, studies focused on 
determining whether in addition to responding to inflammatory mediators, canine 
adipocytes are also able to respond to agents whose properties include an anti­
inflammatory action such as peroxisome proliferator-activated receptor-y (PPARy) 
agonists and dexamethasone.
Changes in morphology and composition of adipose tissue in obesity lead to changes 
in protein production and secretion. As outlined in Chapter 1, the changes in the 
inflammatory status of adipose tissue with obesity have led to a growing recognition 
that obesity represents a state of chronic low-grade inflammation. Various molecular 
mechanisms have been implicated in obesity-induced inflammation, some of which 
are thought to be modulated by the peroxisome proliferatior-activated receptors 
(PPARs), in particular PPARy which is considered the master regulator of 
adipogenesis in adipose tissue (Stienstra et al., 2006). In Chapter 3 it was shown that 
both iso forms of PPARy (PPARy 1 and 2) are expressed in canine WAT, and that as 
documented in humans (Lehrke & Lazar, 2005), PPARy 1 is the iso form expressed in 
non-adipose tissues, whereas PPARy2 is adipose-tissue specific.
The target genes o f PPARy include those involved in adipocyte differentiation, lipid 
storage and glucose metabolism and are thus of key importance to adipose tissue 
homeostasis. PPARy is also involved in the modulation of the inflammatory 
response, especially in macrophages (Stienstra et a l, 2006). Adipose tissue 
macrophage numbers have been found to increase in obesity and to participate in 
inflammatory pathways that are activated in adipose tissue of obese individuals 
(Weisberg et a l, 2003). Endogenous agonists of PPARy include unsaturated fatty 
acids and several eicosanoids, while anti-diabetic drugs belonging to the 
thiazolidinediones (TZDs) act as synthetic agonists of PPARy (Stienstra et a l, 2006).
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Studies in this chapter investigated the effect o f treatment o f canine adipocytes with 
two PPARy agonists, rosiglitazone and ciglitazone. Both o f these agents have been 
used, in humans, to treat type II diabetes by improving insulin sensitivity 
(Hammarstedt et a l, 2005). However, all TZDs are subject to liver metabolism and 
have varying degrees of hepatotoxicity making them less suitable as treatment agents 
in certain instances (Guo et a l, 2006). In addition, canine adipocytes were also 
treated with the synthetic glucocorticoid dexamethasone which is a potent anti­
inflammatory agent and has been shown to have a significant effect on the expression 
and secretion of several adipokines including leptin (Considine et a i, 1997; Mitchell 
et a l, 1997) and NGF (Peeraully et a l, 2004).
6.2 Methods
6.2.1 Cell culture
White adipose tissue from both the subcutaneous inguinal and gonadal depots of 
SBT dogs were harvested as described in sections 2.1.1 and 2.1.2. Cells were 
cultured as described in section 2.2 at 37°C in a humidified atmosphere o f 5% 
CCV95% air. Twenty four hours after they were inoculated, cells from the gonadal 
depot were washed three times in lx  PBS and the inoculation medium replaced by 
induction medium. Cells from the subcutaneous inguinal depot had their inoculation 
medium changed 48 h post-inoculation and 24 h later (at 72 h post-inoculation) were 
washed three times in lx  PBS and the inoculation medium replaced by induction 
medium. Cells of both depots were exposed to the adipogénie medium for 48 h. This 
was replaced by feeding medium, which was renewed every 48 h.
The cells were pre-incubated 12 days after differentiation for 24 h with FCS-free 
feeding medium. Cells were then treated with FCS-free feeding media containing 
each of the specific agents; the control cells for each study had their pre-incubation 
media renewed. Cells from both depots were treated with the PPARy agonist, 
rosiglitazone at doses of 50 nM, 200 nM and 5 pM. Cells were harvested at the time 
of treatment and at 4 and 24 h post-treatment, as described in section 2.2.5. Only 
cells from the subcutaneous inguinal depot (see section 4.4), were treated with the 
PPARy agonist ciglitazone at doses o f 500 nM, 10 pM and 50 pM, and
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dexamethasone at doses of 2 and 20 nM. Cells were harvested at the time of 
treatment for all treatment agents and, in the case of ciglitazone, at 4 and 24 h post­
treatment, whereas those treated with dexamethasone were harvested at 2 and 24 h 
post-treatment. All cells were harvested as described in section 2.2.5. Eight 
individual wells in cell culture plates were treated with each agent, or used as 
controls.
6.2.2 qPCR and ELISA
RNA was extracted from cultured cells using Tri-Reagent as described in section
2.3.1. RNA, which was to be analysed by qPCR, was subsequently treated using a 
DNA-free kit to minimise levels o f genomic DNA contamination (section 2.3.2). 
Once extracted, the total RNA was quantified using a BioPhotometer and reverse 
transcribed using the Reverse-iT First Strand Synthesis kit (sections 2.3.3 and 2.3.1). 
The cDNA was then analysed by real-time PCR (qPCR) using the qPCR Core Kit 
and an Mx3005P real-time machine (section 2.5.3 and 2.5.4). \
PCR products were purified using a NuceloSpin Extract 2-in-l kit and sequenced 
commercially (see section 2.4.4). All qPCR data was analysed using MxPro- 
Mx3005P software. Conditioned media samples were analysed for NGF protein 
concentration using the NGF Emax Immunoassay System (section 2.6.1). TNFa, IL-6 
and MCP-1 protein concentration were analysed using ELISA kits from R&D 
Systems (see section 2.6.2). Adiponectin protein concentration in conditioned media 
was assayed commercially by LINCO (section 2.6.3).
6.3 Results
6.3.1 Regulation of adipokine expression in canine adipocytes: 
Response to rosiglitazone
TZDs are PPARy agonists with a thiazolidinedione ring as the common structural 
characteristic (Fig. 6.1). The first experiments examined the effect of the PPARy 
agonist rosiglitazone on adipokine expression and secretion by canine adipocytes. 
Data from murine 3T3-L1 cells described the use of rosiglitazone at lower treatment 
doses of 100 nM and 1 pM (do Nascimento et al., 2004; Peeraully et al., 2004).
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However, it was unknown whether canine adipocytes were responsive to exogenous 
treatment with rosiglitazone and therefore adipocytes from the subcutaneous inguinal 
depot were treated with rosiglitazone at doses of 50 nM, 200 nM and at 5 pM.
Rosiglitazone significantly reduced the level o f expression of key inflammation- 
related adipokines by canine adipocytes at both 4 and 24 h, while augmenting the 
expression of key adipocyte hormones leptin and adiponectin by cells of both depots 
(Fig. 6.2 and 6.3). In cells from the subcutaneous inguinal depot, this effect was clear 
and dose dependent for TNFa at 4 h with low-, medium- and high-dose rosiglitazone 
where expression was significantly reduced by 25, 55 and 74%, respectively (Fig. 
6.2A). At 24 h, high-dose rosiglitazone treatment reduced TNFa mRNA level to a 
similar extent as that observed at 4 h. In cells of the gonadal depot, at 4 h treatment, 
TNFa mRNA levels were reduced by 41% with high doses o f rosiglitazone, whereas 
at 24 h the response to both medium and high doses of rosiglitazone was similar in 
magnitude to that of cells of the subcutaneous inguinal depot, with a reduction in 
TNFa mRNA level of approximately 70% (Fig. 6.3A). The effect of rosiglitazone on 
TNFa secretion was examined in cells o f the subcutaneous inguinal depot. Here, 
there was a modest, but nevertheless significant reduction, of 14% in the level of 
protein secreted into the medium at 4 h post-treatment with high-dose rosiglitazone 
(Fig. 6.4A).
A substantial decrease in IL-6 mRNA level was seen in cells of both depots on 
treatment with rosiglitazone. In cells of the subcutaneous inguinal depot, at 4 h of 
treatment, there was a marked reduction in IL-6 mRNA level of approximately 55% 
with both medium and high doses of rosiglitazone. This effect was even more 
marked at 24 h, where IL-6 expression was reduced in a dose-dependent manner by 
74 and 95% with medium and high doses of rosiglitazone, respectively (Fig. 6.2B). 
Gonadal adipocytes responded in a similar manner to high dose rosiglitazone 
treatment with IL-6 mRNA levels falling by 39 and 50% at 4 and 24 h of treatment 
respectively (Fig. 6.3B). Both low and high doses of rosiglitazone significantly 
reduced IL-6 secretion by cells of the subcutaneous inguinal depot by an average of 
25% at 4 h post-treatment. This effect was not dose dependent (Fig. 6.4B).
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Figure 6.1 Chemical structures of four anti-diabetic thiazolinediones
(Guo et a l, 2006)
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Figure 6.2 Regulation of adipokine gene expression in canine
subcutaneous inguinal adipocytes by rosiglitazone
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Differentiated canine adipocytes from the subcutaneous inguinal depot at day 12 post­
induction were pre-treated with FCS-free feeding medium for 24 h and then incubated in 
medium containing rosiglitazone for 4 and 24 h at low -50, 50 nM; medium -200, 200 nM 
and high -5, 5 pM rosiglitazone. Adipokine mRNA level was measured by qPCR and 
normalised to canine P-actin relative to the untreated control group at the same time-point 
(=1). Results are means ± SE (bars) for groups of 8. (A), TNFa; (B), IL-6; (C), MCP-1; (D), 
NGF; (E), Leptin; (F), Adiponectin. *P < 0.05, **P < 0.01, ***P < 0.001 compared with 
controls at the same time-point.
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Figure 6.3 Regulation of adipokine gene expression in canine gonadal
adipocytes by rosiglitazone
(A) (B) 2.0
1.2 n
Differentiated canine adipocytes from the gonadal depot at day 12 post-induction were pre­
treated with FCS-free feeding medium for 24 h and then incubated in medium containing 
rosiglitazone for 4 and 24 h at low -50, 50 nM; medium -200, 200 nM and high -5, 5 pM 
rosiglitazone. Adipokine mRNA level was measured by qPCR and normalised to canine p- 
actin relative to the untreated control group at the same time-point (=1). Results are means ± 
SE (bars) for groups o f  8. (A), TNFa; (B), IL-6; (C), MCP-1; (D), NGF; (E), Leptin; (F), 
Adiponectin. * P  <  0.05, * * P  < 0.01, * * * P  <  0.001 compared with controls at the same time- 
point.
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Figure 6.4 Regulation of adipokine protein secretion in canine
subcutaneous inguinal adipocytes by rosiglitazone
(A)
E
O)
(C)
(E) ~
Differentiated canine adipocytes from the subcutaneous inguinal depot, at day 12 post­
induction, were pre-treated with FCS-free feeding medium for 24 h and then incubated in 
medium containing rosiglitazone for 4 and 24 h at low -50, 50 nM; medium -200, 200 nM 
and high -5, 5 pM rosiglitazone. Adipokine concentration was measured by ELISA 
normalised to control at the same time-point. Results are means ± SE (bars) for groups of 3- 
8. (A), TNFa; (B), IL-6; (C), MCP-1; (D), NGF; (E), Adiponectin. *P < 0.05, **P < 0.01, 
***P < 0.001 compared with controls at the same time-point.
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The mRNA levels of the inflammation-related chemokine MCP-1 were also reduced 
by rosiglitazone treatment in a similar manner to TNFa and IL-6. In cells of the 
subcutaneous inguinal depot, MCP-1 mRNA levels were reduced by 33% with the 
medium dose of rosiglitazone at 4 h and by 60% with the high dose at both 4 and 24 
h o f treatment (Fig. 6.2C). High doses of rosiglitazone reduced MCP-1 mRNA levels 
by a similar extent in gonadal adipocytes at 4 h post-treatment (Fig. 6.3C). In 
addition, rosiglitazone significantly reduced MCP-1 protein secretion by canine 
subcutaneous inguinal adipocytes, where levels fell by 20% at 4 h with low doses of 
rosiglitazone, an effect which doubled with the high dose treatment. Furthermore, at 
24 h post-treatment with high dose rosiglitazone MCP-1 protein levels were reduced 
by more than 66% (Fig. 6.4C).
In a similar manner to other inflammation-related adipokines, treatment with 
rosiglitazone for 4 h at the higher dose of 5 pM, reduced NGF mRNA level by more 
than 60% in subcutaneous inguinal adipocytes (Fig. 6.2D). A similar magnitude of 
effect on NGF protein secretion was observed at 24 h (Fig. 6.4D). In contrast, 
rosiglitazone had no effect on NGF mRNA level of gonadal adipocytes (Fig. 6.3D), 
and led to a modest, but nevertheless statistically significant, increase in NGF mRNA 
level with the medium dose at 24 h post-treatment in subcutaneous inguinal 
adipocytes (Fig. 6.2D).
Unlike the effect on inflammation-related adipokines, treatment of canine adipocytes 
of both depots with rosiglitazone led to a significant increase in the level of leptin 
and adiponectin mRNA. Leptin mRNA levels in cells of both depots were raised by 
nearly 3-fold with high doses of rosiglitazone at 4 h and an effect of similar 
magnitude was observed at 24 h with the medium dose of rosiglitazone. Furthermore, 
the high doses led to an increase in leptin mRNA level of 6-fold in cells of the 
gonadal depot and of over 8-fold in cells o f the subcutaneous inguinal depot (Fig. 
6.2E and 6.3E).
Like leptin, adiponectin mRNA levels in cells of both depots were raised by 
rosiglitazone treatment. A 1.5-fold increase in level o f expression was seen at 4 h 
with high doses of rosiglitazone in cells of the subcutaneous inguinal depot (Fig.
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6.2F). Levels were raised to a similar extent at the same time-point in cells o f the 
gonadal depot with both medium and high doses of rosiglitazone (Fig. 6.3F). At 24 h 
post-treatment, adiponectin mRNA levels were significantly increased by both 
medium and high dose treatment with a peak response of nearly 3-fold in cells o f the 
subcutaneous inguinal depot (Fig. 6.2F). The response by cells of the gonadal depot 
was more marked with a nearly 4-fold up-regulation in gene expression by all three 
treatment doses 24 h (Fig. 6.3F). However, in contrast to changes in gene expression, 
adiponectin protein secretion fell by over 75% in cells of the subcutaneous inguinal 
depot with high doses of rosiglitazone (Fig. 6.4E).
6.3.2 Regulation of adipokine expression in canine adipocytes: 
Response to ciglitazone
The next experiment investigated the effects of a different PPARy agonist, 
ciglitazone, on canine subcutaneous inguinal adipocytes. Like rosiglitazone, 
treatment of canine adipocytes with ciglitazone led to a significant reduction in 
TNFa mRNA level (60% with the low dose and >85% with the high dose) as 
compared with the controls at the same time point. In contrast, TNFa mRNA levels 
were unchanged at 24 h o f treatment (Fig. 6.5A). In terms o f TNFa protein secretion 
in response to ciglitazone, a small but nevertheless significant rise in secretion was 
noted at 24 h with the high dose of ciglitazone (Fig. 6.6A).
IL-6 mRNA levels were also significantly reduced by treatment with ciglitazone. At 
4 h, a substantial decrease in IL-6 mRNA levels of just over 95% with the low dose 
was observed (Fig. 6.5B). A marked reduction in mRNA level was also seen with the 
medium and high doses of ciglitazone treatment at 4 h of 47 and 77% respectively. 
IL-6 protein secretion into the medium by canine adipocytes was reduced by just 
over 40% at 4 h with the high doses o f ciglitazone. At 24 h, IL-6 mRNA levels were 
significantly reduced by an average of just over 50% with medium- and high-dose 
ciglitazone. However, at 24 h post-treatment, there were no changes in IL-6 protein 
secretion with ciglitazone at any of the dose levels (Fig. 6.6B).
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Figure 6.5 Regulation of adipokine gene expression in canine
subcutaneous inguinal adipocytes by ciglitazone
(A ) 1.8 (B )
Differentiated canine adipocytes from the subcutaneous inguinal depot at day 12 post­
induction were pre-treated with FCS-free feeding medium for 24 h and then incubated in 
medium containing ciglitazone for 4 and 24 h at low -500, 500 nM; medium -10, 10 pM and 
high -50, 50 pM ciglitazone. Adipokine mRNA level was measured by qPCR and 
normalised to canine P-actin relative to the untreated control group at the same time-point 
(=1). Results are means ± SE (bars) for groups o f  8. (A), TNFa; (B), IL-6; (C), MCP-1; (D), 
NGF; (E), Leptin; (F), Adiponectin. * P  <  0.05, * * P  < 0.01, * * * p  <  0.001 compared with 
controls at the same time-point.
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Figure 6.6 Regulation of adipokine protein secretion in canine
subcutaneous inguinal adipocytes by ciglitazone
Differentiated canine adipocytes from the subcutaneous inguinal depot at day 12 post­
induction were pre-treated with FCS-free feeding medium for 24 h and then incubated in 
medium containing ciglitazone for 4 and 24 h at low -500, 500 nM; medium -10, 10 pM and 
high -50, 50 pM ciglitazone. Adipokine concentration was measured by ELISA normalised 
to control at the same time-point. Results are means ±  SE (bars) for groups o f 3-8. (A), 
TNFa; (B), IL-6; (C), MCP-1; (D), NGF; (E), Adiponectin. * P  < 0.05, **P < 0.01, * * * P  <  
0.001 compared with controls at the same time-point.
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In a similar manner to both IL-6 and TNFa, MCP-1 mRNA levels were also reduced 
by treatment with ciglitazone. At 4 h, levels were reduced by as much as 82% with 
the low dose. In contrast, treatment with the medium dose had no effect on mRNA 
levels. However, treatment with the high dose o f ciglitazone reduced MCP-1 mRNA 
levels significantly by just over 50% at 4 h (Fig. 6.5C). MCP-1 protein secretion by 
canine adipocytes was significantly reduced at 4 h, by an average o f 65% with both 
the low and high dose of ciglitazone (Fig. 6.6C). In contrast, at 24 h, only the high 
dose of ciglitazone affected MCP-1 mRNA and protein levels, where a reduction of 
just over 50% was seen (Fig. 6.5C and 6.6C).
Treatment of canine adipocytes with ciglitazone also led to a significant decrease in 
NGF mRNA levels. At 4 h with the low dose o f ciglitazone, a fall o f approximately 
60% in mRNA levels was observed. This effect was even more marked at 24 h with 
the high dose o f ciglitazone where a decrease o f over 70% in NGF mRNA level was 
observed (Fig. 6.5D). In contrast to other inflammation-related adipokines, 
ciglitazone had no effect on NGF protein secretion into the medium by canine 
adipocytes (Fig. 6.6D).
Unlike rosiglitazone, treatment of canine subcutaneous inguinal adipocytes with 
ciglitazone led to a reduction in the cellular mRNA levels of leptin at both 4 and 24 
h. Initially, at 4 h, leptin mRNA levels fell by an average of 40% with the low and 
high doses of ciglitazone. At 24 h, this effect was even more marked, with a 
reduction of 55% in leptin mRNA level with the medium dose of ciglitazone. The 
effect of high dose was even greater, with mRNA levels falling by as much as 91% 
(Fig. 6.5E).
In contrast to rosiglitazone, treatment of canine adipocytes with ciglitazone had no 
effect on cellular adiponectin mRNA levels (Fig. 6.5F). However, levels o f protein 
secreted into the medium by cells treated with the high dose of ciglitazone were 
reduced by just over 75% in a similar manner to cells treated with the high dose of 
rosiglitazone (Fig. 6.6E).
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6.3.3 Regulation of adipokine expression in canine adipocytes: 
Response to dexamethasone
The next experiment examined the effect of dexamethasone treatment on canine 
subcutaneous inguinal adipocytes. Here, unlike treatment with PPARy, both high and 
low doses of dexamethasone led to a small, but significant increase in TNFa mRNA 
level at 2 h o f just over 3-fold (Fig. 6.7A). In contrast, levels of TNFa protein 
secreted into the medium by canine adipocytes were significantly reduced at 2 h with 
the low dose of dexamethasone by approximately 16% (Fig. 6.8A). No significant 
changes in either cell TNFa mRNA level or protein secretion were detected with 
either low or high doses of dexamethasone at 24 h (Fig. 6.7 and 6.8A).
A substantial decrease in both IL-6 mRNA and protein occurred when the adipocytes 
were treated with dexamethasone (Fig. 6.7B and 6.8B). With the lower dose at 2 h, 
there was a reduction of 87% in IL-6 mRNA level in the cells and just over a 55% 
fall in IL-6 protein in the medium. With the high dose of dexamethasone at 2 h, IL-6 
gene expression fell by 66% and protein secretion by approximately 53%. At 24 h, 
mRNA level at both low and high doses was reduced on average by 85% (Fig. 6.7B); 
while protein secretion was reduced by 30% at both doses (Fig. 6.8B).
In a similar manner to IL-6, treatment of canine adipocytes with dexamethasone led 
to a significant reduction in both MCP-1 mRNA and protein levels at 2 and 24 h. At 
2 h with the low dose of dexamethasone, MCP-1 mRNA levels were reduced by 47% 
(Fig. 6.7C). The effect of dexamethasone treatment at 2 h on MCP-1 protein 
secretion was more dramatic, with the amount being reduced by an average o f 91% 
(Fig. 6.8C). At 24 h, MCP-1 mRNA levels were reduced by 52% with low and high 
dose treatment, while protein secretion fell in a dose-dependent manner by 31 and 
52% for the low and high doses respectively (Fig. 6.7 and 6.8C).
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Figure 6.7 Regulation of adipokine gene expression in canine
subcutaneous inguinal adipocytes by dexamethasone
Differentiated canine adipocytes from the subcutaneous inguinal depot at day 12 post­
induction were pre-treated with FCS-free feeding medium for 24 h and then incubated in 
medium containing dexamethasone for 2 and 24 h at low -2, 2 nM and high -20, 20 nM 
dexamethasone. Adipokine mRNA level was measured by qPCR and normalised to canine 0- 
actin relative to the untreated control group at the same time-point (=1). Results are means ± 
SE (bars) for groups o f 8. (A), TNFa; (B), IL-6; (C), MCP-1; (D), NGF; (E), Leptin; (F), 
Adiponectin. * P  < 0.05, * * P  < 0 .01 , * * * P  < 0.001 compared with controls.
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Figure 6.8 Regulation of adipokine protein secretion in canine
subcutaneous inguinal adipocytes by dexamethasone
(A)
(C)
Differentiated canine adipocytes from the subcutaneous inguinal depot at day 12 post­
induction were pre-treated with FCS-free feeding medium for 24 h and then incubated in 
medium containing dexamethasone for 2 and 24 h at low -2, 2 nM and high -20, 20 nM 
dexamethasone. Adipokine concentration was measured by ELISA normalised to control at 
the same time-point. Results are means ±  SE (bars) for groups o f  3-8. (A), TNFa; (B), IL-6; 
(C), MCP-1; (D), NGF; (E), Adiponectin. * P  < 0.05, * * P  < 0.01, * * * P  < 0.001 compared 
with controls.
2 1 4
Treatment of canine adipocytes with dexamethasone led to a marked reduction of 
approximately 80% in NGF mRNA levels at 2 h (Fig. 6.7D). This was coupled with 
a reduction in NGF protein secretion by adipocytes into the medium, of 60% with 
both the low and high doses (Fig. 6.8D). In contrast, at 24 h no significant change in 
cellular NGF mRNA level was detected with qPCR (Fig 6.7D). However, NGF 
protein levels fell in a dose-dependent manner by 52 and 61% with the low and high 
doses respectively (Fig. 6.8D).
Unlike the effect on mRNA level of inflammation-related adipokines such as MCP-1 
and NGF, dexamethasone treatment led to an increase in canine adipocyte leptin 
mRNA level in both a time- and dose-dependent manner. Levels were raised by 1.5 
and 2.3-fold respectively with low and high doses at 2 h, whereas at 24 h, the effects 
were more marked with a nearly 5-fold up-regulation with the low dose and a 10-fold 
up-regulation with the high dose (Fig. 6.7E).
Treatment of canine adipocytes with dexamethasone had no effect on either 
adiponectin mRNA level or protein secretion at 2 or 24 h of treatment (Fig. 6.7F and 
6.8E).
215
6.4 Discussion
In Chapter 5, it was demonstrated that adipokine expression and secretion, by canine 
adipocytes, is modulated by proinflammatory cytokines and LPS. The results in this 
Chapter indicate, using the robust method of adipocyte primary cell culture outlined 
in Chapter 4, that in addition to responding to a proinflammatory stimulus, canine 
adipocytes from both visceral and subcutaneous depots are also strongly influenced 
by agents such as TZDs and dexamethasone.
As outlined in Chapter 1, PPARy is a member of the nuclear receptor family that 
includes 48 human transcription factors whose activity is regulated by direct binding 
o f ligands, including fatty acids, eicosanoids and steroid hormones. (Lehrke & Lazar,
2005). TZDs are a class of oral anti-diabetic drugs with a high affinity for PPARy 
used to treat type II diabetes in humans. TZDs activate gene expression, leading to a 
net increase in lipid partitioning into adipocytes from the circulation (Lehrke & 
Lazar, 2005). However, this increase in fat storage does not appear to lead to 
adipocyte hypertrophy as there is also an increase in adipocyte differentiation and 
increased mitochondrial biogenesis leading to an increase in fatty acid oxidation.
Ciglitazone, the first PPARy agonist tested in clinical trials, was not marketed 
because o f hepatotoxic effects. Troglitazone, was the first PPARy agonist approved 
for treatment of type II diabetes, but was subsequently withdrawn after reports of 
severe liver toxicity and death (Isley, 2003). Currently, two TZD compounds, 
rosiglitazone and pioglitazone, are prescribed for the treatment of type II diabetes in 
humans (Lehrke & Lazar, 2005), and although hepatotoxicity has been observed with 
these agents, this is much less frequent and severe (Farley-Hills et al., 2004).
Natural and synthetic PPARy ligands have been shown to exert potent anti­
inflammatory effects. Several mechanisms have been suggested for this effect, 
including interference with proinflammatory transcription factors such as NF-kB and 
STAT (Welch et al., 2003). Furthermore, PPARy ligands have been shown to 
prevent the removal of co-repressor complexes from gene promoter regions resulting 
in suppression of inflammatory gene transcription, thus retaining inflammatory genes 
in a suppressed state (Pascual et al., 2005). PPARy nuclear receptor agonists have
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been shown to suppress expression and secretion of inflammation-related adipokines 
by both murine and human adipocytes (do Nascimento et al., 2004; Peeraully et al., 
2004; Hammarstedt et al., 2005). The results outlined in this Chapter demonstrate a 
distinct inhibition o f gene expression and protein secretion o f several inflammation- 
related adipokines with both synthetic PPARy agonists in the dog.
In terms of treatment with rosiglitazone, a clear inhibition at both the level o f gene 
expression and protein secretion was seen in cells of both depots. Expression levels 
o f several pro-inflammatory adipokines, including TNFa, IL-6 and MCP-1 were 
reduced. Both PPARy agonists effectively reduced NGF expression and secretion, in 
cells of the subcutaneous inguinal depot, with rosiglitazone also having a significant 
effect on the level of protein secretion by canine adipocytes from the subcutaneous 
inguinal depot. However, there was no significant effect on NGF expression by cells 
o f the visceral depot with rosiglitazone treatment. This discrepancy may be 
associated with the fact that visceral adiposity is associated with worsening pro- 
inflammatory metabolic profile (Stienstra et al., 2006); thus in the case o f NGF, 
rosiglitazone treatment at the doses used, may not have had a significant effect on 
NGF gene expression.
Treatment of canine adipocytes derived from both subcutaneous and visceral depots 
with rosiglitazone, led to a significant rise in levels o f leptin gene expression. This 
effect was significant in cells of both depots by 4 h of treatment. The levels of 
expression continued to rise over the 24 h, at times in a dose-dependent manner in 
cells of both depots. This is in contrast to data from both rodents and humans, where 
treatment of adipocytes with rosiglitazone has been shown to lead to a reduction in 
leptin expression (De Vos et al., 1996; Kallen & Lazar, 1996; Rieusset et al., 1999). 
PPARy agonists are thought to suppress leptin expression in humans and rodents 
thereby limiting lipolysis and fatty acid oxidation both of which are stimulated by 
leptin. Thus, decreased PPARy expression may lead to increased leptin levels and 
lower food intake and weight gain in humans (Wang et al., 1999). This difference 
between these two species and the dog is very intriguing and presumably reflects a 
major species difference and a possible route for further investigations into leptin 
signalling and metabolism in the dog.
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In contrast to rosiglitazone, treatment of canine adipocytes o f the subcutaneous 
inguinal depot with ciglitazone led to a clear dose-dependent decrease in leptin gene 
expression at both 4 and 24 h. Data on the effects of ciglitazone on leptin expression 
in either human or murine WAT tissue is limited, but this effect may be specific to 
this agent and to the dog. The fact that the two PPARy activators had different effects 
on leptin production in the dog may suggest that the mode o f action o f rosiglitazone 
is different in this species, at least in some respects.
In a similar manner to leptin, adiponectin expression increased in cells of both depots 
with rosiglitazone treatment. In both cases, effects were significant as early as 4 h o f 
treatment and at 24 h, significant up-regulation in adiponectin gene expression was 
evident at several doses. This is in accordance with data from human studies, where 
adiponectin expression has been shown to be up-regulated with rosiglitazone 
treatment in both visceral and subcutaneous WAT (Motoshima et al., 2002). 
Furthermore, the results in this chapter suggest that canine adipocytes respond in a 
similar manner to human adipocytes in terms of the response to rosiglitazone 
treatment with a greater effect seen in adipocytes from the visceral compared to the 
subcutaneous depot (Motoshima et al., 2002). Thus, in the dog as in humans, 
enhanced expression of adiponectin from visceral adipocytes in response to 
rosiglitazone may play a role in the systemic insulin-sensitization and improvement 
o f the inflammatory metabolic profile.
Unlike rosiglitazone, treatment of canine subcutaneous inguinal adipocytes with the 
PPARy agonist ciglitazone had no effect on adiponectin expression in canine 
adipocytes at any of the treatment doses used. Furthermore, in contrast to gene 
expression data, adiponectin secretion by subcutaneous inguinal adipocytes declined 
by a similar extent (75%), in response to both treatment with high doses of 
rosiglitazone and ciglitazone for 24 h. This may have been due to either a delayed 
response in terms of protein secretion or to an increased protein tumover/degradation 
o f adiponectin in the cell culture medium.
Adipokine expression and secretion has been known to be strongly influenced by 
glucocorticoids, with the expression o f several pro-inflammatory adipokines 
including IL-6 and NGF, for example, being inhibited by dexamethasone (Fasshauer
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et al., 2003a; Peeraully et al., 2004). The results in this chapter indicate that, in a 
manner similar to rodents and humans, the synthetic glucocorticoid dexamethasone is 
a potent inhibitor of the expression and secretion of inflammation-related adipokines 
in the dog. A substantial fall in the expression and release o f IL-6, MCP-1 and NGF 
could be seen as early as 2 h of treatment with a low dose of dexamethasone in cells 
o f the subcutaneous inguinal depot. The effect of dexamethasone treatment on TNFa 
expression was unlike that seen with other pro-inflammatory adipokines in that a 
small but nevertheless significant up-regulation in gene expression was seen at 2 h of 
treatment, an effect which was later undetectable at 24 h. There was, however, a 
modest but nevertheless significant reduction in adiponectin protein secretion at the 
same time-point with low dose dexamethasone treatment.
The production of several adipokines has been shown to be strongly stimulated by 
dexamethasone, and these include leptin, resistin and haptoglobin (De Vos et al., 
1995; Haugen et al., 2001; do Nascimento et al., 2004). As such, leptin expression 
by canine subcutaneous inguinal adipocytes was augmented in both a time- and dose- 
dependent manner with exogenous dexamethasone treatment. Dexamethasone has 
been found to reduce significantly adiponectin secretion from human subcutaneous 
adipocytes (Degawa-Yamauchi et al., 2005). However, the synthetic glucocorticoid 
appeared to have no effect on adiponectin expression or secretion in canine 
adipocytes. Thus, while glucocorticoids appear to be important in the regulation o f 
leptin production by canine adipocytes, they appear to have little effect on 
adiponectin.
In summary, the expression and secretion of several inflammation-related adipokines 
is down-regulated by TZDs and synthetic glucocorticoids in the dog and as such, 
they appear to be important regulators of adipokine production in canine visceral and 
subcutaneous WAT. In contrast, the expression of adipokines involved in insulin- 
sensitivity and appetite regulation, appear to be augmented by PPARy agonists and 
glucocorticoids and this effect may relate in both cases to their anti-inflammatory 
effects.
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Chapter 7
11p-HSD-1 expression by canine adipocytes in primary 
culture: Regulation by inflammatory mediators, PPARy 
agonists and dexamethasone
7.1 Introduction
Glucocorticoids exert potent immunomodulatory effects. At pharmacological levels 
they are powerful immunosuppressive and anti-inflammatory agents. Clinically, they 
are therefore, widely used to treat inflammation where often they are the most 
effective therapy (Bevier, 1990; Padrid & Amis, 1992). Glucocorticoids have been 
shown to potentiate the adipogénie process and anabolic lipid metabolism in 
adipocytes (Hauner et a l, 1989). Both humans and dogs suffering from 
hypercortisolism due to hyperadrenocorticism or those undergoing corticosteroid 
therapy demonstrate specific increases in visceral adiposity and suffer metabolic and 
signal transduction disturbances mirroring those observed in type II diabetes 
mellitus, including insulin resistance, hyperglycaemia and hyperlipidaemia (Kelly & 
Darke, 1976; Rebuffe-Scrive et a l, 1988; Walker, 2006).
As outlined in Chapter 1, corticosteroid activity is regulated, in part, by the enzyme 
11 P-hydroxysteroid dehydrogenase (11-p-HSD-l) which exists as two isoenzymes; 
1 ip-HSD-1 which is predominantly expressed in adipose tissue, liver, gonadal tissue 
and the central nervous system where it mainly serves as a reductase responsible for 
the conversion of inactive cortisone to the active glucocorticoid receptor agonist 
cortisol and lip-HSD-2, which is expressed primarily in aldosterone target tissues 
such as kidney and colon where it inactivates cortisol via its dehydrogenase activity, 
thereby preventing excessive activation o f the mineralocorticoid receptor and 
sequelae including hypertension (Stewart & Krozowski, 1999).
Studies have shown that expression and activity of 11P-HSD-1 is higher in omental 
compared to subcutaneous sites in humans (Bujalska et a l, 1997), and it is possible 
that the autocrine generation of active cortisol may be a crucial factor in explaining 
the differential effects of glucocorticoids on different adipose tissue depots and, in 
turn, the pathogenesis of visceral obesity (Stewart et a l, 1999). Furthermore, 1 lp- 
HSD-1 knockout mice have been shown to resist diet-induced insulin resistance and 
hyperglycaemia (Kotelevtsev et a l, 1997). Such observations have led to the 
suggestion that 11 P-HSD-1 may play a key role in the dysrégulation of metabolism 
observed in type II diabetes mellitus and other metabolic disorders linked to central 
obesity in humans (Andrews & Walker, 1999).
221
Thus far, there are no published studies into the role o f 1 ip-HSD-1 in canine adipose 
tissue. In this chapter, lip-HSD-1 expression was investigated in different WAT 
depots in the dog. Furthermore, expression was also examined in cells of both 
visceral and subcutaneous depots during differentiation in vitro. Since lip-HSD-1 is 
recognised as having an important role in inflammation (Chapman et a l, 2006), the 
effects of the pro-inflammatory agents lipopolysaccharide, TNF-a and IL-6 on 11 p~ 
HSD-1 were examined in canine adipocytes. Finally, llp-HSD-1 expression was 
also investigated in relation to the response to treatment with key agents involved in 
the regulation of adipokine expression, including dexamethasone and the PPARy 
agonists rosiglitazone and ciglitazone.
7.2 Methods
7.2.1 Animals and tissues
Tissues from entire adult male and female SBT dogs were obtained from those 
euthanased at an animal shelter, for reasons unrelated to the study. Animals were 
only included if there was no indication of disease, both externally and during gross 
examination o f abdominal organs. All WAT samples (subcutaneous inguinal, 
omental, perirenal, gonadal and falciform ligament depots) and samples from liver, 
spleen and kidney were obtained within thirty minutes of euthanasia and immediately 
frozen in liquid nitrogen.
7.2.2 Cell culture
White adipose tissue from both the subcutaneous inguinal and gonadal depots of 
SBT dogs were harvested as described in sections 2.1.1 and 2.1.2. Cells were 
cultured as described in section 2.2 at 37°C in a humidified atmosphere of 5% 
C02/95% air. Twenty four hours after they were inoculated, cells from the gonadal 
depot were washed three times in lx  PBS and the inoculation medium replaced by 
induction medium. Cells from the subcutaneous inguinal depot had their inoculation 
medium changed 48 h post-inoculation and 24 h later (at 72 h post-inoculation) were 
washed three times in lx  PBS and the inoculation medium replaced by induction 
medium. Cells of both depots were exposed to the adipogénie medium for 48 h. This 
was replaced by feeding medium, which was renewed every 48 h.
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7.2.2.1 Time-course of expression during differentiation
To investigate the time course of 1 lp-HSD-1 gene expression during adipocyte 
differentiation, cells from both depots were collected as described in section 2.2.5 
from three individual wells of culture plates when cells were induced (day 0) and 
subsequently at days 1-4, 6, 8, 10, 12 and 15 post-induction. Cell cultures were 
carried out in triplicate for each depot.
7.2.2.2 Studies on the regulation of 11(3-HSD-1 expression
Cells were pre-incubated 12 days after differentiation for 24 h with FCS-free feeding 
medium. Cells were then treated with FCS-free feeding media containing each of the 
specific agents; the control cells for each study had their pre-incubation media 
renewed. Cells from both depots were treated with canine recombinant TNFa at 
doses of 5 and 50 ng/ml. Only cells from the subcutaneous inguinal depot (see 
section 4.4), were treated with dexamethasone and this was with doses of 2 and 20 
nM.
Cells from the subcutaneous inguinal depot (see section 4.4), were treated with IL-6 
(1 and 25 ng/ml), LPS (10 and 100 ng/ml), rosiglitazone (50 nM, 200 nM and 5 pM) 
and ciglitazone (500 nM, 10 pM and 50 pM). Cells were harvested at the time of 
treatment and at 4 and 24 h post-treatment as described in section 2.2.5. All cells 
were harvested as described in section 2.2.5. Either 7 or 8 individual wells in cell 
culture plates were treated with each agent, or used as controls.
7.2.3 qPCR
RNA was extracted from tissues and cultured cells using Tri-Reagent as described in 
section 2.3.1. RNA, which was to be analysed by qPCR, was subsequently treated 
using a DNA-free kit to minimise levels of genomic DNA contamination (section 
2.3.2). Once extracted, the total RNA was quantified using a BioPhotometer and 
reverse transcribed using the Reverse-iT First Strand Synthesis kit (sections 2.3.3 and 
2.5.1). The cDNA was then analysed by real-time PCR (qPCR) using the qPCR Core 
Kit and an Mx3005P real-time machine (section 2.5.3 and 2.5.4).
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PCR products were purified using a NuceloSpin Extract 2-in-l kit and sequenced 
commercially (see section 2.4.4). All qPCR data was analysed using MxPro- 
Mx3005P software.
7.3 Results
7.3.1 Expression of 110-HSD-1 in canine white adipose tissue
lip-HSD-1 expression was identified in all o f the five main WAT depots of dog, 
with a clear signal for lip-HSD-1 mRNA being obtained in all cases using qPCR. 
Although there were no differences in the level of 1 ip-HSD-1 expression in different 
depots in either male or female dogs, when male and female data were directly 
compared, a significant up-regulation in the level of lip-HSD-1 mRNA was found 
in the omental depot in female compared to male dogs (Fig. 7.1).
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Figure 7.1 Expression of 11f3-HDS-1 by canine white adipose tissue
t
IHTHTTl] Males
Females
Total RNA was extracted from subcutaneous inguinal (sc), omental (om), perirenal (pr), 
gonadal (gon) and falciform (fal) WAT depots from SBT dogs. Once extracted, total RNA 
was quantified and reverse transcribed to cDNA. Real-time PCR was used for relative 
quantification o f lip-H SD-1 mRNA levels. Results are expressed relative to the expression 
o f  P-actin in the subcutaneous inguinal depot for each gender and are presented as means ± 
SE (bars) 6-7 individuals  ^P  < 0.05, compared to male animals.
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7.3.2 Time course of 11P-HSD-1 gene expression in canine adipocytes 
of the gonadal and subcutaneous depots differentiated in primary 
culture
A signal for 1 ip-HSD-1 mRNA was detected in cells both pre- and post-induction of 
differentiation. Relative levels of 11 p-HSD-1 mRNA were raised from day 1 post­
induction by nearly 7-fold in cells o f the subcutaneous inguinal depot (Fig. 7.2A). 
Peak expression occurred at day 2 post-induction of differentiation, with 11 P-HSD-1 
mRNA levels reaching 9-fold up-regulation. Levels of 1 1 P-HSD-1 fell thereafter and 
remained essentially unchanged as cells matured. In contrast to cells from the 
subcutaneous inguinal depot, levels o f lip-HSD-1 in cells o f the gonadal depot fell 
immediately post-induction of differentiation and in a similar manner to cells of the 
subcutaneous inguinal depot, this decrease in mRNA level persisted as cells matured 
(Fig. 7.2B).
7.3.3 Regulation of 1 ip-HSD-1 expression in canine adipocytes: 
Response to inflammatory mediators
Since the time-course study indicated that lip-HSD-1 is expressed in canine 
adipocytes, subsequent studies examined the factors which might regulate this 
expression. The first experiments examined the response o f inflammatory mediators. 
Treatment of canine subcutaneous inguinal adipocytes with canine recombinant 
TNFa resulted in significant increases in lip-HSD-1 mRNA level in a time- 
dependent manner of on average 4-fold at 2 h and of approximately 80-fold at 24 h 
(Fig. 7.3A). However, there seemed to be no effect in terms of the two dose regimes 
used. Treatment of gonadal adipocytes with canine recombinant TNFa, in a similar 
manner to subcutaneous inguinal adipocytes, resulted in a significant increase in 1 ip* 
HSD-1 mRNA level at both 2 and 24 h. This effect, however, was more muted with 
increases of on average 2.5 and 12.5-fold at 2 and 24 h respectively (Fig. 7.3B).
In the next experiments, cells from the subcutaneous inguinal depot were treated with 
the pro-inflammatory cytokine IL-6. In contrast to TNFa, canine recombinant IL-6 
treatment had no effect on lip-HSD-1 gene expression by canine adipocytes (Fig. 
7.3C).
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Figure 7.2 Time course of gene expression of 11 p-HSD-1 in canine
adipocytes in primary culture
(A)
(B)
Days post-induction
Days post-induction
Canine adipocytes from both subcutaneous inguinal (A) and gonadal depots (B) were 
collected at various time points both before (day 0) and after the induction of differentiation 
into adipocytes (days 1-4, 6, 8, 10, 12 and 15). Total RNA was extracted and lip-HSD-1 
gene expression examined by qPCR. The mRNA levels were normalised to canine P-actin 
relative to day 0. Results are ± SE (bars) for groups of 3 at each time point. N = 3 
individuals.
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Figure 7.3 Regulation of 11 (3-HSD-1 gene expression in canine
adipocytes by inflammatory mediators
Differentiated canine adipocytes at day 12 post-induction were pre-treated with FCS-ffee 
feeding medium for 24 h and then incubated in medium containing different inflammatory 
mediators. (A), Adipocytes from the subcutaneous inguinal depot and (B), adipocytes from 
the gonadal depot treated with canine recombinant TNFa for 2 and 24 h at low -5, 5 ng/ml 
TNFa; and high -50, 50 ng/ml TNFa. (C), Adipocytes from the subcutaneous inguinal depot 
treated with canine recombinant IL-6 for 4 and 24 h at low -1, 1 ng/ml IL-6; and high -25, 25 
ng/ml IL-6. (D), Adipocytes from the subcutaneous inguinal depot treated with LPS for 4 
and 24 h at low -10, 10 ng/ml LPS; and high -100, 100 ng/ml LPS. 11 P-HSD-1 mRNA level 
was measured by qPCR and normalised to canine RNAPolIIa relative to the untreated 
control group (=1). Results are means ± SE (bars) for groups of 7 or 8. ***P < 0.001 
compared with controls at the same time-points.
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The next experiments examined the effect o f the pro-inflammatory agent LPS on 
11(3-HSD-1 expression in canine adipocytes of the subcutaneous inguinal depot. The 
response was similar in both manner and magnitude to treatment of adipocytes from 
the same depot with TNFa, where LPS resulted in an average of 4-fold increase in 
1 ip-HSD-1 mRNA level at 2 h. At 24 h, levels o f 1 ip-HSD-1 mRNA rose to nearly 
27- and 36-fold with low and high dose treatment respectively (Fig. 7.3D).
7.3.4 Regulation of 11P-HSD-1 expression in canine adipocytes: 
Regulation by PPARy agonists and dexamethasone
Next, the effect of PPARy agonists and dexamethasone on the regulation o f 11 p- 
HSD-1 expression in canine adipocytes was examined. Treatment of canine 
subcutaneous inguinal adipocytes with rosiglitazone had no effect on lip-HSD-1 
expression at 4 h. However, at 24 h, there was a significant and dose-dependent 
increase in the level of 1 ip-HSD-1 expression where mRNA levels reached a peak of 
nearly 50-fold with high-dose treatment (Fig. 7.4A). The effect of rosiglitazone 
treatment on lip-HSD-1 mRNA levels was more muted in cells o f the gonadal 
depot. Here, a modest but nevertheless significant increase of approximately 1.5-fold 
in mRNA levels was seen at both 4 and 24 h with high-dose treatment (Fig. 7.4B). 
In contrast to rosiglitazone, treatment of subcutaneous inguinal adipocytes with 
ciglitazone had no effect on 1 ip-HSD-1 mRNA levels (Fig. 7.4C).
Treatment of canine subcutaneous inguinal adipocytes with dexamethasone, in a 
similar manner to rosiglitazone treatment of the same cell type, resulted in a 
significant time- and dose-dependent increase in lip-HSD-1 mRNA levels. Levels 
were increased by 3- and just over 13-fold at 24 h with low and high dose treatment 
respectively (Fig. 7.4D).
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Figure 7.4 Regulation of 11 P-HSD-1 gene expression in canine 
adipocytes by PPARy agonists and dexamethasone
Differentiated canine adipocytes at day 12 post-induction were pre-treated with FCS-ffee 
feeding medium for 24 h and then incubated in medium containing different inflammatory 
mediators. (A), Adipocytes from the subcutaneous inguinal depot and (B), adipocytes from 
the gonadal depot treated with rosiglitazone for 4 and 24 h at low -50, 50 nM; medium -500, 
500 nM and high -5, 5 pM rosiglitazone. (C), Adipocytes from the subcutaneous inguinal 
depot treated with ciglitazone for 4 and 24 h at low -500, 500 nM; medium -10, 10 pM and 
high -50, 50 pM ciglitazone. (D), Adipocytes from the subcutaneous inguinal depot treated 
with dexamethasone for 2 and 24 h at low -2, 2 nM; and high -20, 20 nM dexamethasone. 
1 lp-HSD-1 mRNA level was measured by qPCR and normalised to canine p-actin or 
RNAPolIIa relative to the untreated control group (=1). Results are means ± SE (bars) for 
groups of 7 or 8. *P < 0.05, **P < 0.01, ***P < 0.001 compared with controls at the same 
time-points.
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7.4  D iscussion
The studies described in this chapter are the first to investigate the expression of the 
enzyme 11 (3-HSD-1 in both canine adipose tissue and adipocytes. 11(3-HSD-1 is a 
key enzyme involved in the conversion of inactive cortisone to active cortisol locally 
in adipose tissues and thereby plays an important role in regulating the actions of 
corticosteroids within WAT (Wake & Walker, 2004). A signal for 11 P-HSD-1 was 
detected in all WAT depots examined for both male and female SBT dogs; thus, the 
gene is expressed in each of the depots.
In humans, it has been shown that omental adipocytes contain significantly more 
11 P-HSD-1 activity than those from the subcutaneous depot (Bujalska et al., 1997), 
with higher levels o f 1 ip-HSD-1 mRNA also being reported in omental compared to 
subcutaneous adipocytes (Tomlinson et al., 2002). In women, unlike men, 17p~ 
oestradiol has been reported to strongly stimulate 1 ip-HSD-1 expression in visceral 
preadipocytes (Dieudonne et al., 2006). Studies reported here show levels of mRNA 
encoding lip-HSD-1 to be significantly higher in the omental adipose tissue o f 
female compared to male dogs. These findings suggest, in a similar manner to 
humans, that factors such as sex steroids may play a significant role in the control o f 
local cortisol production in adipose tissues of dogs.
Subsequent studies utilised the preadipocyte cell culture system to examine whether 
lip-HSD-1 is expressed in canine adipocytes and the expression pattern during 
differentiation in both subcutaneous inguinal and gonadal adipocytes. Quantitatively, 
levels of 11P-HSD-1 mRNA were found to be higher in preadipocytes of both depots 
compared to differentiated adipocytes with levels declining as cells matured. In 
humans, 11 P-HSD-1 has been found to be highly expressed in preadipocytes and it is 
thought that once differentiation is initiated, 11 P-HSD-1 activity is vital to the 
production of cortisol, and the promotion of adipogenesis (De Sousa Peixoto et al., 
2008). Conversely, in the murine cell lines 3T3-L1 and 3T3-F442A, lip-HSD-1 is 
characterised as a late marker of differentiation with levels peaking at around day 6-8 
post-induction of differentiation (Napolitano et al., 1998). These differences, and the 
fact that in absolute terms expression o f 11 P-HSD-1 was greater in cells of the
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subcutaneous depot compared to the visceral depot in the dog throughout 
differentiation, suggest key differences in the role of lip-HSD-1 and steroid 
metabolism between different species.
Treatment of canine subcutaneous inguinal and gonadal adipocytes with canine 
recombinant TNFa led to a significant increase in lip-HSD-1 expression at both 2 
and 24 h. This is in accordance with data from human adipocytes treated with TNFa 
where similar increases in levels of lip-HSD-1 expression have been documented 
with treatment with this pro-inflammatory cytokine (Tomlinson et al., 2001; 
Friedberg et al., 2003). In addition, the average fold increase in mRNA level was 
higher in cells of the subcutaneous inguinal depot in dogs compared to the visceral 
gonadal depot. This again has been observed in human adipocytes treated with TNFa 
(Tomlinson et al., 2001). However, TNFa has potent direct effects on developing 
adipocytes to inhibit differentiation and proliferation and to promote apoptosis and 
de-differentiation (Patton et al., 1986; Petruschke & Hauner, 1993; Prins et al., 
1997). It is possible that enhanced expression of lip-HSD-1 and the resulting 
increased local production of cortisol may serve as a regulatory feedback loop to 
balance these direct effects of TNFa.
Unlike TNFa, treatment of canine adipocytes with canine recombinant IL-6 had no 
effect on lip-HSD-1 expression in canine adipocytes. This was unexpected as pro- 
inflammatory cytokines such as IL-ip and IL-6 have been found to significantly up- 
regulate lip-HSD-1 expression in human adipocytes (Tomlinson et al., 2001; 
Friedberg et al., 2003). Thus, this apparent lack of effect to this pro-inflammatory 
cytokine may reflect a species specific difference in the response o f canine 
adipocytes to this pro-inflammatory cytokine.
Treatment of canine adipocytes with LPS induced a significant up-regulation o f 1 ip- 
HSD-1 expression at both 4 and 24 h. Studies examining the effect of LPS treatment 
on adipose tissue expression of lip-HSD-1 are scarce. However, an investigation 
into the effect of LPS treatment on murine macrophages has documented a 
significant increase in the level of lip-HSD-1 expression with LPS treatment (Ishii 
et al., 2007). Macrophage infiltration into adipose tissue in obesity provokes local 
inflammation and insulin resistance. The fact that LPS leads to an increase in the
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level o f expression of lip-HSD-1 in canine adipocytes and that a similar effect has 
been observed in rodent macrophages, highlights a possible role for this enzyme in 
local cortisol metabolism in canine obesity, where the conversion of inactive 
cortisone to active cortisol may be augmented not only by production by adipocytes 
but also by infiltrating macrophages.
Treatment of canine adipocytes with the PPARy agonist rosiglitazone led to a 
significant up-regulation of lip-HSD-1 expression in cells o f both subcutaneous 
inguinal and gonadal depots. This effect was much more marked in cells of the 
subcutaneous inguinal depot with nearly a 50-fold up-regulation in expression at 24 h 
with high-dose treatment. Such an effect has also been documented in human 
adipocytes (Tomlinson et al., 2001). However, there have been several reports to the 
contrary in both rodents and humans (Berger et al., 2001) (Wake et al., 2007) (Mai et 
al., 2007). Thus, despite contradictory results, in the dog it is evident that the PPARy 
agonist rosiglitazone has a significant effect on lip-HSD-1 expression in adipocytes 
o f both subcutaneous and visceral depots and some of the effects o f PPARy agonists 
on canine adipocyte differentiation may be mediated indirectly via glucocorticoids 
through this action on 1 ip-HSD-1.
However, unlike rosiglitazone, treatment of canine subcutaneous inguinal adipocytes 
with another TZD, ciglitazone, had no effect on lip-HSD-1 expression. There are 
currently no published studies into the effect of ciglitazone treatment on 1 ip-HSD-1 
expression in adipocytes. Therefore, this lack of effect on lip-HSD-1 expression 
may be due to structural differences between the two agents. In order to clarify these 
differences investigations using further agents such as pioglitazone may help clarify 
the response o f canine adipocytes to PPARy agonists and their effect on 1 lp-HSD-1 
expression.
In a similar manner to rosiglitazone, treatment of canine adipocytes from the 
subcutaneous inguinal depot with dexamethasone led to a significant up-regulation in 
lip-HSD-1 expression at 24 h in a dose-dependent manner. While exogenous 
cortisone has been found to stimulate preadipocyte proliferation in humans, 
dexamethasone has been shown to have a positive effect on adipocyte maturation 
(Bader et al., 2002). Thus, the increase in lip-HSD-1 expression seen in canine
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adipocytes with dexamethasone treatment may reflect an increased conversion of 
cortisone to the active metabolite cortisol in mature adipocytes and increased 
adipocyte maturation and lipid accumulation.
In summary, studies in this chapter have outlined differential and tissue specific 
regulation of lip-HSD-1 expression by pro-inflammatory regulators as well as 
PPARy agonists and dexamethasone in the dog. The induction of expression by pro- 
inflammatory cytokines such as TNFa and agents such as LPS has important 
implications for the pathogenesis o f obesity in the dog. Furthermore, regulation of 
expression by PPARy agonists and dexamethasone point towards a more complex 
interaction in terms of inflammation and cortisol metabolism regulation.
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Discussion
8.1 In troduction
White adipose tissue, previously regarded as a site for passive lipid storage, is now 
widely viewed as a highly dynamic organ (Wang et a l, 2008). With the discovery of 
leptin (Zhang et a l, 1994), there resulted a critical shift in perspectives on the role o f 
WAT in the regulation of energy balance and characterised it as a complex secretory 
and endocrine organ (Trayhum & Beattie, 2001). Over the past few decades, 
although the concern with obesity as a health problem has inevitably focused on 
humans, the disorder and the diseases with which it is associated are now also 
recognised as a growing problem in companion animals (German, 2006).
With this in mind, over the last few years there has been increasing interest in obesity 
biology in the dog (Eisele et a l, 2005; Gayet et a l, 2007). Prospective studies have 
investigated the levels o f key adipokines such as the hormone leptin in dogs under 
controlled dietary conditions of weight gain and subsequent weight loss (Ishioka et 
a l,  2005a; Ishioka et a l, 2007). However, despite these recent advances into the 
understanding of canine obesity biology, there is still a paucity of information on the 
endocrine and secretory role o f the canine WAT.
With the sequencing of the canine genome (Lindblad-Toh et a l, 2005) it became 
possible to identify key sequences encoding genes of interest in canine adipose tissue 
and to more easily construct oligonucleotide primers and probes to search for the 
expression of these genes using known molecular biology techniques. Inasmuch, the 
hypothesis was proposed that canine, like human and rodent WAT was also 
responsible for the synthesis and active secretion o f protein factors, namely 
adipokines. Thus, the main focus of the work described in this thesis was the 
expression and secretion o f adipokines by canine white adipocytes. The results 
presented in Chapters 4, 5, 6 and 7 demonstrate that adipokine genes are indeed 
expressed by canine white adipocytes and several factors, including the pleiotropic 
pro-inflammatory adipokine TNFa, are involved in the regulation of adipokine gene 
expression in canine adipocytes in vitro.
Four techniques were employed in the course of these investigations, namely 
conventional RT-PCR and real-time PCR (qPCR) for the analysis o f gene
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expression, primary cell culture, and ELISA for the analysis o f protein secretion. 
During this project other studies were carried out using canine lipomatous tissue. 
Although the data obtained from these studies have not been presented, some 
consideration will be given to them in the following sections.
8.2 A d ipokine gene expression in canine w h ite  adipose  
tissues
Expression of key adipokine genes including leptin and adiponectin were detected 
and levels of expression quantitated in each o f the major white adipose tissue depots 
o f dog. In addition, it was further demonstrated that key adipose tissue-related 
proteins are also expressed in canine WAT. One such protein is the adipose tissue- 
specific transcription factor PPARy2, whose mRNA was documented in all depots 
examined. In contrast, PPARyl was found to be ubiquitously expressed, and as such, 
a signal was obtained in all tissues. Genes whose expression is characteristic of 
adipocytes (although not exclusively to these cells) namely GLUT4 and LPS, were 
also shown to be expressed in all depots examined.
Quantitatively, there were no clear-cut trends in the level of adipokine expression 
between depots in dog in terms of visceral and subcutaneous tissues. However, when 
levels of expression were compared between male and female dogs, levels of mRNA 
encoding leptin were found to be higher in the adipose tissues of female, compared 
with male dogs for four out of the five depots examined. In humans, mRNA levels of 
leptin appear to be higher in subcutaneous compared to omental depots (Montague et 
al., 1997b; Montague et al., 1998). Since in females this is the main depot to expand 
in obesity, women have been found to have higher levels o f circulating leptin 
compared to age matched men (Castracane et al., 1998). This is unlike the dog were 
there is no correlation between sex and fat depot distribution (gynoid/android 
obesity). Thus, the work described in this thesis demonstrates that the major visceral 
and subcutaneous WAT depots in dogs express key adipokines and that interesting 
species differences exist between dogs and humans in terms of the possible increased 
overall expression of the adipocyte hormone leptin in the adipose tissue of female as 
compared to male dogs.
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8.3 Adipokine gene expression and secretion in canine 
visceral and subcutaneous adipocytes during differentiation 
in vitro
Expression of adipokine genes in WAT does not necessarily imply adipocyte- 
specific expression, thus, studies were focused on the development of a cell culture 
protocol for the study o f canine adipocytes in vitro. Studies outlined in this thesis 
demonstrate the successful isolation of viable canine preadipocytes from both 
visceral and subcutaneous depots. It has also outlined the establishment of a robust 
method o f canine adipocyte cell culture in which fibroblastic preadipocytes were 
successfully induced to differentiate into adipocytes. The validity of the culture 
system was confirmed not only by profiling the expression of differentiation- 
dependent genes, such as; LPL, GLUT4, PPARy2 and haptoglobin (Wabitsch et a l, 
2001; do Nascimento et a l, 2004), but also by examining the expression o f key 
adipokines including leptin and adiponectin whose level of expression increased in 
canine adipocytes of both visceral and subcutaneous depots during differentiation.
Importantly, it was also demonstrated that canine adipocytes both express and 
actively secrete inflammation-related cytokines such as TNFa, IL- 6  and MCP-1 
during differentiation and development. Therefore, it is possible that adipocytes in 
the dog may contribute to increases in systemic levels of these cytokines in obesity. 
In addition, by establishing that these biologically-active molecules are expressed 
and actively secreted by canine adipocytes, the system can then be used as a valuable 
tool for the investigation of adipocyte biology; thus, responses to various 
inflammatory stimuli and agents which may improve proinflammatory states and 
insulin sensitivity can then be assessed.
8.4 Effect of inflammation-related agents and pro- 
inflammatory cytokines on adipokine expression and 
secretion
Obesity is characterised by chronic mild inflammation, and as outlined in Chapter 1, 
WAT may be the main site o f the inflammatory state, being responsible for the 
production of cytokines, chemokines and acute-phase proteins, all of which have 
been linked to inflammation and the inflammatory response (Rajala & Scherer, 2003;
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Trayhurn, 2005b). It is, therefore, possible that adipose tissue is a significant source 
o f the increase in inflammatory markers seen in obesity (Trayhum & Wood, 2005). 
The system of primary adipocyte cell culture outlined in Chapter 4 was used to 
investigate the effects of such agents on adipocytes from both visceral and 
subcutaneous depots in the dog.
A substantial increase in both the level of expression and secretion of key 
inflammation-related adipokines such as MCP-1 and NGF was seen in response to 
treatment of cells with the pleiotropic pro-inflammatory cytokine TNFa. This is in 
accordance with other in vitro data from similar experiments carried out investigating 
the effect of TNFa on human and rodent adipocytes (Peeraully et al., 2004; Wang et 
al., 2004). The magnitude of the effect of TNFa treatment on its own level o f 
expression in the dog was considerable with levels of expression increasing by nearly 
2,000-fold at 24 h. This mirrors data obtained from human adipocytes treated with 
exogenous TNFa (Wang & Trayhum, 2006).
The level of similarity, both in terms of effect and magnitude, between canine and 
human adipocytes is suggestive of a close metabolic link in terms of TNFa signalling 
pathways in adipose tissue between dogs and humans. Although the precise 
mechanism by which TNFa up-regulates the expression and secretion of 
inflammation-related adipokines such as MCP-1 and TNFa itself in the dog has not 
been determined, it would be likely to be through induction of NF-Kb activity, this 
being the key signalling pathway through which TNFa stimulates the expression of 
many other pro-inflammatory genes (MacEwan, 2002).
Alongside TNFa, IL- 6  has been shown to be another adipokine strongly implicated 
in the development of insulin resistance in humans (Bastard et al., 2002) and rodents 
(Lagathu et al., 2003; Rotter et al., 2003). Therefore, the impact of IL- 6  on canine 
adipocytes in vitro was investigated as part of studies into the effects of pro- 
inflammatory cytokines on canine adipocytes. However, unlike TNFa, IL- 6  had only 
muted effects, if any, on the expression and secretion of adipokines by canine 
adipocytes o f both subcutaneous and visceral depots. IL- 6  signal transduction 
involves the JAK (janus-activated kinase)/STAT (signal transducers and activators of 
transcription) signalling pathway, and further work would be needed to reveal
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possible differences in these signalling pathways which may be responsible for the 
differences in regulation of cytokine expression and secretion in response to IL- 6  
treatment in the dog.
The work presented in this thesis also demonstrates significant effects of the pro- 
inflammatory agent LPS on adipokine expression and secretion by canine adipocytes. 
LPS is responsible for the activation of the innate immune pathway which represents 
the first site of defence against infection, and as outlined in Chapter 5, is known to 
act via toll-like receptors (TLRs) (Kaisho & Akira, 2002). Studies have reported the 
expression o f TLR-2 and -4 in 3T3-L1 adipocytes where LPS has been shown to 
signal through TLR-4 and induce both IL- 6  and TNFa secretion (Lin et al., 2000). 
The response of canine adipocytes to LPS treatment, characterised by a significant 
up-regulation in the level of expression and secretion o f inflammation-related 
adipokines, is in accordance with data published for human and rodents (Peeraully et 
al., 2004; Creely et al., 2007). Thus, canine adipocytes are also likely to respond to 
LPS in a similar manner to those of other species, via TLR4, and follow-up work to 
that effect would be needed to show expression of the receptor protein by canine 
adipocytes and activation of the receptor-linked signalling cascade.
8.5 Effect of PPARy agonists and dexamethasone on 
adipokine expression and secretion
Agents such as the PPARy agonists rosiglitazone and ciglitazone and the synthetic 
steroid dexamethasone have well-recognised anti-inflammatory properties as well as 
having other key properties such as improvement of insulin sensitivity in the case of 
TZDs. Unlike pro-inflammatory agents, these strongly down-regulate both the 
expression and secretion of inflammation related adipokines such as NGF and MCP- 
1 by canine adipocytes. This inhibitory effect clearly suggests that these 
inflammation-related adipokines may play a significant role in the inflammatory 
response o f adipose tissue in the dog.
In contrast, treatment of canine adipocytes from both subcutaneous and visceral 
depots with rosiglitazone, led to a significant rise in levels o f leptin gene expression. 
As outlined in Chapter 6 , this is in contrast to data from both rodents and humans,
240
where treatment of adipocytes with rosiglitazone has been shown to lead to a 
reduction in leptin expression (De Vos et al., 1996; Kallen & Lazar, 1996; Rieusset 
et al., 1999). This difference between these two species and the dog may reflect a 
major species difference and a possible route for further investigations into leptin 
signalling and metabolism in the dog.
However, unlike rosiglitazone, treatment of canine adipocytes with the PPARy 
agonist ciglitazone led to a dose-dependent decrease in leptin gene expression. 
Unlike rosiglitazone, ciglitazone is mainly used as an experimental tool due to severe 
hepatotoxicity during clinical trials in humans (Guo et al., 2006; Masubuchi et al.,
2006). Therefore, data on the effects of this agent on leptin expression in either 
human or murine WAT tissue are limited and it is possible that this effect may be 
specific to this agent and to the dog.
Studies presented in this thesis have also described how, in accordance with human 
studies (Motoshima et al., 2002), adiponectin expression increased in cells o f both 
depots with rosiglitazone treatment. These results suggest that canine adipocytes 
respond to rosiglitazone in a similar manner to human adipocytes, with a greater 
effect seen in adipocytes from the visceral compared to the subcutaneous depot. 
Unlike rosiglitazone, ciglitazone had no effect on adiponectin expression in canine 
adipocytes at any of the treatment doses used. The fact that these two PPARy 
activators had different effects on leptin and adiponectin production in the dog is 
suggestive o f a different mechanism of action and it would be tempting to suggest 
that this may have been due to inherent biochemical differences in the structure of 
the agents themselves, or that they might differ in their site of action on specific steps 
o f the regulatory pathway in this species.
Dexamethasone has been shown to strongly stimulate leptin production by 
adipocytes (De Vos et al., 1995). In a similar manner, exogenous dexamethasone 
treatment augmented leptin expression in canine adipocytes. In contrast, 
dexamethasone has been found to reduce adiponectin secretion from human 
subcutaneous adipocytes (Degawa-Yamauchi et al., 2005). Studies presented here 
have shown that the synthetic glucocorticoid had no effect on adiponectin expression 
or secretion in canine adipocytes. Thus, whilst glucocorticoids appear to be important
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in the regulation of leptin production by canine adipocytes, they appear to be less so 
in terms of adiponectin.
8.6 Regulation of adipokine expression in canine 
lipomatous tissue by treatment with dexamethasone and 
TNFa
One of the initial aims of the thesis was to compare adipokine expression and 
secretion by canine adipocytes from dogs of different breeds. As outlined in Chapter 
1 , over the past hundred years, due to extensive human intervention, dogs have been 
bred to meet specific human requirements, be it for coat colour or body shape, and 
have evolved distinct genetic traits (Ostrander & Comstock, 2004). Despite our best 
efforts, some breed comparisons were not possible due to the lack o f a consistent 
supply o f dogs from breeds other than the SBT. However, we were able to obtain 
lipomatous and perilipomatous (subcutaneous adipose tissue) tissue from a dog of the 
Labrador retriever breed undergoing routine surgery for the removal o f the lipoma. 
Lipomas are adipose tumours that are slow-growing, nearly always benign and are 
often located in the subcutaneous tissues o f the head, neck, shoulders and back of 
both dogs and humans (Reimann et al., 1999; Salam, 2002). It was hypothesised that 
lipomatous tissue would respond more acutely and with greater magnitude to the 
effects of treatment agents than lipomatous tissue due to increased rates of cell turn­
over and metabolism.
Preadipocytes from both tissue-types were successfully harvested and induced to 
differentiate in vitro using the same method outlined in Chapter 2. Cells were treated 
with agents such as TNFa (low- 5 ng/ml and high 50 ng/ml) and dexamethasone 
(high- 20 nM) in a similar manner to SBT subcutaneous inguinal and gonadal cells, 
in order to examine their effect on adipokine expression on both tissue types. 
Treatment of both cell-types with canine recombinant TNFa, in a similar manner to 
cells from the SBT dog of both visceral and subcutaneous depots, resulted in the up- 
regulation of mRNA levels o f all inflammation-related adipokine genes, namely IL- 
6 , MCP-1, NGF and TNFa itself. Adiponectin mRNA levels were reduced at 24 h for 
both cell types, and leptin levels were unaffected (data not shown). Dexamethasone 
treatment led to a significant reduction in mRNA levels of several inflammation-
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related adipokine genes in both tissues. There was no effect on adiponectin mRNA 
levels and, in a similar manner to the SBT, levels of leptin were significantly raised 
in both lipomatous and perilipomatous tissues at 24 h (data not shown).
There were no significant trends in the levels of expression of any adipokines 
examined between lipomatous and perilipomatous adipose tissues. lip-HSD-1 
mRNA levels were significantly increased by both treatment with TNFa and 
dexamethasone in a similar manner to SBT subcutaneous inguinal and gonadal 
adipocytes (data not shown). Despite this being a small study in which tissues from 
only one dog were used, the results suggest that that adipocytes from other dog 
breeds can be successfully extracted and induced to differentiate in culture using the 
method outlined in Chapter 2. Further, it is likely that canine adipocytes from 
different breeds respond in a similar manner to treatment with exogenous TNFa and 
dexamethasone and finally, there appears to be no difference between the response of 
canine lipomatous and perilipomatous adipocytes to TNFa and dexamethasone. It 
must be emphasised, however, that although interesting, this data would need to be 
refined both in terms of numbers of animals used and adipose tissue collection sites.
8.7 11P-HSD-1 expression in canine adipose tissue and
adipocytes in primary culture
Thus far, there is little insight into the local control o f cortisol metabolism in adipose 
tissue in the dog. Therefore, the work carried out in this thesis is, to date, the first to 
examine such a process in this species. As outlined in Chapter 7, both the dog and 
human develop clinical signs associated with naturally-occurring
hyperadrenocorticism, or iatrogenic signs when treated with glucocorticoid therapy; 
both species demonstrate specific increases in visceral adiposity and suffer metabolic 
disturbances mirroring those observed in type II diabetes mellitus, including insulin 
resistance, hyperglycaemia and hyperlipidaemia (Kelly & Darke, 1976; Rebuffe- 
Scrive et al., 1988). In simple obesity in humans, plasma cortisol levels are not 
elevated,; however, lip-hydroxysteroid dehydrogenase type 1 (lip-HSD-1) is 
elevated in mature adipocytes, where it is responsible for the conversion of inactive 
cortisone to cortisol, thereby amplifying local glucocorticoid action in those tissues 
(Seckl et al., 2004).
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11 (3-HSD-1 expression was documented in all o f the five main WAT depots in the 
dog. Expression was also shown in other canine tissues where, in a similar manner to 
humans and rodents (Morton et al., 2004; Seckl et al., 2004), the liver was the main 
site o f expression in both sexes with mRNA levels being up-regulated by nearly 140- 
fold (data not shown). However, the other important site of action of this enzyme is 
WAT, and in obesity lip-HSD-1 levels are reduced in the liver but elevated in 
adipose tissue (Wake & Walker, 2006). With increasing size o f the adipose organ in 
obesity, increased activation of cortisol is thought to contribute to the metabolic 
syndrome.
Studies reported in this thesis show levels o f mRNA encoding lip-HSD-1 to be 
higher in the omental adipose tissue of female compared to male dogs. Human 
omental adipose tissue contains significantly higher levels of 1 ip-HSD-1 mRNA and 
activity than subcutaneous adipocytes (Bujalska et al., 1997; Tomlinson et al., 2002). 
In women, unlike men, 17P-oestradiol has been reported to stimulate strongly the 
expression of lip-HSD-1 in visceral preadipocytes (Dieudonne et al., 2006). 
Therefore, these findings demonstrate that in a similar manner to humans, sex 
steroids may play an important role in the control o f local cortisol production in 
adipose tissues of dogs.
Studies on the regulation o f 1 ip-HSD-1 in canine adipose tissue examined the effect 
o f pro-inflammatory mediators such as TNFa and LPS, which in accordance with 
human data (Tomlinson et al., 2001), led to increased levels o f 1 ip-HSD-1 mRNA in 
cells o f both depots. However, in contrast to most data presented for human and 
rodent adipocytes treated with PPARy agonists, treatment of canine adipocytes with 
rosiglitazone led to an increase in levels of lip-HSD-1 expression in the dog. It 
seems, therefore, that the regulation of this key enzyme in dog WAT is influenced 
not only by pro-inflammatory mediators, but that agents with proven anti­
inflammatory effects may also allow an increased conversion of cortisone to cortisol. 
It is, therefore, possible to speculate that a delicate balance in terms o f lip-HSD-1 
expression may exist in canine adipocytes allowing the control o f adipocyte 
maturation, lipid accumulation and cytokine production.
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8.8 Concluding comments
The studies described in this thesis have examined the expression of key adipose 
tissue-related proteins and adipokines in canine WAT and isolated adipocytes in 
primary culture. The establishment of a robust system for isolation and culture of 
preadipocytes, from both visceral and subcutaneous depots, allowed the active 
secretion o f several key adipokines including the adipocyte hormone adiponectin to 
be documented. Several inflammation-related cytokines, including TNFa, IL- 6  and 
MCP-1, have clearly been shown to be actively secreted by adipocytes, and therefore 
fit the definition of adipokines in the dog.
Some of the factors and mechanisms regulating the expression and secretion of 
adipokines from canine white adipocytes have also been investigated. Therefore, this 
work lays the foundation for future work which, in the first instance, could involve 
detailed examination o f the role of TNFa in canine WAT using a multiplicity of 
approaches including the use of NFkB inhibitors. Clearly other hormonal factors 
such as insulin are also likely to be involved, and there is a need to examine this in 
future studies.
Furthermore, the relationship between obesity and levels of inflammation-related 
adipokines and insulin resistance remains to be clarified in the dog. Additional 
studies could be aimed at determining whether WAT is a significant source of these 
adipokines and the contribution that these make to plasma levels in obesity. The 
receptors and signalling mechanisms underlying the stimulation o f production and 
secretion o f these adipokines by pro-inflammatory cytokines such as TNFa and IL - 6  
also require detailed investigation.
Obesity is associated with macrophage accumulation in adipose tissue (Weisberg et 
al., 2003). These have a significant role in contributing to cytokine secretion and 
metabolic complications associated with the metabolic syndrome in humans 
(Bouloumie et al., 2005). As such, the role of resident tissue macrophages and active 
macrophage recruitment in canine adipose tissue in the obese state, and their 
contribution to cytokine secretion and inflammation would also be an interesting 
topic for future research in the dog.
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Appendix
Appendix I Publications and presentations associated 
with the thesis
Part o f the work in this thesis has been presented in the following publications, oral 
communications and posters:
Publications
1. Ryan VR, German AJ, Wood IS, Hunter L, Morris P and Trayhurn P. (2008). 
NGF gene expression and secretion by canine adipocytes in primary culture: 
Upregulation by the inflammatory mediators LPS and TNFa. Hormone and 
Metabolic Research (Accepted for publication).
Oral Presentations
1. Development and optimisation o f a primary cell culture system for canine 
adipocytes (2006) British Small Animal Veterinary Association Congress, 
Birmingham, UK.
2. Expression of inflammation-related adipokines by canine adipocytes 
differentiated in primary cell culture: Response to TNFa (2007) British Small Animal 
Veterinary Association Congress, Birmingham, UK -  Prize for best abstract in 
internal medicine.
3. Obesity in companion animals (2007) Integrative Physiology Postgraduate 
Conference, University o f Aberdeen, UK.
4. Expression o f inflammation-related adipokines by canine white adipose tissue and 
adipocytes differentiated in primary cell culture (2007) Euriscon Conference, 
London, UK.
Poster presentations
1. Expression of inflammation-related adipokines by canine adipocytes differentiated 
in primary cell culture: Response to TNFa (2006) European Congress on Obesity, 
Budapest, Hungary.
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Appendix II Reagents and equipment
Chemical Reagents
Reagent Source
Ammonium chloride Sigma
Agarose Preprotech
D-Biotin Sigma
Bovine serum albumin (BSA) - Fraction V Qbiogene
Bromophenol blue Sigma
Chloroform Fisher
Ciglitazone Tocris
Collagenase -  Type VIII Sigma
Cortisol Sigma
Dexamethasone Sigma
DMEM Invitrogen
D-MEM:F12 Invitrogen
D-Panthothenic acid Sigma
Ethylenediaminetetraacetic acid Sigma
Ethanol 100% molecular biology grade VWR
Ethidium bromide Sigma
Foetal calf serum Biosera
Fungizone -  amphotericin B Invitrogen
GeneRuler™ 100 bp DNA ladder Fermentas
Glycerol Sigma
Haematoxylin HD Supplies
HEPES Sigma
Hydrochloric acid Fisher
Hydrogen peroxide R&D Systems
1 -methyl-3-isobutylxanthine Sigma
IL- 6  - Canine recombinant R&D Systems
Indomethacin Sigma
Insulin Sigma
Isopropanol Sigma
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Lipopolysaccharide 
Liquid nitrogen 
Oil red O
Penicillin G sodium/streptomycin sulphate 
Di-Potassium hydrogen orthophosphate 
Potassium chloride
Potassium dihydrogen orthophosphate 
Potassium hydrogen carbonate 
RNase AWAY™
Rosiglitazone 
Sodium chloride
Di-Sodium hydrogen orthophosphate 
Sodium dihydrogen orthophosphate 
Sodium hydrogen carbonate 
2 N Sulphuric acid
Superladder-Low 100 bp Ladder with ReddyRun™
T etramethylbenzidine
Transferrin
3,3’,5-triiodo-L-thyronine (T3)
Tri-Reagent™
Tris-Borate-EDTA lOx 
TNFa - Canine recombinant 
TNFa -  Human recombinant 
Tween 20™
Trypan Blue 
Ultra-pure water 
Virkon
Sigma
BOC
HD Supplies 
Invitrogen 
BHD Lab Supplies 
Sigma
BHD Lab Supplies 
BHD Lab Supplies 
Molecular BioProd 
GlaxoSmithKline 
Fisher
BHD Lab Supplies
BHD Lab Supplies
BHD Lab Supplies
R&D Systems
ABgene
R&D Systems
Sigma
Sigma
Sigma
Fisher
R&D Systems 
Sigma
DakoCytomation
Sigma
Sigma
Antec International
Kits
Turbo DNA-free
DuoSet® ELISA -  Canine CCL2/MCP-1 
DuoSet® ELISA -  Canine IL- 6  
DuoSet® ELISA -  Canine TNFa 
NGF Emax® ImmunoAssay System
Ambion 
R&D Systems 
R&D Systems 
R&D Systems 
Promega
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NuceloSpin® Extract 2 in 1 
qPCR Core Kit
Reverse-iT™ 1st Strand Synthesis Kit 
ReddyMix™ Master PCR Master Mix Kit
Equipment
Beckman Preparative Ultracentrifuge
Benchmark™ Plus microplate spectrophotometer
BioPhotometer
Centrifuge 5415D and 5471R
Gallenkamp shaking water bath
HB-1000 hybridisation oven
Heptovac VR-1 vacuum centrifuge
IEC Centra-7R Centrifuge
Kodak Digital Science DC 120 digital camera
2011 Macrovue™ UV Transilluminator
Mk II incubator
MxPro-Mx3005P® real-time PCR machine 
PCR Express® thermal cycler 
Polytron Ultra-Turrax® T25 electric homogenizer 
PRODIGY Advance Lunar Densitometer 
Rocker
Sequence Detector vl.7a 
Vari-Shaker plate shaker 
Water bath
Zeiss Axiovert 200M inverted microscope
Software
Beacon Designer 4.02 software 
enCORE 2004 software 
Excel 2003
Graph Pad Prism 5 for Windows
Kodak digital Science ID 1 image analysis software
Microplate Manager v5.2 software
Machery-Nagel
Eurogentec
ABgene
ABgene
Beckman
Bio-Rad
Eppendorf
Eppendorf
Sanyo
Ultra-Violet Products
Thermo
Damon
Kodak
Ultra-Violet Products
LEEC
Stratagene
Hybaid
Janke & Kunkel 
GE Healthcare 
Bibby Sterilin 
Applied Biosystems 
Dynatech 
Grant Instruments 
Hitachi
Premier Biosoft
GE Healthcare
Microsoft
Microsoft
Kodak
Bio-Rad
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MxPro-Mx3005P software 
Primer Express® software 
Primer Premier 5 software 
Word 2003
Stratagene 
Applied Biosystems 
Premier Biosoft 
Microsoft
Consumables
Coming filter system (0.22 pm membrane) Fisher
Nescofilm® membrane Fisher
Nunc Maxisorp™ 96-well EIA microplates Fisher
Real-time PCR plates ABgene
Uvette® plastic disposable cuvettes Eppendorf
Eppendorfs StarLab
Pipette tips Anachem
1 0 0  pm filter membrane Fisher
Universals white topped Fisher
Addresses & URLs
ABgene - ABgene House, Blenheim Road, Epsom UK http://www.abgene.com 
Am bion Ltd -  Spitfire close, Ermine Business Park, Huntingdon, Cambridgeshire 
UK www.ambion.com
Anachem Ltd -  Anachem House, Luton, Bedfordshire, UK 
http://www.anachem.co.uk
A ntec International - DuPont Animal Health Solutions, Chilton Industrial Estate, 
Sudbury, Suffolk, UK http://www.antecint.co.uk
Applied Biosystems UK Ltd -  Kelvin Close, Birchwood Science Park North,
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